primaryid,caseid,drug_seq,role_cod,drugname,prod_ai,val_vbm,route,dose_vbm,cum_dose_chr,cum_dose_unit,dechal,rechal,lot_num,exp_dt,nda_num,dose_amt,dose_unit,dose_form,dose_freq,year_x,quarter_x,pt,drug_rec_act,year_y,quarter_y,caseversion,i_f_code,event_dt,mfr_dt,init_fda_dt,fda_dt,rept_cod,auth_num,mfr_num,mfr_sndr,lit_ref,age,age_cod,age_grp,sex,e_sub,wt,wt_cod,rept_dt,to_mfr,occp_cod,reporter_country,occr_country,year,quarter,age_group
156353636,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Arthralgia,,2021,Q1,6,F,,20210216.0,20181120,20210301,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210301.0,,HP,CA,CA,2021,Q1,Adult
156353636,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Blood pressure diastolic increased,,2021,Q1,6,F,,20210216.0,20181120,20210301,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210301.0,,HP,CA,CA,2021,Q1,Adult
156353636,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Blood pressure fluctuation,,2021,Q1,6,F,,20210216.0,20181120,20210301,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210301.0,,HP,CA,CA,2021,Q1,Adult
156353636,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Blood pressure increased,,2021,Q1,6,F,,20210216.0,20181120,20210301,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210301.0,,HP,CA,CA,2021,Q1,Adult
156353636,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Blood pressure systolic abnormal,,2021,Q1,6,F,,20210216.0,20181120,20210301,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210301.0,,HP,CA,CA,2021,Q1,Adult
156353636,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Blood pressure systolic increased,,2021,Q1,6,F,,20210216.0,20181120,20210301,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210301.0,,HP,CA,CA,2021,Q1,Adult
156353636,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Dental caries,,2021,Q1,6,F,,20210216.0,20181120,20210301,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210301.0,,HP,CA,CA,2021,Q1,Adult
156353636,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Diabetes mellitus inadequate control,,2021,Q1,6,F,,20210216.0,20181120,20210301,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210301.0,,HP,CA,CA,2021,Q1,Adult
156353636,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Hypertension,,2021,Q1,6,F,,20210216.0,20181120,20210301,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210301.0,,HP,CA,CA,2021,Q1,Adult
156353636,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Musculoskeletal stiffness,,2021,Q1,6,F,,20210216.0,20181120,20210301,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210301.0,,HP,CA,CA,2021,Q1,Adult
156353636,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Oxygen saturation decreased,,2021,Q1,6,F,,20210216.0,20181120,20210301,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210301.0,,HP,CA,CA,2021,Q1,Adult
156353636,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Rheumatoid arthritis,,2021,Q1,6,F,,20210216.0,20181120,20210301,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210301.0,,HP,CA,CA,2021,Q1,Adult
156353636,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Tooth disorder,,2021,Q1,6,F,,20210216.0,20181120,20210301,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210301.0,,HP,CA,CA,2021,Q1,Adult
156353636,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Tooth fracture,,2021,Q1,6,F,,20210216.0,20181120,20210301,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210301.0,,HP,CA,CA,2021,Q1,Adult
156353636,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Treatment failure,,2021,Q1,6,F,,20210216.0,20181120,20210301,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210301.0,,HP,CA,CA,2021,Q1,Adult
156353636,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Walking aid user,,2021,Q1,6,F,,20210216.0,20181120,20210301,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210301.0,,HP,CA,CA,2021,Q1,Adult
156353636,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Weight decreased,,2021,Q1,6,F,,20210216.0,20181120,20210301,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210301.0,,HP,CA,CA,2021,Q1,Adult
156353636,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Weight increased,,2021,Q1,6,F,,20210216.0,20181120,20210301,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210301.0,,HP,CA,CA,2021,Q1,Adult
162437973,16243797,12,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"7.5 MG, Q.WK.",,,D,,,,,7.5,MG,,/wk,2021,Q1,Colitis,,2021,Q1,3,F,,20210114.0,20190426,20210125,EXP,,CA-APOTEX-2019AP012426,APOTEX,,73.0,YR,,F,Y,,,20210125.0,,CN,CA,CA,2021,Q1,Elderly
162437973,16243797,12,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"7.5 MG, Q.WK.",,,D,,,,,7.5,MG,,/wk,2021,Q1,Colitis ulcerative,,2021,Q1,3,F,,20210114.0,20190426,20210125,EXP,,CA-APOTEX-2019AP012426,APOTEX,,73.0,YR,,F,Y,,,20210125.0,,CN,CA,CA,2021,Q1,Elderly
162437973,16243797,12,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"7.5 MG, Q.WK.",,,D,,,,,7.5,MG,,/wk,2021,Q1,Decreased activity,,2021,Q1,3,F,,20210114.0,20190426,20210125,EXP,,CA-APOTEX-2019AP012426,APOTEX,,73.0,YR,,F,Y,,,20210125.0,,CN,CA,CA,2021,Q1,Elderly
162437973,16243797,12,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"7.5 MG, Q.WK.",,,D,,,,,7.5,MG,,/wk,2021,Q1,Frequent bowel movements,,2021,Q1,3,F,,20210114.0,20190426,20210125,EXP,,CA-APOTEX-2019AP012426,APOTEX,,73.0,YR,,F,Y,,,20210125.0,,CN,CA,CA,2021,Q1,Elderly
162437973,16243797,12,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"7.5 MG, Q.WK.",,,D,,,,,7.5,MG,,/wk,2021,Q1,Rectal haemorrhage,,2021,Q1,3,F,,20210114.0,20190426,20210125,EXP,,CA-APOTEX-2019AP012426,APOTEX,,73.0,YR,,F,Y,,,20210125.0,,CN,CA,CA,2021,Q1,Elderly
172884833,17288483,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Abscess,,2021,Q1,3,F,,20210105.0,20200120,20210107,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-002918,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20210107.0,,CN,CA,CA,2021,Q1,Adult
172884833,17288483,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Blood glucose fluctuation,,2021,Q1,3,F,,20210105.0,20200120,20210107,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-002918,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20210107.0,,CN,CA,CA,2021,Q1,Adult
172884833,17288483,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Cardiac disorder,,2021,Q1,3,F,,20210105.0,20200120,20210107,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-002918,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20210107.0,,CN,CA,CA,2021,Q1,Adult
172884833,17288483,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Constipation,,2021,Q1,3,F,,20210105.0,20200120,20210107,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-002918,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20210107.0,,CN,CA,CA,2021,Q1,Adult
172884833,17288483,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Headache,,2021,Q1,3,F,,20210105.0,20200120,20210107,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-002918,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20210107.0,,CN,CA,CA,2021,Q1,Adult
172884833,17288483,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Hypoaesthesia,,2021,Q1,3,F,,20210105.0,20200120,20210107,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-002918,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20210107.0,,CN,CA,CA,2021,Q1,Adult
172884833,17288483,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Night sweats,,2021,Q1,3,F,,20210105.0,20200120,20210107,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-002918,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20210107.0,,CN,CA,CA,2021,Q1,Adult
172884833,17288483,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Swelling,,2021,Q1,3,F,,20210105.0,20200120,20210107,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-002918,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20210107.0,,CN,CA,CA,2021,Q1,Adult
172884833,17288483,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Swelling face,,2021,Q1,3,F,,20210105.0,20200120,20210107,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-002918,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20210107.0,,CN,CA,CA,2021,Q1,Adult
172884833,17288483,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Taste disorder,,2021,Q1,3,F,,20210105.0,20200120,20210107,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-002918,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20210107.0,,CN,CA,CA,2021,Q1,Adult
172884833,17288483,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Thirst decreased,,2021,Q1,3,F,,20210105.0,20200120,20210107,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-002918,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20210107.0,,CN,CA,CA,2021,Q1,Adult
172884833,17288483,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Weight increased,,2021,Q1,3,F,,20210105.0,20200120,20210107,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-002918,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20210107.0,,CN,CA,CA,2021,Q1,Adult
173047994,17304799,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Abscess,,2021,Q1,4,F,,20210105.0,20200123,20210108,EXP,,CA-PFIZER INC-2020027179,PFIZER,,50.0,YR,,F,Y,75.0,KG,20210108.0,,HP,CA,CA,2021,Q1,Adult
173047994,17304799,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Blood glucose fluctuation,,2021,Q1,4,F,,20210105.0,20200123,20210108,EXP,,CA-PFIZER INC-2020027179,PFIZER,,50.0,YR,,F,Y,75.0,KG,20210108.0,,HP,CA,CA,2021,Q1,Adult
173047994,17304799,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Cardiac disorder,,2021,Q1,4,F,,20210105.0,20200123,20210108,EXP,,CA-PFIZER INC-2020027179,PFIZER,,50.0,YR,,F,Y,75.0,KG,20210108.0,,HP,CA,CA,2021,Q1,Adult
173047994,17304799,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Constipation,,2021,Q1,4,F,,20210105.0,20200123,20210108,EXP,,CA-PFIZER INC-2020027179,PFIZER,,50.0,YR,,F,Y,75.0,KG,20210108.0,,HP,CA,CA,2021,Q1,Adult
173047994,17304799,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Headache,,2021,Q1,4,F,,20210105.0,20200123,20210108,EXP,,CA-PFIZER INC-2020027179,PFIZER,,50.0,YR,,F,Y,75.0,KG,20210108.0,,HP,CA,CA,2021,Q1,Adult
173047994,17304799,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Hypoaesthesia,,2021,Q1,4,F,,20210105.0,20200123,20210108,EXP,,CA-PFIZER INC-2020027179,PFIZER,,50.0,YR,,F,Y,75.0,KG,20210108.0,,HP,CA,CA,2021,Q1,Adult
173047994,17304799,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Night sweats,,2021,Q1,4,F,,20210105.0,20200123,20210108,EXP,,CA-PFIZER INC-2020027179,PFIZER,,50.0,YR,,F,Y,75.0,KG,20210108.0,,HP,CA,CA,2021,Q1,Adult
173047994,17304799,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Swelling,,2021,Q1,4,F,,20210105.0,20200123,20210108,EXP,,CA-PFIZER INC-2020027179,PFIZER,,50.0,YR,,F,Y,75.0,KG,20210108.0,,HP,CA,CA,2021,Q1,Adult
173047994,17304799,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Swelling face,,2021,Q1,4,F,,20210105.0,20200123,20210108,EXP,,CA-PFIZER INC-2020027179,PFIZER,,50.0,YR,,F,Y,75.0,KG,20210108.0,,HP,CA,CA,2021,Q1,Adult
173047994,17304799,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Taste disorder,,2021,Q1,4,F,,20210105.0,20200123,20210108,EXP,,CA-PFIZER INC-2020027179,PFIZER,,50.0,YR,,F,Y,75.0,KG,20210108.0,,HP,CA,CA,2021,Q1,Adult
173047994,17304799,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Thirst decreased,,2021,Q1,4,F,,20210105.0,20200123,20210108,EXP,,CA-PFIZER INC-2020027179,PFIZER,,50.0,YR,,F,Y,75.0,KG,20210108.0,,HP,CA,CA,2021,Q1,Adult
173047994,17304799,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MILLIGRAM, QWK",,,U,,,,,0.75,MG,,/wk,2021,Q1,Weight increased,,2021,Q1,4,F,,20210105.0,20200123,20210108,EXP,,CA-PFIZER INC-2020027179,PFIZER,,50.0,YR,,F,Y,75.0,KG,20210108.0,,HP,CA,CA,2021,Q1,Adult
173125882,17312588,71,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Acute kidney injury,,2021,Q1,2,F,,20210222.0,20200123,20210302,EXP,,US-ASTRAZENECA-2020SE08796,ASTRAZENECA,,23632.0,DY,,F,Y,79.4,KG,20210302.0,,,US,US,2021,Q1,Elderly
173125882,17312588,71,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Chronic kidney disease,,2021,Q1,2,F,,20210222.0,20200123,20210302,EXP,,US-ASTRAZENECA-2020SE08796,ASTRAZENECA,,23632.0,DY,,F,Y,79.4,KG,20210302.0,,,US,US,2021,Q1,Elderly
173125882,17312588,71,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,End stage renal disease,,2021,Q1,2,F,,20210222.0,20200123,20210302,EXP,,US-ASTRAZENECA-2020SE08796,ASTRAZENECA,,23632.0,DY,,F,Y,79.4,KG,20210302.0,,,US,US,2021,Q1,Elderly
173125882,17312588,71,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Hyperparathyroidism secondary,,2021,Q1,2,F,,20210222.0,20200123,20210302,EXP,,US-ASTRAZENECA-2020SE08796,ASTRAZENECA,,23632.0,DY,,F,Y,79.4,KG,20210302.0,,,US,US,2021,Q1,Elderly
173125882,17312588,71,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Nephrogenic anaemia,,2021,Q1,2,F,,20210222.0,20200123,20210302,EXP,,US-ASTRAZENECA-2020SE08796,ASTRAZENECA,,23632.0,DY,,F,Y,79.4,KG,20210302.0,,,US,US,2021,Q1,Elderly
173125882,17312588,71,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Renal failure,,2021,Q1,2,F,,20210222.0,20200123,20210302,EXP,,US-ASTRAZENECA-2020SE08796,ASTRAZENECA,,23632.0,DY,,F,Y,79.4,KG,20210302.0,,,US,US,2021,Q1,Elderly
173125882,17312588,71,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Renal tubular necrosis,,2021,Q1,2,F,,20210222.0,20200123,20210302,EXP,,US-ASTRAZENECA-2020SE08796,ASTRAZENECA,,23632.0,DY,,F,Y,79.4,KG,20210302.0,,,US,US,2021,Q1,Elderly
179206182,17920618,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,0.75,MG,,/wk,2021,Q1,Alcoholic ketoacidosis,,2021,Q1,2,F,,20210203.0,20200621,20210209,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-029872",BOEHRINGER INGELHEIM,"LATIF A, GASTELUM A, SOOD A, EUGLYCAEMIC DIABETIC KETOACIDOSIS IN A 43? YEAR? OLD WOMAN WITH TYPE 2 DIABETES MELLITUS ON SGLT?2 INHIBITOR (EMPAGLIFLOZIN). DRUG AND THERAPEUTICS BULLETIN. 2021?",43.0,YR,A,,Y,,,20210209.0,,CN,US,US,2021,Q1,Adult
179206182,17920618,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,0.75,MG,,/wk,2021,Q1,Bacteraemia,,2021,Q1,2,F,,20210203.0,20200621,20210209,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-029872",BOEHRINGER INGELHEIM,"LATIF A, GASTELUM A, SOOD A, EUGLYCAEMIC DIABETIC KETOACIDOSIS IN A 43? YEAR? OLD WOMAN WITH TYPE 2 DIABETES MELLITUS ON SGLT?2 INHIBITOR (EMPAGLIFLOZIN). DRUG AND THERAPEUTICS BULLETIN. 2021?",43.0,YR,A,,Y,,,20210209.0,,CN,US,US,2021,Q1,Adult
179206182,17920618,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,0.75,MG,,/wk,2021,Q1,Blood ketone body increased,,2021,Q1,2,F,,20210203.0,20200621,20210209,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-029872",BOEHRINGER INGELHEIM,"LATIF A, GASTELUM A, SOOD A, EUGLYCAEMIC DIABETIC KETOACIDOSIS IN A 43? YEAR? OLD WOMAN WITH TYPE 2 DIABETES MELLITUS ON SGLT?2 INHIBITOR (EMPAGLIFLOZIN). DRUG AND THERAPEUTICS BULLETIN. 2021?",43.0,YR,A,,Y,,,20210209.0,,CN,US,US,2021,Q1,Adult
179206182,17920618,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,0.75,MG,,/wk,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,2,F,,20210203.0,20200621,20210209,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-029872",BOEHRINGER INGELHEIM,"LATIF A, GASTELUM A, SOOD A, EUGLYCAEMIC DIABETIC KETOACIDOSIS IN A 43? YEAR? OLD WOMAN WITH TYPE 2 DIABETES MELLITUS ON SGLT?2 INHIBITOR (EMPAGLIFLOZIN). DRUG AND THERAPEUTICS BULLETIN. 2021?",43.0,YR,A,,Y,,,20210209.0,,CN,US,US,2021,Q1,Adult
179206182,17920618,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,0.75,MG,,/wk,2021,Q1,Gastroenteritis,,2021,Q1,2,F,,20210203.0,20200621,20210209,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-029872",BOEHRINGER INGELHEIM,"LATIF A, GASTELUM A, SOOD A, EUGLYCAEMIC DIABETIC KETOACIDOSIS IN A 43? YEAR? OLD WOMAN WITH TYPE 2 DIABETES MELLITUS ON SGLT?2 INHIBITOR (EMPAGLIFLOZIN). DRUG AND THERAPEUTICS BULLETIN. 2021?",43.0,YR,A,,Y,,,20210209.0,,CN,US,US,2021,Q1,Adult
179206182,17920618,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,0.75,MG,,/wk,2021,Q1,Ketonuria,,2021,Q1,2,F,,20210203.0,20200621,20210209,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-029872",BOEHRINGER INGELHEIM,"LATIF A, GASTELUM A, SOOD A, EUGLYCAEMIC DIABETIC KETOACIDOSIS IN A 43? YEAR? OLD WOMAN WITH TYPE 2 DIABETES MELLITUS ON SGLT?2 INHIBITOR (EMPAGLIFLOZIN). DRUG AND THERAPEUTICS BULLETIN. 2021?",43.0,YR,A,,Y,,,20210209.0,,CN,US,US,2021,Q1,Adult
179206182,17920618,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,0.75,MG,,/wk,2021,Q1,Lactic acidosis,,2021,Q1,2,F,,20210203.0,20200621,20210209,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-029872",BOEHRINGER INGELHEIM,"LATIF A, GASTELUM A, SOOD A, EUGLYCAEMIC DIABETIC KETOACIDOSIS IN A 43? YEAR? OLD WOMAN WITH TYPE 2 DIABETES MELLITUS ON SGLT?2 INHIBITOR (EMPAGLIFLOZIN). DRUG AND THERAPEUTICS BULLETIN. 2021?",43.0,YR,A,,Y,,,20210209.0,,CN,US,US,2021,Q1,Adult
179206182,17920618,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,0.75,MG,,/wk,2021,Q1,Metabolic acidosis,,2021,Q1,2,F,,20210203.0,20200621,20210209,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-029872",BOEHRINGER INGELHEIM,"LATIF A, GASTELUM A, SOOD A, EUGLYCAEMIC DIABETIC KETOACIDOSIS IN A 43? YEAR? OLD WOMAN WITH TYPE 2 DIABETES MELLITUS ON SGLT?2 INHIBITOR (EMPAGLIFLOZIN). DRUG AND THERAPEUTICS BULLETIN. 2021?",43.0,YR,A,,Y,,,20210209.0,,CN,US,US,2021,Q1,Adult
179206182,17920618,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,0.75,MG,,/wk,2021,Q1,Pancreatitis,,2021,Q1,2,F,,20210203.0,20200621,20210209,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-029872",BOEHRINGER INGELHEIM,"LATIF A, GASTELUM A, SOOD A, EUGLYCAEMIC DIABETIC KETOACIDOSIS IN A 43? YEAR? OLD WOMAN WITH TYPE 2 DIABETES MELLITUS ON SGLT?2 INHIBITOR (EMPAGLIFLOZIN). DRUG AND THERAPEUTICS BULLETIN. 2021?",43.0,YR,A,,Y,,,20210209.0,,CN,US,US,2021,Q1,Adult
179206182,17920618,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,0.75,MG,,/wk,2021,Q1,Tachycardia,,2021,Q1,2,F,,20210203.0,20200621,20210209,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-029872",BOEHRINGER INGELHEIM,"LATIF A, GASTELUM A, SOOD A, EUGLYCAEMIC DIABETIC KETOACIDOSIS IN A 43? YEAR? OLD WOMAN WITH TYPE 2 DIABETES MELLITUS ON SGLT?2 INHIBITOR (EMPAGLIFLOZIN). DRUG AND THERAPEUTICS BULLETIN. 2021?",43.0,YR,A,,Y,,,20210209.0,,CN,US,US,2021,Q1,Adult
179206182,17920618,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,0.75,MG,,/wk,2021,Q1,Tachypnoea,,2021,Q1,2,F,,20210203.0,20200621,20210209,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-029872",BOEHRINGER INGELHEIM,"LATIF A, GASTELUM A, SOOD A, EUGLYCAEMIC DIABETIC KETOACIDOSIS IN A 43? YEAR? OLD WOMAN WITH TYPE 2 DIABETES MELLITUS ON SGLT?2 INHIBITOR (EMPAGLIFLOZIN). DRUG AND THERAPEUTICS BULLETIN. 2021?",43.0,YR,A,,Y,,,20210209.0,,CN,US,US,2021,Q1,Adult
179206182,17920618,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,0.75,MG,,/wk,2021,Q1,Viral upper respiratory tract infection,,2021,Q1,2,F,,20210203.0,20200621,20210209,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-029872",BOEHRINGER INGELHEIM,"LATIF A, GASTELUM A, SOOD A, EUGLYCAEMIC DIABETIC KETOACIDOSIS IN A 43? YEAR? OLD WOMAN WITH TYPE 2 DIABETES MELLITUS ON SGLT?2 INHIBITOR (EMPAGLIFLOZIN). DRUG AND THERAPEUTICS BULLETIN. 2021?",43.0,YR,A,,Y,,,20210209.0,,CN,US,US,2021,Q1,Adult
180718142,18071814,52,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Chronic kidney disease,,2021,Q1,2,F,20170428.0,20210323.0,20200727,20210331,EXP,,US-ASTRAZENECA-2020SE92550,ASTRAZENECA,,22978.0,DY,,F,Y,89.4,KG,20210331.0,,,US,US,2021,Q1,Elderly
180718142,18071814,52,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Gastrooesophageal reflux disease,,2021,Q1,2,F,20170428.0,20210323.0,20200727,20210331,EXP,,US-ASTRAZENECA-2020SE92550,ASTRAZENECA,,22978.0,DY,,F,Y,89.4,KG,20210331.0,,,US,US,2021,Q1,Elderly
181731922,18173192,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MILLIGRAM, ONCE A DAY",,,U,,,,,1.5,MG,,QD,2021,Q1,Blood pressure decreased,,2021,Q1,2,F,,20210105.0,20200820,20210112,EXP,,DE-AUROBINDO-AUR-APL-2020-039409,AUROBINDO,,70.0,YR,,M,Y,101.0,KG,20210112.0,,CN,FR,DE,2021,Q1,Elderly
181731922,18173192,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MILLIGRAM, ONCE A DAY",,,U,,,,,1.5,MG,,QD,2021,Q1,Constipation,,2021,Q1,2,F,,20210105.0,20200820,20210112,EXP,,DE-AUROBINDO-AUR-APL-2020-039409,AUROBINDO,,70.0,YR,,M,Y,101.0,KG,20210112.0,,CN,FR,DE,2021,Q1,Elderly
181731922,18173192,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MILLIGRAM, ONCE A DAY",,,U,,,,,1.5,MG,,QD,2021,Q1,Dysuria,,2021,Q1,2,F,,20210105.0,20200820,20210112,EXP,,DE-AUROBINDO-AUR-APL-2020-039409,AUROBINDO,,70.0,YR,,M,Y,101.0,KG,20210112.0,,CN,FR,DE,2021,Q1,Elderly
181731922,18173192,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MILLIGRAM, ONCE A DAY",,,U,,,,,1.5,MG,,QD,2021,Q1,Labelled drug-drug interaction medication error,,2021,Q1,2,F,,20210105.0,20200820,20210112,EXP,,DE-AUROBINDO-AUR-APL-2020-039409,AUROBINDO,,70.0,YR,,M,Y,101.0,KG,20210112.0,,CN,FR,DE,2021,Q1,Elderly
181731922,18173192,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MILLIGRAM, ONCE A DAY",,,U,,,,,1.5,MG,,QD,2021,Q1,Nocturia,,2021,Q1,2,F,,20210105.0,20200820,20210112,EXP,,DE-AUROBINDO-AUR-APL-2020-039409,AUROBINDO,,70.0,YR,,M,Y,101.0,KG,20210112.0,,CN,FR,DE,2021,Q1,Elderly
181731922,18173192,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MILLIGRAM, ONCE A DAY",,,U,,,,,1.5,MG,,QD,2021,Q1,Polyuria,,2021,Q1,2,F,,20210105.0,20200820,20210112,EXP,,DE-AUROBINDO-AUR-APL-2020-039409,AUROBINDO,,70.0,YR,,M,Y,101.0,KG,20210112.0,,CN,FR,DE,2021,Q1,Elderly
181731922,18173192,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MILLIGRAM, ONCE A DAY",,,U,,,,,1.5,MG,,QD,2021,Q1,Product monitoring error,,2021,Q1,2,F,,20210105.0,20200820,20210112,EXP,,DE-AUROBINDO-AUR-APL-2020-039409,AUROBINDO,,70.0,YR,,M,Y,101.0,KG,20210112.0,,CN,FR,DE,2021,Q1,Elderly
181731922,18173192,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MILLIGRAM, ONCE A DAY",,,U,,,,,1.5,MG,,QD,2021,Q1,Product prescribing error,,2021,Q1,2,F,,20210105.0,20200820,20210112,EXP,,DE-AUROBINDO-AUR-APL-2020-039409,AUROBINDO,,70.0,YR,,M,Y,101.0,KG,20210112.0,,CN,FR,DE,2021,Q1,Elderly
181731922,18173192,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MILLIGRAM, ONCE A DAY",,,U,,,,,1.5,MG,,QD,2021,Q1,Pyrexia,,2021,Q1,2,F,,20210105.0,20200820,20210112,EXP,,DE-AUROBINDO-AUR-APL-2020-039409,AUROBINDO,,70.0,YR,,M,Y,101.0,KG,20210112.0,,CN,FR,DE,2021,Q1,Elderly
181735922,18173592,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,,"1.5 MG, 1?0?0?0, Q24H",,,,,,,,1.5,MG,,,2021,Q1,Blood pressure decreased,,2021,Q1,2,F,,20210106.0,20200820,20210118,EXP,DE-BFARM-20008806,DE-ACCORD-196173,ACCORD,,70.0,YR,E,M,Y,101.0,KG,20210118.0,,CN,FR,DE,2021,Q1,Elderly
181735922,18173592,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,,"1.5 MG, 1?0?0?0, Q24H",,,,,,,,1.5,MG,,,2021,Q1,Constipation,,2021,Q1,2,F,,20210106.0,20200820,20210118,EXP,DE-BFARM-20008806,DE-ACCORD-196173,ACCORD,,70.0,YR,E,M,Y,101.0,KG,20210118.0,,CN,FR,DE,2021,Q1,Elderly
181735922,18173592,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,,"1.5 MG, 1?0?0?0, Q24H",,,,,,,,1.5,MG,,,2021,Q1,Dysuria,,2021,Q1,2,F,,20210106.0,20200820,20210118,EXP,DE-BFARM-20008806,DE-ACCORD-196173,ACCORD,,70.0,YR,E,M,Y,101.0,KG,20210118.0,,CN,FR,DE,2021,Q1,Elderly
181735922,18173592,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,,"1.5 MG, 1?0?0?0, Q24H",,,,,,,,1.5,MG,,,2021,Q1,Labelled drug-drug interaction medication error,,2021,Q1,2,F,,20210106.0,20200820,20210118,EXP,DE-BFARM-20008806,DE-ACCORD-196173,ACCORD,,70.0,YR,E,M,Y,101.0,KG,20210118.0,,CN,FR,DE,2021,Q1,Elderly
181735922,18173592,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,,"1.5 MG, 1?0?0?0, Q24H",,,,,,,,1.5,MG,,,2021,Q1,Nocturia,,2021,Q1,2,F,,20210106.0,20200820,20210118,EXP,DE-BFARM-20008806,DE-ACCORD-196173,ACCORD,,70.0,YR,E,M,Y,101.0,KG,20210118.0,,CN,FR,DE,2021,Q1,Elderly
181735922,18173592,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,,"1.5 MG, 1?0?0?0, Q24H",,,,,,,,1.5,MG,,,2021,Q1,Polyuria,,2021,Q1,2,F,,20210106.0,20200820,20210118,EXP,DE-BFARM-20008806,DE-ACCORD-196173,ACCORD,,70.0,YR,E,M,Y,101.0,KG,20210118.0,,CN,FR,DE,2021,Q1,Elderly
181735922,18173592,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,,"1.5 MG, 1?0?0?0, Q24H",,,,,,,,1.5,MG,,,2021,Q1,Product monitoring error,,2021,Q1,2,F,,20210106.0,20200820,20210118,EXP,DE-BFARM-20008806,DE-ACCORD-196173,ACCORD,,70.0,YR,E,M,Y,101.0,KG,20210118.0,,CN,FR,DE,2021,Q1,Elderly
181735922,18173592,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,,"1.5 MG, 1?0?0?0, Q24H",,,,,,,,1.5,MG,,,2021,Q1,Product prescribing error,,2021,Q1,2,F,,20210106.0,20200820,20210118,EXP,DE-BFARM-20008806,DE-ACCORD-196173,ACCORD,,70.0,YR,E,M,Y,101.0,KG,20210118.0,,CN,FR,DE,2021,Q1,Elderly
181735922,18173592,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,,"1.5 MG, 1?0?0?0, Q24H",,,,,,,,1.5,MG,,,2021,Q1,Pyrexia,,2021,Q1,2,F,,20210106.0,20200820,20210118,EXP,DE-BFARM-20008806,DE-ACCORD-196173,ACCORD,,70.0,YR,E,M,Y,101.0,KG,20210118.0,,CN,FR,DE,2021,Q1,Elderly
181736344,18173634,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, QD (1.5 MG, 1?0?0?0)",,,U,,,,,1.5,MG,,QD,2021,Q1,Blood pressure decreased,,2021,Q1,4,F,,20210112.0,20200819,20210125,EXP,DE-EMA-DD-20210104-JAIN_H1-155628,DE-SA-2020SA215618,SANOFI AVENTIS,,70.0,YR,E,M,Y,101.0,KG,20210125.0,,HP,DE,DE,2021,Q1,Elderly
181736344,18173634,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, QD (1.5 MG, 1?0?0?0)",,,U,,,,,1.5,MG,,QD,2021,Q1,Constipation,,2021,Q1,4,F,,20210112.0,20200819,20210125,EXP,DE-EMA-DD-20210104-JAIN_H1-155628,DE-SA-2020SA215618,SANOFI AVENTIS,,70.0,YR,E,M,Y,101.0,KG,20210125.0,,HP,DE,DE,2021,Q1,Elderly
181736344,18173634,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, QD (1.5 MG, 1?0?0?0)",,,U,,,,,1.5,MG,,QD,2021,Q1,Dysuria,,2021,Q1,4,F,,20210112.0,20200819,20210125,EXP,DE-EMA-DD-20210104-JAIN_H1-155628,DE-SA-2020SA215618,SANOFI AVENTIS,,70.0,YR,E,M,Y,101.0,KG,20210125.0,,HP,DE,DE,2021,Q1,Elderly
181736344,18173634,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, QD (1.5 MG, 1?0?0?0)",,,U,,,,,1.5,MG,,QD,2021,Q1,Labelled drug-drug interaction medication error,,2021,Q1,4,F,,20210112.0,20200819,20210125,EXP,DE-EMA-DD-20210104-JAIN_H1-155628,DE-SA-2020SA215618,SANOFI AVENTIS,,70.0,YR,E,M,Y,101.0,KG,20210125.0,,HP,DE,DE,2021,Q1,Elderly
181736344,18173634,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, QD (1.5 MG, 1?0?0?0)",,,U,,,,,1.5,MG,,QD,2021,Q1,Nocturia,,2021,Q1,4,F,,20210112.0,20200819,20210125,EXP,DE-EMA-DD-20210104-JAIN_H1-155628,DE-SA-2020SA215618,SANOFI AVENTIS,,70.0,YR,E,M,Y,101.0,KG,20210125.0,,HP,DE,DE,2021,Q1,Elderly
181736344,18173634,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, QD (1.5 MG, 1?0?0?0)",,,U,,,,,1.5,MG,,QD,2021,Q1,Polyuria,,2021,Q1,4,F,,20210112.0,20200819,20210125,EXP,DE-EMA-DD-20210104-JAIN_H1-155628,DE-SA-2020SA215618,SANOFI AVENTIS,,70.0,YR,E,M,Y,101.0,KG,20210125.0,,HP,DE,DE,2021,Q1,Elderly
181736344,18173634,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, QD (1.5 MG, 1?0?0?0)",,,U,,,,,1.5,MG,,QD,2021,Q1,Product monitoring error,,2021,Q1,4,F,,20210112.0,20200819,20210125,EXP,DE-EMA-DD-20210104-JAIN_H1-155628,DE-SA-2020SA215618,SANOFI AVENTIS,,70.0,YR,E,M,Y,101.0,KG,20210125.0,,HP,DE,DE,2021,Q1,Elderly
181736344,18173634,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, QD (1.5 MG, 1?0?0?0)",,,U,,,,,1.5,MG,,QD,2021,Q1,Product prescribing error,,2021,Q1,4,F,,20210112.0,20200819,20210125,EXP,DE-EMA-DD-20210104-JAIN_H1-155628,DE-SA-2020SA215618,SANOFI AVENTIS,,70.0,YR,E,M,Y,101.0,KG,20210125.0,,HP,DE,DE,2021,Q1,Elderly
181736344,18173634,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, QD (1.5 MG, 1?0?0?0)",,,U,,,,,1.5,MG,,QD,2021,Q1,Pyrexia,,2021,Q1,4,F,,20210112.0,20200819,20210125,EXP,DE-EMA-DD-20210104-JAIN_H1-155628,DE-SA-2020SA215618,SANOFI AVENTIS,,70.0,YR,E,M,Y,101.0,KG,20210125.0,,HP,DE,DE,2021,Q1,Elderly
181931852,18193185,18,C,DULAGLUTIDE.,DULAGLUTIDE,1,,"1.5 MILLIGRAM, 1 IN 7 DAYS",,,,,,,,1.5,MG,,/wk,2021,Q1,Drug interaction,,2021,Q1,2,F,201905.0,20210319.0,20200825,20210329,PER,,US-BEH-2020121562,CSL BEHRING,,56.0,YR,A,M,Y,105.21,KG,20210329.0,,CN,US,US,2021,Q1,Adult
181931852,18193185,18,C,DULAGLUTIDE.,DULAGLUTIDE,1,,"1.5 MILLIGRAM, 1 IN 7 DAYS",,,,,,,,1.5,MG,,/wk,2021,Q1,Headache,,2021,Q1,2,F,201905.0,20210319.0,20200825,20210329,PER,,US-BEH-2020121562,CSL BEHRING,,56.0,YR,A,M,Y,105.21,KG,20210329.0,,CN,US,US,2021,Q1,Adult
181931852,18193185,18,C,DULAGLUTIDE.,DULAGLUTIDE,1,,"1.5 MILLIGRAM, 1 IN 7 DAYS",,,,,,,,1.5,MG,,/wk,2021,Q1,Migraine,,2021,Q1,2,F,201905.0,20210319.0,20200825,20210329,PER,,US-BEH-2020121562,CSL BEHRING,,56.0,YR,A,M,Y,105.21,KG,20210329.0,,CN,US,US,2021,Q1,Adult
182003022,18200302,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2021,Q1,Arthropod bite,,2021,Q1,2,F,2019.0,20210312.0,20200827,20210318,EXP,,US-ABBVIE-19K-163-2819139-00,ABBVIE,,55.0,YR,,M,Y,105.33,KG,20210318.0,,CN,US,US,2021,Q1,Adult
182003022,18200302,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2021,Q1,Dermatitis,,2021,Q1,2,F,2019.0,20210312.0,20200827,20210318,EXP,,US-ABBVIE-19K-163-2819139-00,ABBVIE,,55.0,YR,,M,Y,105.33,KG,20210318.0,,CN,US,US,2021,Q1,Adult
182003022,18200302,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2021,Q1,Device issue,,2021,Q1,2,F,2019.0,20210312.0,20200827,20210318,EXP,,US-ABBVIE-19K-163-2819139-00,ABBVIE,,55.0,YR,,M,Y,105.33,KG,20210318.0,,CN,US,US,2021,Q1,Adult
182003022,18200302,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2021,Q1,Diarrhoea,,2021,Q1,2,F,2019.0,20210312.0,20200827,20210318,EXP,,US-ABBVIE-19K-163-2819139-00,ABBVIE,,55.0,YR,,M,Y,105.33,KG,20210318.0,,CN,US,US,2021,Q1,Adult
182003022,18200302,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2021,Q1,Drug interaction,,2021,Q1,2,F,2019.0,20210312.0,20200827,20210318,EXP,,US-ABBVIE-19K-163-2819139-00,ABBVIE,,55.0,YR,,M,Y,105.33,KG,20210318.0,,CN,US,US,2021,Q1,Adult
182003022,18200302,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2021,Q1,Fatigue,,2021,Q1,2,F,2019.0,20210312.0,20200827,20210318,EXP,,US-ABBVIE-19K-163-2819139-00,ABBVIE,,55.0,YR,,M,Y,105.33,KG,20210318.0,,CN,US,US,2021,Q1,Adult
182003022,18200302,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2021,Q1,Feeling abnormal,,2021,Q1,2,F,2019.0,20210312.0,20200827,20210318,EXP,,US-ABBVIE-19K-163-2819139-00,ABBVIE,,55.0,YR,,M,Y,105.33,KG,20210318.0,,CN,US,US,2021,Q1,Adult
182003022,18200302,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2021,Q1,Headache,,2021,Q1,2,F,2019.0,20210312.0,20200827,20210318,EXP,,US-ABBVIE-19K-163-2819139-00,ABBVIE,,55.0,YR,,M,Y,105.33,KG,20210318.0,,CN,US,US,2021,Q1,Adult
182003022,18200302,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2021,Q1,Inflammation,,2021,Q1,2,F,2019.0,20210312.0,20200827,20210318,EXP,,US-ABBVIE-19K-163-2819139-00,ABBVIE,,55.0,YR,,M,Y,105.33,KG,20210318.0,,CN,US,US,2021,Q1,Adult
182003022,18200302,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2021,Q1,Migraine,,2021,Q1,2,F,2019.0,20210312.0,20200827,20210318,EXP,,US-ABBVIE-19K-163-2819139-00,ABBVIE,,55.0,YR,,M,Y,105.33,KG,20210318.0,,CN,US,US,2021,Q1,Adult
182003022,18200302,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2021,Q1,Pruritus,,2021,Q1,2,F,2019.0,20210312.0,20200827,20210318,EXP,,US-ABBVIE-19K-163-2819139-00,ABBVIE,,55.0,YR,,M,Y,105.33,KG,20210318.0,,CN,US,US,2021,Q1,Adult
182003022,18200302,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2021,Q1,Psoriasis,,2021,Q1,2,F,2019.0,20210312.0,20200827,20210318,EXP,,US-ABBVIE-19K-163-2819139-00,ABBVIE,,55.0,YR,,M,Y,105.33,KG,20210318.0,,CN,US,US,2021,Q1,Adult
182003022,18200302,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2021,Q1,Sinusitis,,2021,Q1,2,F,2019.0,20210312.0,20200827,20210318,EXP,,US-ABBVIE-19K-163-2819139-00,ABBVIE,,55.0,YR,,M,Y,105.33,KG,20210318.0,,CN,US,US,2021,Q1,Adult
182003022,18200302,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2021,Q1,Swelling,,2021,Q1,2,F,2019.0,20210312.0,20200827,20210318,EXP,,US-ABBVIE-19K-163-2819139-00,ABBVIE,,55.0,YR,,M,Y,105.33,KG,20210318.0,,CN,US,US,2021,Q1,Adult
182003022,18200302,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2021,Q1,Therapeutic product effect incomplete,,2021,Q1,2,F,2019.0,20210312.0,20200827,20210318,EXP,,US-ABBVIE-19K-163-2819139-00,ABBVIE,,55.0,YR,,M,Y,105.33,KG,20210318.0,,CN,US,US,2021,Q1,Adult
182003022,18200302,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2021,Q1,Weight decreased,,2021,Q1,2,F,2019.0,20210312.0,20200827,20210318,EXP,,US-ABBVIE-19K-163-2819139-00,ABBVIE,,55.0,YR,,M,Y,105.33,KG,20210318.0,,CN,US,US,2021,Q1,Adult
182003022,18200302,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,1.5,MG,,,2021,Q1,Wrong technique in product usage process,,2021,Q1,2,F,2019.0,20210312.0,20200827,20210318,EXP,,US-ABBVIE-19K-163-2819139-00,ABBVIE,,55.0,YR,,M,Y,105.33,KG,20210318.0,,CN,US,US,2021,Q1,Adult
182032612,18203261,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MILLIGRAM, 1?0?0?0, Q24H, 24 HOUR",,,,,,,,1.5,MG,,,2021,Q1,Blood pressure decreased,,2021,Q1,2,F,,20210121.0,20200827,20210126,EXP,,DE-SYNTHON BV-IN51PV20_55010,SYNTHON,,70.0,YR,,M,Y,101.0,KG,20210126.0,,PH,DE,DE,2021,Q1,Elderly
182032612,18203261,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MILLIGRAM, 1?0?0?0, Q24H, 24 HOUR",,,,,,,,1.5,MG,,,2021,Q1,Constipation,,2021,Q1,2,F,,20210121.0,20200827,20210126,EXP,,DE-SYNTHON BV-IN51PV20_55010,SYNTHON,,70.0,YR,,M,Y,101.0,KG,20210126.0,,PH,DE,DE,2021,Q1,Elderly
182032612,18203261,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MILLIGRAM, 1?0?0?0, Q24H, 24 HOUR",,,,,,,,1.5,MG,,,2021,Q1,Dysuria,,2021,Q1,2,F,,20210121.0,20200827,20210126,EXP,,DE-SYNTHON BV-IN51PV20_55010,SYNTHON,,70.0,YR,,M,Y,101.0,KG,20210126.0,,PH,DE,DE,2021,Q1,Elderly
182032612,18203261,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MILLIGRAM, 1?0?0?0, Q24H, 24 HOUR",,,,,,,,1.5,MG,,,2021,Q1,Labelled drug-drug interaction medication error,,2021,Q1,2,F,,20210121.0,20200827,20210126,EXP,,DE-SYNTHON BV-IN51PV20_55010,SYNTHON,,70.0,YR,,M,Y,101.0,KG,20210126.0,,PH,DE,DE,2021,Q1,Elderly
182032612,18203261,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MILLIGRAM, 1?0?0?0, Q24H, 24 HOUR",,,,,,,,1.5,MG,,,2021,Q1,Nocturia,,2021,Q1,2,F,,20210121.0,20200827,20210126,EXP,,DE-SYNTHON BV-IN51PV20_55010,SYNTHON,,70.0,YR,,M,Y,101.0,KG,20210126.0,,PH,DE,DE,2021,Q1,Elderly
182032612,18203261,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MILLIGRAM, 1?0?0?0, Q24H, 24 HOUR",,,,,,,,1.5,MG,,,2021,Q1,Polyuria,,2021,Q1,2,F,,20210121.0,20200827,20210126,EXP,,DE-SYNTHON BV-IN51PV20_55010,SYNTHON,,70.0,YR,,M,Y,101.0,KG,20210126.0,,PH,DE,DE,2021,Q1,Elderly
182032612,18203261,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MILLIGRAM, 1?0?0?0, Q24H, 24 HOUR",,,,,,,,1.5,MG,,,2021,Q1,Product monitoring error,,2021,Q1,2,F,,20210121.0,20200827,20210126,EXP,,DE-SYNTHON BV-IN51PV20_55010,SYNTHON,,70.0,YR,,M,Y,101.0,KG,20210126.0,,PH,DE,DE,2021,Q1,Elderly
182032612,18203261,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MILLIGRAM, 1?0?0?0, Q24H, 24 HOUR",,,,,,,,1.5,MG,,,2021,Q1,Product prescribing error,,2021,Q1,2,F,,20210121.0,20200827,20210126,EXP,,DE-SYNTHON BV-IN51PV20_55010,SYNTHON,,70.0,YR,,M,Y,101.0,KG,20210126.0,,PH,DE,DE,2021,Q1,Elderly
182032612,18203261,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MILLIGRAM, 1?0?0?0, Q24H, 24 HOUR",,,,,,,,1.5,MG,,,2021,Q1,Pyrexia,,2021,Q1,2,F,,20210121.0,20200827,20210126,EXP,,DE-SYNTHON BV-IN51PV20_55010,SYNTHON,,70.0,YR,,M,Y,101.0,KG,20210126.0,,PH,DE,DE,2021,Q1,Elderly
182392142,18239214,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2021,Q1,Interstitial lung disease,,2021,Q1,2,F,202004.0,20210111.0,20200907,20210113,EXP,,NVSC2020DE240576,NOVARTIS,,64.0,YR,,M,Y,,,20210113.0,,HP,DE,DE,2021,Q1,Adult
183317703,18331770,25,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/wk,2021,Q1,Colitis,,2021,Q1,3,F,,20210222.0,20200930,20210301,EXP,,CA-JNJFOC-20200941497,JOHNSON AND JOHNSON,,73.0,YR,E,F,Y,,,20210301.0,,CN,CA,CA,2021,Q1,Elderly
183317703,18331770,25,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/wk,2021,Q1,Colitis ulcerative,,2021,Q1,3,F,,20210222.0,20200930,20210301,EXP,,CA-JNJFOC-20200941497,JOHNSON AND JOHNSON,,73.0,YR,E,F,Y,,,20210301.0,,CN,CA,CA,2021,Q1,Elderly
183317703,18331770,25,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/wk,2021,Q1,Decreased activity,,2021,Q1,3,F,,20210222.0,20200930,20210301,EXP,,CA-JNJFOC-20200941497,JOHNSON AND JOHNSON,,73.0,YR,E,F,Y,,,20210301.0,,CN,CA,CA,2021,Q1,Elderly
183317703,18331770,25,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/wk,2021,Q1,Frequent bowel movements,,2021,Q1,3,F,,20210222.0,20200930,20210301,EXP,,CA-JNJFOC-20200941497,JOHNSON AND JOHNSON,,73.0,YR,E,F,Y,,,20210301.0,,CN,CA,CA,2021,Q1,Elderly
183317703,18331770,25,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/wk,2021,Q1,Rectal haemorrhage,,2021,Q1,3,F,,20210222.0,20200930,20210301,EXP,,CA-JNJFOC-20200941497,JOHNSON AND JOHNSON,,73.0,YR,E,F,Y,,,20210301.0,,CN,CA,CA,2021,Q1,Elderly
183561956,18356195,24,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2021,Q1,Colitis,,2021,Q1,6,F,,20210302.0,20201007,20210309,EXP,,CA-PFIZER INC-2020385258,PFIZER,,73.0,YR,,F,Y,,,20210309.0,,CN,CA,CA,2021,Q1,Elderly
183561956,18356195,24,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2021,Q1,Colitis ulcerative,,2021,Q1,6,F,,20210302.0,20201007,20210309,EXP,,CA-PFIZER INC-2020385258,PFIZER,,73.0,YR,,F,Y,,,20210309.0,,CN,CA,CA,2021,Q1,Elderly
183561956,18356195,24,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2021,Q1,Decreased activity,,2021,Q1,6,F,,20210302.0,20201007,20210309,EXP,,CA-PFIZER INC-2020385258,PFIZER,,73.0,YR,,F,Y,,,20210309.0,,CN,CA,CA,2021,Q1,Elderly
183561956,18356195,24,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2021,Q1,Frequent bowel movements,,2021,Q1,6,F,,20210302.0,20201007,20210309,EXP,,CA-PFIZER INC-2020385258,PFIZER,,73.0,YR,,F,Y,,,20210309.0,,CN,CA,CA,2021,Q1,Elderly
183561956,18356195,24,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2021,Q1,Rectal haemorrhage,,2021,Q1,6,F,,20210302.0,20201007,20210309,EXP,,CA-PFIZER INC-2020385258,PFIZER,,73.0,YR,,F,Y,,,20210309.0,,CN,CA,CA,2021,Q1,Elderly
186990813,18699081,30,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QWK",,,,,,,,1.5,MG,,/wk,2021,Q1,Abdominal discomfort,,2021,Q1,3,F,20201007.0,20210219.0,20210105,20210226,PER,,US-AMGEN-USASP2020213256,AMGEN,,65.0,YR,E,F,Y,87.5,KG,20210226.0,,CN,US,US,2021,Q1,Elderly
186990813,18699081,30,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QWK",,,,,,,,1.5,MG,,/wk,2021,Q1,Arteriosclerosis coronary artery,,2021,Q1,3,F,20201007.0,20210219.0,20210105,20210226,PER,,US-AMGEN-USASP2020213256,AMGEN,,65.0,YR,E,F,Y,87.5,KG,20210226.0,,CN,US,US,2021,Q1,Elderly
186990813,18699081,30,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QWK",,,,,,,,1.5,MG,,/wk,2021,Q1,Cellulitis,,2021,Q1,3,F,20201007.0,20210219.0,20210105,20210226,PER,,US-AMGEN-USASP2020213256,AMGEN,,65.0,YR,E,F,Y,87.5,KG,20210226.0,,CN,US,US,2021,Q1,Elderly
186990813,18699081,30,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QWK",,,,,,,,1.5,MG,,/wk,2021,Q1,Cerebral atrophy,,2021,Q1,3,F,20201007.0,20210219.0,20210105,20210226,PER,,US-AMGEN-USASP2020213256,AMGEN,,65.0,YR,E,F,Y,87.5,KG,20210226.0,,CN,US,US,2021,Q1,Elderly
186990813,18699081,30,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QWK",,,,,,,,1.5,MG,,/wk,2021,Q1,Cerebral venous thrombosis,,2021,Q1,3,F,20201007.0,20210219.0,20210105,20210226,PER,,US-AMGEN-USASP2020213256,AMGEN,,65.0,YR,E,F,Y,87.5,KG,20210226.0,,CN,US,US,2021,Q1,Elderly
186990813,18699081,30,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QWK",,,,,,,,1.5,MG,,/wk,2021,Q1,Cholelithiasis,,2021,Q1,3,F,20201007.0,20210219.0,20210105,20210226,PER,,US-AMGEN-USASP2020213256,AMGEN,,65.0,YR,E,F,Y,87.5,KG,20210226.0,,CN,US,US,2021,Q1,Elderly
186990813,18699081,30,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QWK",,,,,,,,1.5,MG,,/wk,2021,Q1,Diabetes mellitus inadequate control,,2021,Q1,3,F,20201007.0,20210219.0,20210105,20210226,PER,,US-AMGEN-USASP2020213256,AMGEN,,65.0,YR,E,F,Y,87.5,KG,20210226.0,,CN,US,US,2021,Q1,Elderly
186990813,18699081,30,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QWK",,,,,,,,1.5,MG,,/wk,2021,Q1,Diarrhoea,,2021,Q1,3,F,20201007.0,20210219.0,20210105,20210226,PER,,US-AMGEN-USASP2020213256,AMGEN,,65.0,YR,E,F,Y,87.5,KG,20210226.0,,CN,US,US,2021,Q1,Elderly
186990813,18699081,30,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QWK",,,,,,,,1.5,MG,,/wk,2021,Q1,Gangrene,,2021,Q1,3,F,20201007.0,20210219.0,20210105,20210226,PER,,US-AMGEN-USASP2020213256,AMGEN,,65.0,YR,E,F,Y,87.5,KG,20210226.0,,CN,US,US,2021,Q1,Elderly
186990813,18699081,30,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QWK",,,,,,,,1.5,MG,,/wk,2021,Q1,Haemangioma of spleen,,2021,Q1,3,F,20201007.0,20210219.0,20210105,20210226,PER,,US-AMGEN-USASP2020213256,AMGEN,,65.0,YR,E,F,Y,87.5,KG,20210226.0,,CN,US,US,2021,Q1,Elderly
186990813,18699081,30,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QWK",,,,,,,,1.5,MG,,/wk,2021,Q1,Ischaemic stroke,,2021,Q1,3,F,20201007.0,20210219.0,20210105,20210226,PER,,US-AMGEN-USASP2020213256,AMGEN,,65.0,YR,E,F,Y,87.5,KG,20210226.0,,CN,US,US,2021,Q1,Elderly
186990813,18699081,30,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QWK",,,,,,,,1.5,MG,,/wk,2021,Q1,Mitral valve incompetence,,2021,Q1,3,F,20201007.0,20210219.0,20210105,20210226,PER,,US-AMGEN-USASP2020213256,AMGEN,,65.0,YR,E,F,Y,87.5,KG,20210226.0,,CN,US,US,2021,Q1,Elderly
186990813,18699081,30,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QWK",,,,,,,,1.5,MG,,/wk,2021,Q1,Osteomyelitis,,2021,Q1,3,F,20201007.0,20210219.0,20210105,20210226,PER,,US-AMGEN-USASP2020213256,AMGEN,,65.0,YR,E,F,Y,87.5,KG,20210226.0,,CN,US,US,2021,Q1,Elderly
186990813,18699081,30,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QWK",,,,,,,,1.5,MG,,/wk,2021,Q1,Peripheral arterial occlusive disease,,2021,Q1,3,F,20201007.0,20210219.0,20210105,20210226,PER,,US-AMGEN-USASP2020213256,AMGEN,,65.0,YR,E,F,Y,87.5,KG,20210226.0,,CN,US,US,2021,Q1,Elderly
186990813,18699081,30,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QWK",,,,,,,,1.5,MG,,/wk,2021,Q1,Peripheral artery occlusion,,2021,Q1,3,F,20201007.0,20210219.0,20210105,20210226,PER,,US-AMGEN-USASP2020213256,AMGEN,,65.0,YR,E,F,Y,87.5,KG,20210226.0,,CN,US,US,2021,Q1,Elderly
186990813,18699081,30,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QWK",,,,,,,,1.5,MG,,/wk,2021,Q1,Sepsis,,2021,Q1,3,F,20201007.0,20210219.0,20210105,20210226,PER,,US-AMGEN-USASP2020213256,AMGEN,,65.0,YR,E,F,Y,87.5,KG,20210226.0,,CN,US,US,2021,Q1,Elderly
186990813,18699081,30,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QWK",,,,,,,,1.5,MG,,/wk,2021,Q1,Splenic granuloma,,2021,Q1,3,F,20201007.0,20210219.0,20210105,20210226,PER,,US-AMGEN-USASP2020213256,AMGEN,,65.0,YR,E,F,Y,87.5,KG,20210226.0,,CN,US,US,2021,Q1,Elderly
186990813,18699081,30,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QWK",,,,,,,,1.5,MG,,/wk,2021,Q1,Tricuspid valve incompetence,,2021,Q1,3,F,20201007.0,20210219.0,20210105,20210226,PER,,US-AMGEN-USASP2020213256,AMGEN,,65.0,YR,E,F,Y,87.5,KG,20210226.0,,CN,US,US,2021,Q1,Elderly
186990813,18699081,30,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QWK",,,,,,,,1.5,MG,,/wk,2021,Q1,Ventricular hypokinesia,,2021,Q1,3,F,20201007.0,20210219.0,20210105,20210226,PER,,US-AMGEN-USASP2020213256,AMGEN,,65.0,YR,E,F,Y,87.5,KG,20210226.0,,CN,US,US,2021,Q1,Elderly
187012522,18701252,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, WEEKLY (1/W)",3.0,MG,Y,, D204652,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q1,Diarrhoea,,2021,Q1,2,F,20201209.0,20210201.0,20210105,20210208,EXP,,AR-ELI_LILLY_AND_COMPANY-AR202012009089,ELI LILLY AND CO,,62.0,YR,,M,Y,91.0,KG,20210208.0,,MD,AR,AR,2021,Q1,Adult
187012522,18701252,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, WEEKLY (1/W)",3.0,MG,Y,, D204652,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q1,Fournier's gangrene,,2021,Q1,2,F,20201209.0,20210201.0,20210105,20210208,EXP,,AR-ELI_LILLY_AND_COMPANY-AR202012009089,ELI LILLY AND CO,,62.0,YR,,M,Y,91.0,KG,20210208.0,,MD,AR,AR,2021,Q1,Adult
187062031,18706203,1,PS,"DULAGLUTIDE (DULAGLUTIDE 0.75MG/0.5ML INJ, SOLN PEN)",DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,0.75,MG,,QW,2021,Q1,Diarrhoea,,2021,Q1,1,I,20200924.0,,20210105,20210105,DIR,,,FDA-CTU,,60.0,YR,,M,N,,,20201119.0,N,PH,US,US,2021,Q1,Adult
187062831,18706283,1,PS,"DULAGLUTIDE (DULAGLUTIDE 0.75MG/0.5ML INJ, SOLN PEN)",DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,0.75,MG,,QW,2021,Q1,Diarrhoea,,2021,Q1,1,I,20200911.0,,20210105,20210105,DIR,,,FDA-CTU,,66.0,YR,,M,N,,,20201119.0,N,PH,US,US,2021,Q1,Elderly
187062831,18706283,1,PS,"DULAGLUTIDE (DULAGLUTIDE 0.75MG/0.5ML INJ, SOLN PEN)",DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,0.75,MG,,QW,2021,Q1,Nausea,,2021,Q1,1,I,20200911.0,,20210105,20210105,DIR,,,FDA-CTU,,66.0,YR,,M,N,,,20201119.0,N,PH,US,US,2021,Q1,Elderly
187062831,18706283,1,PS,"DULAGLUTIDE (DULAGLUTIDE 0.75MG/0.5ML INJ, SOLN PEN)",DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,0.75,MG,,QW,2021,Q1,Vomiting,,2021,Q1,1,I,20200911.0,,20210105,20210105,DIR,,,FDA-CTU,,66.0,YR,,M,N,,,20201119.0,N,PH,US,US,2021,Q1,Elderly
187067301,18706730,1,PS,"DULAGLUTIDE (DULAGLUTIDE 0.75MG/0.5ML INJ, SOLN PEN)",DULAGLUTIDE,1,Subcutaneous,?          OTHER DOSE:.75MG ;?,,,Y,D,,,,,,,QW,2021,Q1,Fungal skin infection,,2021,Q1,1,I,20200928.0,,20210105,20210105,DIR,,,FDA-CTU,,69.0,YR,,M,N,,,20201119.0,N,PH,US,US,2021,Q1,Elderly
187101951,18710195,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, OW",,,,,,,,1.5,MG,,/wk,2021,Q1,Atrial fibrillation,,2021,Q1,1,I,,20201231.0,20210106,20210106,EXP,,HR-JNJFOC-20210106896,JOHNSON AND JOHNSON,,55.0,YR,A,M,Y,90.0,KG,20210107.0,,MD,HR,HR,2021,Q1,Adult
187101951,18710195,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, OW",,,,,,,,1.5,MG,,/wk,2021,Q1,COVID-19 pneumonia,,2021,Q1,1,I,,20201231.0,20210106,20210106,EXP,,HR-JNJFOC-20210106896,JOHNSON AND JOHNSON,,55.0,YR,A,M,Y,90.0,KG,20210107.0,,MD,HR,HR,2021,Q1,Adult
187101951,18710195,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, OW",,,,,,,,1.5,MG,,/wk,2021,Q1,Guillain-Barre syndrome,,2021,Q1,1,I,,20201231.0,20210106,20210106,EXP,,HR-JNJFOC-20210106896,JOHNSON AND JOHNSON,,55.0,YR,A,M,Y,90.0,KG,20210107.0,,MD,HR,HR,2021,Q1,Adult
187101951,18710195,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, OW",,,,,,,,1.5,MG,,/wk,2021,Q1,Polyneuropathy,,2021,Q1,1,I,,20201231.0,20210106,20210106,EXP,,HR-JNJFOC-20210106896,JOHNSON AND JOHNSON,,55.0,YR,A,M,Y,90.0,KG,20210107.0,,MD,HR,HR,2021,Q1,Adult
187101951,18710195,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, OW",,,,,,,,1.5,MG,,/wk,2021,Q1,Renal impairment,,2021,Q1,1,I,,20201231.0,20210106,20210106,EXP,,HR-JNJFOC-20210106896,JOHNSON AND JOHNSON,,55.0,YR,A,M,Y,90.0,KG,20210107.0,,MD,HR,HR,2021,Q1,Adult
187111451,18711145,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Interstitial lung disease,,2021,Q1,1,I,202004.0,20200820.0,20210107,20210107,EXP,,DE-ROCHE-2664249,ROCHE,,64.0,YR,,M,Y,,,20210107.0,,MD,DE,DE,2021,Q1,Adult
187182721,18718272,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q1,Diverticulitis,,2021,Q1,1,I,20200525.0,20210106.0,20210108,20210108,EXP,,GB-JNJFOC-20210109345,JOHNSON AND JOHNSON,,44.0,YR,A,M,Y,94.6,KG,20210108.0,,HP,GB,GB,2021,Q1,Adult
187182721,18718272,5,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q1,Diverticulitis,,2021,Q1,1,I,20200525.0,20210106.0,20210108,20210108,EXP,,GB-JNJFOC-20210109345,JOHNSON AND JOHNSON,,44.0,YR,A,M,Y,94.6,KG,20210108.0,,HP,GB,GB,2021,Q1,Adult
187283591,18728359,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Drug ineffective,,2021,Q1,1,I,,20201230.0,20210112,20210112,EXP,AU-TOPROL-2020000443,AU-TOPROL-2020000443,TOPROL ACQUISITION,,59.0,YR,A,F,Y,,,20210112.0,,CN,SE,AU,2021,Q1,Adult
187283591,18728359,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Frequent bowel movements,,2021,Q1,1,I,,20201230.0,20210112,20210112,EXP,AU-TOPROL-2020000443,AU-TOPROL-2020000443,TOPROL ACQUISITION,,59.0,YR,A,F,Y,,,20210112.0,,CN,SE,AU,2021,Q1,Adult
187283591,18728359,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Nausea,,2021,Q1,1,I,,20201230.0,20210112,20210112,EXP,AU-TOPROL-2020000443,AU-TOPROL-2020000443,TOPROL ACQUISITION,,59.0,YR,A,F,Y,,,20210112.0,,CN,SE,AU,2021,Q1,Adult
187283591,18728359,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Nightmare,,2021,Q1,1,I,,20201230.0,20210112,20210112,EXP,AU-TOPROL-2020000443,AU-TOPROL-2020000443,TOPROL ACQUISITION,,59.0,YR,A,F,Y,,,20210112.0,,CN,SE,AU,2021,Q1,Adult
187283591,18728359,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Overdose,,2021,Q1,1,I,,20201230.0,20210112,20210112,EXP,AU-TOPROL-2020000443,AU-TOPROL-2020000443,TOPROL ACQUISITION,,59.0,YR,A,F,Y,,,20210112.0,,CN,SE,AU,2021,Q1,Adult
187283591,18728359,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Paroxysmal perceptual alteration,,2021,Q1,1,I,,20201230.0,20210112,20210112,EXP,AU-TOPROL-2020000443,AU-TOPROL-2020000443,TOPROL ACQUISITION,,59.0,YR,A,F,Y,,,20210112.0,,CN,SE,AU,2021,Q1,Adult
187283591,18728359,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Speech disorder,,2021,Q1,1,I,,20201230.0,20210112,20210112,EXP,AU-TOPROL-2020000443,AU-TOPROL-2020000443,TOPROL ACQUISITION,,59.0,YR,A,F,Y,,,20210112.0,,CN,SE,AU,2021,Q1,Adult
187283591,18728359,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Toxicity to various agents,,2021,Q1,1,I,,20201230.0,20210112,20210112,EXP,AU-TOPROL-2020000443,AU-TOPROL-2020000443,TOPROL ACQUISITION,,59.0,YR,A,F,Y,,,20210112.0,,CN,SE,AU,2021,Q1,Adult
187283591,18728359,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Vomiting,,2021,Q1,1,I,,20201230.0,20210112,20210112,EXP,AU-TOPROL-2020000443,AU-TOPROL-2020000443,TOPROL ACQUISITION,,59.0,YR,A,F,Y,,,20210112.0,,CN,SE,AU,2021,Q1,Adult
187283591,18728359,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Withdrawal syndrome,,2021,Q1,1,I,,20201230.0,20210112,20210112,EXP,AU-TOPROL-2020000443,AU-TOPROL-2020000443,TOPROL ACQUISITION,,59.0,YR,A,F,Y,,,20210112.0,,CN,SE,AU,2021,Q1,Adult
187597011,18759701,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Blood creatinine increased,,2021,Q1,1,I,,20210112.0,20210120,20210120,EXP,,AU-JNJFOC-20210116313,JOHNSON AND JOHNSON,,46.0,YR,A,F,Y,78.5,KG,20210120.0,,MD,AU,AU,2021,Q1,Adult
187597011,18759701,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Electrocardiogram QT prolonged,,2021,Q1,1,I,,20210112.0,20210120,20210120,EXP,,AU-JNJFOC-20210116313,JOHNSON AND JOHNSON,,46.0,YR,A,F,Y,78.5,KG,20210120.0,,MD,AU,AU,2021,Q1,Adult
187597011,18759701,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Inappropriate schedule of product administration,,2021,Q1,1,I,,20210112.0,20210120,20210120,EXP,,AU-JNJFOC-20210116313,JOHNSON AND JOHNSON,,46.0,YR,A,F,Y,78.5,KG,20210120.0,,MD,AU,AU,2021,Q1,Adult
187597011,18759701,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Off label use,,2021,Q1,1,I,,20210112.0,20210120,20210120,EXP,,AU-JNJFOC-20210116313,JOHNSON AND JOHNSON,,46.0,YR,A,F,Y,78.5,KG,20210120.0,,MD,AU,AU,2021,Q1,Adult
187597011,18759701,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Schizophrenia,,2021,Q1,1,I,,20210112.0,20210120,20210120,EXP,,AU-JNJFOC-20210116313,JOHNSON AND JOHNSON,,46.0,YR,A,F,Y,78.5,KG,20210120.0,,MD,AU,AU,2021,Q1,Adult
187597011,18759701,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Sepsis,,2021,Q1,1,I,,20210112.0,20210120,20210120,EXP,,AU-JNJFOC-20210116313,JOHNSON AND JOHNSON,,46.0,YR,A,F,Y,78.5,KG,20210120.0,,MD,AU,AU,2021,Q1,Adult
187597011,18759701,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Substance use disorder,,2021,Q1,1,I,,20210112.0,20210120,20210120,EXP,,AU-JNJFOC-20210116313,JOHNSON AND JOHNSON,,46.0,YR,A,F,Y,78.5,KG,20210120.0,,MD,AU,AU,2021,Q1,Adult
187667081,18766708,5,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Pruritus,,2021,Q1,1,I,20210116.0,,20210120,20210120,DIR,,,FDA-CTU,,40.0,YR,,F,N,,,20210120.0,Y,PH,US,US,2021,Q1,Adult
187667081,18766708,5,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Urticaria,,2021,Q1,1,I,20210116.0,,20210120,20210120,DIR,,,FDA-CTU,,40.0,YR,,F,N,,,20210120.0,Y,PH,US,US,2021,Q1,Adult
187759531,18775953,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Oropharyngeal pain,,2021,Q1,1,I,20210107.0,20210112.0,20210122,20210122,EXP,,US-ELI_LILLY_AND_COMPANY-US202101005817,ELI LILLY AND CO,,81.0,YR,,M,Y,73.92,KG,20210122.0,,MD,US,US,2021,Q1,Elderly
187759531,18775953,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Oxygen saturation decreased,,2021,Q1,1,I,20210107.0,20210112.0,20210122,20210122,EXP,,US-ELI_LILLY_AND_COMPANY-US202101005817,ELI LILLY AND CO,,81.0,YR,,M,Y,73.92,KG,20210122.0,,MD,US,US,2021,Q1,Elderly
187822271,18782227,17,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QW (1.5 MG / WEEK,, 1?0?0?0,INJECTION/INFUSION SOLUTION)",,,,,,,,1.5,MG,,/wk,2021,Q1,Cardiac failure,,2021,Q1,1,I,,20210118.0,20210125,20210125,EXP,,DE-MYLANLABS-2021M1003522,MYLAN,,67.0,YR,,M,Y,114.0,KG,20210125.0,,MD,DE,DE,2021,Q1,Elderly
187822271,18782227,17,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QW (1.5 MG / WEEK,, 1?0?0?0,INJECTION/INFUSION SOLUTION)",,,,,,,,1.5,MG,,/wk,2021,Q1,Cough,,2021,Q1,1,I,,20210118.0,20210125,20210125,EXP,,DE-MYLANLABS-2021M1003522,MYLAN,,67.0,YR,,M,Y,114.0,KG,20210125.0,,MD,DE,DE,2021,Q1,Elderly
187822271,18782227,17,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QW (1.5 MG / WEEK,, 1?0?0?0,INJECTION/INFUSION SOLUTION)",,,,,,,,1.5,MG,,/wk,2021,Q1,Dyspnoea exertional,,2021,Q1,1,I,,20210118.0,20210125,20210125,EXP,,DE-MYLANLABS-2021M1003522,MYLAN,,67.0,YR,,M,Y,114.0,KG,20210125.0,,MD,DE,DE,2021,Q1,Elderly
187822271,18782227,17,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM, QW (1.5 MG / WEEK,, 1?0?0?0,INJECTION/INFUSION SOLUTION)",,,,,,,,1.5,MG,,/wk,2021,Q1,Peripheral swelling,,2021,Q1,1,I,,20210118.0,20210125,20210125,EXP,,DE-MYLANLABS-2021M1003522,MYLAN,,67.0,YR,,M,Y,114.0,KG,20210125.0,,MD,DE,DE,2021,Q1,Elderly
187865331,18786533,1,PS,"DULAGLUTIDE (DULAGLUTIDE 0.75MG/0.5ML INJ, SOLN PEN)",DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,QW,2021,Q1,Acute kidney injury,,2021,Q1,1,I,20201021.0,,20210125,20210125,DIR,,,FDA-CTU,,82.0,YR,,M,N,90.72,KG,20201218.0,N,PH,US,US,2021,Q1,Elderly
187865331,18786533,1,PS,"DULAGLUTIDE (DULAGLUTIDE 0.75MG/0.5ML INJ, SOLN PEN)",DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,QW,2021,Q1,Balance disorder,,2021,Q1,1,I,20201021.0,,20210125,20210125,DIR,,,FDA-CTU,,82.0,YR,,M,N,90.72,KG,20201218.0,N,PH,US,US,2021,Q1,Elderly
187865331,18786533,1,PS,"DULAGLUTIDE (DULAGLUTIDE 0.75MG/0.5ML INJ, SOLN PEN)",DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,QW,2021,Q1,Fall,,2021,Q1,1,I,20201021.0,,20210125,20210125,DIR,,,FDA-CTU,,82.0,YR,,M,N,90.72,KG,20201218.0,N,PH,US,US,2021,Q1,Elderly
187865331,18786533,1,PS,"DULAGLUTIDE (DULAGLUTIDE 0.75MG/0.5ML INJ, SOLN PEN)",DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,QW,2021,Q1,Hypophagia,,2021,Q1,1,I,20201021.0,,20210125,20210125,DIR,,,FDA-CTU,,82.0,YR,,M,N,90.72,KG,20201218.0,N,PH,US,US,2021,Q1,Elderly
187865331,18786533,1,PS,"DULAGLUTIDE (DULAGLUTIDE 0.75MG/0.5ML INJ, SOLN PEN)",DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,QW,2021,Q1,Hypotension,,2021,Q1,1,I,20201021.0,,20210125,20210125,DIR,,,FDA-CTU,,82.0,YR,,M,N,90.72,KG,20201218.0,N,PH,US,US,2021,Q1,Elderly
187865331,18786533,1,PS,"DULAGLUTIDE (DULAGLUTIDE 0.75MG/0.5ML INJ, SOLN PEN)",DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,QW,2021,Q1,Hypovolaemia,,2021,Q1,1,I,20201021.0,,20210125,20210125,DIR,,,FDA-CTU,,82.0,YR,,M,N,90.72,KG,20201218.0,N,PH,US,US,2021,Q1,Elderly
187865331,18786533,1,PS,"DULAGLUTIDE (DULAGLUTIDE 0.75MG/0.5ML INJ, SOLN PEN)",DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,QW,2021,Q1,Vomiting,,2021,Q1,1,I,20201021.0,,20210125,20210125,DIR,,,FDA-CTU,,82.0,YR,,M,N,90.72,KG,20201218.0,N,PH,US,US,2021,Q1,Elderly
187931052,18793105,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Oral,,,,,,,,,0.75,MG,,,2021,Q1,Aggression,,2021,Q1,2,F,20210114.0,20210129.0,20210127,20210209,EXP,,FR-JNJFOC-20210129128,JOHNSON AND JOHNSON,,32.0,YR,A,F,Y,70.0,KG,20210209.0,,MD,FR,FR,2021,Q1,Young Adult
187931052,18793105,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Oral,,,,,,,,,0.75,MG,,,2021,Q1,Anxiety,,2021,Q1,2,F,20210114.0,20210129.0,20210127,20210209,EXP,,FR-JNJFOC-20210129128,JOHNSON AND JOHNSON,,32.0,YR,A,F,Y,70.0,KG,20210209.0,,MD,FR,FR,2021,Q1,Young Adult
187931052,18793105,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Oral,,,,,,,,,0.75,MG,,,2021,Q1,Delirium,,2021,Q1,2,F,20210114.0,20210129.0,20210127,20210209,EXP,,FR-JNJFOC-20210129128,JOHNSON AND JOHNSON,,32.0,YR,A,F,Y,70.0,KG,20210209.0,,MD,FR,FR,2021,Q1,Young Adult
187931052,18793105,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Oral,,,,,,,,,0.75,MG,,,2021,Q1,"Hallucination, auditory",,2021,Q1,2,F,20210114.0,20210129.0,20210127,20210209,EXP,,FR-JNJFOC-20210129128,JOHNSON AND JOHNSON,,32.0,YR,A,F,Y,70.0,KG,20210209.0,,MD,FR,FR,2021,Q1,Young Adult
188079461,18807946,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,COVID-19 pneumonia,,2021,Q1,1,I,20210128.0,,20210129,20210129,DIR,,,FDA-CTU,,39.0,YR,,M,N,124.7,KG,20210129.0,Y,PH,US,US,2021,Q1,Adult
188079461,18807946,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Cough,,2021,Q1,1,I,20210128.0,,20210129,20210129,DIR,,,FDA-CTU,,39.0,YR,,M,N,124.7,KG,20210129.0,Y,PH,US,US,2021,Q1,Adult
188079461,18807946,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Dyspnoea,,2021,Q1,1,I,20210128.0,,20210129,20210129,DIR,,,FDA-CTU,,39.0,YR,,M,N,124.7,KG,20210129.0,Y,PH,US,US,2021,Q1,Adult
188079461,18807946,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Lung infiltration,,2021,Q1,1,I,20210128.0,,20210129,20210129,DIR,,,FDA-CTU,,39.0,YR,,M,N,124.7,KG,20210129.0,Y,PH,US,US,2021,Q1,Adult
188079461,18807946,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Oxygen saturation decreased,,2021,Q1,1,I,20210128.0,,20210129,20210129,DIR,,,FDA-CTU,,39.0,YR,,M,N,124.7,KG,20210129.0,Y,PH,US,US,2021,Q1,Adult
188079461,18807946,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Pyrexia,,2021,Q1,1,I,20210128.0,,20210129,20210129,DIR,,,FDA-CTU,,39.0,YR,,M,N,124.7,KG,20210129.0,Y,PH,US,US,2021,Q1,Adult
188560441,18856044,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, WEEKLY (1/W)",,,U,, D268648C,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q1,Inappropriate schedule of product administration,,2021,Q1,1,I,20210126.0,20210127.0,20210206,20210206,PER,,US-ELI_LILLY_AND_COMPANY-US202101012678,ELI LILLY AND CO,,69.0,YR,,M,Y,,,20210206.0,,CN,US,US,2021,Q1,Elderly
188560441,18856044,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, WEEKLY (1/W)",,,U,, D268648C,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q1,Overdose,,2021,Q1,1,I,20210126.0,20210127.0,20210206,20210206,PER,,US-ELI_LILLY_AND_COMPANY-US202101012678,ELI LILLY AND CO,,69.0,YR,,M,Y,,,20210206.0,,CN,US,US,2021,Q1,Elderly
188580281,18858028,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Asthenia,,2021,Q1,1,I,20210118.0,,20210205,20210205,DIR,,,FDA-CTU,,80.0,YR,,M,N,107.5,KG,20210205.0,Y,PH,US,US,2021,Q1,Elderly
188580281,18858028,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Blood pressure systolic increased,,2021,Q1,1,I,20210118.0,,20210205,20210205,DIR,,,FDA-CTU,,80.0,YR,,M,N,107.5,KG,20210205.0,Y,PH,US,US,2021,Q1,Elderly
188580281,18858028,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Heart rate decreased,,2021,Q1,1,I,20210118.0,,20210205,20210205,DIR,,,FDA-CTU,,80.0,YR,,M,N,107.5,KG,20210205.0,Y,PH,US,US,2021,Q1,Elderly
188580281,18858028,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Oxygen saturation decreased,,2021,Q1,1,I,20210118.0,,20210205,20210205,DIR,,,FDA-CTU,,80.0,YR,,M,N,107.5,KG,20210205.0,Y,PH,US,US,2021,Q1,Elderly
188580281,18858028,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Respiratory rate increased,,2021,Q1,1,I,20210118.0,,20210205,20210205,DIR,,,FDA-CTU,,80.0,YR,,M,N,107.5,KG,20210205.0,Y,PH,US,US,2021,Q1,Elderly
188696851,18869685,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Intravenous (not otherwise specified),,,,U,,,,,,,PEN,,2021,Q1,Dehydration,,2021,Q1,1,I,20201231.0,20210120.0,20210209,20210209,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-077504",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20210209.0,,HP,DE,DE,2021,Q1,Adult
188696851,18869685,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Intravenous (not otherwise specified),,,,U,,,,,,,PEN,,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,20201231.0,20210120.0,20210209,20210209,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-077504",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20210209.0,,HP,DE,DE,2021,Q1,Adult
188696851,18869685,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Intravenous (not otherwise specified),,,,U,,,,,,,PEN,,2021,Q1,Hyponatraemia,,2021,Q1,1,I,20201231.0,20210120.0,20210209,20210209,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-077504",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20210209.0,,HP,DE,DE,2021,Q1,Adult
188696851,18869685,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Intravenous (not otherwise specified),,,,U,,,,,,,PEN,,2021,Q1,Metabolic acidosis,,2021,Q1,1,I,20201231.0,20210120.0,20210209,20210209,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-077504",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20210209.0,,HP,DE,DE,2021,Q1,Adult
188696851,18869685,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Intravenous (not otherwise specified),,,,U,,,,,,,PEN,,2021,Q1,Overdose,,2021,Q1,1,I,20201231.0,20210120.0,20210209,20210209,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-077504",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20210209.0,,HP,DE,DE,2021,Q1,Adult
188758661,18875866,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,COVID-19 pneumonia,,2021,Q1,1,I,20210128.0,20210129.0,20210210,20210210,EXP,,US-ELI_LILLY_AND_COMPANY-US202102003929,ELI LILLY AND CO,,39.0,YR,,M,Y,124.7,KG,20210210.0,,PH,US,US,2021,Q1,Adult
188837431,18883743,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Unknown,"1.5 MG, WEEKLY (1/W)",,,Y,,,,125469.0,1.5,MG,,/wk,2021,Q1,Haemorrhoids,,2021,Q1,1,I,,20210202.0,20210212,20210212,EXP,,RU-ELI_LILLY_AND_COMPANY-RU202102002358,ELI LILLY AND CO,,38.0,YR,,F,Y,,,20210212.0,,MD,RU,RU,2021,Q1,Adult
188843412,18884341,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q1,Diabetic ketoacidosis,,2021,Q1,2,F,202102.0,20210212.0,20210212,20210219,EXP,,"GR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-081677",BOEHRINGER INGELHEIM,,28.0,YR,A,M,Y,128.0,KG,20210219.0,,MD,GR,GR,2021,Q1,Young Adult
188880211,18888021,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q1,Blood glucose decreased,,2021,Q1,1,I,20210113.0,20210210.0,20210212,20210212,EXP,,ES-AMERICAN REGENT INC-2021000380,AMERICAN REGENT,,78.0,YR,,F,Y,,,20210212.0,,CN,ES,ES,2021,Q1,Elderly
188880211,18888021,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q1,Blood glucose increased,,2021,Q1,1,I,20210113.0,20210210.0,20210212,20210212,EXP,,ES-AMERICAN REGENT INC-2021000380,AMERICAN REGENT,,78.0,YR,,F,Y,,,20210212.0,,CN,ES,ES,2021,Q1,Elderly
188880211,18888021,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q1,Blood iron abnormal,,2021,Q1,1,I,20210113.0,20210210.0,20210212,20210212,EXP,,ES-AMERICAN REGENT INC-2021000380,AMERICAN REGENT,,78.0,YR,,F,Y,,,20210212.0,,CN,ES,ES,2021,Q1,Elderly
188880211,18888021,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q1,Decreased appetite,,2021,Q1,1,I,20210113.0,20210210.0,20210212,20210212,EXP,,ES-AMERICAN REGENT INC-2021000380,AMERICAN REGENT,,78.0,YR,,F,Y,,,20210212.0,,CN,ES,ES,2021,Q1,Elderly
188880211,18888021,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q1,Discomfort,,2021,Q1,1,I,20210113.0,20210210.0,20210212,20210212,EXP,,ES-AMERICAN REGENT INC-2021000380,AMERICAN REGENT,,78.0,YR,,F,Y,,,20210212.0,,CN,ES,ES,2021,Q1,Elderly
188880211,18888021,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q1,Dizziness,,2021,Q1,1,I,20210113.0,20210210.0,20210212,20210212,EXP,,ES-AMERICAN REGENT INC-2021000380,AMERICAN REGENT,,78.0,YR,,F,Y,,,20210212.0,,CN,ES,ES,2021,Q1,Elderly
188880211,18888021,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q1,Fear,,2021,Q1,1,I,20210113.0,20210210.0,20210212,20210212,EXP,,ES-AMERICAN REGENT INC-2021000380,AMERICAN REGENT,,78.0,YR,,F,Y,,,20210212.0,,CN,ES,ES,2021,Q1,Elderly
188880211,18888021,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q1,Hot flush,,2021,Q1,1,I,20210113.0,20210210.0,20210212,20210212,EXP,,ES-AMERICAN REGENT INC-2021000380,AMERICAN REGENT,,78.0,YR,,F,Y,,,20210212.0,,CN,ES,ES,2021,Q1,Elderly
188880211,18888021,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q1,Hyperglycaemia,,2021,Q1,1,I,20210113.0,20210210.0,20210212,20210212,EXP,,ES-AMERICAN REGENT INC-2021000380,AMERICAN REGENT,,78.0,YR,,F,Y,,,20210212.0,,CN,ES,ES,2021,Q1,Elderly
188880211,18888021,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q1,Hypertension,,2021,Q1,1,I,20210113.0,20210210.0,20210212,20210212,EXP,,ES-AMERICAN REGENT INC-2021000380,AMERICAN REGENT,,78.0,YR,,F,Y,,,20210212.0,,CN,ES,ES,2021,Q1,Elderly
188880211,18888021,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q1,Intentional dose omission,,2021,Q1,1,I,20210113.0,20210210.0,20210212,20210212,EXP,,ES-AMERICAN REGENT INC-2021000380,AMERICAN REGENT,,78.0,YR,,F,Y,,,20210212.0,,CN,ES,ES,2021,Q1,Elderly
188880211,18888021,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q1,Intestinal infarction,,2021,Q1,1,I,20210113.0,20210210.0,20210212,20210212,EXP,,ES-AMERICAN REGENT INC-2021000380,AMERICAN REGENT,,78.0,YR,,F,Y,,,20210212.0,,CN,ES,ES,2021,Q1,Elderly
188880211,18888021,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q1,Shoulder operation,,2021,Q1,1,I,20210113.0,20210210.0,20210212,20210212,EXP,,ES-AMERICAN REGENT INC-2021000380,AMERICAN REGENT,,78.0,YR,,F,Y,,,20210212.0,,CN,ES,ES,2021,Q1,Elderly
188955071,18895507,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,, UNKNOWN,,,,,,,2021,Q1,Abdominal distension,,2021,Q1,1,I,20210208.0,20210211.0,20210216,20210216,EXP,GB-MHRA-WEBCOVID-202102091850045760,GB-ROCHE-2769043,ROCHE,,62.0,YR,,M,Y,111.0,KG,20210216.0,,MD,GB,GB,2021,Q1,Adult
188955071,18895507,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,, UNKNOWN,,,,,,,2021,Q1,Large intestine perforation,,2021,Q1,1,I,20210208.0,20210211.0,20210216,20210216,EXP,GB-MHRA-WEBCOVID-202102091850045760,GB-ROCHE-2769043,ROCHE,,62.0,YR,,M,Y,111.0,KG,20210216.0,,MD,GB,GB,2021,Q1,Adult
188955071,18895507,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,, UNKNOWN,,,,,,,2021,Q1,Sepsis,,2021,Q1,1,I,20210208.0,20210211.0,20210216,20210216,EXP,GB-MHRA-WEBCOVID-202102091850045760,GB-ROCHE-2769043,ROCHE,,62.0,YR,,M,Y,111.0,KG,20210216.0,,MD,GB,GB,2021,Q1,Adult
189011641,18901164,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNKNOWN",,,,, D348715,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Injection site pain,,2021,Q1,1,I,20210209.0,20210209.0,20210216,20210216,PER,,US-ELI_LILLY_AND_COMPANY-US202102005574,ELI LILLY AND CO,,58.0,YR,,M,Y,,,20210216.0,,CN,US,US,2021,Q1,Adult
189011641,18901164,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNKNOWN",,,,, D348715,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Overdose,,2021,Q1,1,I,20210209.0,20210209.0,20210216,20210216,PER,,US-ELI_LILLY_AND_COMPANY-US202102005574,ELI LILLY AND CO,,58.0,YR,,M,Y,,,20210216.0,,CN,US,US,2021,Q1,Adult
189011641,18901164,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNKNOWN",,,,, D348715,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Injection site pain,,2021,Q1,1,I,20210209.0,20210209.0,20210216,20210216,PER,,US-ELI_LILLY_AND_COMPANY-US202102005574,ELI LILLY AND CO,,58.0,YR,,M,Y,,,20210216.0,,CN,US,US,2021,Q1,Adult
189011641,18901164,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNKNOWN",,,,, D348715,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Overdose,,2021,Q1,1,I,20210209.0,20210209.0,20210216,20210216,PER,,US-ELI_LILLY_AND_COMPANY-US202102005574,ELI LILLY AND CO,,58.0,YR,,M,Y,,,20210216.0,,CN,US,US,2021,Q1,Adult
189145031,18914503,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,U,, D162178F,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Injury associated with device,,2021,Q1,1,I,,20210211.0,20210218,20210218,PER,,US-ELI_LILLY_AND_COMPANY-US202102006713,ELI LILLY AND CO,,40.0,YR,,M,Y,,,20210218.0,,MD,US,US,2021,Q1,Adult
189145031,18914503,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,U,, D162178F,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Injury associated with device,,2021,Q1,1,I,,20210211.0,20210218,20210218,PER,,US-ELI_LILLY_AND_COMPANY-US202102006713,ELI LILLY AND CO,,40.0,YR,,M,Y,,,20210218.0,,MD,US,US,2021,Q1,Adult
189150631,18915063,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,,,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q1,Injection site bruising,,2021,Q1,1,I,202010.0,20210209.0,20210218,20210218,PER,,US-ELI_LILLY_AND_COMPANY-US202102005596,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210218.0,,CN,US,US,2021,Q1,Elderly
189150631,18915063,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,,,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q1,Injection site pain,,2021,Q1,1,I,202010.0,20210209.0,20210218,20210218,PER,,US-ELI_LILLY_AND_COMPANY-US202102005596,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210218.0,,CN,US,US,2021,Q1,Elderly
189150631,18915063,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,,,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q1,Needle track marks,,2021,Q1,1,I,202010.0,20210209.0,20210218,20210218,PER,,US-ELI_LILLY_AND_COMPANY-US202102005596,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210218.0,,CN,US,US,2021,Q1,Elderly
189150631,18915063,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,,,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q1,Product dose omission issue,,2021,Q1,1,I,202010.0,20210209.0,20210218,20210218,PER,,US-ELI_LILLY_AND_COMPANY-US202102005596,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210218.0,,CN,US,US,2021,Q1,Elderly
189150631,18915063,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,,,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q1,Injection site bruising,,2021,Q1,1,I,202010.0,20210209.0,20210218,20210218,PER,,US-ELI_LILLY_AND_COMPANY-US202102005596,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210218.0,,CN,US,US,2021,Q1,Elderly
189150631,18915063,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,,,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q1,Injection site pain,,2021,Q1,1,I,202010.0,20210209.0,20210218,20210218,PER,,US-ELI_LILLY_AND_COMPANY-US202102005596,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210218.0,,CN,US,US,2021,Q1,Elderly
189150631,18915063,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,,,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q1,Needle track marks,,2021,Q1,1,I,202010.0,20210209.0,20210218,20210218,PER,,US-ELI_LILLY_AND_COMPANY-US202102005596,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210218.0,,CN,US,US,2021,Q1,Elderly
189150631,18915063,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,,,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q1,Product dose omission issue,,2021,Q1,1,I,202010.0,20210209.0,20210218,20210218,PER,,US-ELI_LILLY_AND_COMPANY-US202102005596,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210218.0,,CN,US,US,2021,Q1,Elderly
189150631,18915063,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,, D301916C,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q1,Injection site bruising,,2021,Q1,1,I,202010.0,20210209.0,20210218,20210218,PER,,US-ELI_LILLY_AND_COMPANY-US202102005596,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210218.0,,CN,US,US,2021,Q1,Elderly
189150631,18915063,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,, D301916C,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q1,Injection site pain,,2021,Q1,1,I,202010.0,20210209.0,20210218,20210218,PER,,US-ELI_LILLY_AND_COMPANY-US202102005596,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210218.0,,CN,US,US,2021,Q1,Elderly
189150631,18915063,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,, D301916C,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q1,Needle track marks,,2021,Q1,1,I,202010.0,20210209.0,20210218,20210218,PER,,US-ELI_LILLY_AND_COMPANY-US202102005596,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210218.0,,CN,US,US,2021,Q1,Elderly
189150631,18915063,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,, D301916C,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q1,Product dose omission issue,,2021,Q1,1,I,202010.0,20210209.0,20210218,20210218,PER,,US-ELI_LILLY_AND_COMPANY-US202102005596,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210218.0,,CN,US,US,2021,Q1,Elderly
189150631,18915063,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,, D301916C,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q1,Injection site bruising,,2021,Q1,1,I,202010.0,20210209.0,20210218,20210218,PER,,US-ELI_LILLY_AND_COMPANY-US202102005596,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210218.0,,CN,US,US,2021,Q1,Elderly
189150631,18915063,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,, D301916C,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q1,Injection site pain,,2021,Q1,1,I,202010.0,20210209.0,20210218,20210218,PER,,US-ELI_LILLY_AND_COMPANY-US202102005596,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210218.0,,CN,US,US,2021,Q1,Elderly
189150631,18915063,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,, D301916C,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q1,Needle track marks,,2021,Q1,1,I,202010.0,20210209.0,20210218,20210218,PER,,US-ELI_LILLY_AND_COMPANY-US202102005596,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210218.0,,CN,US,US,2021,Q1,Elderly
189150631,18915063,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, WEEKLY (1/W)",,,,, D301916C,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q1,Product dose omission issue,,2021,Q1,1,I,202010.0,20210209.0,20210218,20210218,PER,,US-ELI_LILLY_AND_COMPANY-US202102005596,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210218.0,,CN,US,US,2021,Q1,Elderly
189249951,18924995,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q1,Transient ischaemic attack,,2021,Q1,1,I,202102.0,20210215.0,20210223,20210223,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-015310,BRISTOL MYERS SQUIBB,,80.0,YR,,M,Y,,,20210223.0,,CN,US,US,2021,Q1,Elderly
189422961,18942296,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Cutaneous,"1.5 MG, WEEKLY (1/W)",154.648,MG,,U,,,125469.0,1.5,MG,,/wk,2021,Q1,Pancreatic carcinoma,,2021,Q1,1,I,20210101.0,20210221.0,20210225,20210225,EXP,GB-MHRA-EYC 00241370,GB-ELI_LILLY_AND_COMPANY-GB202102010470,ELI LILLY AND CO,,67.0,YR,,M,Y,,,20210225.0,,MD,GB,GB,2021,Q1,Elderly
189480991,18948099,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,,, UNKNOWN,,,,,,,2021,Q1,Confusional state,,2021,Q1,1,I,20210203.0,20210224.0,20210226,20210226,EXP,FR-AFSSAPS-LY20210745,FR-FRESENIUS KABI-FK202101868,FRESENIUS KABI,,80.0,YR,,F,Y,94.0,KG,20210227.0,,HP,NL,FR,2021,Q1,Elderly
189480991,18948099,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,,, UNKNOWN,,,,,,,2021,Q1,"Hallucination, visual",,2021,Q1,1,I,20210203.0,20210224.0,20210226,20210226,EXP,FR-AFSSAPS-LY20210745,FR-FRESENIUS KABI-FK202101868,FRESENIUS KABI,,80.0,YR,,F,Y,94.0,KG,20210227.0,,HP,NL,FR,2021,Q1,Elderly
189587921,18958792,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5MG, ONCE EVERY 7 DAYS",,,,, D256503,,,,,,,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,20210127.0,20210223.0,20210302,20210302,EXP,,CN-ASTRAZENECA-2021A087383,ASTRAZENECA,,20012.0,DY,,M,Y,74.0,KG,20210302.0,,HP,CN,CN,2021,Q1,Elderly
189631501,18963150,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",,,Y,,,,125469.0,1.5,MG,INJECTION,/wk,2021,Q1,Hypoglycaemia,,2021,Q1,1,I,20210206.0,20210223.0,20210303,20210303,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202102012067,ELI LILLY AND CO,,74.0,YR,,M,Y,76.0,KG,20210303.0,,MD,CN,CN,2021,Q1,Elderly
189671491,18967149,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,, UNKNOWN,,,,,,,2021,Q1,Angioedema,,2021,Q1,1,I,20210201.0,20210223.0,20210304,20210304,EXP,PT-INFARMED-R202102-1242,PT-TEVA-2021-PT-1885365,TEVA,,83.0,YR,E,F,Y,103.0,KG,20210304.0,,MD,PT,PT,2021,Q1,Elderly
189671491,18967149,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,, UNKNOWN,,,,,,,2021,Q1,Dysphonia,,2021,Q1,1,I,20210201.0,20210223.0,20210304,20210304,EXP,PT-INFARMED-R202102-1242,PT-TEVA-2021-PT-1885365,TEVA,,83.0,YR,E,F,Y,103.0,KG,20210304.0,,MD,PT,PT,2021,Q1,Elderly
189712631,18971263,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/wk,2021,Q1,Colitis,,2021,Q1,1,I,,20210222.0,20210305,20210305,EXP,,CA-BAUSCH-BL-2021-006677,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189712631,18971263,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/wk,2021,Q1,Colitis ulcerative,,2021,Q1,1,I,,20210222.0,20210305,20210305,EXP,,CA-BAUSCH-BL-2021-006677,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189712631,18971263,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/wk,2021,Q1,Decreased activity,,2021,Q1,1,I,,20210222.0,20210305,20210305,EXP,,CA-BAUSCH-BL-2021-006677,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189712631,18971263,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/wk,2021,Q1,Frequent bowel movements,,2021,Q1,1,I,,20210222.0,20210305,20210305,EXP,,CA-BAUSCH-BL-2021-006677,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189712631,18971263,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/wk,2021,Q1,Rectal haemorrhage,,2021,Q1,1,I,,20210222.0,20210305,20210305,EXP,,CA-BAUSCH-BL-2021-006677,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20210305.0,,CN,CA,CA,2021,Q1,Elderly
190043151,19004315,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,U,,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Inappropriate schedule of product administration,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,U,,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Incorrect dose administered,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,U,,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Injection site pain,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,U,,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Visual impairment,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,U,,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Inappropriate schedule of product administration,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,U,,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Incorrect dose administered,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,U,,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Injection site pain,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,U,,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Visual impairment,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,U,,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Inappropriate schedule of product administration,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,U,,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Incorrect dose administered,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,U,,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Injection site pain,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,U,,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Visual impairment,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,U,, D268647C,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Inappropriate schedule of product administration,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,U,, D268647C,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Incorrect dose administered,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,U,, D268647C,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Injection site pain,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,U,, D268647C,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Visual impairment,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,5,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,U,, D268647C,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Inappropriate schedule of product administration,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,5,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,U,, D268647C,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Incorrect dose administered,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,5,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,U,, D268647C,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Injection site pain,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,5,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"1.5 MG, UNKNOWN",,,U,, D268647C,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Visual impairment,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,6,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,1.5 MG,,,U,, D348715,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Inappropriate schedule of product administration,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,6,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,1.5 MG,,,U,, D348715,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Incorrect dose administered,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,6,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,1.5 MG,,,U,, D348715,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Injection site pain,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,6,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,1.5 MG,,,U,, D348715,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Visual impairment,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,7,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,1.5 MG,,,U,, D348715,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Inappropriate schedule of product administration,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,7,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,1.5 MG,,,U,, D348715,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Incorrect dose administered,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,7,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,1.5 MG,,,U,, D348715,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Injection site pain,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190043151,19004315,7,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,1.5 MG,,,U,, D348715,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q1,Visual impairment,,2021,Q1,1,I,20210212.0,20210215.0,20210312,20210312,PER,,US-ELI_LILLY_AND_COMPANY-US202102008002,ELI LILLY AND CO,,58.0,YR,,F,Y,,,20210312.0,,CN,US,US,2021,Q1,Adult
190075052,19007505,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,0.75 MG,,,U,,,,,0.75,MG,,,2021,Q1,Cardiac failure chronic,,2021,Q1,2,F,,20210315.0,20210315,20210328,EXP,,NVSJ2021JP003743,NOVARTIS,,90.0,YR,,F,Y,,,20210329.0,,MD,JP,JP,2021,Q1,Elderly
190075052,19007505,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,0.75 MG,,,U,,,,,0.75,MG,,,2021,Q1,Concomitant disease aggravated,,2021,Q1,2,F,,20210315.0,20210315,20210328,EXP,,NVSJ2021JP003743,NOVARTIS,,90.0,YR,,F,Y,,,20210329.0,,MD,JP,JP,2021,Q1,Elderly
190075052,19007505,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,0.75 MG,,,U,,,,,0.75,MG,,,2021,Q1,Dyspnoea exertional,,2021,Q1,2,F,,20210315.0,20210315,20210328,EXP,,NVSJ2021JP003743,NOVARTIS,,90.0,YR,,F,Y,,,20210329.0,,MD,JP,JP,2021,Q1,Elderly
190075052,19007505,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,0.75 MG,,,U,,,,,0.75,MG,,,2021,Q1,Jugular vein distension,,2021,Q1,2,F,,20210315.0,20210315,20210328,EXP,,NVSJ2021JP003743,NOVARTIS,,90.0,YR,,F,Y,,,20210329.0,,MD,JP,JP,2021,Q1,Elderly
190075052,19007505,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,0.75 MG,,,U,,,,,0.75,MG,,,2021,Q1,Mitral valve incompetence,,2021,Q1,2,F,,20210315.0,20210315,20210328,EXP,,NVSJ2021JP003743,NOVARTIS,,90.0,YR,,F,Y,,,20210329.0,,MD,JP,JP,2021,Q1,Elderly
190075052,19007505,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,0.75 MG,,,U,,,,,0.75,MG,,,2021,Q1,Oedema peripheral,,2021,Q1,2,F,,20210315.0,20210315,20210328,EXP,,NVSJ2021JP003743,NOVARTIS,,90.0,YR,,F,Y,,,20210329.0,,MD,JP,JP,2021,Q1,Elderly
190075052,19007505,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,0.75 MG,,,U,,,,,0.75,MG,,,2021,Q1,Rales,,2021,Q1,2,F,,20210315.0,20210315,20210328,EXP,,NVSJ2021JP003743,NOVARTIS,,90.0,YR,,F,Y,,,20210329.0,,MD,JP,JP,2021,Q1,Elderly
190091541,19009154,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,UNKNOWN,,2021,Q1,Cutaneous calcification,,2021,Q1,1,I,,20210302.0,20210315,20210315,EXP,,US-JNJFOC-20210308040,JOHNSON AND JOHNSON,HIRNER J. FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS AND NONUREMIC CALCIPHYLAXIS. JAMA DERMATOL.,8.0,DEC,E,F,Y,,,20210315.0,,MD,US,US,2021,Q1,Child
190091541,19009154,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,UNKNOWN,,2021,Q1,Hyperphosphataemia,,2021,Q1,1,I,,20210302.0,20210315,20210315,EXP,,US-JNJFOC-20210308040,JOHNSON AND JOHNSON,HIRNER J. FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS AND NONUREMIC CALCIPHYLAXIS. JAMA DERMATOL.,8.0,DEC,E,F,Y,,,20210315.0,,MD,US,US,2021,Q1,Child
190091541,19009154,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,UNKNOWN,,2021,Q1,Skin necrosis,,2021,Q1,1,I,,20210302.0,20210315,20210315,EXP,,US-JNJFOC-20210308040,JOHNSON AND JOHNSON,HIRNER J. FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS AND NONUREMIC CALCIPHYLAXIS. JAMA DERMATOL.,8.0,DEC,E,F,Y,,,20210315.0,,MD,US,US,2021,Q1,Child
190284821,19028482,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/wk,2021,Q1,Colitis,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210318.0,,CN,CA,CA,2021,Q1,Elderly
190284821,19028482,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/wk,2021,Q1,Colitis ulcerative,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210318.0,,CN,CA,CA,2021,Q1,Elderly
190284821,19028482,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/wk,2021,Q1,Decreased activity,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210318.0,,CN,CA,CA,2021,Q1,Elderly
190284821,19028482,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/wk,2021,Q1,Frequent bowel movements,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210318.0,,CN,CA,CA,2021,Q1,Elderly
190284821,19028482,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/wk,2021,Q1,Rectal haemorrhage,,2021,Q1,1,I,,20210308.0,20210318,20210318,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210318.0,,CN,CA,CA,2021,Q1,Elderly
190341471,19034147,12,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5MG/0.5ML PEN INJECTOR,,,,,,,,,,,/wk,2021,Q1,Death,,2021,Q1,1,I,20200930.0,20210318.0,20210320,20210320,EXP,,US-ABBVIE-21K-163-3824119-00,ABBVIE,,69.0,YR,,M,Y,,,20210320.0,,MD,US,US,2021,Q1,Elderly
190363861,19036386,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q1,Bladder cancer,,2021,Q1,1,I,20210302.0,,20210319,20210319,DIR,,,FDA-CTU,,67.0,YR,,M,N,142.0,KG,20210319.0,N,PH,US,US,2021,Q1,Elderly
190554121,19055412,21,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,1.0714 MILLIGRAM DAILY;,,,U,,,,,7.5,MG,,/wk,2021,Q1,Colitis,,2021,Q1,1,I,,20210315.0,20210324,20210324,EXP,,CA-TEVA-2021-CA-1892397,TEVA,,73.0,YR,E,F,Y,,,20210324.0,,CN,CA,CA,2021,Q1,Elderly
190554121,19055412,21,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,1.0714 MILLIGRAM DAILY;,,,U,,,,,7.5,MG,,/wk,2021,Q1,Colitis ulcerative,,2021,Q1,1,I,,20210315.0,20210324,20210324,EXP,,CA-TEVA-2021-CA-1892397,TEVA,,73.0,YR,E,F,Y,,,20210324.0,,CN,CA,CA,2021,Q1,Elderly
190554121,19055412,21,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,1.0714 MILLIGRAM DAILY;,,,U,,,,,7.5,MG,,/wk,2021,Q1,Decreased activity,,2021,Q1,1,I,,20210315.0,20210324,20210324,EXP,,CA-TEVA-2021-CA-1892397,TEVA,,73.0,YR,E,F,Y,,,20210324.0,,CN,CA,CA,2021,Q1,Elderly
190554121,19055412,21,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,1.0714 MILLIGRAM DAILY;,,,U,,,,,7.5,MG,,/wk,2021,Q1,Frequent bowel movements,,2021,Q1,1,I,,20210315.0,20210324,20210324,EXP,,CA-TEVA-2021-CA-1892397,TEVA,,73.0,YR,E,F,Y,,,20210324.0,,CN,CA,CA,2021,Q1,Elderly
190554121,19055412,21,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,1.0714 MILLIGRAM DAILY;,,,U,,,,,7.5,MG,,/wk,2021,Q1,Rectal haemorrhage,,2021,Q1,1,I,,20210315.0,20210324,20210324,EXP,,CA-TEVA-2021-CA-1892397,TEVA,,73.0,YR,E,F,Y,,,20210324.0,,CN,CA,CA,2021,Q1,Elderly
190567761,19056776,5,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, SOLUTION FOR INJECTION IN PRE?FILLED SYRINGE",,,,,,,,1.0,DF,,,2021,Q1,Acute kidney injury,,2021,Q1,1,I,20210106.0,20210314.0,20210325,20210325,EXP,FR-AFSSAPS-AM20210196,FR-ACCORD-220708,ACCORD,,79.0,YR,,F,Y,,,20210325.0,,PH,FR,FR,2021,Q1,Elderly
190567761,19056776,5,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, SOLUTION FOR INJECTION IN PRE?FILLED SYRINGE",,,,,,,,1.0,DF,,,2021,Q1,Hypokalaemia,,2021,Q1,1,I,20210106.0,20210314.0,20210325,20210325,EXP,FR-AFSSAPS-AM20210196,FR-ACCORD-220708,ACCORD,,79.0,YR,,F,Y,,,20210325.0,,PH,FR,FR,2021,Q1,Elderly
190567761,19056776,5,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, SOLUTION FOR INJECTION IN PRE?FILLED SYRINGE",,,,,,,,1.0,DF,,,2021,Q1,Product prescribing error,,2021,Q1,1,I,20210106.0,20210314.0,20210325,20210325,EXP,FR-AFSSAPS-AM20210196,FR-ACCORD-220708,ACCORD,,79.0,YR,,F,Y,,,20210325.0,,PH,FR,FR,2021,Q1,Elderly
190567761,19056776,5,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, SOLUTION FOR INJECTION IN PRE?FILLED SYRINGE",,,,,,,,1.0,DF,,,2021,Q1,Transcription medication error,,2021,Q1,1,I,20210106.0,20210314.0,20210325,20210325,EXP,FR-AFSSAPS-AM20210196,FR-ACCORD-220708,ACCORD,,79.0,YR,,F,Y,,,20210325.0,,PH,FR,FR,2021,Q1,Elderly
190610471,19061047,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK UNK, UNKNOWN",,,,U,,,125469.0,,,,,2021,Q1,Atrial fibrillation,,2021,Q1,1,I,,20210321.0,20210325,20210325,EXP,,US-ELI_LILLY_AND_COMPANY-US202103011090,ELI LILLY AND CO,LEE J.? NGUYEN J.? UMANA I..EXACERBATION OF ATRIAL FIBRILLATION RELATED TO DULAGLUTIDE USE: A CASE REPORT.JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY (JACCP) 2019?2:597?598.DOI:HTTP://DX.DOI.ORG/10.1002/JAC5.1154,75.0,YR,,F,Y,,,20210325.0,,PH,US,US,2021,Q1,Elderly
190610471,19061047,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK UNK, UNKNOWN",,,,U,,,125469.0,,,,,2021,Q1,Nausea,,2021,Q1,1,I,,20210321.0,20210325,20210325,EXP,,US-ELI_LILLY_AND_COMPANY-US202103011090,ELI LILLY AND CO,LEE J.? NGUYEN J.? UMANA I..EXACERBATION OF ATRIAL FIBRILLATION RELATED TO DULAGLUTIDE USE: A CASE REPORT.JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY (JACCP) 2019?2:597?598.DOI:HTTP://DX.DOI.ORG/10.1002/JAC5.1154,75.0,YR,,F,Y,,,20210325.0,,PH,US,US,2021,Q1,Elderly
190610471,19061047,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK UNK, UNKNOWN",,,,U,,,125469.0,,,,,2021,Q1,Vomiting,,2021,Q1,1,I,,20210321.0,20210325,20210325,EXP,,US-ELI_LILLY_AND_COMPANY-US202103011090,ELI LILLY AND CO,LEE J.? NGUYEN J.? UMANA I..EXACERBATION OF ATRIAL FIBRILLATION RELATED TO DULAGLUTIDE USE: A CASE REPORT.JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY (JACCP) 2019?2:597?598.DOI:HTTP://DX.DOI.ORG/10.1002/JAC5.1154,75.0,YR,,F,Y,,,20210325.0,,PH,US,US,2021,Q1,Elderly
190627061,19062706,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2021,Q1,Coma,,2021,Q1,1,I,2018.0,20210322.0,20210326,20210326,PER,,HU-AMGEN-HUNSP2021044482,AMGEN,BORONKAI A. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. JOURNAL OF MEDICAL CASE REPORTS. 2021?15 (1),66.0,YR,E,M,Y,,,20210326.0,,HP,HU,HU,2021,Q1,Elderly
190627061,19062706,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2021,Q1,Diarrhoea,,2021,Q1,1,I,2018.0,20210322.0,20210326,20210326,PER,,HU-AMGEN-HUNSP2021044482,AMGEN,BORONKAI A. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. JOURNAL OF MEDICAL CASE REPORTS. 2021?15 (1),66.0,YR,E,M,Y,,,20210326.0,,HP,HU,HU,2021,Q1,Elderly
190627061,19062706,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2021,Q1,Haemorrhagic stroke,,2021,Q1,1,I,2018.0,20210322.0,20210326,20210326,PER,,HU-AMGEN-HUNSP2021044482,AMGEN,BORONKAI A. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. JOURNAL OF MEDICAL CASE REPORTS. 2021?15 (1),66.0,YR,E,M,Y,,,20210326.0,,HP,HU,HU,2021,Q1,Elderly
190627061,19062706,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2021,Q1,Hypomagnesaemia,,2021,Q1,1,I,2018.0,20210322.0,20210326,20210326,PER,,HU-AMGEN-HUNSP2021044482,AMGEN,BORONKAI A. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. JOURNAL OF MEDICAL CASE REPORTS. 2021?15 (1),66.0,YR,E,M,Y,,,20210326.0,,HP,HU,HU,2021,Q1,Elderly
190627061,19062706,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2021,Q1,Metastases to lymph nodes,,2021,Q1,1,I,2018.0,20210322.0,20210326,20210326,PER,,HU-AMGEN-HUNSP2021044482,AMGEN,BORONKAI A. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. JOURNAL OF MEDICAL CASE REPORTS. 2021?15 (1),66.0,YR,E,M,Y,,,20210326.0,,HP,HU,HU,2021,Q1,Elderly
190627061,19062706,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2021,Q1,Rash,,2021,Q1,1,I,2018.0,20210322.0,20210326,20210326,PER,,HU-AMGEN-HUNSP2021044482,AMGEN,BORONKAI A. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. JOURNAL OF MEDICAL CASE REPORTS. 2021?15 (1),66.0,YR,E,M,Y,,,20210326.0,,HP,HU,HU,2021,Q1,Elderly
190627061,19062706,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2021,Q1,Weight decreased,,2021,Q1,1,I,2018.0,20210322.0,20210326,20210326,PER,,HU-AMGEN-HUNSP2021044482,AMGEN,BORONKAI A. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. JOURNAL OF MEDICAL CASE REPORTS. 2021?15 (1),66.0,YR,E,M,Y,,,20210326.0,,HP,HU,HU,2021,Q1,Elderly
190721911,19072191,1,PS,"DULAGLUTIDE (DULAGLUTIDE 1.5MG/0.5ML INJ,SOLN,PEN)",DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,1.5,MG,,QW,2021,Q1,Blood triglycerides increased,,2021,Q1,1,I,20210315.0,,20210326,20210326,DIR,,,FDA-CTU,,70.0,YR,,M,N,97.0,KG,20210318.0,N,PH,US,US,2021,Q1,Elderly
190721911,19072191,1,PS,"DULAGLUTIDE (DULAGLUTIDE 1.5MG/0.5ML INJ,SOLN,PEN)",DULAGLUTIDE,1,Subcutaneous,,,,Y,D,,,,1.5,MG,,QW,2021,Q1,Pancreatitis,,2021,Q1,1,I,20210315.0,,20210326,20210326,DIR,,,FDA-CTU,,70.0,YR,,M,N,97.0,KG,20210318.0,N,PH,US,US,2021,Q1,Elderly
190820171,19082017,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,?          OTHER FREQUENCY:WEEKLY;?,,,Y,D,,,,1.5,MG,,,2021,Q1,Nausea,,2021,Q1,1,I,20200123.0,,20210331,20210331,DIR,,,FDA-CTU,,45.0,YR,,F,N,107.1,KG,20210331.0,N,PH,US,US,2021,Q1,Adult
190820171,19082017,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,?          OTHER FREQUENCY:WEEKLY;?,,,Y,D,,,,1.5,MG,,,2021,Q1,Vomiting,,2021,Q1,1,I,20200123.0,,20210331,20210331,DIR,,,FDA-CTU,,45.0,YR,,F,N,107.1,KG,20210331.0,N,PH,US,US,2021,Q1,Adult
167286415,16728641,12,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"7.5 MILLIGRAM, EVERY WEEK",,,U,,,,,7.5,MG,,/wk,2021,Q2,Colitis,,2021,Q2,5,F,,20210326.0,20190822,20210403,EXP,,CA-AUROBINDO-AUR-APL-2019-054419,AUROBINDO,,73.0,YR,,F,Y,,,20210403.0,,CN,CA,CA,2021,Q2,Elderly
167286415,16728641,12,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"7.5 MILLIGRAM, EVERY WEEK",,,U,,,,,7.5,MG,,/wk,2021,Q2,Colitis ulcerative,,2021,Q2,5,F,,20210326.0,20190822,20210403,EXP,,CA-AUROBINDO-AUR-APL-2019-054419,AUROBINDO,,73.0,YR,,F,Y,,,20210403.0,,CN,CA,CA,2021,Q2,Elderly
167286415,16728641,12,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"7.5 MILLIGRAM, EVERY WEEK",,,U,,,,,7.5,MG,,/wk,2021,Q2,Decreased activity,,2021,Q2,5,F,,20210326.0,20190822,20210403,EXP,,CA-AUROBINDO-AUR-APL-2019-054419,AUROBINDO,,73.0,YR,,F,Y,,,20210403.0,,CN,CA,CA,2021,Q2,Elderly
167286415,16728641,12,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"7.5 MILLIGRAM, EVERY WEEK",,,U,,,,,7.5,MG,,/wk,2021,Q2,Frequent bowel movements,,2021,Q2,5,F,,20210326.0,20190822,20210403,EXP,,CA-AUROBINDO-AUR-APL-2019-054419,AUROBINDO,,73.0,YR,,F,Y,,,20210403.0,,CN,CA,CA,2021,Q2,Elderly
167286415,16728641,12,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"7.5 MILLIGRAM, EVERY WEEK",,,U,,,,,7.5,MG,,/wk,2021,Q2,Rectal haemorrhage,,2021,Q2,5,F,,20210326.0,20190822,20210403,EXP,,CA-AUROBINDO-AUR-APL-2019-054419,AUROBINDO,,73.0,YR,,F,Y,,,20210403.0,,CN,CA,CA,2021,Q2,Elderly
169914795,16991479,19,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MILLIGRAM,,,,,,,,1.5,MG,UNKNOWN,/wk,2021,Q2,Arthritis bacterial,,2021,Q2,5,F,20191024.0,20210519.0,20191104,20210525,EXP,,AU-CELGENEUS-AUS-20191011603,CELGENE,,65.0,YR,,M,Y,168.0,KG,20210525.0,,MD,AU,AU,2021,Q2,Elderly
174176069,17417606,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q2,Transaminases increased,,2021,Q2,9,F,20200130.0,20210617.0,20200213,20210623,EXP,,US-EXELIXIS-XL18420027272,EXELIXIS,,67.0,YR,,M,Y,96.2,KG,20210623.0,,MD,US,US,2021,Q2,Elderly
174272295,17427229,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q2,Transaminases increased,,2021,Q2,5,F,20200130.0,20210617.0,20200218,20210628,EXP,,US-ROCHE-2551809,ROCHE,,67.0,YR,,M,Y,96.2,KG,20210628.0,,MD,US,US,2021,Q2,Elderly
175608634,17560863,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q2,Blood glucose increased,,2021,Q2,4,F,,20210426.0,20200319,20210428,EXP,,PT-MYLANLABS-2020M1028430,MYLAN,,61.0,YR,,M,Y,,,20210428.0,,HP,PT,PT,2021,Q2,Adult
175608634,17560863,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q2,Drug ineffective,,2021,Q2,4,F,,20210426.0,20200319,20210428,EXP,,PT-MYLANLABS-2020M1028430,MYLAN,,61.0,YR,,M,Y,,,20210428.0,,HP,PT,PT,2021,Q2,Adult
175608634,17560863,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q2,Gastrointestinal disorder,,2021,Q2,4,F,,20210426.0,20200319,20210428,EXP,,PT-MYLANLABS-2020M1028430,MYLAN,,61.0,YR,,M,Y,,,20210428.0,,HP,PT,PT,2021,Q2,Adult
175608634,17560863,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q2,Product administration error,,2021,Q2,4,F,,20210426.0,20200319,20210428,EXP,,PT-MYLANLABS-2020M1028430,MYLAN,,61.0,YR,,M,Y,,,20210428.0,,HP,PT,PT,2021,Q2,Adult
175608634,17560863,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q2,Urinary tract disorder,,2021,Q2,4,F,,20210426.0,20200319,20210428,EXP,,PT-MYLANLABS-2020M1028430,MYLAN,,61.0,YR,,M,Y,,,20210428.0,,HP,PT,PT,2021,Q2,Adult
180572552,18057255,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,,,,/wk,2021,Q2,Abscess,,2021,Q2,2,F,,20200714.0,20200722,20210628,EXP,,CA-TEVA-2020-CA-1802449,TEVA,,50.0,YR,A,F,Y,75.0,KG,20210628.0,,HP,CA,CA,2021,Q2,Adult
180572552,18057255,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,,,,/wk,2021,Q2,Blood glucose fluctuation,,2021,Q2,2,F,,20200714.0,20200722,20210628,EXP,,CA-TEVA-2020-CA-1802449,TEVA,,50.0,YR,A,F,Y,75.0,KG,20210628.0,,HP,CA,CA,2021,Q2,Adult
180572552,18057255,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,,,,/wk,2021,Q2,Cardiac disorder,,2021,Q2,2,F,,20200714.0,20200722,20210628,EXP,,CA-TEVA-2020-CA-1802449,TEVA,,50.0,YR,A,F,Y,75.0,KG,20210628.0,,HP,CA,CA,2021,Q2,Adult
180572552,18057255,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,,,,/wk,2021,Q2,Constipation,,2021,Q2,2,F,,20200714.0,20200722,20210628,EXP,,CA-TEVA-2020-CA-1802449,TEVA,,50.0,YR,A,F,Y,75.0,KG,20210628.0,,HP,CA,CA,2021,Q2,Adult
180572552,18057255,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,,,,/wk,2021,Q2,Headache,,2021,Q2,2,F,,20200714.0,20200722,20210628,EXP,,CA-TEVA-2020-CA-1802449,TEVA,,50.0,YR,A,F,Y,75.0,KG,20210628.0,,HP,CA,CA,2021,Q2,Adult
180572552,18057255,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,,,,/wk,2021,Q2,Hypoaesthesia,,2021,Q2,2,F,,20200714.0,20200722,20210628,EXP,,CA-TEVA-2020-CA-1802449,TEVA,,50.0,YR,A,F,Y,75.0,KG,20210628.0,,HP,CA,CA,2021,Q2,Adult
180572552,18057255,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,,,,/wk,2021,Q2,Night sweats,,2021,Q2,2,F,,20200714.0,20200722,20210628,EXP,,CA-TEVA-2020-CA-1802449,TEVA,,50.0,YR,A,F,Y,75.0,KG,20210628.0,,HP,CA,CA,2021,Q2,Adult
180572552,18057255,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,,,,/wk,2021,Q2,Swelling,,2021,Q2,2,F,,20200714.0,20200722,20210628,EXP,,CA-TEVA-2020-CA-1802449,TEVA,,50.0,YR,A,F,Y,75.0,KG,20210628.0,,HP,CA,CA,2021,Q2,Adult
180572552,18057255,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,,,,/wk,2021,Q2,Swelling face,,2021,Q2,2,F,,20200714.0,20200722,20210628,EXP,,CA-TEVA-2020-CA-1802449,TEVA,,50.0,YR,A,F,Y,75.0,KG,20210628.0,,HP,CA,CA,2021,Q2,Adult
180572552,18057255,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,,,,/wk,2021,Q2,Taste disorder,,2021,Q2,2,F,,20200714.0,20200722,20210628,EXP,,CA-TEVA-2020-CA-1802449,TEVA,,50.0,YR,A,F,Y,75.0,KG,20210628.0,,HP,CA,CA,2021,Q2,Adult
180572552,18057255,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,,,,/wk,2021,Q2,Thirst decreased,,2021,Q2,2,F,,20200714.0,20200722,20210628,EXP,,CA-TEVA-2020-CA-1802449,TEVA,,50.0,YR,A,F,Y,75.0,KG,20210628.0,,HP,CA,CA,2021,Q2,Adult
180572552,18057255,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,,,,/wk,2021,Q2,Weight increased,,2021,Q2,2,F,,20200714.0,20200722,20210628,EXP,,CA-TEVA-2020-CA-1802449,TEVA,,50.0,YR,A,F,Y,75.0,KG,20210628.0,,HP,CA,CA,2021,Q2,Adult
181920826,18192082,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,INJECTION,/wk,2021,Q2,Anal fistula,,2021,Q2,6,F,20200812.0,20210519.0,20200825,20210525,EXP,,AU-CELGENEUS-AUS-20200804512,CELGENE,,66.0,YR,,M,Y,150.0,KG,20210525.0,,HP,AU,AU,2021,Q2,Elderly
181920826,18192082,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,INJECTION,/wk,2021,Q2,Febrile neutropenia,,2021,Q2,6,F,20200812.0,20210519.0,20200825,20210525,EXP,,AU-CELGENEUS-AUS-20200804512,CELGENE,,66.0,YR,,M,Y,150.0,KG,20210525.0,,HP,AU,AU,2021,Q2,Elderly
181920826,18192082,11,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,INJECTION,/wk,2021,Q2,Lung abscess,,2021,Q2,6,F,20200812.0,20210519.0,20200825,20210525,EXP,,AU-CELGENEUS-AUS-20200804512,CELGENE,,66.0,YR,,M,Y,150.0,KG,20210525.0,,HP,AU,AU,2021,Q2,Elderly
187182722,18718272,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q2,Diverticulitis,,2021,Q2,2,F,20200525.0,20210427.0,20210108,20210428,EXP,,GB-JNJFOC-20210109345,JOHNSON AND JOHNSON,,44.0,YR,A,M,Y,94.6,KG,20210428.0,,HP,GB,GB,2021,Q2,Adult
187182722,18718272,5,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q2,Diverticulitis,,2021,Q2,2,F,20200525.0,20210427.0,20210108,20210428,EXP,,GB-JNJFOC-20210109345,JOHNSON AND JOHNSON,,44.0,YR,A,M,Y,94.6,KG,20210428.0,,HP,GB,GB,2021,Q2,Adult
189063652,18906365,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q2,Asthenia,,2021,Q2,2,F,20210118.0,20210329.0,20210217,20210405,PER,,US-ELI_LILLY_AND_COMPANY-US202102004802,ELI LILLY AND CO,,80.0,YR,,M,Y,107.5,KG,20210405.0,,PH,US,US,2021,Q2,Elderly
189063652,18906365,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q2,Fatigue,,2021,Q2,2,F,20210118.0,20210329.0,20210217,20210405,PER,,US-ELI_LILLY_AND_COMPANY-US202102004802,ELI LILLY AND CO,,80.0,YR,,M,Y,107.5,KG,20210405.0,,PH,US,US,2021,Q2,Elderly
189063652,18906365,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q2,Hypersomnia,,2021,Q2,2,F,20210118.0,20210329.0,20210217,20210405,PER,,US-ELI_LILLY_AND_COMPANY-US202102004802,ELI LILLY AND CO,,80.0,YR,,M,Y,107.5,KG,20210405.0,,PH,US,US,2021,Q2,Elderly
189145032,18914503,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,U,, D162178F,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q2,No adverse event,,2021,Q2,2,F,,20210211.0,20210218,20210611,30DAY,,US-ELI_LILLY_AND_COMPANY-US202102006713,ELI LILLY AND CO,,40.0,YR,,M,Y,,,20210611.0,,MD,US,US,2021,Q2,Adult
189145032,18914503,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,U,, D162178F,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q2,No adverse event,,2021,Q2,2,F,,20210211.0,20210218,20210611,30DAY,,US-ELI_LILLY_AND_COMPANY-US202102006713,ELI LILLY AND CO,,40.0,YR,,M,Y,,,20210611.0,,MD,US,US,2021,Q2,Adult
189145032,18914503,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,U,, D162178F,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q2,No adverse event,,2021,Q2,2,F,,20210211.0,20210218,20210611,30DAY,,US-ELI_LILLY_AND_COMPANY-US202102006713,ELI LILLY AND CO,,40.0,YR,,M,Y,,,20210611.0,,MD,US,US,2021,Q2,Adult
189145032,18914503,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,U,,,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q2,No adverse event,,2021,Q2,2,F,,20210211.0,20210218,20210611,30DAY,,US-ELI_LILLY_AND_COMPANY-US202102006713,ELI LILLY AND CO,,40.0,YR,,M,Y,,,20210611.0,,MD,US,US,2021,Q2,Adult
189145032,18914503,5,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,U,,,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q2,No adverse event,,2021,Q2,2,F,,20210211.0,20210218,20210611,30DAY,,US-ELI_LILLY_AND_COMPANY-US202102006713,ELI LILLY AND CO,,40.0,YR,,M,Y,,,20210611.0,,MD,US,US,2021,Q2,Adult
189145032,18914503,6,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, UNKNOWN",,,U,,,,125469.0,0.75,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q2,No adverse event,,2021,Q2,2,F,,20210211.0,20210218,20210611,30DAY,,US-ELI_LILLY_AND_COMPANY-US202102006713,ELI LILLY AND CO,,40.0,YR,,M,Y,,,20210611.0,,MD,US,US,2021,Q2,Adult
189631502,18963150,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",,,Y,,,,125469.0,1.5,MG,INJECTION,/wk,2021,Q2,Hypoglycaemia,,2021,Q2,2,F,20210206.0,20210513.0,20210303,20210520,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202102012067,ELI LILLY AND CO,,74.0,YR,,M,Y,76.0,KG,20210520.0,,MD,CN,CN,2021,Q2,Elderly
190284822,19028482,21,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/wk,2021,Q2,Colitis,,2021,Q2,2,F,,20210503.0,20210318,20210511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210511.0,,CN,CA,CA,2021,Q2,Elderly
190284822,19028482,21,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/wk,2021,Q2,Colitis ulcerative,,2021,Q2,2,F,,20210503.0,20210318,20210511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210511.0,,CN,CA,CA,2021,Q2,Elderly
190284822,19028482,21,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/wk,2021,Q2,Decreased activity,,2021,Q2,2,F,,20210503.0,20210318,20210511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210511.0,,CN,CA,CA,2021,Q2,Elderly
190284822,19028482,21,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/wk,2021,Q2,Frequent bowel movements,,2021,Q2,2,F,,20210503.0,20210318,20210511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210511.0,,CN,CA,CA,2021,Q2,Elderly
190284822,19028482,21,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/wk,2021,Q2,Rectal haemorrhage,,2021,Q2,2,F,,20210503.0,20210318,20210511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210511.0,,CN,CA,CA,2021,Q2,Elderly
190284822,19028482,22,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNKNOWN,,,,,,,,,,,,2021,Q2,Colitis,,2021,Q2,2,F,,20210503.0,20210318,20210511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210511.0,,CN,CA,CA,2021,Q2,Elderly
190284822,19028482,22,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNKNOWN,,,,,,,,,,,,2021,Q2,Colitis ulcerative,,2021,Q2,2,F,,20210503.0,20210318,20210511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210511.0,,CN,CA,CA,2021,Q2,Elderly
190284822,19028482,22,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNKNOWN,,,,,,,,,,,,2021,Q2,Decreased activity,,2021,Q2,2,F,,20210503.0,20210318,20210511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210511.0,,CN,CA,CA,2021,Q2,Elderly
190284822,19028482,22,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNKNOWN,,,,,,,,,,,,2021,Q2,Frequent bowel movements,,2021,Q2,2,F,,20210503.0,20210318,20210511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210511.0,,CN,CA,CA,2021,Q2,Elderly
190284822,19028482,22,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNKNOWN,,,,,,,,,,,,2021,Q2,Rectal haemorrhage,,2021,Q2,2,F,,20210503.0,20210318,20210511,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210511.0,,CN,CA,CA,2021,Q2,Elderly
190813921,19081392,14,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q2,Colitis,,2021,Q2,1,I,,20210322.0,20210401,20210401,EXP,,CA-BAUSCH-BL-2021-010407,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20210401.0,,CN,CA,CA,2021,Q2,Elderly
190813921,19081392,14,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q2,Colitis ulcerative,,2021,Q2,1,I,,20210322.0,20210401,20210401,EXP,,CA-BAUSCH-BL-2021-010407,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20210401.0,,CN,CA,CA,2021,Q2,Elderly
190813921,19081392,14,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q2,Decreased activity,,2021,Q2,1,I,,20210322.0,20210401,20210401,EXP,,CA-BAUSCH-BL-2021-010407,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20210401.0,,CN,CA,CA,2021,Q2,Elderly
190813921,19081392,14,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q2,Frequent bowel movements,,2021,Q2,1,I,,20210322.0,20210401,20210401,EXP,,CA-BAUSCH-BL-2021-010407,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20210401.0,,CN,CA,CA,2021,Q2,Elderly
190813921,19081392,14,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q2,Rectal haemorrhage,,2021,Q2,1,I,,20210322.0,20210401,20210401,EXP,,CA-BAUSCH-BL-2021-010407,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20210401.0,,CN,CA,CA,2021,Q2,Elderly
190849111,19084911,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2021,Q2,Coma,,2021,Q2,1,I,20190718.0,20210323.0,20210401,20210401,EXP,,HU-ELI_LILLY_AND_COMPANY-HU202104000360,ELI LILLY AND CO,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L..EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT..JOURNAL OF MEDICAL CASE REPORTS 2021?15:125.",66.0,YR,,M,Y,,,20210401.0,,MD,HU,HU,2021,Q2,Elderly
190849111,19084911,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,,,,,,,,,,2021,Q2,Haemorrhagic stroke,,2021,Q2,1,I,20190718.0,20210323.0,20210401,20210401,EXP,,HU-ELI_LILLY_AND_COMPANY-HU202104000360,ELI LILLY AND CO,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L..EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT..JOURNAL OF MEDICAL CASE REPORTS 2021?15:125.",66.0,YR,,M,Y,,,20210401.0,,MD,HU,HU,2021,Q2,Elderly
190881881,19088188,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,,,,,,,,,2021,Q2,Blood glucose fluctuation,,2021,Q2,1,I,2018.0,20210323.0,20210402,20210402,EXP,,HU-ELI_LILLY_AND_COMPANY-HU202104000295,ELI LILLY AND CO,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L..EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT.JOURNAL OF MEDICAL CASE REPORTS 2021?15:125.",66.0,YR,,M,Y,,,20210402.0,,MD,HU,HU,2021,Q2,Elderly
190881881,19088188,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,,,,,,,,,2021,Q2,Diarrhoea,,2021,Q2,1,I,2018.0,20210323.0,20210402,20210402,EXP,,HU-ELI_LILLY_AND_COMPANY-HU202104000295,ELI LILLY AND CO,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L..EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT.JOURNAL OF MEDICAL CASE REPORTS 2021?15:125.",66.0,YR,,M,Y,,,20210402.0,,MD,HU,HU,2021,Q2,Elderly
190881881,19088188,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,,,,,,,,,2021,Q2,Hypomagnesaemia,,2021,Q2,1,I,2018.0,20210323.0,20210402,20210402,EXP,,HU-ELI_LILLY_AND_COMPANY-HU202104000295,ELI LILLY AND CO,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L..EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT.JOURNAL OF MEDICAL CASE REPORTS 2021?15:125.",66.0,YR,,M,Y,,,20210402.0,,MD,HU,HU,2021,Q2,Elderly
190932431,19093243,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q2,Euglycaemic diabetic ketoacidosis,,2021,Q2,1,I,20210323.0,20210328.0,20210405,20210405,EXP,GB-MHRA-EYC 00245400,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-093894",BOEHRINGER INGELHEIM,,34.0,YR,A,M,Y,78.0,KG,20210405.0,,PH,GB,GB,2021,Q2,Young Adult
191229001,19122900,12,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q2,Colon cancer metastatic,,2021,Q2,1,I,201804.0,20210406.0,20210412,20210412,EXP,,HU-FRESENIUS KABI-FK202103621,FRESENIUS KABI,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. JOURNAL OF MEDICAL CASE REPORTS. 2021?15 (125):.",66.0,YR,,M,Y,,,20210412.0,,HP,HU,HU,2021,Q2,Elderly
191270151,19127015,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Off label use,,2021,Q2,1,I,,20210407.0,20210412,20210412,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-034211,BRISTOL MYERS SQUIBB,,69.0,YR,,F,Y,60.32,KG,20210412.0,,CN,US,US,2021,Q2,Elderly
191270151,19127015,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2021,Q2,Weight increased,,2021,Q2,1,I,,20210407.0,20210412,20210412,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-034211,BRISTOL MYERS SQUIBB,,69.0,YR,,F,Y,60.32,KG,20210412.0,,CN,US,US,2021,Q2,Elderly
191328771,19132877,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",,,,,,,125469.0,1.5,MG,INJECTION,/wk,2021,Q2,Arrhythmia supraventricular,,2021,Q2,1,I,20210401.0,20210406.0,20210414,20210414,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202104004219,ELI LILLY AND CO,,78.0,YR,,F,Y,55.0,KG,20210414.0,,MD,CN,CN,2021,Q2,Elderly
191328771,19132877,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",,,,,,,125469.0,1.5,MG,INJECTION,/wk,2021,Q2,Supraventricular tachycardia,,2021,Q2,1,I,20210401.0,20210406.0,20210414,20210414,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202104004219,ELI LILLY AND CO,,78.0,YR,,F,Y,55.0,KG,20210414.0,,MD,CN,CN,2021,Q2,Elderly
191345851,19134585,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,U,,,,,,,,2021,Q2,Diarrhoea,,2021,Q2,1,I,2018.0,20210406.0,20210414,20210414,EXP,,HU-MYLANLABS-2021M1022059,MYLAN,,66.0,YR,,M,Y,,,20210414.0,,HP,HU,HU,2021,Q2,Elderly
191345851,19134585,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,U,,,,,,,,2021,Q2,Weight decreased,,2021,Q2,1,I,2018.0,20210406.0,20210414,20210414,EXP,,HU-MYLANLABS-2021M1022059,MYLAN,,66.0,YR,,M,Y,,,20210414.0,,HP,HU,HU,2021,Q2,Elderly
191512731,19151273,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q2,Diabetic ketoacidosis,,2021,Q2,1,I,20210410.0,20210414.0,20210419,20210419,EXP,GB-MHRA-EYC 00247537,GB-JNJFOC-20210429446,JOHNSON AND JOHNSON,,73.0,YR,E,M,Y,,,20210419.0,,PH,GB,GB,2021,Q2,Elderly
191630381,19163038,17,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q2,Blood glucose fluctuation,,2021,Q2,1,I,,20210406.0,20210421,20210421,EXP,,HU-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-292440,RANBAXY,,66.0,YR,,M,Y,,,20210421.0,,HP,HU,HU,2021,Q2,Elderly
191630381,19163038,17,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q2,Diarrhoea,,2021,Q2,1,I,,20210406.0,20210421,20210421,EXP,,HU-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-292440,RANBAXY,,66.0,YR,,M,Y,,,20210421.0,,HP,HU,HU,2021,Q2,Elderly
191630381,19163038,17,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q2,Hypomagnesaemia,,2021,Q2,1,I,,20210406.0,20210421,20210421,EXP,,HU-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-292440,RANBAXY,,66.0,YR,,M,Y,,,20210421.0,,HP,HU,HU,2021,Q2,Elderly
191630381,19163038,17,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q2,Weight decreased,,2021,Q2,1,I,,20210406.0,20210421,20210421,EXP,,HU-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-292440,RANBAXY,,66.0,YR,,M,Y,,,20210421.0,,HP,HU,HU,2021,Q2,Elderly
191683561,19168356,19,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q2,Blood glucose fluctuation,,2021,Q2,1,I,2018.0,20210412.0,20210422,20210422,EXP,,HU-TEVA-2021-HU-1902270,TEVA,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. J?MED?CASE?REP 2021?15(1):125.",66.0,YR,E,M,Y,,,20210422.0,,HP,HU,HU,2021,Q2,Elderly
191683561,19168356,19,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q2,Colon cancer metastatic,,2021,Q2,1,I,2018.0,20210412.0,20210422,20210422,EXP,,HU-TEVA-2021-HU-1902270,TEVA,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. J?MED?CASE?REP 2021?15(1):125.",66.0,YR,E,M,Y,,,20210422.0,,HP,HU,HU,2021,Q2,Elderly
191683561,19168356,19,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q2,Diarrhoea,,2021,Q2,1,I,2018.0,20210412.0,20210422,20210422,EXP,,HU-TEVA-2021-HU-1902270,TEVA,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. J?MED?CASE?REP 2021?15(1):125.",66.0,YR,E,M,Y,,,20210422.0,,HP,HU,HU,2021,Q2,Elderly
191683561,19168356,19,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q2,Hypomagnesaemia,,2021,Q2,1,I,2018.0,20210412.0,20210422,20210422,EXP,,HU-TEVA-2021-HU-1902270,TEVA,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. J?MED?CASE?REP 2021?15(1):125.",66.0,YR,E,M,Y,,,20210422.0,,HP,HU,HU,2021,Q2,Elderly
191683561,19168356,19,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q2,Rash,,2021,Q2,1,I,2018.0,20210412.0,20210422,20210422,EXP,,HU-TEVA-2021-HU-1902270,TEVA,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. J?MED?CASE?REP 2021?15(1):125.",66.0,YR,E,M,Y,,,20210422.0,,HP,HU,HU,2021,Q2,Elderly
191683561,19168356,19,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q2,Weight decreased,,2021,Q2,1,I,2018.0,20210412.0,20210422,20210422,EXP,,HU-TEVA-2021-HU-1902270,TEVA,"BELLYEI S, BORONKAI A, POZSGAI E, FODOR D, MANGEL L. EFFECTIVE CHEMOTHERAPY AND TARGETED THERAPY SUPPLEMENTED WITH STEREOTACTIC RADIOTHERAPY OF A PATIENT WITH METASTATIC COLON CANCER FOLLOWING RENAL TRANSPLANTATION: A CASE REPORT. J?MED?CASE?REP 2021?15(1):125.",66.0,YR,E,M,Y,,,20210422.0,,HP,HU,HU,2021,Q2,Elderly
191716861,19171686,1,PS,"DULAGLUTIDE (DULAGLUTIDE 1.5MG/0.5ML INJ,SOLN,PEN)",DULAGLUTIDE,1,Subcutaneous,,,,N,D,,,,1.5,MG,,QW,2021,Q2,Cholecystitis,,2021,Q2,1,I,20210127.0,,20210422,20210422,DIR,,,FDA-CTU,,52.0,YR,,M,N,110.0,KG,20210318.0,N,PH,US,US,2021,Q2,Adult
191819711,19181971,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q2,Penile swelling,,2021,Q2,1,I,2021.0,20210413.0,20210426,20210426,PER,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-097748",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,,,20210426.0,,CN,US,US,2021,Q2,Elderly
191953301,19195330,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,?          OTHER FREQUENCY:WEEKLY;?,,,Y,D,,,,0.5,ML,,QW,2021,Q2,Nausea,,2021,Q2,1,I,20200323.0,,20210429,20210429,DIR,,,FDA-CTU,,46.0,YR,,F,N,116.46,KG,20210429.0,N,HP,US,US,2021,Q2,Adult
191953301,19195330,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,?          OTHER FREQUENCY:WEEKLY;?,,,Y,D,,,,0.5,ML,,QW,2021,Q2,Vomiting,,2021,Q2,1,I,20200323.0,,20210429,20210429,DIR,,,FDA-CTU,,46.0,YR,,F,N,116.46,KG,20210429.0,N,HP,US,US,2021,Q2,Adult
192037591,19203759,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Unknown,"1 DOSAGE FORM, WEEKLY (1/W)",,,N,,,,125469.0,1.0,DF,,/wk,2021,Q2,Hypoaesthesia,,2021,Q2,1,I,20200203.0,20210420.0,20210430,20210430,EXP,NL-LRB-00507568,NL-ELI_LILLY_AND_COMPANY-NL202104009352,ELI LILLY AND CO,,44.0,YR,,F,Y,93.0,KG,20210430.0,,CN,NL,NL,2021,Q2,Adult
192037591,19203759,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Unknown,"1 DOSAGE FORM, WEEKLY (1/W)",,,N,,,,125469.0,1.0,DF,,/wk,2021,Q2,Neuralgia,,2021,Q2,1,I,20200203.0,20210420.0,20210430,20210430,EXP,NL-LRB-00507568,NL-ELI_LILLY_AND_COMPANY-NL202104009352,ELI LILLY AND CO,,44.0,YR,,F,Y,93.0,KG,20210430.0,,CN,NL,NL,2021,Q2,Adult
192037591,19203759,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Unknown,"1 DOSAGE FORM, WEEKLY (1/W)",,,N,,,,125469.0,1.0,DF,,/wk,2021,Q2,Visual impairment,,2021,Q2,1,I,20200203.0,20210420.0,20210430,20210430,EXP,NL-LRB-00507568,NL-ELI_LILLY_AND_COMPANY-NL202104009352,ELI LILLY AND CO,,44.0,YR,,F,Y,93.0,KG,20210430.0,,CN,NL,NL,2021,Q2,Adult
192201151,19220115,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,UNK,,,D,,,,,,,,,2021,Q2,Drug reaction with eosinophilia and systemic symptoms,,2021,Q2,1,I,,20210423.0,20210505,20210505,EXP,,CA-APOTEX-2021AP010663,APOTEX,,55.0,YR,,M,Y,,,20210505.0,,CN,CA,CA,2021,Q2,Adult
192201151,19220115,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,UNK,,,D,,,,,,,,,2021,Q2,Off label use,,2021,Q2,1,I,,20210423.0,20210505,20210505,EXP,,CA-APOTEX-2021AP010663,APOTEX,,55.0,YR,,M,Y,,,20210505.0,,CN,CA,CA,2021,Q2,Adult
192201151,19220115,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,UNK,,,D,,,,,,,,,2021,Q2,Therapeutic product effect incomplete,,2021,Q2,1,I,,20210423.0,20210505,20210505,EXP,,CA-APOTEX-2021AP010663,APOTEX,,55.0,YR,,M,Y,,,20210505.0,,CN,CA,CA,2021,Q2,Adult
192230291,19223029,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",1.5,MG,Y,, D347699,,125469.0,1.5,MG,,/wk,2021,Q2,Dry mouth,,2021,Q2,1,I,20210420.0,20210423.0,20210505,20210505,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202104011479,ELI LILLY AND CO,,51.0,YR,,M,Y,,,20210505.0,,HP,CN,CN,2021,Q2,Adult
192230291,19223029,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",1.5,MG,Y,, D347699,,125469.0,1.5,MG,,/wk,2021,Q2,Muscular weakness,,2021,Q2,1,I,20210420.0,20210423.0,20210505,20210505,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202104011479,ELI LILLY AND CO,,51.0,YR,,M,Y,,,20210505.0,,HP,CN,CN,2021,Q2,Adult
192230291,19223029,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",1.5,MG,Y,, D347699,,125469.0,1.5,MG,,/wk,2021,Q2,Nausea,,2021,Q2,1,I,20210420.0,20210423.0,20210505,20210505,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202104011479,ELI LILLY AND CO,,51.0,YR,,M,Y,,,20210505.0,,HP,CN,CN,2021,Q2,Adult
192230291,19223029,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",1.5,MG,Y,, D347699,,125469.0,1.5,MG,,/wk,2021,Q2,Vomiting,,2021,Q2,1,I,20210420.0,20210423.0,20210505,20210505,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202104011479,ELI LILLY AND CO,,51.0,YR,,M,Y,,,20210505.0,,HP,CN,CN,2021,Q2,Adult
192264381,19226438,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q2,Euglycaemic diabetic ketoacidosis,,2021,Q2,1,I,,20210427.0,20210505,20210505,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-101356",BOEHRINGER INGELHEIM,"DYATLOVA N, OMOTOSHO Y, SHERCHAN R, SHRESTHA J, BUDDHARAJU V, A CASE OF SEVERE METABOLIC ACIDOSIS DUE TO JARDIANCE?INDUCED EUGLYCEMIC DIABETIC KETOACIDOSIS. CUREUS . 2021 APR 20? 13(4): 14580?",23.0,YR,A,F,Y,,,20210506.0,,HP,US,US,2021,Q2,Youth
192671381,19267138,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Off label use,,2021,Q2,1,I,,20210506.0,20210518,20210518,EXP,,US-LUPIN PHARMACEUTICALS INC.-2021-07218,LUPIN,,76.0,YR,,M,Y,,,20210518.0,,HP,US,US,2021,Q2,Elderly
192727901,19272790,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,125469.0,,,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q2,Abdominal pain upper,,2021,Q2,1,I,20210324.0,20210419.0,20210518,20210518,PER,,US-ELI_LILLY_AND_COMPANY-US202104008531,ELI LILLY AND CO,,60.0,YR,,F,Y,,,20210518.0,,CN,US,US,2021,Q2,Adult
192727901,19272790,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,125469.0,,,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q2,Injection site dryness,,2021,Q2,1,I,20210324.0,20210419.0,20210518,20210518,PER,,US-ELI_LILLY_AND_COMPANY-US202104008531,ELI LILLY AND CO,,60.0,YR,,F,Y,,,20210518.0,,CN,US,US,2021,Q2,Adult
192727901,19272790,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,125469.0,,,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q2,Injection site erythema,,2021,Q2,1,I,20210324.0,20210419.0,20210518,20210518,PER,,US-ELI_LILLY_AND_COMPANY-US202104008531,ELI LILLY AND CO,,60.0,YR,,F,Y,,,20210518.0,,CN,US,US,2021,Q2,Adult
192727901,19272790,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,125469.0,,,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q2,Injection site pain,,2021,Q2,1,I,20210324.0,20210419.0,20210518,20210518,PER,,US-ELI_LILLY_AND_COMPANY-US202104008531,ELI LILLY AND CO,,60.0,YR,,F,Y,,,20210518.0,,CN,US,US,2021,Q2,Adult
192727901,19272790,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,125469.0,,,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q2,Injection site scar,,2021,Q2,1,I,20210324.0,20210419.0,20210518,20210518,PER,,US-ELI_LILLY_AND_COMPANY-US202104008531,ELI LILLY AND CO,,60.0,YR,,F,Y,,,20210518.0,,CN,US,US,2021,Q2,Adult
192727901,19272790,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,125469.0,,,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q2,Muscle spasms,,2021,Q2,1,I,20210324.0,20210419.0,20210518,20210518,PER,,US-ELI_LILLY_AND_COMPANY-US202104008531,ELI LILLY AND CO,,60.0,YR,,F,Y,,,20210518.0,,CN,US,US,2021,Q2,Adult
192727901,19272790,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,125469.0,,,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q2,Nausea,,2021,Q2,1,I,20210324.0,20210419.0,20210518,20210518,PER,,US-ELI_LILLY_AND_COMPANY-US202104008531,ELI LILLY AND CO,,60.0,YR,,F,Y,,,20210518.0,,CN,US,US,2021,Q2,Adult
192727901,19272790,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,125469.0,,,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q2,Overweight,,2021,Q2,1,I,20210324.0,20210419.0,20210518,20210518,PER,,US-ELI_LILLY_AND_COMPANY-US202104008531,ELI LILLY AND CO,,60.0,YR,,F,Y,,,20210518.0,,CN,US,US,2021,Q2,Adult
192727901,19272790,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,125469.0,,,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q2,Stress,,2021,Q2,1,I,20210324.0,20210419.0,20210518,20210518,PER,,US-ELI_LILLY_AND_COMPANY-US202104008531,ELI LILLY AND CO,,60.0,YR,,F,Y,,,20210518.0,,CN,US,US,2021,Q2,Adult
192727901,19272790,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK UNK, UNKNOWN",,,U,,,,125469.0,,,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q2,Vomiting,,2021,Q2,1,I,20210324.0,20210419.0,20210518,20210518,PER,,US-ELI_LILLY_AND_COMPANY-US202104008531,ELI LILLY AND CO,,60.0,YR,,F,Y,,,20210518.0,,CN,US,US,2021,Q2,Adult
192996251,19299625,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q2,Brain injury,,2021,Q2,1,I,,20210512.0,20210524,20210524,EXP,,US-AMNEAL PHARMACEUTICALS-2021-AMRX-01839,AMNEAL,"KOHLI V, SABA Y, SONTI S, KAHLOON R. TYPE II KOUNIS SYNDROME IN A PATIENT WITH ANAPHYLAXIS TO DULAGLUTIDE. J AM COLL CARDIOL. 2021?77 (18):2557",47.0,YR,,M,Y,,,20210524.0,,HP,US,US,2021,Q2,Adult
192996251,19299625,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q2,Cardiac arrest,,2021,Q2,1,I,,20210512.0,20210524,20210524,EXP,,US-AMNEAL PHARMACEUTICALS-2021-AMRX-01839,AMNEAL,"KOHLI V, SABA Y, SONTI S, KAHLOON R. TYPE II KOUNIS SYNDROME IN A PATIENT WITH ANAPHYLAXIS TO DULAGLUTIDE. J AM COLL CARDIOL. 2021?77 (18):2557",47.0,YR,,M,Y,,,20210524.0,,HP,US,US,2021,Q2,Adult
192996251,19299625,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q2,Cardiogenic shock,,2021,Q2,1,I,,20210512.0,20210524,20210524,EXP,,US-AMNEAL PHARMACEUTICALS-2021-AMRX-01839,AMNEAL,"KOHLI V, SABA Y, SONTI S, KAHLOON R. TYPE II KOUNIS SYNDROME IN A PATIENT WITH ANAPHYLAXIS TO DULAGLUTIDE. J AM COLL CARDIOL. 2021?77 (18):2557",47.0,YR,,M,Y,,,20210524.0,,HP,US,US,2021,Q2,Adult
192996251,19299625,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q2,Kounis syndrome,,2021,Q2,1,I,,20210512.0,20210524,20210524,EXP,,US-AMNEAL PHARMACEUTICALS-2021-AMRX-01839,AMNEAL,"KOHLI V, SABA Y, SONTI S, KAHLOON R. TYPE II KOUNIS SYNDROME IN A PATIENT WITH ANAPHYLAXIS TO DULAGLUTIDE. J AM COLL CARDIOL. 2021?77 (18):2557",47.0,YR,,M,Y,,,20210524.0,,HP,US,US,2021,Q2,Adult
193107471,19310747,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,,,,125469.0,,,,,2021,Q2,Brain injury,,2021,Q2,1,I,,20210521.0,20210526,20210526,EXP,,US-ELI_LILLY_AND_COMPANY-US202105011344,ELI LILLY AND CO,"VARUN KOHLI, YAZAN SABA, SRAVANTHI SONTI, REHAN KAHLOON.TYPE II KOUNIS SYNDROME IN A PATIENT WITH ANAPHYLAXIS TO DULAGLUTIDE.JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 2021?77 (18):2557.",47.0,YR,,M,Y,,,20210526.0,,HP,US,US,2021,Q2,Adult
193107471,19310747,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,,,,125469.0,,,,,2021,Q2,Cardiac arrest,,2021,Q2,1,I,,20210521.0,20210526,20210526,EXP,,US-ELI_LILLY_AND_COMPANY-US202105011344,ELI LILLY AND CO,"VARUN KOHLI, YAZAN SABA, SRAVANTHI SONTI, REHAN KAHLOON.TYPE II KOUNIS SYNDROME IN A PATIENT WITH ANAPHYLAXIS TO DULAGLUTIDE.JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 2021?77 (18):2557.",47.0,YR,,M,Y,,,20210526.0,,HP,US,US,2021,Q2,Adult
193107471,19310747,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,,,,125469.0,,,,,2021,Q2,Cardiogenic shock,,2021,Q2,1,I,,20210521.0,20210526,20210526,EXP,,US-ELI_LILLY_AND_COMPANY-US202105011344,ELI LILLY AND CO,"VARUN KOHLI, YAZAN SABA, SRAVANTHI SONTI, REHAN KAHLOON.TYPE II KOUNIS SYNDROME IN A PATIENT WITH ANAPHYLAXIS TO DULAGLUTIDE.JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 2021?77 (18):2557.",47.0,YR,,M,Y,,,20210526.0,,HP,US,US,2021,Q2,Adult
193107471,19310747,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, UNKNOWN",,,U,,,,125469.0,,,,,2021,Q2,Kounis syndrome,,2021,Q2,1,I,,20210521.0,20210526,20210526,EXP,,US-ELI_LILLY_AND_COMPANY-US202105011344,ELI LILLY AND CO,"VARUN KOHLI, YAZAN SABA, SRAVANTHI SONTI, REHAN KAHLOON.TYPE II KOUNIS SYNDROME IN A PATIENT WITH ANAPHYLAXIS TO DULAGLUTIDE.JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 2021?77 (18):2557.",47.0,YR,,M,Y,,,20210526.0,,HP,US,US,2021,Q2,Adult
193278441,19327844,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q2,Treatment failure,,2021,Q2,1,I,,20210518.0,20210528,20210528,EXP,,US-MICRO LABS LIMITED-ML2021-01666,MICRO LABS,"LEWIS P, THARP J. BREAKTHROUGH VENOUS THROMBOEMBOLIC EVENTS IN FIVE PATIENTS WITH COVID?19 ON DIRECT ORAL ANTICOAGULANTS.. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. 2021?46 (2):519?523.",70.0,YR,,M,Y,,,20210528.0,,HP,US,US,2021,Q2,Elderly
193582131,19358213,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,"0.75 MILLIGRAM, QW",,,,,,,,0.75,MG,,/wk,2021,Q2,Contraindicated product administered,,2021,Q2,1,I,,20210513.0,20210602,20210602,PER,,US-009507513-2105USA004232,MERCK,"KUHADIYA ND, ISRAA M. EFFECTS OF CONCOMITANT COMBINATION OF SGLT?2 INHIBITOR AND GLP?1 RECEPTOR AGONIST ON RENAL OUTCOMES IN T2D WITH EGFR BELOW 30 AND MACROALBUMINURIA: A CASE SERIES. CLINICAL CASE REPORTS. 2021?9(9):2310?6",62.0,YR,,M,Y,87.1,KG,20210602.0,,HP,US,US,2021,Q2,Adult
193582131,19358213,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,,1.5 MILLIGRAM,,,,,,,,1.5,MG,,/wk,2021,Q2,Contraindicated product administered,,2021,Q2,1,I,,20210513.0,20210602,20210602,PER,,US-009507513-2105USA004232,MERCK,"KUHADIYA ND, ISRAA M. EFFECTS OF CONCOMITANT COMBINATION OF SGLT?2 INHIBITOR AND GLP?1 RECEPTOR AGONIST ON RENAL OUTCOMES IN T2D WITH EGFR BELOW 30 AND MACROALBUMINURIA: A CASE SERIES. CLINICAL CASE REPORTS. 2021?9(9):2310?6",62.0,YR,,M,Y,87.1,KG,20210602.0,,HP,US,US,2021,Q2,Adult
194063261,19406326,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,U,,,,,,,,,2021,Q2,Abdominal sepsis,,2021,Q2,1,I,20210606.0,20210609.0,20210612,20210612,EXP,GB-MHRA-EYC 00252752,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-108800",BOEHRINGER INGELHEIM,,47.0,YR,A,F,Y,100.2,KG,20210612.0,,PH,GB,GB,2021,Q2,Adult
194063261,19406326,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,U,,,,,,,,,2021,Q2,Euglycaemic diabetic ketoacidosis,,2021,Q2,1,I,20210606.0,20210609.0,20210612,20210612,EXP,GB-MHRA-EYC 00252752,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-108800",BOEHRINGER INGELHEIM,,47.0,YR,A,F,Y,100.2,KG,20210612.0,,PH,GB,GB,2021,Q2,Adult
194063261,19406326,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,U,,,,,,,,,2021,Q2,Malaise,,2021,Q2,1,I,20210606.0,20210609.0,20210612,20210612,EXP,GB-MHRA-EYC 00252752,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-108800",BOEHRINGER INGELHEIM,,47.0,YR,A,F,Y,100.2,KG,20210612.0,,PH,GB,GB,2021,Q2,Adult
194063261,19406326,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,U,,,,,,,,,2021,Q2,Oedema,,2021,Q2,1,I,20210606.0,20210609.0,20210612,20210612,EXP,GB-MHRA-EYC 00252752,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-108800",BOEHRINGER INGELHEIM,,47.0,YR,A,F,Y,100.2,KG,20210612.0,,PH,GB,GB,2021,Q2,Adult
194063261,19406326,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,U,,,,,,,,,2021,Q2,Post procedural infection,,2021,Q2,1,I,20210606.0,20210609.0,20210612,20210612,EXP,GB-MHRA-EYC 00252752,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-108800",BOEHRINGER INGELHEIM,,47.0,YR,A,F,Y,100.2,KG,20210612.0,,PH,GB,GB,2021,Q2,Adult
194063261,19406326,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,U,,,,,,,,,2021,Q2,Procedural pain,,2021,Q2,1,I,20210606.0,20210609.0,20210612,20210612,EXP,GB-MHRA-EYC 00252752,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-108800",BOEHRINGER INGELHEIM,,47.0,YR,A,F,Y,100.2,KG,20210612.0,,PH,GB,GB,2021,Q2,Adult
194063261,19406326,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,U,,,,,,,,,2021,Q2,Sinus tachycardia,,2021,Q2,1,I,20210606.0,20210609.0,20210612,20210612,EXP,GB-MHRA-EYC 00252752,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-108800",BOEHRINGER INGELHEIM,,47.0,YR,A,F,Y,100.2,KG,20210612.0,,PH,GB,GB,2021,Q2,Adult
194123691,19412369,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1X A WEEK, SOLUTION FOR INJECTION / INFUSION",,,U,,,,,,,,/wk,2021,Q2,Acute respiratory failure,,2021,Q2,1,I,,20210601.0,20210614,20210614,EXP,,DE-SA-2021SA184197,SANOFI AVENTIS,,79.0,YR,E,M,Y,,,20210614.0,,PH,DE,DE,2021,Q2,Elderly
194123691,19412369,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1X A WEEK, SOLUTION FOR INJECTION / INFUSION",,,U,,,,,,,,/wk,2021,Q2,Somnolence,,2021,Q2,1,I,,20210601.0,20210614,20210614,EXP,,DE-SA-2021SA184197,SANOFI AVENTIS,,79.0,YR,E,M,Y,,,20210614.0,,PH,DE,DE,2021,Q2,Elderly
194557261,19455726,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,"1.5 MG, ONCE A WEEK",,,,,,,,1.5,MG,,,2021,Q2,Anaphylactic reaction,,2021,Q2,1,I,20201229.0,20210118.0,20210624,20210624,EXP,,US-BRACCO-2021US00170,BRACCO,,65.0,YR,,M,Y,,,20210624.0,,PH,US,US,2021,Q2,Elderly
194557331,19455733,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q2,Drug ineffective,,2021,Q2,1,I,20210415.0,20210415.0,20210624,20210624,PER,,US-BRACCO-2021US01509,BRACCO,,74.0,YR,,M,Y,,,20210624.0,,HP,US,US,2021,Q2,Elderly
194557331,19455733,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q2,Extravasation,,2021,Q2,1,I,20210415.0,20210415.0,20210624,20210624,PER,,US-BRACCO-2021US01509,BRACCO,,74.0,YR,,M,Y,,,20210624.0,,HP,US,US,2021,Q2,Elderly
194557331,19455733,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q2,Skin discolouration,,2021,Q2,1,I,20210415.0,20210415.0,20210624,20210624,PER,,US-BRACCO-2021US01509,BRACCO,,74.0,YR,,M,Y,,,20210624.0,,HP,US,US,2021,Q2,Elderly
194684721,19468472,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,USE AS DIRECTED BY DIABETIC SPECIALIST NURSE,,,,,,,,,,,,2021,Q2,Cold sweat,,2021,Q2,1,I,20210603.0,20210618.0,20210628,20210628,EXP,,GB-AMERICAN REGENT INC-2021001613,AMERICAN REGENT,,74.0,YR,,F,Y,107.0,KG,20210628.0,,HP,CH,GB,2021,Q2,Elderly
194684721,19468472,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,USE AS DIRECTED BY DIABETIC SPECIALIST NURSE,,,,,,,,,,,,2021,Q2,Malaise,,2021,Q2,1,I,20210603.0,20210618.0,20210628,20210628,EXP,,GB-AMERICAN REGENT INC-2021001613,AMERICAN REGENT,,74.0,YR,,F,Y,107.0,KG,20210628.0,,HP,CH,GB,2021,Q2,Elderly
156353637,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q3,Arthralgia,,2021,Q3,7,F,,20210909.0,20181120,20210914,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210914.0,,HP,CA,CA,2021,Q3,Adult
156353637,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q3,Blood pressure diastolic increased,,2021,Q3,7,F,,20210909.0,20181120,20210914,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210914.0,,HP,CA,CA,2021,Q3,Adult
156353637,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q3,Blood pressure fluctuation,,2021,Q3,7,F,,20210909.0,20181120,20210914,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210914.0,,HP,CA,CA,2021,Q3,Adult
156353637,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q3,Blood pressure increased,,2021,Q3,7,F,,20210909.0,20181120,20210914,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210914.0,,HP,CA,CA,2021,Q3,Adult
156353637,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q3,Blood pressure systolic abnormal,,2021,Q3,7,F,,20210909.0,20181120,20210914,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210914.0,,HP,CA,CA,2021,Q3,Adult
156353637,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q3,Blood pressure systolic increased,,2021,Q3,7,F,,20210909.0,20181120,20210914,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210914.0,,HP,CA,CA,2021,Q3,Adult
156353637,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q3,Dental caries,,2021,Q3,7,F,,20210909.0,20181120,20210914,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210914.0,,HP,CA,CA,2021,Q3,Adult
156353637,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q3,Diabetes mellitus inadequate control,,2021,Q3,7,F,,20210909.0,20181120,20210914,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210914.0,,HP,CA,CA,2021,Q3,Adult
156353637,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q3,Hypertension,,2021,Q3,7,F,,20210909.0,20181120,20210914,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210914.0,,HP,CA,CA,2021,Q3,Adult
156353637,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q3,Musculoskeletal stiffness,,2021,Q3,7,F,,20210909.0,20181120,20210914,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210914.0,,HP,CA,CA,2021,Q3,Adult
156353637,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q3,Oxygen saturation decreased,,2021,Q3,7,F,,20210909.0,20181120,20210914,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210914.0,,HP,CA,CA,2021,Q3,Adult
156353637,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q3,Rheumatoid arthritis,,2021,Q3,7,F,,20210909.0,20181120,20210914,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210914.0,,HP,CA,CA,2021,Q3,Adult
156353637,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q3,Tooth disorder,,2021,Q3,7,F,,20210909.0,20181120,20210914,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210914.0,,HP,CA,CA,2021,Q3,Adult
156353637,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q3,Tooth fracture,,2021,Q3,7,F,,20210909.0,20181120,20210914,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210914.0,,HP,CA,CA,2021,Q3,Adult
156353637,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q3,Treatment failure,,2021,Q3,7,F,,20210909.0,20181120,20210914,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210914.0,,HP,CA,CA,2021,Q3,Adult
156353637,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q3,Walking aid user,,2021,Q3,7,F,,20210909.0,20181120,20210914,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210914.0,,HP,CA,CA,2021,Q3,Adult
156353637,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q3,Weight decreased,,2021,Q3,7,F,,20210909.0,20181120,20210914,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210914.0,,HP,CA,CA,2021,Q3,Adult
156353637,15635363,23,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q3,Weight increased,,2021,Q3,7,F,,20210909.0,20181120,20210914,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,,M,Y,105.0,KG,20210914.0,,HP,CA,CA,2021,Q3,Adult
162437975,16243797,14,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"7.5 MG, Q.WK.",,,D,,,,,7.5,MG,,/wk,2021,Q3,Colitis,,2021,Q3,5,F,,20210628.0,20190426,20210709,EXP,,CA-APOTEX-2019AP012426,APOTEX,,73.0,YR,,F,Y,,,20210709.0,,CN,CA,CA,2021,Q3,Elderly
162437975,16243797,14,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"7.5 MG, Q.WK.",,,D,,,,,7.5,MG,,/wk,2021,Q3,Colitis ulcerative,,2021,Q3,5,F,,20210628.0,20190426,20210709,EXP,,CA-APOTEX-2019AP012426,APOTEX,,73.0,YR,,F,Y,,,20210709.0,,CN,CA,CA,2021,Q3,Elderly
162437975,16243797,14,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"7.5 MG, Q.WK.",,,D,,,,,7.5,MG,,/wk,2021,Q3,Decreased activity,,2021,Q3,5,F,,20210628.0,20190426,20210709,EXP,,CA-APOTEX-2019AP012426,APOTEX,,73.0,YR,,F,Y,,,20210709.0,,CN,CA,CA,2021,Q3,Elderly
162437975,16243797,14,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"7.5 MG, Q.WK.",,,D,,,,,7.5,MG,,/wk,2021,Q3,Frequent bowel movements,,2021,Q3,5,F,,20210628.0,20190426,20210709,EXP,,CA-APOTEX-2019AP012426,APOTEX,,73.0,YR,,F,Y,,,20210709.0,,CN,CA,CA,2021,Q3,Elderly
162437975,16243797,14,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"7.5 MG, Q.WK.",,,D,,,,,7.5,MG,,/wk,2021,Q3,Rectal haemorrhage,,2021,Q3,5,F,,20210628.0,20190426,20210709,EXP,,CA-APOTEX-2019AP012426,APOTEX,,73.0,YR,,F,Y,,,20210709.0,,CN,CA,CA,2021,Q3,Elderly
1741760610,17417606,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q3,Transaminases increased,,2021,Q3,10,F,20200130.0,20210713.0,20200213,20210719,EXP,,US-EXELIXIS-XL18420027272,EXELIXIS,,67.0,YR,,M,Y,96.2,KG,20210719.0,,MD,US,US,2021,Q3,Elderly
174272296,17427229,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q3,Transaminases increased,,2021,Q3,6,F,20200130.0,20210719.0,20200218,20210726,EXP,,US-ROCHE-2551809,ROCHE,,67.0,YR,,M,Y,96.2,KG,20210726.0,,MD,US,US,2021,Q3,Elderly
175684873,17568487,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Abdominal distension,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Cellulitis,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Chills,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Condition aggravated,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Device infusion issue,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Device leakage,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Headache,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Influenza like illness,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Injection site erythema,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Injection site swelling,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Palpitations,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
175684873,17568487,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Pyrexia,,2021,Q3,3,F,20200222.0,20210810.0,20200320,20210821,EXP,,CA-SHIRE-CA202010478,TAKEDA,,59.0,YR,,F,Y,83.0,KG,20210821.0,,HP,CA,CA,2021,Q3,Adult
183317705,18331770,26,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/wk,2021,Q3,Colitis,,2021,Q3,5,F,,20210816.0,20200930,20210910,EXP,,CA-JNJFOC-20200941497,JOHNSON AND JOHNSON,,73.0,YR,E,F,Y,,,20210911.0,,CN,CA,CA,2021,Q3,Elderly
183317705,18331770,26,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/wk,2021,Q3,Colitis ulcerative,,2021,Q3,5,F,,20210816.0,20200930,20210910,EXP,,CA-JNJFOC-20200941497,JOHNSON AND JOHNSON,,73.0,YR,E,F,Y,,,20210911.0,,CN,CA,CA,2021,Q3,Elderly
183317705,18331770,26,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/wk,2021,Q3,Decreased activity,,2021,Q3,5,F,,20210816.0,20200930,20210910,EXP,,CA-JNJFOC-20200941497,JOHNSON AND JOHNSON,,73.0,YR,E,F,Y,,,20210911.0,,CN,CA,CA,2021,Q3,Elderly
183317705,18331770,26,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/wk,2021,Q3,Frequent bowel movements,,2021,Q3,5,F,,20210816.0,20200930,20210910,EXP,,CA-JNJFOC-20200941497,JOHNSON AND JOHNSON,,73.0,YR,E,F,Y,,,20210911.0,,CN,CA,CA,2021,Q3,Elderly
183317705,18331770,26,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/wk,2021,Q3,Rectal haemorrhage,,2021,Q3,5,F,,20210816.0,20200930,20210910,EXP,,CA-JNJFOC-20200941497,JOHNSON AND JOHNSON,,73.0,YR,E,F,Y,,,20210911.0,,CN,CA,CA,2021,Q3,Elderly
1835619511,18356195,28,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2021,Q3,Colitis,,2021,Q3,11,F,,20210916.0,20201007,20210921,EXP,,CA-PFIZER INC-2020385258,PFIZER,,73.0,YR,,F,Y,,,20210921.0,,CN,CA,CA,2021,Q3,Elderly
1835619511,18356195,28,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2021,Q3,Colitis ulcerative,,2021,Q3,11,F,,20210916.0,20201007,20210921,EXP,,CA-PFIZER INC-2020385258,PFIZER,,73.0,YR,,F,Y,,,20210921.0,,CN,CA,CA,2021,Q3,Elderly
1835619511,18356195,28,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2021,Q3,Decreased activity,,2021,Q3,11,F,,20210916.0,20201007,20210921,EXP,,CA-PFIZER INC-2020385258,PFIZER,,73.0,YR,,F,Y,,,20210921.0,,CN,CA,CA,2021,Q3,Elderly
1835619511,18356195,28,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2021,Q3,Frequent bowel movements,,2021,Q3,11,F,,20210916.0,20201007,20210921,EXP,,CA-PFIZER INC-2020385258,PFIZER,,73.0,YR,,F,Y,,,20210921.0,,CN,CA,CA,2021,Q3,Elderly
1835619511,18356195,28,C,DULAGLUTIDE.,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2021,Q3,Rectal haemorrhage,,2021,Q3,11,F,,20210916.0,20201007,20210921,EXP,,CA-PFIZER INC-2020385258,PFIZER,,73.0,YR,,F,Y,,,20210921.0,,CN,CA,CA,2021,Q3,Elderly
185612613,18561261,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Atrial fibrillation,,2021,Q3,3,F,20200510.0,20210628.0,20201130,20210706,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,69.0,YR,,F,Y,,,20210706.0,,HP,DE,DE,2021,Q3,Elderly
185612613,18561261,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Eye disorder,,2021,Q3,3,F,20200510.0,20210628.0,20201130,20210706,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,69.0,YR,,F,Y,,,20210706.0,,HP,DE,DE,2021,Q3,Elderly
185612613,18561261,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Eye haemorrhage,,2021,Q3,3,F,20200510.0,20210628.0,20201130,20210706,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,69.0,YR,,F,Y,,,20210706.0,,HP,DE,DE,2021,Q3,Elderly
185612613,18561261,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Gastrointestinal haemorrhage,,2021,Q3,3,F,20200510.0,20210628.0,20201130,20210706,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,69.0,YR,,F,Y,,,20210706.0,,HP,DE,DE,2021,Q3,Elderly
185612613,18561261,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,General physical health deterioration,,2021,Q3,3,F,20200510.0,20210628.0,20201130,20210706,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,69.0,YR,,F,Y,,,20210706.0,,HP,DE,DE,2021,Q3,Elderly
185612613,18561261,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Haemoglobin decreased,,2021,Q3,3,F,20200510.0,20210628.0,20201130,20210706,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,69.0,YR,,F,Y,,,20210706.0,,HP,DE,DE,2021,Q3,Elderly
185612613,18561261,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Melaena,,2021,Q3,3,F,20200510.0,20210628.0,20201130,20210706,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,69.0,YR,,F,Y,,,20210706.0,,HP,DE,DE,2021,Q3,Elderly
185612613,18561261,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Ocular hyperaemia,,2021,Q3,3,F,20200510.0,20210628.0,20201130,20210706,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,69.0,YR,,F,Y,,,20210706.0,,HP,DE,DE,2021,Q3,Elderly
187597012,18759701,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q3,Accidental overdose,,2021,Q3,2,F,,20210824.0,20210120,20210905,EXP,,AU-JNJFOC-20210116313,JOHNSON AND JOHNSON,"VELLAR K, PARKER R, KHALID U, WOOD D. CLINICAL MANAGEMENT OF MEDICATION OVERDOSE: THREE?MONTHLY PALIPERIDONE PALIMITATE INJECTABLE MEDICATION. AUST N Z J PSYCHIATRY. 2021?.",46.0,YR,A,F,Y,78.5,KG,20210906.0,,MD,AU,AU,2021,Q3,Adult
187597012,18759701,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q3,Hypotension,,2021,Q3,2,F,,20210824.0,20210120,20210905,EXP,,AU-JNJFOC-20210116313,JOHNSON AND JOHNSON,"VELLAR K, PARKER R, KHALID U, WOOD D. CLINICAL MANAGEMENT OF MEDICATION OVERDOSE: THREE?MONTHLY PALIPERIDONE PALIMITATE INJECTABLE MEDICATION. AUST N Z J PSYCHIATRY. 2021?.",46.0,YR,A,F,Y,78.5,KG,20210906.0,,MD,AU,AU,2021,Q3,Adult
190284823,19028482,21,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/wk,2021,Q3,Colitis,,2021,Q3,3,F,,20210901.0,20210318,20210909,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210909.0,,CN,CA,CA,2021,Q3,Elderly
190284823,19028482,21,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/wk,2021,Q3,Colitis ulcerative,,2021,Q3,3,F,,20210901.0,20210318,20210909,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210909.0,,CN,CA,CA,2021,Q3,Elderly
190284823,19028482,21,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/wk,2021,Q3,Decreased activity,,2021,Q3,3,F,,20210901.0,20210318,20210909,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210909.0,,CN,CA,CA,2021,Q3,Elderly
190284823,19028482,21,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/wk,2021,Q3,Frequent bowel movements,,2021,Q3,3,F,,20210901.0,20210318,20210909,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210909.0,,CN,CA,CA,2021,Q3,Elderly
190284823,19028482,21,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/wk,2021,Q3,Rectal haemorrhage,,2021,Q3,3,F,,20210901.0,20210318,20210909,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210909.0,,CN,CA,CA,2021,Q3,Elderly
190284823,19028482,22,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNKNOWN,,,,,,,,,,,,2021,Q3,Colitis,,2021,Q3,3,F,,20210901.0,20210318,20210909,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210909.0,,CN,CA,CA,2021,Q3,Elderly
190284823,19028482,22,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNKNOWN,,,,,,,,,,,,2021,Q3,Colitis ulcerative,,2021,Q3,3,F,,20210901.0,20210318,20210909,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210909.0,,CN,CA,CA,2021,Q3,Elderly
190284823,19028482,22,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNKNOWN,,,,,,,,,,,,2021,Q3,Decreased activity,,2021,Q3,3,F,,20210901.0,20210318,20210909,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210909.0,,CN,CA,CA,2021,Q3,Elderly
190284823,19028482,22,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNKNOWN,,,,,,,,,,,,2021,Q3,Frequent bowel movements,,2021,Q3,3,F,,20210901.0,20210318,20210909,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210909.0,,CN,CA,CA,2021,Q3,Elderly
190284823,19028482,22,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNKNOWN,,,,,,,,,,,,2021,Q3,Rectal haemorrhage,,2021,Q3,3,F,,20210901.0,20210318,20210909,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20210909.0,,CN,CA,CA,2021,Q3,Elderly
190610472,19061047,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"0.75 MG, WEEKLY (1/W)",,,Y,U,,,125469.0,0.75,MG,,/wk,2021,Q3,Acute kidney injury,,2021,Q3,2,F,,20210627.0,20210325,20210702,EXP,,US-ELI_LILLY_AND_COMPANY-US202103011090,ELI LILLY AND CO,LEE J.? NGUYEN J.? UMANA I..EXACERBATION OF ATRIAL FIBRILLATION RELATED TO DULAGLUTIDE USE: A CASE REPORT.JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY (JACCP) 2019?2:597?598.DOI:HTTP://DX.DOI.ORG/10.1002/JAC5.1154,75.0,YR,,F,Y,,,20210702.0,,PH,US,US,2021,Q3,Elderly
190610472,19061047,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"0.75 MG, WEEKLY (1/W)",,,Y,U,,,125469.0,0.75,MG,,/wk,2021,Q3,Asthenia,,2021,Q3,2,F,,20210627.0,20210325,20210702,EXP,,US-ELI_LILLY_AND_COMPANY-US202103011090,ELI LILLY AND CO,LEE J.? NGUYEN J.? UMANA I..EXACERBATION OF ATRIAL FIBRILLATION RELATED TO DULAGLUTIDE USE: A CASE REPORT.JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY (JACCP) 2019?2:597?598.DOI:HTTP://DX.DOI.ORG/10.1002/JAC5.1154,75.0,YR,,F,Y,,,20210702.0,,PH,US,US,2021,Q3,Elderly
190610472,19061047,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"0.75 MG, WEEKLY (1/W)",,,Y,U,,,125469.0,0.75,MG,,/wk,2021,Q3,Atrial fibrillation,,2021,Q3,2,F,,20210627.0,20210325,20210702,EXP,,US-ELI_LILLY_AND_COMPANY-US202103011090,ELI LILLY AND CO,LEE J.? NGUYEN J.? UMANA I..EXACERBATION OF ATRIAL FIBRILLATION RELATED TO DULAGLUTIDE USE: A CASE REPORT.JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY (JACCP) 2019?2:597?598.DOI:HTTP://DX.DOI.ORG/10.1002/JAC5.1154,75.0,YR,,F,Y,,,20210702.0,,PH,US,US,2021,Q3,Elderly
190610472,19061047,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"0.75 MG, WEEKLY (1/W)",,,Y,U,,,125469.0,0.75,MG,,/wk,2021,Q3,Bradycardia,,2021,Q3,2,F,,20210627.0,20210325,20210702,EXP,,US-ELI_LILLY_AND_COMPANY-US202103011090,ELI LILLY AND CO,LEE J.? NGUYEN J.? UMANA I..EXACERBATION OF ATRIAL FIBRILLATION RELATED TO DULAGLUTIDE USE: A CASE REPORT.JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY (JACCP) 2019?2:597?598.DOI:HTTP://DX.DOI.ORG/10.1002/JAC5.1154,75.0,YR,,F,Y,,,20210702.0,,PH,US,US,2021,Q3,Elderly
190610472,19061047,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"0.75 MG, WEEKLY (1/W)",,,Y,U,,,125469.0,0.75,MG,,/wk,2021,Q3,Decreased appetite,,2021,Q3,2,F,,20210627.0,20210325,20210702,EXP,,US-ELI_LILLY_AND_COMPANY-US202103011090,ELI LILLY AND CO,LEE J.? NGUYEN J.? UMANA I..EXACERBATION OF ATRIAL FIBRILLATION RELATED TO DULAGLUTIDE USE: A CASE REPORT.JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY (JACCP) 2019?2:597?598.DOI:HTTP://DX.DOI.ORG/10.1002/JAC5.1154,75.0,YR,,F,Y,,,20210702.0,,PH,US,US,2021,Q3,Elderly
190610472,19061047,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"0.75 MG, WEEKLY (1/W)",,,Y,U,,,125469.0,0.75,MG,,/wk,2021,Q3,Dehydration,,2021,Q3,2,F,,20210627.0,20210325,20210702,EXP,,US-ELI_LILLY_AND_COMPANY-US202103011090,ELI LILLY AND CO,LEE J.? NGUYEN J.? UMANA I..EXACERBATION OF ATRIAL FIBRILLATION RELATED TO DULAGLUTIDE USE: A CASE REPORT.JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY (JACCP) 2019?2:597?598.DOI:HTTP://DX.DOI.ORG/10.1002/JAC5.1154,75.0,YR,,F,Y,,,20210702.0,,PH,US,US,2021,Q3,Elderly
190610472,19061047,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"0.75 MG, WEEKLY (1/W)",,,Y,U,,,125469.0,0.75,MG,,/wk,2021,Q3,Fatigue,,2021,Q3,2,F,,20210627.0,20210325,20210702,EXP,,US-ELI_LILLY_AND_COMPANY-US202103011090,ELI LILLY AND CO,LEE J.? NGUYEN J.? UMANA I..EXACERBATION OF ATRIAL FIBRILLATION RELATED TO DULAGLUTIDE USE: A CASE REPORT.JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY (JACCP) 2019?2:597?598.DOI:HTTP://DX.DOI.ORG/10.1002/JAC5.1154,75.0,YR,,F,Y,,,20210702.0,,PH,US,US,2021,Q3,Elderly
190610472,19061047,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"0.75 MG, WEEKLY (1/W)",,,Y,U,,,125469.0,0.75,MG,,/wk,2021,Q3,Increased appetite,,2021,Q3,2,F,,20210627.0,20210325,20210702,EXP,,US-ELI_LILLY_AND_COMPANY-US202103011090,ELI LILLY AND CO,LEE J.? NGUYEN J.? UMANA I..EXACERBATION OF ATRIAL FIBRILLATION RELATED TO DULAGLUTIDE USE: A CASE REPORT.JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY (JACCP) 2019?2:597?598.DOI:HTTP://DX.DOI.ORG/10.1002/JAC5.1154,75.0,YR,,F,Y,,,20210702.0,,PH,US,US,2021,Q3,Elderly
190610472,19061047,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"0.75 MG, WEEKLY (1/W)",,,Y,U,,,125469.0,0.75,MG,,/wk,2021,Q3,Nausea,,2021,Q3,2,F,,20210627.0,20210325,20210702,EXP,,US-ELI_LILLY_AND_COMPANY-US202103011090,ELI LILLY AND CO,LEE J.? NGUYEN J.? UMANA I..EXACERBATION OF ATRIAL FIBRILLATION RELATED TO DULAGLUTIDE USE: A CASE REPORT.JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY (JACCP) 2019?2:597?598.DOI:HTTP://DX.DOI.ORG/10.1002/JAC5.1154,75.0,YR,,F,Y,,,20210702.0,,PH,US,US,2021,Q3,Elderly
190610472,19061047,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"0.75 MG, WEEKLY (1/W)",,,Y,U,,,125469.0,0.75,MG,,/wk,2021,Q3,Vomiting,,2021,Q3,2,F,,20210627.0,20210325,20210702,EXP,,US-ELI_LILLY_AND_COMPANY-US202103011090,ELI LILLY AND CO,LEE J.? NGUYEN J.? UMANA I..EXACERBATION OF ATRIAL FIBRILLATION RELATED TO DULAGLUTIDE USE: A CASE REPORT.JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY (JACCP) 2019?2:597?598.DOI:HTTP://DX.DOI.ORG/10.1002/JAC5.1154,75.0,YR,,F,Y,,,20210702.0,,PH,US,US,2021,Q3,Elderly
194056363,19405636,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WE",,,,,,,,1.5,MG,,/wk,2021,Q3,Diabetic foot,,2021,Q3,3,F,20210515.0,20210811.0,20210611,20210813,EXP,,US-GLAXOSMITHKLINE-US2021115893,GLAXOSMITHKLINE,,55.0,YR,,M,Y,,,20210813.0,,MD,US,US,2021,Q3,Adult
194083284,19408328,5,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q3,Breast cancer metastatic,,2021,Q3,4,F,20210120.0,20210712.0,20210611,20210715,EXP,,US-ROCHE-2846463,ROCHE,,64.0,YR,,F,Y,,,20210715.0,,MD,US,US,2021,Q3,Adult
194400332,19440033,12,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q3,Diarrhoea,,2021,Q3,2,F,20210419.0,20210707.0,20210620,20210709,EXP,,US-SEAGEN-2021SGN03234,SEATTLE GENETICS,,64.0,YR,,F,Y,,,20210709.0,,MD,US,US,2021,Q3,Adult
194701792,19470179,12,C,DULAGLUTIDE.,DULAGLUTIDE,1,,"0.75 MILLIGRAM, QWK",,,,,,,,0.75,MG,INJECTION,/wk,2021,Q3,Spinal cord compression,,2021,Q3,2,F,20210618.0,20210629.0,20210628,20210705,PER,,US-AMGEN-USACT2021096089,AMGEN,,64.0,YR,A,M,Y,121.2,KG,20210705.0,,CN,US,US,2021,Q3,Adult
194799981,19479998,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"UNK (ONCE A WEEK,SOLUTION FOR INJECTION/INFUSION)",,,,,,,,,,INJECTION FOR INFUSION,,2021,Q3,Fall,,2021,Q3,1,I,,20210622.0,20210701,20210701,EXP,,DE-AUROBINDO-AUR-APL-2021-027220,AUROBINDO,,82.0,YR,,F,Y,,,20210701.0,,PH,DE,DE,2021,Q3,Elderly
194799981,19479998,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"UNK (ONCE A WEEK,SOLUTION FOR INJECTION/INFUSION)",,,,,,,,,,INJECTION FOR INFUSION,,2021,Q3,Pain,,2021,Q3,1,I,,20210622.0,20210701,20210701,EXP,,DE-AUROBINDO-AUR-APL-2021-027220,AUROBINDO,,82.0,YR,,F,Y,,,20210701.0,,PH,DE,DE,2021,Q3,Elderly
194810742,19481074,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Diabetic ketoacidosis,,2021,Q3,2,F,,20210712.0,20210630,20210714,EXP,,"GR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-111536",BOEHRINGER INGELHEIM,"ADAMIDOU S, FEIDAKIS A, LAZARI E, DALAOUTIS A, SAMARAS A, POLITI A. ET AL. EUGLYCEMIC DIABETIC KETOACIDOSIS IN A PATIENT WITH T2DM UNDER TREATMENT WITH EMPAGLIFLOZIN.. 19TH PANHELLENIC DIABETOLOGICAL CONFERENCE, 2?5 JUNE 2021. 2021 JUN?",26.0,YR,A,M,Y,,,20210714.0,,CN,GR,GR,2021,Q3,Young Adult
194810742,19481074,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Fatigue,,2021,Q3,2,F,,20210712.0,20210630,20210714,EXP,,"GR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-111536",BOEHRINGER INGELHEIM,"ADAMIDOU S, FEIDAKIS A, LAZARI E, DALAOUTIS A, SAMARAS A, POLITI A. ET AL. EUGLYCEMIC DIABETIC KETOACIDOSIS IN A PATIENT WITH T2DM UNDER TREATMENT WITH EMPAGLIFLOZIN.. 19TH PANHELLENIC DIABETOLOGICAL CONFERENCE, 2?5 JUNE 2021. 2021 JUN?",26.0,YR,A,M,Y,,,20210714.0,,CN,GR,GR,2021,Q3,Young Adult
194810742,19481074,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Soft tissue infection,,2021,Q3,2,F,,20210712.0,20210630,20210714,EXP,,"GR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-111536",BOEHRINGER INGELHEIM,"ADAMIDOU S, FEIDAKIS A, LAZARI E, DALAOUTIS A, SAMARAS A, POLITI A. ET AL. EUGLYCEMIC DIABETIC KETOACIDOSIS IN A PATIENT WITH T2DM UNDER TREATMENT WITH EMPAGLIFLOZIN.. 19TH PANHELLENIC DIABETOLOGICAL CONFERENCE, 2?5 JUNE 2021. 2021 JUN?",26.0,YR,A,M,Y,,,20210714.0,,CN,GR,GR,2021,Q3,Young Adult
194810742,19481074,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Somnolence,,2021,Q3,2,F,,20210712.0,20210630,20210714,EXP,,"GR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-111536",BOEHRINGER INGELHEIM,"ADAMIDOU S, FEIDAKIS A, LAZARI E, DALAOUTIS A, SAMARAS A, POLITI A. ET AL. EUGLYCEMIC DIABETIC KETOACIDOSIS IN A PATIENT WITH T2DM UNDER TREATMENT WITH EMPAGLIFLOZIN.. 19TH PANHELLENIC DIABETOLOGICAL CONFERENCE, 2?5 JUNE 2021. 2021 JUN?",26.0,YR,A,M,Y,,,20210714.0,,CN,GR,GR,2021,Q3,Young Adult
194810742,19481074,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Tachypnoea,,2021,Q3,2,F,,20210712.0,20210630,20210714,EXP,,"GR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-111536",BOEHRINGER INGELHEIM,"ADAMIDOU S, FEIDAKIS A, LAZARI E, DALAOUTIS A, SAMARAS A, POLITI A. ET AL. EUGLYCEMIC DIABETIC KETOACIDOSIS IN A PATIENT WITH T2DM UNDER TREATMENT WITH EMPAGLIFLOZIN.. 19TH PANHELLENIC DIABETOLOGICAL CONFERENCE, 2?5 JUNE 2021. 2021 JUN?",26.0,YR,A,M,Y,,,20210714.0,,CN,GR,GR,2021,Q3,Young Adult
194818971,19481897,5,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG (1 MAL PRO WOCHE SONNTAGS, INJEKTIONS?/INFUSIONSL?SUNG))",,,U,,,,,1.5,MG,,,2021,Q3,Hyperglycaemia,,2021,Q3,1,I,20200811.0,20210624.0,20210701,20210701,EXP,DE-ADRED-06004-01,NVSC2021DE142828,NOVARTIS,,73.0,YR,,M,Y,,,20210701.0,,HP,DE,DE,2021,Q3,Elderly
194820711,19482071,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,0.75,MG,,/wk,2021,Q3,Hypertriglyceridaemia,,2021,Q3,1,I,,20210616.0,20210701,20210701,EXP,,JP-ASTRAZENECA-2021A536278,ASTRAZENECA,,47.0,YR,,F,Y,,,20210701.0,,HP,JP,JP,2021,Q3,Adult
194820711,19482071,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,0.75,MG,,/wk,2021,Q3,Renal impairment,,2021,Q3,1,I,,20210616.0,20210701,20210701,EXP,,JP-ASTRAZENECA-2021A536278,ASTRAZENECA,,47.0,YR,,F,Y,,,20210701.0,,HP,JP,JP,2021,Q3,Adult
194841711,19484171,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MILLIGRAM,,,U,,,,,1.5,MG,,,2021,Q3,Anaemia,,2021,Q3,1,I,,20210625.0,20210701,20210701,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-062680,BRISTOL MYERS SQUIBB,,79.0,YR,,F,Y,,,20210701.0,,PH,DE,DE,2021,Q3,Elderly
194841711,19484171,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MILLIGRAM,,,U,,,,,1.5,MG,,,2021,Q3,Dizziness,,2021,Q3,1,I,,20210625.0,20210701,20210701,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-062680,BRISTOL MYERS SQUIBB,,79.0,YR,,F,Y,,,20210701.0,,PH,DE,DE,2021,Q3,Elderly
194841711,19484171,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MILLIGRAM,,,U,,,,,1.5,MG,,,2021,Q3,Dyspnoea,,2021,Q3,1,I,,20210625.0,20210701,20210701,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-062680,BRISTOL MYERS SQUIBB,,79.0,YR,,F,Y,,,20210701.0,,PH,DE,DE,2021,Q3,Elderly
194841711,19484171,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MILLIGRAM,,,U,,,,,1.5,MG,,,2021,Q3,Haematochezia,,2021,Q3,1,I,,20210625.0,20210701,20210701,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-062680,BRISTOL MYERS SQUIBB,,79.0,YR,,F,Y,,,20210701.0,,PH,DE,DE,2021,Q3,Elderly
194841711,19484171,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MILLIGRAM,,,U,,,,,1.5,MG,,,2021,Q3,Headache,,2021,Q3,1,I,,20210625.0,20210701,20210701,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-062680,BRISTOL MYERS SQUIBB,,79.0,YR,,F,Y,,,20210701.0,,PH,DE,DE,2021,Q3,Elderly
194841711,19484171,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MILLIGRAM,,,U,,,,,1.5,MG,,,2021,Q3,Night sweats,,2021,Q3,1,I,,20210625.0,20210701,20210701,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-062680,BRISTOL MYERS SQUIBB,,79.0,YR,,F,Y,,,20210701.0,,PH,DE,DE,2021,Q3,Elderly
194841711,19484171,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MILLIGRAM,,,U,,,,,1.5,MG,,,2021,Q3,Pain,,2021,Q3,1,I,,20210625.0,20210701,20210701,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-062680,BRISTOL MYERS SQUIBB,,79.0,YR,,F,Y,,,20210701.0,,PH,DE,DE,2021,Q3,Elderly
194841711,19484171,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MILLIGRAM,,,U,,,,,1.5,MG,,,2021,Q3,Weight decreased,,2021,Q3,1,I,,20210625.0,20210701,20210701,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-062680,BRISTOL MYERS SQUIBB,,79.0,YR,,F,Y,,,20210701.0,,PH,DE,DE,2021,Q3,Elderly
194882721,19488272,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Intramuscular,"1 MAL W?CHENTLICH, INJEKTIONS?/INFUSIONSL?SUNG",,,U,,,,,,,,,2021,Q3,Nausea,,2021,Q3,1,I,,20210624.0,20210702,20210702,EXP,DE-ADRED-06529-01,NVSC2021DE142684,NOVARTIS,,80.0,YR,,F,Y,,,20210702.0,,HP,DE,DE,2021,Q3,Elderly
194882721,19488272,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Intramuscular,"1 MAL W?CHENTLICH, INJEKTIONS?/INFUSIONSL?SUNG",,,U,,,,,,,,,2021,Q3,Syncope,,2021,Q3,1,I,,20210624.0,20210702,20210702,EXP,DE-ADRED-06529-01,NVSC2021DE142684,NOVARTIS,,80.0,YR,,F,Y,,,20210702.0,,HP,DE,DE,2021,Q3,Elderly
194884911,19488491,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",,,Y,, D347700,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q3,Abdominal distension,,2021,Q3,1,I,20210609.0,20210622.0,20210702,20210702,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202106012127,ELI LILLY AND CO,,26.0,YR,,F,Y,78.0,KG,20210702.0,,HP,CN,CN,2021,Q3,Young Adult
194884911,19488491,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",,,Y,, D347700,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q3,Diabetic ketoacidosis,,2021,Q3,1,I,20210609.0,20210622.0,20210702,20210702,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202106012127,ELI LILLY AND CO,,26.0,YR,,F,Y,78.0,KG,20210702.0,,HP,CN,CN,2021,Q3,Young Adult
194884911,19488491,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",,,Y,, D347700,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q3,Diarrhoea,,2021,Q3,1,I,20210609.0,20210622.0,20210702,20210702,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202106012127,ELI LILLY AND CO,,26.0,YR,,F,Y,78.0,KG,20210702.0,,HP,CN,CN,2021,Q3,Young Adult
194884911,19488491,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",,,Y,, D347700,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q3,Eating disorder,,2021,Q3,1,I,20210609.0,20210622.0,20210702,20210702,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202106012127,ELI LILLY AND CO,,26.0,YR,,F,Y,78.0,KG,20210702.0,,HP,CN,CN,2021,Q3,Young Adult
194884911,19488491,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",,,Y,, D347700,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q3,Feeling abnormal,,2021,Q3,1,I,20210609.0,20210622.0,20210702,20210702,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202106012127,ELI LILLY AND CO,,26.0,YR,,F,Y,78.0,KG,20210702.0,,HP,CN,CN,2021,Q3,Young Adult
194884911,19488491,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",,,Y,, D347700,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q3,Nausea,,2021,Q3,1,I,20210609.0,20210622.0,20210702,20210702,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202106012127,ELI LILLY AND CO,,26.0,YR,,F,Y,78.0,KG,20210702.0,,HP,CN,CN,2021,Q3,Young Adult
194884911,19488491,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",,,Y,, D347700,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,/wk,2021,Q3,Vomiting,,2021,Q3,1,I,20210609.0,20210622.0,20210702,20210702,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202106012127,ELI LILLY AND CO,,26.0,YR,,F,Y,78.0,KG,20210702.0,,HP,CN,CN,2021,Q3,Young Adult
194884911,19488491,2,SS,Dulaglutide 1.5mg,DULAGLUTIDE,1,,,,,Y,,,,125469.0,,,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q3,Abdominal distension,,2021,Q3,1,I,20210609.0,20210622.0,20210702,20210702,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202106012127,ELI LILLY AND CO,,26.0,YR,,F,Y,78.0,KG,20210702.0,,HP,CN,CN,2021,Q3,Young Adult
194884911,19488491,2,SS,Dulaglutide 1.5mg,DULAGLUTIDE,1,,,,,Y,,,,125469.0,,,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q3,Diabetic ketoacidosis,,2021,Q3,1,I,20210609.0,20210622.0,20210702,20210702,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202106012127,ELI LILLY AND CO,,26.0,YR,,F,Y,78.0,KG,20210702.0,,HP,CN,CN,2021,Q3,Young Adult
194884911,19488491,2,SS,Dulaglutide 1.5mg,DULAGLUTIDE,1,,,,,Y,,,,125469.0,,,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q3,Diarrhoea,,2021,Q3,1,I,20210609.0,20210622.0,20210702,20210702,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202106012127,ELI LILLY AND CO,,26.0,YR,,F,Y,78.0,KG,20210702.0,,HP,CN,CN,2021,Q3,Young Adult
194884911,19488491,2,SS,Dulaglutide 1.5mg,DULAGLUTIDE,1,,,,,Y,,,,125469.0,,,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q3,Eating disorder,,2021,Q3,1,I,20210609.0,20210622.0,20210702,20210702,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202106012127,ELI LILLY AND CO,,26.0,YR,,F,Y,78.0,KG,20210702.0,,HP,CN,CN,2021,Q3,Young Adult
194884911,19488491,2,SS,Dulaglutide 1.5mg,DULAGLUTIDE,1,,,,,Y,,,,125469.0,,,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q3,Feeling abnormal,,2021,Q3,1,I,20210609.0,20210622.0,20210702,20210702,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202106012127,ELI LILLY AND CO,,26.0,YR,,F,Y,78.0,KG,20210702.0,,HP,CN,CN,2021,Q3,Young Adult
194884911,19488491,2,SS,Dulaglutide 1.5mg,DULAGLUTIDE,1,,,,,Y,,,,125469.0,,,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q3,Nausea,,2021,Q3,1,I,20210609.0,20210622.0,20210702,20210702,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202106012127,ELI LILLY AND CO,,26.0,YR,,F,Y,78.0,KG,20210702.0,,HP,CN,CN,2021,Q3,Young Adult
194884911,19488491,2,SS,Dulaglutide 1.5mg,DULAGLUTIDE,1,,,,,Y,,,,125469.0,,,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q3,Vomiting,,2021,Q3,1,I,20210609.0,20210622.0,20210702,20210702,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202106012127,ELI LILLY AND CO,,26.0,YR,,F,Y,78.0,KG,20210702.0,,HP,CN,CN,2021,Q3,Young Adult
194890381,19489038,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Intramuscular,"UNK (ONCE A WEEK, SOLUTION FOR INJECTION / INFUSION)",,,,,,,,,,,,2021,Q3,Nausea,,2021,Q3,1,I,,20210622.0,20210703,20210703,EXP,,DE-AUROBINDO-AUR-APL-2021-027326,AUROBINDO,,80.0,YR,,F,Y,,,20210703.0,,MD,DE,DE,2021,Q3,Elderly
194890381,19489038,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Intramuscular,"UNK (ONCE A WEEK, SOLUTION FOR INJECTION / INFUSION)",,,,,,,,,,,,2021,Q3,Syncope,,2021,Q3,1,I,,20210622.0,20210703,20210703,EXP,,DE-AUROBINDO-AUR-APL-2021-027326,AUROBINDO,,80.0,YR,,F,Y,,,20210703.0,,MD,DE,DE,2021,Q3,Elderly
194913521,19491352,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES",,,U,,,,,,,,,2021,Q3,Cellulitis,,2021,Q3,1,I,,20210630.0,20210705,20210705,EXP,,DE-009507513-2107DEU000011,MERCK,,70.0,YR,,M,Y,89.0,KG,20210705.0,,PH,DE,DE,2021,Q3,Elderly
194913521,19491352,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES",,,U,,,,,,,,,2021,Q3,Skin ulcer,,2021,Q3,1,I,,20210630.0,20210705,20210705,EXP,,DE-009507513-2107DEU000011,MERCK,,70.0,YR,,M,Y,89.0,KG,20210705.0,,PH,DE,DE,2021,Q3,Elderly
194932441,19493244,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Intramuscular,"UNK UNK, WEEKLY",,,,,,,,,,,/wk,2021,Q3,Nausea,,2021,Q3,1,I,,20210624.0,20210705,20210705,EXP,DE-ADRED-06529-01,DE-PFIZER INC-2021770601,PFIZER,,80.0,YR,,F,Y,,,20210705.0,,MD,DE,DE,2021,Q3,Elderly
194932441,19493244,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Intramuscular,"UNK UNK, WEEKLY",,,,,,,,,,,/wk,2021,Q3,Syncope,,2021,Q3,1,I,,20210624.0,20210705,20210705,EXP,DE-ADRED-06529-01,DE-PFIZER INC-2021770601,PFIZER,,80.0,YR,,F,Y,,,20210705.0,,MD,DE,DE,2021,Q3,Elderly
194951681,19495168,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,SOLUTION FOR INJECTION / INFUSION,,,,,,,,,,,/wk,2021,Q3,Fall,,2021,Q3,1,I,,20210628.0,20210706,20210706,EXP,,DE-TEVA-2021-DE-1928318,TEVA,,82.0,YR,E,F,Y,,,20210706.0,,PH,DE,DE,2021,Q3,Elderly
194951681,19495168,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,SOLUTION FOR INJECTION / INFUSION,,,,,,,,,,,/wk,2021,Q3,Pain,,2021,Q3,1,I,,20210628.0,20210706,20210706,EXP,,DE-TEVA-2021-DE-1928318,TEVA,,82.0,YR,E,F,Y,,,20210706.0,,PH,DE,DE,2021,Q3,Elderly
194964111,19496411,1,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,,,,,2021,Q3,Fall,,2021,Q3,1,I,,20210625.0,20210706,20210706,EXP,DE-ADRED-06007-02,DE-TORRENT-00020596,TORRENT,,82.0,YR,E,F,Y,,,20210706.0,,PH,DE,DE,2021,Q3,Elderly
194964111,19496411,1,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,,,,,2021,Q3,Pain,,2021,Q3,1,I,,20210625.0,20210706,20210706,EXP,DE-ADRED-06007-02,DE-TORRENT-00020596,TORRENT,,82.0,YR,E,F,Y,,,20210706.0,,PH,DE,DE,2021,Q3,Elderly
194983391,19498339,8,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES",,,U,,,,,1.5,MG,,,2021,Q3,Cellulitis,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,DE-SA-2021SA218615,SANOFI AVENTIS,,70.0,YR,E,M,Y,89.0,KG,20210706.0,,PH,DE,DE,2021,Q3,Elderly
194983391,19498339,8,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES",,,U,,,,,1.5,MG,,,2021,Q3,Skin ulcer,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,DE-SA-2021SA218615,SANOFI AVENTIS,,70.0,YR,E,M,Y,89.0,KG,20210706.0,,PH,DE,DE,2021,Q3,Elderly
194999261,19499926,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MILLIGRAM,,,U,,,,,1.5,MG,,,2021,Q3,Anaemia,,2021,Q3,1,I,,20210628.0,20210707,20210707,EXP,,DE-AUROBINDO-AUR-APL-2021-028117,AUROBINDO,,79.0,YR,,F,Y,,,20210707.0,,PH,DE,DE,2021,Q3,Elderly
194999261,19499926,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MILLIGRAM,,,U,,,,,1.5,MG,,,2021,Q3,Dizziness,,2021,Q3,1,I,,20210628.0,20210707,20210707,EXP,,DE-AUROBINDO-AUR-APL-2021-028117,AUROBINDO,,79.0,YR,,F,Y,,,20210707.0,,PH,DE,DE,2021,Q3,Elderly
194999261,19499926,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MILLIGRAM,,,U,,,,,1.5,MG,,,2021,Q3,Dyspnoea,,2021,Q3,1,I,,20210628.0,20210707,20210707,EXP,,DE-AUROBINDO-AUR-APL-2021-028117,AUROBINDO,,79.0,YR,,F,Y,,,20210707.0,,PH,DE,DE,2021,Q3,Elderly
194999261,19499926,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MILLIGRAM,,,U,,,,,1.5,MG,,,2021,Q3,Haematochezia,,2021,Q3,1,I,,20210628.0,20210707,20210707,EXP,,DE-AUROBINDO-AUR-APL-2021-028117,AUROBINDO,,79.0,YR,,F,Y,,,20210707.0,,PH,DE,DE,2021,Q3,Elderly
194999261,19499926,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MILLIGRAM,,,U,,,,,1.5,MG,,,2021,Q3,Headache,,2021,Q3,1,I,,20210628.0,20210707,20210707,EXP,,DE-AUROBINDO-AUR-APL-2021-028117,AUROBINDO,,79.0,YR,,F,Y,,,20210707.0,,PH,DE,DE,2021,Q3,Elderly
194999261,19499926,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MILLIGRAM,,,U,,,,,1.5,MG,,,2021,Q3,Night sweats,,2021,Q3,1,I,,20210628.0,20210707,20210707,EXP,,DE-AUROBINDO-AUR-APL-2021-028117,AUROBINDO,,79.0,YR,,F,Y,,,20210707.0,,PH,DE,DE,2021,Q3,Elderly
194999261,19499926,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MILLIGRAM,,,U,,,,,1.5,MG,,,2021,Q3,Pain,,2021,Q3,1,I,,20210628.0,20210707,20210707,EXP,,DE-AUROBINDO-AUR-APL-2021-028117,AUROBINDO,,79.0,YR,,F,Y,,,20210707.0,,PH,DE,DE,2021,Q3,Elderly
194999261,19499926,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MILLIGRAM,,,U,,,,,1.5,MG,,,2021,Q3,Weight decreased,,2021,Q3,1,I,,20210628.0,20210707,20210707,EXP,,DE-AUROBINDO-AUR-APL-2021-028117,AUROBINDO,,79.0,YR,,F,Y,,,20210707.0,,PH,DE,DE,2021,Q3,Elderly
194999951,19499995,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO SCHEME, PREFILLED PENS",,,U,U,,,,,,,,2021,Q3,Cellulitis,,2021,Q3,1,I,,20210625.0,20210707,20210707,EXP,DE-ADRED-06617-01,DE-NOVOPROD-824135,NOVO NORDISK,,70.0,YR,,M,Y,89.0,KG,20210707.0,,PH,DE,DE,2021,Q3,Elderly
194999951,19499995,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO SCHEME, PREFILLED PENS",,,U,U,,,,,,,,2021,Q3,Skin ulcer,,2021,Q3,1,I,,20210625.0,20210707,20210707,EXP,DE-ADRED-06617-01,DE-NOVOPROD-824135,NOVO NORDISK,,70.0,YR,,M,Y,89.0,KG,20210707.0,,PH,DE,DE,2021,Q3,Elderly
195000551,19500055,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,UNK,,,,, UNKNOWN,,,,,,,2021,Q3,Fall,,2021,Q3,1,I,,20210622.0,20210707,20210707,EXP,DE-ADRED-06007-02,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-04132,ALKEM,,82.0,YR,,F,Y,,,20210707.0,,HP,DE,DE,2021,Q3,Elderly
195000551,19500055,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,UNK,,,,, UNKNOWN,,,,,,,2021,Q3,Pain,,2021,Q3,1,I,,20210622.0,20210707,20210707,EXP,DE-ADRED-06007-02,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-04132,ALKEM,,82.0,YR,,F,Y,,,20210707.0,,HP,DE,DE,2021,Q3,Elderly
195003771,19500377,8,C,DULAGLUTIDE(GENETICAL RECOMBINATION),DULAGLUTIDE,1,Unknown,DOSE UNKNOWN,,,,,,,,,,,,2021,Q3,Hypertriglyceridaemia,,2021,Q3,1,I,201809.0,20200728.0,20210706,20210706,EXP,,JP-ASTRAZENECA-2020SE96018,ASTRAZENECA,"ISOBE H, ET AL.. A CASE OF TAMOXIFEN?INDUCED HYPERTRIGLYCERIDEMIA MONITORING THE CHANGES IN LIPOPROTEIN FRACTIONS OVER TIME.. BMC ENDOCRINE DISORDER. 2020?",47.0,YR,,F,Y,52.0,KG,20210706.0,,MD,JP,JP,2021,Q3,Adult
195003771,19500377,8,C,DULAGLUTIDE(GENETICAL RECOMBINATION),DULAGLUTIDE,1,Unknown,DOSE UNKNOWN,,,,,,,,,,,,2021,Q3,Renal impairment,,2021,Q3,1,I,201809.0,20200728.0,20210706,20210706,EXP,,JP-ASTRAZENECA-2020SE96018,ASTRAZENECA,"ISOBE H, ET AL.. A CASE OF TAMOXIFEN?INDUCED HYPERTRIGLYCERIDEMIA MONITORING THE CHANGES IN LIPOPROTEIN FRACTIONS OVER TIME.. BMC ENDOCRINE DISORDER. 2020?",47.0,YR,,F,Y,52.0,KG,20210706.0,,MD,JP,JP,2021,Q3,Adult
195035431,19503543,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"EINMAL WOCHENTLICH, INJEKTIONS?/INFUSIONSLOSUNG ()",,,U,,,,,,,,,2021,Q3,Fall,,2021,Q3,1,I,,20210623.0,20210708,20210708,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-303245,RANBAXY,,82.0,YR,,F,Y,,,20210708.0,,HP,NL,DE,2021,Q3,Elderly
195035431,19503543,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"EINMAL WOCHENTLICH, INJEKTIONS?/INFUSIONSLOSUNG ()",,,U,,,,,,,,,2021,Q3,Pain,,2021,Q3,1,I,,20210623.0,20210708,20210708,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-303245,RANBAXY,,82.0,YR,,F,Y,,,20210708.0,,HP,NL,DE,2021,Q3,Elderly
195037422,19503742,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,0.75,MG,,/wk,2021,Q3,Condition aggravated,,2021,Q3,2,F,201709.0,20210818.0,20210707,20210827,EXP,,JP-MYLANLABS-2021M1039353,MYLAN,,45.0,YR,,F,Y,,,20210827.0,,PH,JP,JP,2021,Q3,Adult
195037422,19503742,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,0.75,MG,,/wk,2021,Q3,Hypertriglyceridaemia,,2021,Q3,2,F,201709.0,20210818.0,20210707,20210827,EXP,,JP-MYLANLABS-2021M1039353,MYLAN,,45.0,YR,,F,Y,,,20210827.0,,PH,JP,JP,2021,Q3,Adult
195037422,19503742,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,0.75,MG,,/wk,2021,Q3,Pancreatitis acute,,2021,Q3,2,F,201709.0,20210818.0,20210707,20210827,EXP,,JP-MYLANLABS-2021M1039353,MYLAN,,45.0,YR,,F,Y,,,20210827.0,,PH,JP,JP,2021,Q3,Adult
195037422,19503742,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,0.75,MG,,/wk,2021,Q3,Renal impairment,,2021,Q3,2,F,201709.0,20210818.0,20210707,20210827,EXP,,JP-MYLANLABS-2021M1039353,MYLAN,,45.0,YR,,F,Y,,,20210827.0,,PH,JP,JP,2021,Q3,Adult
195039141,19503914,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, AS PER SCHEME, PRE?FILLED SYRINGE",,,U,,,,,1.5,MG,,,2021,Q3,Cellulitis,,2021,Q3,1,I,,20210625.0,20210707,20210707,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202106013456,ELI LILLY AND CO,,70.0,YR,,M,Y,89.0,KG,20210707.0,,PH,DE,DE,2021,Q3,Elderly
195039141,19503914,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, AS PER SCHEME, PRE?FILLED SYRINGE",,,U,,,,,1.5,MG,,,2021,Q3,Skin ulcer,,2021,Q3,1,I,,20210625.0,20210707,20210707,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202106013456,ELI LILLY AND CO,,70.0,YR,,M,Y,89.0,KG,20210707.0,,PH,DE,DE,2021,Q3,Elderly
195087211,19508721,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1X/WEEK,,,,,,,,,,,/wk,2021,Q3,Fall,,2021,Q3,1,I,,20210624.0,20210708,20210708,EXP,DE-ADRED-06007-02,DE-PFIZER INC-2021770596,PFIZER,,82.0,YR,,F,Y,,,20210708.0,,PH,DE,DE,2021,Q3,Elderly
195087211,19508721,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1X/WEEK,,,,,,,,,,,/wk,2021,Q3,Pain,,2021,Q3,1,I,,20210624.0,20210708,20210708,EXP,DE-ADRED-06007-02,DE-PFIZER INC-2021770596,PFIZER,,82.0,YR,,F,Y,,,20210708.0,,PH,DE,DE,2021,Q3,Elderly
195094082,19509408,5,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,LIQUID,,2021,Q3,Acute kidney injury,,2021,Q3,2,F,20210630.0,20210713.0,20210708,20210721,EXP,,DE-JNJFOC-20210702887,JOHNSON AND JOHNSON,,49.0,YR,A,F,Y,69.7,KG,20210721.0,,MD,DE,DE,2021,Q3,Adult
195111671,19511167,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM (ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES)",,,U,U,,,,1.5,MG,,,2021,Q3,Cellulitis,,2021,Q3,1,I,,20210628.0,20210709,20210709,EXP,,DE-AUROBINDO-AUR-APL-2021-028067,AUROBINDO,,70.0,YR,,M,Y,89.0,KG,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195111671,19511167,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM (ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES)",,,U,U,,,,1.5,MG,,,2021,Q3,Skin ulcer,,2021,Q3,1,I,,20210628.0,20210709,20210709,EXP,,DE-AUROBINDO-AUR-APL-2021-028067,AUROBINDO,,70.0,YR,,M,Y,89.0,KG,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195139991,19513999,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MG,,,U,,,,,1.5,MG,,,2021,Q3,Anaemia,,2021,Q3,1,I,,20210628.0,20210709,20210709,EXP,DE-ADRED-06806-01,DE-TORRENT-00020648,TORRENT,,79.0,YR,E,F,Y,,,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195139991,19513999,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MG,,,U,,,,,1.5,MG,,,2021,Q3,Dizziness,,2021,Q3,1,I,,20210628.0,20210709,20210709,EXP,DE-ADRED-06806-01,DE-TORRENT-00020648,TORRENT,,79.0,YR,E,F,Y,,,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195139991,19513999,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MG,,,U,,,,,1.5,MG,,,2021,Q3,Dyspnoea,,2021,Q3,1,I,,20210628.0,20210709,20210709,EXP,DE-ADRED-06806-01,DE-TORRENT-00020648,TORRENT,,79.0,YR,E,F,Y,,,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195139991,19513999,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MG,,,U,,,,,1.5,MG,,,2021,Q3,Haematochezia,,2021,Q3,1,I,,20210628.0,20210709,20210709,EXP,DE-ADRED-06806-01,DE-TORRENT-00020648,TORRENT,,79.0,YR,E,F,Y,,,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195139991,19513999,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MG,,,U,,,,,1.5,MG,,,2021,Q3,Headache,,2021,Q3,1,I,,20210628.0,20210709,20210709,EXP,DE-ADRED-06806-01,DE-TORRENT-00020648,TORRENT,,79.0,YR,E,F,Y,,,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195139991,19513999,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MG,,,U,,,,,1.5,MG,,,2021,Q3,Night sweats,,2021,Q3,1,I,,20210628.0,20210709,20210709,EXP,DE-ADRED-06806-01,DE-TORRENT-00020648,TORRENT,,79.0,YR,E,F,Y,,,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195139991,19513999,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MG,,,U,,,,,1.5,MG,,,2021,Q3,Pain,,2021,Q3,1,I,,20210628.0,20210709,20210709,EXP,DE-ADRED-06806-01,DE-TORRENT-00020648,TORRENT,,79.0,YR,E,F,Y,,,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195139991,19513999,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MG,,,U,,,,,1.5,MG,,,2021,Q3,Weight decreased,,2021,Q3,1,I,,20210628.0,20210709,20210709,EXP,DE-ADRED-06806-01,DE-TORRENT-00020648,TORRENT,,79.0,YR,E,F,Y,,,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195142761,19514276,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG,  ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES",,,U,,,,,1.5,MG,,,2021,Q3,Anaemia,,2021,Q3,1,I,,20210630.0,20210709,20210709,EXP,DE-ADRED-06806-01,DE-SA-2021SA220173,SANOFI AVENTIS,,79.0,YR,E,F,Y,,,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195142761,19514276,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG,  ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES",,,U,,,,,1.5,MG,,,2021,Q3,Dizziness,,2021,Q3,1,I,,20210630.0,20210709,20210709,EXP,DE-ADRED-06806-01,DE-SA-2021SA220173,SANOFI AVENTIS,,79.0,YR,E,F,Y,,,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195142761,19514276,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG,  ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES",,,U,,,,,1.5,MG,,,2021,Q3,Dyspnoea,,2021,Q3,1,I,,20210630.0,20210709,20210709,EXP,DE-ADRED-06806-01,DE-SA-2021SA220173,SANOFI AVENTIS,,79.0,YR,E,F,Y,,,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195142761,19514276,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG,  ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES",,,U,,,,,1.5,MG,,,2021,Q3,Haematochezia,,2021,Q3,1,I,,20210630.0,20210709,20210709,EXP,DE-ADRED-06806-01,DE-SA-2021SA220173,SANOFI AVENTIS,,79.0,YR,E,F,Y,,,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195142761,19514276,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG,  ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES",,,U,,,,,1.5,MG,,,2021,Q3,Headache,,2021,Q3,1,I,,20210630.0,20210709,20210709,EXP,DE-ADRED-06806-01,DE-SA-2021SA220173,SANOFI AVENTIS,,79.0,YR,E,F,Y,,,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195142761,19514276,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG,  ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES",,,U,,,,,1.5,MG,,,2021,Q3,Night sweats,,2021,Q3,1,I,,20210630.0,20210709,20210709,EXP,DE-ADRED-06806-01,DE-SA-2021SA220173,SANOFI AVENTIS,,79.0,YR,E,F,Y,,,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195142761,19514276,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG,  ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES",,,U,,,,,1.5,MG,,,2021,Q3,Pain,,2021,Q3,1,I,,20210630.0,20210709,20210709,EXP,DE-ADRED-06806-01,DE-SA-2021SA220173,SANOFI AVENTIS,,79.0,YR,E,F,Y,,,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195142761,19514276,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG,  ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES",,,U,,,,,1.5,MG,,,2021,Q3,Weight decreased,,2021,Q3,1,I,,20210630.0,20210709,20210709,EXP,DE-ADRED-06806-01,DE-SA-2021SA220173,SANOFI AVENTIS,,79.0,YR,E,F,Y,,,20210709.0,,PH,DE,DE,2021,Q3,Elderly
195153631,19515363,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG (NACH SCHEMA, FERTIGSPRITZEN)",,,U,, UNK,,,1.5,MG,,,2021,Q3,Cellulitis,,2021,Q3,1,I,,20210628.0,20210710,20210710,EXP,,NVSC2021DE145323,NOVARTIS,,70.0,YR,,M,Y,89.0,KG,20210710.0,,HP,DE,DE,2021,Q3,Elderly
195153631,19515363,4,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG (NACH SCHEMA, FERTIGSPRITZEN)",,,U,, UNK,,,1.5,MG,,,2021,Q3,Skin ulcer,,2021,Q3,1,I,,20210628.0,20210710,20210710,EXP,,NVSC2021DE145323,NOVARTIS,,70.0,YR,,M,Y,89.0,KG,20210710.0,,HP,DE,DE,2021,Q3,Elderly
195217131,19521713,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,U,, UNKNOWN,,,,,,,2021,Q3,Cellulitis,,2021,Q3,1,I,,20210628.0,20210712,20210712,EXP,,DE-PFIZER INC-2021795618,PFIZER,,70.0,YR,,M,Y,89.0,KG,20210712.0,,PH,DE,DE,2021,Q3,Elderly
195217131,19521713,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,U,, UNKNOWN,,,,,,,2021,Q3,Skin ulcer,,2021,Q3,1,I,,20210628.0,20210712,20210712,EXP,,DE-PFIZER INC-2021795618,PFIZER,,70.0,YR,,M,Y,89.0,KG,20210712.0,,PH,DE,DE,2021,Q3,Elderly
195707721,19570772,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,0.75,MG,,/wk,2021,Q3,Condition aggravated,,2021,Q3,1,I,201709.0,20210705.0,20210715,20210715,EXP,,JP-TEVA-2021-JP-1931218,TEVA,"ISOBE H, SHIMODA M, KAN Y, TATSUMI F, KATAKURA Y, KIMURA T, ET AL. A CASE OF TAMOXIFEN?INDUCED HYPERTRIGLYCERIDEMIA MONITORING THE CHANGES IN LIPOPROTEIN FRACTIONS OVER TIME. BMC?ENDOCR?DISORD 2021?21(1):115.",45.0,YR,A,F,Y,,,20210716.0,,HP,JP,JP,2021,Q3,Adult
195707721,19570772,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,0.75,MG,,/wk,2021,Q3,Hypertriglyceridaemia,,2021,Q3,1,I,201709.0,20210705.0,20210715,20210715,EXP,,JP-TEVA-2021-JP-1931218,TEVA,"ISOBE H, SHIMODA M, KAN Y, TATSUMI F, KATAKURA Y, KIMURA T, ET AL. A CASE OF TAMOXIFEN?INDUCED HYPERTRIGLYCERIDEMIA MONITORING THE CHANGES IN LIPOPROTEIN FRACTIONS OVER TIME. BMC?ENDOCR?DISORD 2021?21(1):115.",45.0,YR,A,F,Y,,,20210716.0,,HP,JP,JP,2021,Q3,Adult
195707721,19570772,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,0.75,MG,,/wk,2021,Q3,Pancreatitis acute,,2021,Q3,1,I,201709.0,20210705.0,20210715,20210715,EXP,,JP-TEVA-2021-JP-1931218,TEVA,"ISOBE H, SHIMODA M, KAN Y, TATSUMI F, KATAKURA Y, KIMURA T, ET AL. A CASE OF TAMOXIFEN?INDUCED HYPERTRIGLYCERIDEMIA MONITORING THE CHANGES IN LIPOPROTEIN FRACTIONS OVER TIME. BMC?ENDOCR?DISORD 2021?21(1):115.",45.0,YR,A,F,Y,,,20210716.0,,HP,JP,JP,2021,Q3,Adult
195707721,19570772,7,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,0.75,MG,,/wk,2021,Q3,Renal impairment,,2021,Q3,1,I,201709.0,20210705.0,20210715,20210715,EXP,,JP-TEVA-2021-JP-1931218,TEVA,"ISOBE H, SHIMODA M, KAN Y, TATSUMI F, KATAKURA Y, KIMURA T, ET AL. A CASE OF TAMOXIFEN?INDUCED HYPERTRIGLYCERIDEMIA MONITORING THE CHANGES IN LIPOPROTEIN FRACTIONS OVER TIME. BMC?ENDOCR?DISORD 2021?21(1):115.",45.0,YR,A,F,Y,,,20210716.0,,HP,JP,JP,2021,Q3,Adult
195862582,19586258,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,4.5MG,,,Y,U,,,,,,INJECTION,,2021,Q3,Hypoglycaemia,,2021,Q3,2,F,,20210729.0,20210721,20210809,EXP,,JP-NOVOPROD-830160,NOVO NORDISK,,68.0,YR,,M,Y,,,20210809.0,,MD,JP,JP,2021,Q3,Elderly
195862582,19586258,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,4.5MG,,,Y,U,,,,,,INJECTION,,2021,Q3,Intentional overdose,,2021,Q3,2,F,,20210729.0,20210721,20210809,EXP,,JP-NOVOPROD-830160,NOVO NORDISK,,68.0,YR,,M,Y,,,20210809.0,,MD,JP,JP,2021,Q3,Elderly
195873351,19587335,9,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO SCHEME, READY TO USE SYRINGES",,,U,, UNKNOWN,,,,,,,2021,Q3,Cellulitis,,2021,Q3,1,I,,20210720.0,20210721,20210721,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-116210",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,89.0,KG,20210721.0,,PH,DE,DE,2021,Q3,Elderly
195873351,19587335,9,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO SCHEME, READY TO USE SYRINGES",,,U,, UNKNOWN,,,,,,,2021,Q3,Skin ulcer,,2021,Q3,1,I,,20210720.0,20210721,20210721,EXP,,"DE-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-116210",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,89.0,KG,20210721.0,,PH,DE,DE,2021,Q3,Elderly
195879531,19587953,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Intramuscular,1 TIME A WEEK,,,,,,,,,,SOLUTION FOR INJECTION/INFUSION,,2021,Q3,Nausea,,2021,Q3,1,I,,20210709.0,20210721,20210721,EXP,DE-BFARM-21005934,DE-ACCORD-232323,ACCORD,,80.0,YR,E,F,Y,,,20210721.0,,MD,DE,DE,2021,Q3,Elderly
195879531,19587953,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Intramuscular,1 TIME A WEEK,,,,,,,,,,SOLUTION FOR INJECTION/INFUSION,,2021,Q3,Syncope,,2021,Q3,1,I,,20210709.0,20210721,20210721,EXP,DE-BFARM-21005934,DE-ACCORD-232323,ACCORD,,80.0,YR,E,F,Y,,,20210721.0,,MD,DE,DE,2021,Q3,Elderly
195883921,19588392,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"ONCE A WEEK, SOLUTION FOR INJECTION / INFUSION",,,,,,,,,,,,2021,Q3,Fall,,2021,Q3,1,I,,20210709.0,20210721,20210721,EXP,DE-BFARM-21005983,DE-ACCORD-232213,ACCORD,,82.0,YR,E,F,Y,,,20210721.0,,PH,DE,DE,2021,Q3,Elderly
195883921,19588392,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"ONCE A WEEK, SOLUTION FOR INJECTION / INFUSION",,,,,,,,,,,,2021,Q3,Pain,,2021,Q3,1,I,,20210709.0,20210721,20210721,EXP,DE-BFARM-21005983,DE-ACCORD-232213,ACCORD,,82.0,YR,E,F,Y,,,20210721.0,,PH,DE,DE,2021,Q3,Elderly
195979481,19597948,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,1.5,MG,UNKNOWN,/wk,2021,Q3,Drug eruption,,2021,Q3,1,I,20210705.0,20210716.0,20210723,20210723,EXP,,CN-JNJFOC-20210737694,JOHNSON AND JOHNSON,,69.0,YR,E,M,Y,82.0,KG,20210723.0,,HP,CN,CN,2021,Q3,Elderly
195979481,19597948,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,1.5,MG,UNKNOWN,/wk,2021,Q3,Henoch-Schonlein purpura,,2021,Q3,1,I,20210705.0,20210716.0,20210723,20210723,EXP,,CN-JNJFOC-20210737694,JOHNSON AND JOHNSON,,69.0,YR,E,M,Y,82.0,KG,20210723.0,,HP,CN,CN,2021,Q3,Elderly
195986901,19598690,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",11.786,MG,Y,,,,125469.0,1.5,MG,,/wk,2021,Q3,Palpitations,,2021,Q3,1,I,20210601.0,20210711.0,20210722,20210722,EXP,GB-MHRA-EYC 00255837,GB-ELI_LILLY_AND_COMPANY-GB202107004760,ELI LILLY AND CO,,31.0,YR,,M,Y,,,20210722.0,,PH,GB,GB,2021,Q3,Young Adult
195986901,19598690,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, WEEKLY (1/W)",11.786,MG,Y,,,,125469.0,1.5,MG,,/wk,2021,Q3,Tachycardia,,2021,Q3,1,I,20210601.0,20210711.0,20210722,20210722,EXP,GB-MHRA-EYC 00255837,GB-ELI_LILLY_AND_COMPANY-GB202107004760,ELI LILLY AND CO,,31.0,YR,,M,Y,,,20210722.0,,PH,GB,GB,2021,Q3,Young Adult
196018221,19601822,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG,PRE?FILLED SYRINGES",,,U,,,,,,,,,2021,Q3,Cellulitis,,2021,Q3,1,I,,20210713.0,20210723,20210723,EXP,DE-BFARM-21006294,DE-ACCORD-232689,ACCORD,,70.0,YR,E,M,Y,89.0,KG,20210723.0,,PH,DE,DE,2021,Q3,Elderly
196018221,19601822,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG,PRE?FILLED SYRINGES",,,U,,,,,,,,,2021,Q3,Skin ulcer,,2021,Q3,1,I,,20210713.0,20210723,20210723,EXP,DE-BFARM-21006294,DE-ACCORD-232689,ACCORD,,70.0,YR,E,M,Y,89.0,KG,20210723.0,,PH,DE,DE,2021,Q3,Elderly
196036181,19603618,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES",,,,,,,,,,,,2021,Q3,Anaemia,,2021,Q3,1,I,,20210713.0,20210724,20210724,EXP,DE-BFARM-21006346,DE-ACCORD-232785,ACCORD,,79.0,YR,E,F,Y,,,20210724.0,,PH,DE,DE,2021,Q3,Elderly
196036181,19603618,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES",,,,,,,,,,,,2021,Q3,Dizziness,,2021,Q3,1,I,,20210713.0,20210724,20210724,EXP,DE-BFARM-21006346,DE-ACCORD-232785,ACCORD,,79.0,YR,E,F,Y,,,20210724.0,,PH,DE,DE,2021,Q3,Elderly
196036181,19603618,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES",,,,,,,,,,,,2021,Q3,Dyspnoea,,2021,Q3,1,I,,20210713.0,20210724,20210724,EXP,DE-BFARM-21006346,DE-ACCORD-232785,ACCORD,,79.0,YR,E,F,Y,,,20210724.0,,PH,DE,DE,2021,Q3,Elderly
196036181,19603618,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES",,,,,,,,,,,,2021,Q3,Haematochezia,,2021,Q3,1,I,,20210713.0,20210724,20210724,EXP,DE-BFARM-21006346,DE-ACCORD-232785,ACCORD,,79.0,YR,E,F,Y,,,20210724.0,,PH,DE,DE,2021,Q3,Elderly
196036181,19603618,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES",,,,,,,,,,,,2021,Q3,Headache,,2021,Q3,1,I,,20210713.0,20210724,20210724,EXP,DE-BFARM-21006346,DE-ACCORD-232785,ACCORD,,79.0,YR,E,F,Y,,,20210724.0,,PH,DE,DE,2021,Q3,Elderly
196036181,19603618,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES",,,,,,,,,,,,2021,Q3,Night sweats,,2021,Q3,1,I,,20210713.0,20210724,20210724,EXP,DE-BFARM-21006346,DE-ACCORD-232785,ACCORD,,79.0,YR,E,F,Y,,,20210724.0,,PH,DE,DE,2021,Q3,Elderly
196036181,19603618,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES",,,,,,,,,,,,2021,Q3,Pain,,2021,Q3,1,I,,20210713.0,20210724,20210724,EXP,DE-BFARM-21006346,DE-ACCORD-232785,ACCORD,,79.0,YR,E,F,Y,,,20210724.0,,PH,DE,DE,2021,Q3,Elderly
196036181,19603618,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO THE SCHEME, PRE?FILLED SYRINGES",,,,,,,,,,,,2021,Q3,Weight decreased,,2021,Q3,1,I,,20210713.0,20210724,20210724,EXP,DE-BFARM-21006346,DE-ACCORD-232785,ACCORD,,79.0,YR,E,F,Y,,,20210724.0,,PH,DE,DE,2021,Q3,Elderly
196289831,19628983,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,0.75,MG,INJECTION,/wk,2021,Q3,Colitis,,2021,Q3,1,I,20210714.0,20210721.0,20210728,20210728,EXP,,ES-ROCHE-2876051,ROCHE,,60.0,YR,,F,Y,84.1,KG,20210728.0,,MD,ES,ES,2021,Q3,Adult
196331621,19633162,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,,"1.5 MILLIGRAM, WEEKLY",,,,,,,,1.5,MG,,,2021,Q3,"Hallucination, visual",,2021,Q3,1,I,202107.0,20210706.0,20210730,20210730,PER,,US-ACADIA PHARMACEUTICALS INC.-ACA-2021-PIM-002479,ACADIA PHARMACEUTICALS,,70.0,YR,,M,Y,,,20210730.0,,CN,US,US,2021,Q3,Elderly
196331621,19633162,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,,"1.5 MILLIGRAM, WEEKLY",,,,,,,,1.5,MG,,,2021,Q3,Nausea,,2021,Q3,1,I,202107.0,20210706.0,20210730,20210730,PER,,US-ACADIA PHARMACEUTICALS INC.-ACA-2021-PIM-002479,ACADIA PHARMACEUTICALS,,70.0,YR,,M,Y,,,20210730.0,,CN,US,US,2021,Q3,Elderly
196331621,19633162,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,,"1.5 MILLIGRAM, WEEKLY",,,,,,,,1.5,MG,,,2021,Q3,Vomiting,,2021,Q3,1,I,202107.0,20210706.0,20210730,20210730,PER,,US-ACADIA PHARMACEUTICALS INC.-ACA-2021-PIM-002479,ACADIA PHARMACEUTICALS,,70.0,YR,,M,Y,,,20210730.0,,CN,US,US,2021,Q3,Elderly
196400222,19640022,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, UNKNOWN FREQ.",,,,,,,,,,FORMULATION UNKNOWN,,2021,Q3,Toxic epidermal necrolysis,,2021,Q3,2,F,20210722.0,20210811.0,20210730,20210817,EXP,,FR-ASTELLAS-2021US028727,ASTELLAS,,66.0,YR,,M,Y,,,20210817.0,,CN,US,FR,2021,Q3,Elderly
196412091,19641209,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,1.0,DF,,/wk,2021,Q3,Dizziness,,2021,Q3,1,I,20210323.0,20210728.0,20210729,20210729,EXP,GB-MHRA-TPP9535135C121877YC1627023125829,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-118156",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,95.0,KG,20210730.0,,MD,GB,GB,2021,Q3,Elderly
196412091,19641209,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,1.0,DF,,/wk,2021,Q3,Orchitis,,2021,Q3,1,I,20210323.0,20210728.0,20210729,20210729,EXP,GB-MHRA-TPP9535135C121877YC1627023125829,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-118156",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,95.0,KG,20210730.0,,MD,GB,GB,2021,Q3,Elderly
196412091,19641209,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,1.0,DF,,/wk,2021,Q3,Polyuria,,2021,Q3,1,I,20210323.0,20210728.0,20210729,20210729,EXP,GB-MHRA-TPP9535135C121877YC1627023125829,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-118156",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,95.0,KG,20210730.0,,MD,GB,GB,2021,Q3,Elderly
196412091,19641209,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,1.0,DF,,/wk,2021,Q3,Urinary tract infection,,2021,Q3,1,I,20210323.0,20210728.0,20210729,20210729,EXP,GB-MHRA-TPP9535135C121877YC1627023125829,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-118156",BOEHRINGER INGELHEIM,,67.0,YR,E,M,Y,95.0,KG,20210730.0,,MD,GB,GB,2021,Q3,Elderly
196708191,19670819,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, SINGLE",,,U,, D381210,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q3,Asthenia,,2021,Q3,1,I,20210713.0,20210725.0,20210806,20210806,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202107011297,ELI LILLY AND CO,,52.0,YR,,F,Y,,,20210806.0,,HP,CN,CN,2021,Q3,Adult
196708191,19670819,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, SINGLE",,,U,, D381210,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q3,Gastrointestinal disorder,,2021,Q3,1,I,20210713.0,20210725.0,20210806,20210806,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202107011297,ELI LILLY AND CO,,52.0,YR,,F,Y,,,20210806.0,,HP,CN,CN,2021,Q3,Adult
196708191,19670819,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, SINGLE",,,U,, D381210,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q3,Hyperhidrosis,,2021,Q3,1,I,20210713.0,20210725.0,20210806,20210806,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202107011297,ELI LILLY AND CO,,52.0,YR,,F,Y,,,20210806.0,,HP,CN,CN,2021,Q3,Adult
196708191,19670819,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, SINGLE",,,U,, D381210,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q3,Nausea,,2021,Q3,1,I,20210713.0,20210725.0,20210806,20210806,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202107011297,ELI LILLY AND CO,,52.0,YR,,F,Y,,,20210806.0,,HP,CN,CN,2021,Q3,Adult
196708191,19670819,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, SINGLE",,,U,, D381210,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q3,Palpitations,,2021,Q3,1,I,20210713.0,20210725.0,20210806,20210806,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202107011297,ELI LILLY AND CO,,52.0,YR,,F,Y,,,20210806.0,,HP,CN,CN,2021,Q3,Adult
196708191,19670819,1,PS,Dulaglutide 1.5mg,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, SINGLE",,,U,, D381210,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q3,Supraventricular tachycardia,,2021,Q3,1,I,20210713.0,20210725.0,20210806,20210806,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202107011297,ELI LILLY AND CO,,52.0,YR,,F,Y,,,20210806.0,,HP,CN,CN,2021,Q3,Adult
196941361,19694136,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q3,Hyperglycaemia,,2021,Q3,1,I,20210730.0,20210811.0,20210813,20210813,EXP,,NO-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-079912,BRISTOL MYERS SQUIBB,,62.0,YR,,M,Y,,,20210813.0,,HP,NO,NO,2021,Q3,Adult
197013511,19701351,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG(NACH SCHEMA, FERTIGPEN)",,,U,, UNK,,,1.5,MG,,,2021,Q3,Abdominal pain lower,,2021,Q3,1,I,,20210809.0,20210814,20210814,EXP,DE-ADRED-06862-01,NVSC2021DE179902,NOVARTIS,,67.0,YR,,F,Y,,,20210814.0,,HP,DE,DE,2021,Q3,Elderly
197013511,19701351,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG(NACH SCHEMA, FERTIGPEN)",,,U,, UNK,,,1.5,MG,,,2021,Q3,Blood creatinine increased,,2021,Q3,1,I,,20210809.0,20210814,20210814,EXP,DE-ADRED-06862-01,NVSC2021DE179902,NOVARTIS,,67.0,YR,,F,Y,,,20210814.0,,HP,DE,DE,2021,Q3,Elderly
197013511,19701351,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG(NACH SCHEMA, FERTIGPEN)",,,U,, UNK,,,1.5,MG,,,2021,Q3,Chills,,2021,Q3,1,I,,20210809.0,20210814,20210814,EXP,DE-ADRED-06862-01,NVSC2021DE179902,NOVARTIS,,67.0,YR,,F,Y,,,20210814.0,,HP,DE,DE,2021,Q3,Elderly
197013511,19701351,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG(NACH SCHEMA, FERTIGPEN)",,,U,, UNK,,,1.5,MG,,,2021,Q3,Dysuria,,2021,Q3,1,I,,20210809.0,20210814,20210814,EXP,DE-ADRED-06862-01,NVSC2021DE179902,NOVARTIS,,67.0,YR,,F,Y,,,20210814.0,,HP,DE,DE,2021,Q3,Elderly
197013511,19701351,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG(NACH SCHEMA, FERTIGPEN)",,,U,, UNK,,,1.5,MG,,,2021,Q3,Infection,,2021,Q3,1,I,,20210809.0,20210814,20210814,EXP,DE-ADRED-06862-01,NVSC2021DE179902,NOVARTIS,,67.0,YR,,F,Y,,,20210814.0,,HP,DE,DE,2021,Q3,Elderly
197013511,19701351,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG(NACH SCHEMA, FERTIGPEN)",,,U,, UNK,,,1.5,MG,,,2021,Q3,Pyrexia,,2021,Q3,1,I,,20210809.0,20210814,20210814,EXP,DE-ADRED-06862-01,NVSC2021DE179902,NOVARTIS,,67.0,YR,,F,Y,,,20210814.0,,HP,DE,DE,2021,Q3,Elderly
197066621,19706662,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM (ACCORDING TO THE SCHEME, PRE?FILLED PEN)",,,U,U,,,,1.5,MG,,,2021,Q3,Abdominal pain lower,,2021,Q3,1,I,,20210805.0,20210817,20210817,EXP,,DE-AUROBINDO-AUR-APL-2021-035088,AUROBINDO,,67.0,YR,,F,Y,,,20210817.0,,PH,DE,DE,2021,Q3,Elderly
197066621,19706662,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM (ACCORDING TO THE SCHEME, PRE?FILLED PEN)",,,U,U,,,,1.5,MG,,,2021,Q3,Blood creatinine increased,,2021,Q3,1,I,,20210805.0,20210817,20210817,EXP,,DE-AUROBINDO-AUR-APL-2021-035088,AUROBINDO,,67.0,YR,,F,Y,,,20210817.0,,PH,DE,DE,2021,Q3,Elderly
197066621,19706662,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM (ACCORDING TO THE SCHEME, PRE?FILLED PEN)",,,U,U,,,,1.5,MG,,,2021,Q3,Chills,,2021,Q3,1,I,,20210805.0,20210817,20210817,EXP,,DE-AUROBINDO-AUR-APL-2021-035088,AUROBINDO,,67.0,YR,,F,Y,,,20210817.0,,PH,DE,DE,2021,Q3,Elderly
197066621,19706662,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM (ACCORDING TO THE SCHEME, PRE?FILLED PEN)",,,U,U,,,,1.5,MG,,,2021,Q3,Dysuria,,2021,Q3,1,I,,20210805.0,20210817,20210817,EXP,,DE-AUROBINDO-AUR-APL-2021-035088,AUROBINDO,,67.0,YR,,F,Y,,,20210817.0,,PH,DE,DE,2021,Q3,Elderly
197066621,19706662,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM (ACCORDING TO THE SCHEME, PRE?FILLED PEN)",,,U,U,,,,1.5,MG,,,2021,Q3,Infection,,2021,Q3,1,I,,20210805.0,20210817,20210817,EXP,,DE-AUROBINDO-AUR-APL-2021-035088,AUROBINDO,,67.0,YR,,F,Y,,,20210817.0,,PH,DE,DE,2021,Q3,Elderly
197066621,19706662,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MILLIGRAM (ACCORDING TO THE SCHEME, PRE?FILLED PEN)",,,U,U,,,,1.5,MG,,,2021,Q3,Pyrexia,,2021,Q3,1,I,,20210805.0,20210817,20210817,EXP,,DE-AUROBINDO-AUR-APL-2021-035088,AUROBINDO,,67.0,YR,,F,Y,,,20210817.0,,PH,DE,DE,2021,Q3,Elderly
197080701,19708070,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNKNOWN",,,U,,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q3,Abdominal pain lower,,2021,Q3,1,I,,20210805.0,20210817,20210817,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202108002362,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210817.0,,PH,DE,DE,2021,Q3,Elderly
197080701,19708070,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNKNOWN",,,U,,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q3,Blood creatinine increased,,2021,Q3,1,I,,20210805.0,20210817,20210817,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202108002362,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210817.0,,PH,DE,DE,2021,Q3,Elderly
197080701,19708070,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNKNOWN",,,U,,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q3,Chills,,2021,Q3,1,I,,20210805.0,20210817,20210817,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202108002362,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210817.0,,PH,DE,DE,2021,Q3,Elderly
197080701,19708070,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNKNOWN",,,U,,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q3,Dysuria,,2021,Q3,1,I,,20210805.0,20210817,20210817,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202108002362,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210817.0,,PH,DE,DE,2021,Q3,Elderly
197080701,19708070,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNKNOWN",,,U,,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q3,Infection,,2021,Q3,1,I,,20210805.0,20210817,20210817,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202108002362,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210817.0,,PH,DE,DE,2021,Q3,Elderly
197080701,19708070,1,PS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, UNKNOWN",,,U,,,,125469.0,1.5,MG,SOLUTION FOR INJECTION IN PRE-FILLED PEN,,2021,Q3,Pyrexia,,2021,Q3,1,I,,20210805.0,20210817,20210817,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202108002362,ELI LILLY AND CO,,67.0,YR,,F,Y,,,20210817.0,,PH,DE,DE,2021,Q3,Elderly
197273262,19727326,4,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, Z(QW)",,,,,,,,1.5,MG,,,2021,Q3,Back pain,,2021,Q3,2,F,20210728.0,20210917.0,20210820,20210924,EXP,,ES-GLAXOSMITHKLINE-ES2021GSK171840,GLAXOSMITHKLINE,,67.0,YR,,F,Y,88.0,KG,20210924.0,,MD,ES,ES,2021,Q3,Elderly
197318471,19731847,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Colitis,,2021,Q3,1,I,,20210816.0,20210820,20210820,EXP,,CA-TAKEDA-2021TUS051938,TAKEDA,,73.0,YR,,F,Y,,,20210820.0,,CN,CA,CA,2021,Q3,Elderly
197318471,19731847,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Colitis ulcerative,,2021,Q3,1,I,,20210816.0,20210820,20210820,EXP,,CA-TAKEDA-2021TUS051938,TAKEDA,,73.0,YR,,F,Y,,,20210820.0,,CN,CA,CA,2021,Q3,Elderly
197318471,19731847,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Decreased activity,,2021,Q3,1,I,,20210816.0,20210820,20210820,EXP,,CA-TAKEDA-2021TUS051938,TAKEDA,,73.0,YR,,F,Y,,,20210820.0,,CN,CA,CA,2021,Q3,Elderly
197318471,19731847,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Frequent bowel movements,,2021,Q3,1,I,,20210816.0,20210820,20210820,EXP,,CA-TAKEDA-2021TUS051938,TAKEDA,,73.0,YR,,F,Y,,,20210820.0,,CN,CA,CA,2021,Q3,Elderly
197318471,19731847,15,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q3,Rectal haemorrhage,,2021,Q3,1,I,,20210816.0,20210820,20210820,EXP,,CA-TAKEDA-2021TUS051938,TAKEDA,,73.0,YR,,F,Y,,,20210820.0,,CN,CA,CA,2021,Q3,Elderly
197429122,19742912,20,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,UNK,,,,,,,,,,,,2021,Q3,Multiple organ dysfunction syndrome,,2021,Q3,2,F,20200724.0,20210909.0,20210824,20210914,EXP,,JP-GILEAD-2020-0486704,GILEAD,,91.0,YR,E,F,Y,44.9,KG,20210914.0,,MD,JP,JP,2021,Q3,Elderly
197548441,19754844,18,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Colitis,,2021,Q3,1,I,,20210819.0,20210827,20210827,EXP,,CA-TEVA-2021-CA-1945988,TEVA,,73.0,YR,E,F,Y,,,20210827.0,,CN,CA,CA,2021,Q3,Elderly
197548441,19754844,18,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Colitis ulcerative,,2021,Q3,1,I,,20210819.0,20210827,20210827,EXP,,CA-TEVA-2021-CA-1945988,TEVA,,73.0,YR,E,F,Y,,,20210827.0,,CN,CA,CA,2021,Q3,Elderly
197548441,19754844,18,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Decreased activity,,2021,Q3,1,I,,20210819.0,20210827,20210827,EXP,,CA-TEVA-2021-CA-1945988,TEVA,,73.0,YR,E,F,Y,,,20210827.0,,CN,CA,CA,2021,Q3,Elderly
197548441,19754844,18,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Frequent bowel movements,,2021,Q3,1,I,,20210819.0,20210827,20210827,EXP,,CA-TEVA-2021-CA-1945988,TEVA,,73.0,YR,E,F,Y,,,20210827.0,,CN,CA,CA,2021,Q3,Elderly
197548441,19754844,18,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q3,Rectal haemorrhage,,2021,Q3,1,I,,20210819.0,20210827,20210827,EXP,,CA-TEVA-2021-CA-1945988,TEVA,,73.0,YR,E,F,Y,,,20210827.0,,CN,CA,CA,2021,Q3,Elderly
197732231,19773223,16,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,1.5MG/0.5ML,,,,,,,,,,UNKNOWN,,2021,Q3,Vocal cord thickening,,2021,Q3,1,I,20210820.0,20210824.0,20210901,20210901,EXP,,AU-CELGENEUS-AUS-20210808318,CELGENE,,76.0,YR,,M,Y,,,20210901.0,,MD,AU,AU,2021,Q3,Elderly
197788771,19778877,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO THE SCHEME, PRE?FILLED PEN",,,U,,,,,,,,,2021,Q3,Abdominal pain lower,,2021,Q3,1,I,,20210820.0,20210902,20210902,EXP,DE-BFARM-21007673,DE-ACCORD-237124,ACCORD,,67.0,YR,E,F,Y,,,20210902.0,,PH,DE,DE,2021,Q3,Elderly
197788771,19778877,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO THE SCHEME, PRE?FILLED PEN",,,U,,,,,,,,,2021,Q3,Blood creatinine increased,,2021,Q3,1,I,,20210820.0,20210902,20210902,EXP,DE-BFARM-21007673,DE-ACCORD-237124,ACCORD,,67.0,YR,E,F,Y,,,20210902.0,,PH,DE,DE,2021,Q3,Elderly
197788771,19778877,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO THE SCHEME, PRE?FILLED PEN",,,U,,,,,,,,,2021,Q3,Chills,,2021,Q3,1,I,,20210820.0,20210902,20210902,EXP,DE-BFARM-21007673,DE-ACCORD-237124,ACCORD,,67.0,YR,E,F,Y,,,20210902.0,,PH,DE,DE,2021,Q3,Elderly
197788771,19778877,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO THE SCHEME, PRE?FILLED PEN",,,U,,,,,,,,,2021,Q3,Dysuria,,2021,Q3,1,I,,20210820.0,20210902,20210902,EXP,DE-BFARM-21007673,DE-ACCORD-237124,ACCORD,,67.0,YR,E,F,Y,,,20210902.0,,PH,DE,DE,2021,Q3,Elderly
197788771,19778877,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO THE SCHEME, PRE?FILLED PEN",,,U,,,,,,,,,2021,Q3,Infection,,2021,Q3,1,I,,20210820.0,20210902,20210902,EXP,DE-BFARM-21007673,DE-ACCORD-237124,ACCORD,,67.0,YR,E,F,Y,,,20210902.0,,PH,DE,DE,2021,Q3,Elderly
197788771,19778877,3,SS,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, ACCORDING TO THE SCHEME, PRE?FILLED PEN",,,U,,,,,,,,,2021,Q3,Pyrexia,,2021,Q3,1,I,,20210820.0,20210902,20210902,EXP,DE-BFARM-21007673,DE-ACCORD-237124,ACCORD,,67.0,YR,E,F,Y,,,20210902.0,,PH,DE,DE,2021,Q3,Elderly
197889132,19788913,20,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q3,Multiple sclerosis,,2021,Q3,2,F,2021.0,20210921.0,20210904,20210930,PER,,US-CELGENEUS-USA-20210808451,CELGENE,,66.0,YR,,F,Y,,,20210930.0,,MD,US,US,2021,Q3,Elderly
197889132,19788913,20,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q3,Neutrophil count decreased,,2021,Q3,2,F,2021.0,20210921.0,20210904,20210930,PER,,US-CELGENEUS-USA-20210808451,CELGENE,,66.0,YR,,F,Y,,,20210930.0,,MD,US,US,2021,Q3,Elderly
197910071,19791007,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q3,Colitis,,2021,Q3,1,I,,20210830.0,20210906,20210906,EXP,,CA-BAUSCH-BL-2021-029742,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20210906.0,,CN,CA,CA,2021,Q3,Elderly
197910071,19791007,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q3,Colitis ulcerative,,2021,Q3,1,I,,20210830.0,20210906,20210906,EXP,,CA-BAUSCH-BL-2021-029742,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20210906.0,,CN,CA,CA,2021,Q3,Elderly
197910071,19791007,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q3,Decreased activity,,2021,Q3,1,I,,20210830.0,20210906,20210906,EXP,,CA-BAUSCH-BL-2021-029742,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20210906.0,,CN,CA,CA,2021,Q3,Elderly
197910071,19791007,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q3,Frequent bowel movements,,2021,Q3,1,I,,20210830.0,20210906,20210906,EXP,,CA-BAUSCH-BL-2021-029742,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20210906.0,,CN,CA,CA,2021,Q3,Elderly
197910071,19791007,13,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q3,Rectal haemorrhage,,2021,Q3,1,I,,20210830.0,20210906,20210906,EXP,,CA-BAUSCH-BL-2021-029742,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20210906.0,,CN,CA,CA,2021,Q3,Elderly
198108951,19810895,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, NACH SCHEMA",,,U,,,,,1.5,MG,SOLUTION FOR INJECTION/INFUSION,,2021,Q3,Acute kidney injury,,2021,Q3,1,I,,20210903.0,20210909,20210909,EXP,,NVSC2021DE200658,NOVARTIS,,78.0,YR,,M,Y,80.0,KG,20210909.0,,HP,DE,DE,2021,Q3,Elderly
198108951,19810895,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, NACH SCHEMA",,,U,,,,,1.5,MG,SOLUTION FOR INJECTION/INFUSION,,2021,Q3,Diarrhoea,,2021,Q3,1,I,,20210903.0,20210909,20210909,EXP,,NVSC2021DE200658,NOVARTIS,,78.0,YR,,M,Y,80.0,KG,20210909.0,,HP,DE,DE,2021,Q3,Elderly
198108951,19810895,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, NACH SCHEMA",,,U,,,,,1.5,MG,SOLUTION FOR INJECTION/INFUSION,,2021,Q3,Duodenal ulcer haemorrhage,,2021,Q3,1,I,,20210903.0,20210909,20210909,EXP,,NVSC2021DE200658,NOVARTIS,,78.0,YR,,M,Y,80.0,KG,20210909.0,,HP,DE,DE,2021,Q3,Elderly
198108951,19810895,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, NACH SCHEMA",,,U,,,,,1.5,MG,SOLUTION FOR INJECTION/INFUSION,,2021,Q3,Dyspnoea,,2021,Q3,1,I,,20210903.0,20210909,20210909,EXP,,NVSC2021DE200658,NOVARTIS,,78.0,YR,,M,Y,80.0,KG,20210909.0,,HP,DE,DE,2021,Q3,Elderly
198108951,19810895,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, NACH SCHEMA",,,U,,,,,1.5,MG,SOLUTION FOR INJECTION/INFUSION,,2021,Q3,Haematochezia,,2021,Q3,1,I,,20210903.0,20210909,20210909,EXP,,NVSC2021DE200658,NOVARTIS,,78.0,YR,,M,Y,80.0,KG,20210909.0,,HP,DE,DE,2021,Q3,Elderly
198108951,19810895,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"1.5 MG, NACH SCHEMA",,,U,,,,,1.5,MG,SOLUTION FOR INJECTION/INFUSION,,2021,Q3,Oedema peripheral,,2021,Q3,1,I,,20210903.0,20210909,20210909,EXP,,NVSC2021DE200658,NOVARTIS,,78.0,YR,,M,Y,80.0,KG,20210909.0,,HP,DE,DE,2021,Q3,Elderly
198169342,19816934,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q3,Abdominal pain,,2021,Q3,2,F,,20210915.0,20210910,20210917,EXP,,"GR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-126099",BOEHRINGER INGELHEIM,"MOUSTAKI M, KALOGERIS N, KATSAFYLLOUDI M, PAPANIKOLA N, RIGANA M, SPANOU L. ET AL. CASE OF CONCURRENT EUGLYCEMIC DIABETIC KETOACIDOSIS AND ACUTE PANCREATITIS IN A PATIENT WITH DIABETES MELLITUS. 48TH PANHELLENIC CONGRESS OF ENDOCRINOLOGY, METABOLISM + DIABETES MELLITUS 1?3 JULY 2021. 2021 JUL? 98:",50.0,YR,A,M,Y,,,20210917.0,,MD,GR,GR,2021,Q3,Adult
198169342,19816934,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q3,Decreased appetite,,2021,Q3,2,F,,20210915.0,20210910,20210917,EXP,,"GR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-126099",BOEHRINGER INGELHEIM,"MOUSTAKI M, KALOGERIS N, KATSAFYLLOUDI M, PAPANIKOLA N, RIGANA M, SPANOU L. ET AL. CASE OF CONCURRENT EUGLYCEMIC DIABETIC KETOACIDOSIS AND ACUTE PANCREATITIS IN A PATIENT WITH DIABETES MELLITUS. 48TH PANHELLENIC CONGRESS OF ENDOCRINOLOGY, METABOLISM + DIABETES MELLITUS 1?3 JULY 2021. 2021 JUL? 98:",50.0,YR,A,M,Y,,,20210917.0,,MD,GR,GR,2021,Q3,Adult
198169342,19816934,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q3,Euglycaemic diabetic ketoacidosis,,2021,Q3,2,F,,20210915.0,20210910,20210917,EXP,,"GR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-126099",BOEHRINGER INGELHEIM,"MOUSTAKI M, KALOGERIS N, KATSAFYLLOUDI M, PAPANIKOLA N, RIGANA M, SPANOU L. ET AL. CASE OF CONCURRENT EUGLYCEMIC DIABETIC KETOACIDOSIS AND ACUTE PANCREATITIS IN A PATIENT WITH DIABETES MELLITUS. 48TH PANHELLENIC CONGRESS OF ENDOCRINOLOGY, METABOLISM + DIABETES MELLITUS 1?3 JULY 2021. 2021 JUL? 98:",50.0,YR,A,M,Y,,,20210917.0,,MD,GR,GR,2021,Q3,Adult
198169342,19816934,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q3,Nausea,,2021,Q3,2,F,,20210915.0,20210910,20210917,EXP,,"GR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-126099",BOEHRINGER INGELHEIM,"MOUSTAKI M, KALOGERIS N, KATSAFYLLOUDI M, PAPANIKOLA N, RIGANA M, SPANOU L. ET AL. CASE OF CONCURRENT EUGLYCEMIC DIABETIC KETOACIDOSIS AND ACUTE PANCREATITIS IN A PATIENT WITH DIABETES MELLITUS. 48TH PANHELLENIC CONGRESS OF ENDOCRINOLOGY, METABOLISM + DIABETES MELLITUS 1?3 JULY 2021. 2021 JUL? 98:",50.0,YR,A,M,Y,,,20210917.0,,MD,GR,GR,2021,Q3,Adult
198169342,19816934,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q3,Pancreatitis acute,,2021,Q3,2,F,,20210915.0,20210910,20210917,EXP,,"GR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-126099",BOEHRINGER INGELHEIM,"MOUSTAKI M, KALOGERIS N, KATSAFYLLOUDI M, PAPANIKOLA N, RIGANA M, SPANOU L. ET AL. CASE OF CONCURRENT EUGLYCEMIC DIABETIC KETOACIDOSIS AND ACUTE PANCREATITIS IN A PATIENT WITH DIABETES MELLITUS. 48TH PANHELLENIC CONGRESS OF ENDOCRINOLOGY, METABOLISM + DIABETES MELLITUS 1?3 JULY 2021. 2021 JUL? 98:",50.0,YR,A,M,Y,,,20210917.0,,MD,GR,GR,2021,Q3,Adult
198169342,19816934,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q3,Vomiting,,2021,Q3,2,F,,20210915.0,20210910,20210917,EXP,,"GR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-126099",BOEHRINGER INGELHEIM,"MOUSTAKI M, KALOGERIS N, KATSAFYLLOUDI M, PAPANIKOLA N, RIGANA M, SPANOU L. ET AL. CASE OF CONCURRENT EUGLYCEMIC DIABETIC KETOACIDOSIS AND ACUTE PANCREATITIS IN A PATIENT WITH DIABETES MELLITUS. 48TH PANHELLENIC CONGRESS OF ENDOCRINOLOGY, METABOLISM + DIABETES MELLITUS 1?3 JULY 2021. 2021 JUL? 98:",50.0,YR,A,M,Y,,,20210917.0,,MD,GR,GR,2021,Q3,Adult
198174051,19817405,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q3,Acute kidney injury,,2021,Q3,1,I,20210523.0,20210602.0,20210910,20210910,EXP,,US-GILEAD-2021-0534340,GILEAD,,68.0,YR,E,M,Y,,,20210910.0,,HP,US,US,2021,Q3,Elderly
198174051,19817405,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q3,Anaphylactic reaction,,2021,Q3,1,I,20210523.0,20210602.0,20210910,20210910,EXP,,US-GILEAD-2021-0534340,GILEAD,,68.0,YR,E,M,Y,,,20210910.0,,HP,US,US,2021,Q3,Elderly
198174051,19817405,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q3,Hypoxia,,2021,Q3,1,I,20210523.0,20210602.0,20210910,20210910,EXP,,US-GILEAD-2021-0534340,GILEAD,,68.0,YR,E,M,Y,,,20210910.0,,HP,US,US,2021,Q3,Elderly
198174051,19817405,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q3,Pneumonia serratia,,2021,Q3,1,I,20210523.0,20210602.0,20210910,20210910,EXP,,US-GILEAD-2021-0534340,GILEAD,,68.0,YR,E,M,Y,,,20210910.0,,HP,US,US,2021,Q3,Elderly
198226951,19822695,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MG,,,U,,,,,1.5,MG,,,2021,Q3,Acute kidney injury,,2021,Q3,1,I,,20210902.0,20210913,20210913,EXP,DE-ADRED-07210-01,DE-TORRENT-00021049,TORRENT,,78.0,YR,E,M,Y,80.0,KG,20210913.0,,PH,DE,DE,2021,Q3,Elderly
198226951,19822695,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MG,,,U,,,,,1.5,MG,,,2021,Q3,Diarrhoea,,2021,Q3,1,I,,20210902.0,20210913,20210913,EXP,DE-ADRED-07210-01,DE-TORRENT-00021049,TORRENT,,78.0,YR,E,M,Y,80.0,KG,20210913.0,,PH,DE,DE,2021,Q3,Elderly
198226951,19822695,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MG,,,U,,,,,1.5,MG,,,2021,Q3,Duodenal ulcer haemorrhage,,2021,Q3,1,I,,20210902.0,20210913,20210913,EXP,DE-ADRED-07210-01,DE-TORRENT-00021049,TORRENT,,78.0,YR,E,M,Y,80.0,KG,20210913.0,,PH,DE,DE,2021,Q3,Elderly
198226951,19822695,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MG,,,U,,,,,1.5,MG,,,2021,Q3,Dyspnoea,,2021,Q3,1,I,,20210902.0,20210913,20210913,EXP,DE-ADRED-07210-01,DE-TORRENT-00021049,TORRENT,,78.0,YR,E,M,Y,80.0,KG,20210913.0,,PH,DE,DE,2021,Q3,Elderly
198226951,19822695,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MG,,,U,,,,,1.5,MG,,,2021,Q3,Haematochezia,,2021,Q3,1,I,,20210902.0,20210913,20210913,EXP,DE-ADRED-07210-01,DE-TORRENT-00021049,TORRENT,,78.0,YR,E,M,Y,80.0,KG,20210913.0,,PH,DE,DE,2021,Q3,Elderly
198226951,19822695,6,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,1.5 MG,,,U,,,,,1.5,MG,,,2021,Q3,Oedema peripheral,,2021,Q3,1,I,,20210902.0,20210913,20210913,EXP,DE-ADRED-07210-01,DE-TORRENT-00021049,TORRENT,,78.0,YR,E,M,Y,80.0,KG,20210913.0,,PH,DE,DE,2021,Q3,Elderly
198245751,19824575,5,C,dulaglutide injector,,2,,,,,,,,,,,,,,2021,Q3,Anaemia,,2021,Q3,1,I,20210907.0,,20210913,20210913,DIR,,,FDA-CTU,,68.0,YR,,F,N,114.75,KG,20210913.0,Y,HP,US,US,2021,Q3,Elderly
198245751,19824575,5,C,dulaglutide injector,,2,,,,,,,,,,,,,,2021,Q3,Bacterial infection,,2021,Q3,1,I,20210907.0,,20210913,20210913,DIR,,,FDA-CTU,,68.0,YR,,F,N,114.75,KG,20210913.0,Y,HP,US,US,2021,Q3,Elderly
198245751,19824575,5,C,dulaglutide injector,,2,,,,,,,,,,,,,,2021,Q3,Blood lactic acid increased,,2021,Q3,1,I,20210907.0,,20210913,20210913,DIR,,,FDA-CTU,,68.0,YR,,F,N,114.75,KG,20210913.0,Y,HP,US,US,2021,Q3,Elderly
198245751,19824575,5,C,dulaglutide injector,,2,,,,,,,,,,,,,,2021,Q3,COVID-19 pneumonia,,2021,Q3,1,I,20210907.0,,20210913,20210913,DIR,,,FDA-CTU,,68.0,YR,,F,N,114.75,KG,20210913.0,Y,HP,US,US,2021,Q3,Elderly
198245751,19824575,5,C,dulaglutide injector,,2,,,,,,,,,,,,,,2021,Q3,Chills,,2021,Q3,1,I,20210907.0,,20210913,20210913,DIR,,,FDA-CTU,,68.0,YR,,F,N,114.75,KG,20210913.0,Y,HP,US,US,2021,Q3,Elderly
198245751,19824575,5,C,dulaglutide injector,,2,,,,,,,,,,,,,,2021,Q3,Cough,,2021,Q3,1,I,20210907.0,,20210913,20210913,DIR,,,FDA-CTU,,68.0,YR,,F,N,114.75,KG,20210913.0,Y,HP,US,US,2021,Q3,Elderly
198245751,19824575,5,C,dulaglutide injector,,2,,,,,,,,,,,,,,2021,Q3,Cystitis,,2021,Q3,1,I,20210907.0,,20210913,20210913,DIR,,,FDA-CTU,,68.0,YR,,F,N,114.75,KG,20210913.0,Y,HP,US,US,2021,Q3,Elderly
198245751,19824575,5,C,dulaglutide injector,,2,,,,,,,,,,,,,,2021,Q3,Dyspnoea,,2021,Q3,1,I,20210907.0,,20210913,20210913,DIR,,,FDA-CTU,,68.0,YR,,F,N,114.75,KG,20210913.0,Y,HP,US,US,2021,Q3,Elderly
198245751,19824575,5,C,dulaglutide injector,,2,,,,,,,,,,,,,,2021,Q3,Dysuria,,2021,Q3,1,I,20210907.0,,20210913,20210913,DIR,,,FDA-CTU,,68.0,YR,,F,N,114.75,KG,20210913.0,Y,HP,US,US,2021,Q3,Elderly
198245751,19824575,5,C,dulaglutide injector,,2,,,,,,,,,,,,,,2021,Q3,Electrocardiogram PR shortened,,2021,Q3,1,I,20210907.0,,20210913,20210913,DIR,,,FDA-CTU,,68.0,YR,,F,N,114.75,KG,20210913.0,Y,HP,US,US,2021,Q3,Elderly
198245751,19824575,5,C,dulaglutide injector,,2,,,,,,,,,,,,,,2021,Q3,Electrocardiogram QT prolonged,,2021,Q3,1,I,20210907.0,,20210913,20210913,DIR,,,FDA-CTU,,68.0,YR,,F,N,114.75,KG,20210913.0,Y,HP,US,US,2021,Q3,Elderly
198245751,19824575,5,C,dulaglutide injector,,2,,,,,,,,,,,,,,2021,Q3,Headache,,2021,Q3,1,I,20210907.0,,20210913,20210913,DIR,,,FDA-CTU,,68.0,YR,,F,N,114.75,KG,20210913.0,Y,HP,US,US,2021,Q3,Elderly
198245751,19824575,5,C,dulaglutide injector,,2,,,,,,,,,,,,,,2021,Q3,Nausea,,2021,Q3,1,I,20210907.0,,20210913,20210913,DIR,,,FDA-CTU,,68.0,YR,,F,N,114.75,KG,20210913.0,Y,HP,US,US,2021,Q3,Elderly
198245751,19824575,5,C,dulaglutide injector,,2,,,,,,,,,,,,,,2021,Q3,Pollakiuria,,2021,Q3,1,I,20210907.0,,20210913,20210913,DIR,,,FDA-CTU,,68.0,YR,,F,N,114.75,KG,20210913.0,Y,HP,US,US,2021,Q3,Elderly
198245751,19824575,5,C,dulaglutide injector,,2,,,,,,,,,,,,,,2021,Q3,Pyrexia,,2021,Q3,1,I,20210907.0,,20210913,20210913,DIR,,,FDA-CTU,,68.0,YR,,F,N,114.75,KG,20210913.0,Y,HP,US,US,2021,Q3,Elderly
198245751,19824575,5,C,dulaglutide injector,,2,,,,,,,,,,,,,,2021,Q3,Sinus tachycardia,,2021,Q3,1,I,20210907.0,,20210913,20210913,DIR,,,FDA-CTU,,68.0,YR,,F,N,114.75,KG,20210913.0,Y,HP,US,US,2021,Q3,Elderly
198372692,19837269,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,U,,,,,,,,,2021,Q3,Euglycaemic diabetic ketoacidosis,,2021,Q3,2,F,,20210922.0,20210915,20210924,EXP,,GR-EMD SERONO-9264894,EMD SERONO INC,"MOUSTAKI M, KALOGERIS N, KATSAFYLOUDI M, PAPANIKOLA N, RIGANA M, SPANOU L, ANGELOPOULOS T, KALANTZIS G, VRYONIDOU A. A CASE OF SIMULTANEOUS OCCURRENCE OF EUGLYCEMIC KETOACIDOSIS AND ACUTE PANCREATITIS IN A PATIENT WITH DIABETES MELLITUS. PANHELLENIC CONGRESS OF ENDOCRINOLOGY, METABOLISM DIABETES MELLITUS CONGRESS. 2021 JUL?48:1?3.",50.0,YR,A,M,Y,,,20210924.0,,HP,GR,GR,2021,Q3,Adult
198372692,19837269,2,SS,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,U,,,,,,,,,2021,Q3,Pancreatitis acute,,2021,Q3,2,F,,20210922.0,20210915,20210924,EXP,,GR-EMD SERONO-9264894,EMD SERONO INC,"MOUSTAKI M, KALOGERIS N, KATSAFYLOUDI M, PAPANIKOLA N, RIGANA M, SPANOU L, ANGELOPOULOS T, KALANTZIS G, VRYONIDOU A. A CASE OF SIMULTANEOUS OCCURRENCE OF EUGLYCEMIC KETOACIDOSIS AND ACUTE PANCREATITIS IN A PATIENT WITH DIABETES MELLITUS. PANHELLENIC CONGRESS OF ENDOCRINOLOGY, METABOLISM DIABETES MELLITUS CONGRESS. 2021 JUL?48:1?3.",50.0,YR,A,M,Y,,,20210924.0,,HP,GR,GR,2021,Q3,Adult
198737441,19873744,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, WEEKLY (1/W)",,,U,U,,,,,,,/wk,2021,Q3,Blood glucose abnormal,,2021,Q3,1,I,2019.0,20210914.0,20210922,20210922,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109005920,ELI LILLY AND CO,,59.0,YR,,M,Y,91.0,KG,20210922.0,,CN,CN,CN,2021,Q3,Adult
198737441,19873744,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, WEEKLY (1/W)",,,U,U,,,,,,,/wk,2021,Q3,Diabetic complication,,2021,Q3,1,I,2019.0,20210914.0,20210922,20210922,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109005920,ELI LILLY AND CO,,59.0,YR,,M,Y,91.0,KG,20210922.0,,CN,CN,CN,2021,Q3,Adult
198737441,19873744,2,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,"UNK, WEEKLY (1/W)",,,U,U,,,,,,,/wk,2021,Q3,Hypoaesthesia,,2021,Q3,1,I,2019.0,20210914.0,20210922,20210922,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109005920,ELI LILLY AND CO,,59.0,YR,,M,Y,91.0,KG,20210922.0,,CN,CN,CN,2021,Q3,Adult
198737441,19873744,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,U,U,,,,,,,,2021,Q3,Blood glucose abnormal,,2021,Q3,1,I,2019.0,20210914.0,20210922,20210922,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109005920,ELI LILLY AND CO,,59.0,YR,,M,Y,91.0,KG,20210922.0,,CN,CN,CN,2021,Q3,Adult
198737441,19873744,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,U,U,,,,,,,,2021,Q3,Diabetic complication,,2021,Q3,1,I,2019.0,20210914.0,20210922,20210922,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109005920,ELI LILLY AND CO,,59.0,YR,,M,Y,91.0,KG,20210922.0,,CN,CN,CN,2021,Q3,Adult
198737441,19873744,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,,,,,U,U,,,,,,,,2021,Q3,Hypoaesthesia,,2021,Q3,1,I,2019.0,20210914.0,20210922,20210922,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109005920,ELI LILLY AND CO,,59.0,YR,,M,Y,91.0,KG,20210922.0,,CN,CN,CN,2021,Q3,Adult
198783981,19878398,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, QW",,,U,,,,,0.75,MG,INJECTION,/wk,2021,Q3,Aortic valve incompetence,,2021,Q3,1,I,,20210916.0,20210924,20210924,EXP,,NVSJ2021JP013978,NOVARTIS,,89.0,YR,,M,Y,59.4,KG,20210924.0,,MD,JP,JP,2021,Q3,Elderly
198783981,19878398,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, QW",,,U,,,,,0.75,MG,INJECTION,/wk,2021,Q3,Brain natriuretic peptide increased,,2021,Q3,1,I,,20210916.0,20210924,20210924,EXP,,NVSJ2021JP013978,NOVARTIS,,89.0,YR,,M,Y,59.4,KG,20210924.0,,MD,JP,JP,2021,Q3,Elderly
198783981,19878398,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, QW",,,U,,,,,0.75,MG,INJECTION,/wk,2021,Q3,Cardiac failure,,2021,Q3,1,I,,20210916.0,20210924,20210924,EXP,,NVSJ2021JP013978,NOVARTIS,,89.0,YR,,M,Y,59.4,KG,20210924.0,,MD,JP,JP,2021,Q3,Elderly
198783981,19878398,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, QW",,,U,,,,,0.75,MG,INJECTION,/wk,2021,Q3,Cholelithiasis,,2021,Q3,1,I,,20210916.0,20210924,20210924,EXP,,NVSJ2021JP013978,NOVARTIS,,89.0,YR,,M,Y,59.4,KG,20210924.0,,MD,JP,JP,2021,Q3,Elderly
198783981,19878398,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, QW",,,U,,,,,0.75,MG,INJECTION,/wk,2021,Q3,Colon cancer,,2021,Q3,1,I,,20210916.0,20210924,20210924,EXP,,NVSJ2021JP013978,NOVARTIS,,89.0,YR,,M,Y,59.4,KG,20210924.0,,MD,JP,JP,2021,Q3,Elderly
198783981,19878398,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, QW",,,U,,,,,0.75,MG,INJECTION,/wk,2021,Q3,Drug ineffective,,2021,Q3,1,I,,20210916.0,20210924,20210924,EXP,,NVSJ2021JP013978,NOVARTIS,,89.0,YR,,M,Y,59.4,KG,20210924.0,,MD,JP,JP,2021,Q3,Elderly
198783981,19878398,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, QW",,,U,,,,,0.75,MG,INJECTION,/wk,2021,Q3,Dyspnoea,,2021,Q3,1,I,,20210916.0,20210924,20210924,EXP,,NVSJ2021JP013978,NOVARTIS,,89.0,YR,,M,Y,59.4,KG,20210924.0,,MD,JP,JP,2021,Q3,Elderly
198783981,19878398,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, QW",,,U,,,,,0.75,MG,INJECTION,/wk,2021,Q3,Hypertrophic cardiomyopathy,,2021,Q3,1,I,,20210916.0,20210924,20210924,EXP,,NVSJ2021JP013978,NOVARTIS,,89.0,YR,,M,Y,59.4,KG,20210924.0,,MD,JP,JP,2021,Q3,Elderly
198783981,19878398,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, QW",,,U,,,,,0.75,MG,INJECTION,/wk,2021,Q3,Left ventricular dilatation,,2021,Q3,1,I,,20210916.0,20210924,20210924,EXP,,NVSJ2021JP013978,NOVARTIS,,89.0,YR,,M,Y,59.4,KG,20210924.0,,MD,JP,JP,2021,Q3,Elderly
198783981,19878398,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, QW",,,U,,,,,0.75,MG,INJECTION,/wk,2021,Q3,N-terminal prohormone brain natriuretic peptide increased,,2021,Q3,1,I,,20210916.0,20210924,20210924,EXP,,NVSJ2021JP013978,NOVARTIS,,89.0,YR,,M,Y,59.4,KG,20210924.0,,MD,JP,JP,2021,Q3,Elderly
198783981,19878398,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, QW",,,U,,,,,0.75,MG,INJECTION,/wk,2021,Q3,Prostate cancer,,2021,Q3,1,I,,20210916.0,20210924,20210924,EXP,,NVSJ2021JP013978,NOVARTIS,,89.0,YR,,M,Y,59.4,KG,20210924.0,,MD,JP,JP,2021,Q3,Elderly
198783981,19878398,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, QW",,,U,,,,,0.75,MG,INJECTION,/wk,2021,Q3,Sinus node dysfunction,,2021,Q3,1,I,,20210916.0,20210924,20210924,EXP,,NVSJ2021JP013978,NOVARTIS,,89.0,YR,,M,Y,59.4,KG,20210924.0,,MD,JP,JP,2021,Q3,Elderly
198783981,19878398,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, QW",,,U,,,,,0.75,MG,INJECTION,/wk,2021,Q3,Type 2 diabetes mellitus,,2021,Q3,1,I,,20210916.0,20210924,20210924,EXP,,NVSJ2021JP013978,NOVARTIS,,89.0,YR,,M,Y,59.4,KG,20210924.0,,MD,JP,JP,2021,Q3,Elderly
198783981,19878398,10,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,"0.75 MG, QW",,,U,,,,,0.75,MG,INJECTION,/wk,2021,Q3,Ventricular hypokinesia,,2021,Q3,1,I,,20210916.0,20210924,20210924,EXP,,NVSJ2021JP013978,NOVARTIS,,89.0,YR,,M,Y,59.4,KG,20210924.0,,MD,JP,JP,2021,Q3,Elderly
198799911,19879991,3,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,1.5 MG QWIH,,,,,,,,,,,,2021,Q3,Ketosis,,2021,Q3,1,I,20210909.0,20210916.0,20210924,20210924,EXP,,CN-ASTRAZENECA-2021A733296,ASTRAZENECA,,13580.0,DY,,M,Y,125.0,KG,20210924.0,,HP,CN,CN,2021,Q3,Elderly
198952311,19895231,1,PS,"DULAGLUTIDE (DULAGLUTIDE 0.75MG/0.5ML INJ, SOLN PEN)",DULAGLUTIDE,1,Subcutaneous,?          OTHER DOSE:0.75MG/0.5ML;?,,,N,D,,,,0.75,MG,INJECTION,QW,2021,Q3,Increased appetite,,2021,Q3,1,I,20200930.0,,20210929,20210929,DIR,,,FDA-CTU,,75.0,YR,,M,N,108.86,KG,20210418.0,N,PH,US,US,2021,Q3,Elderly
198956001,19895600,1,PS,"DULAGLUTIDE (DULAGLUTIDE 0.75MG/0.5ML INJ, SOLN, PEN)",DULAGLUTIDE,1,,,,,Y,D,,,,,,,,2021,Q3,Chest discomfort,,2021,Q3,1,I,20210603.0,,20210929,20210929,DIR,,,FDA-CTU,,61.0,YR,,M,N,80.0,KG,20210818.0,N,HP,US,US,2021,Q3,Adult
198956001,19895600,1,PS,"DULAGLUTIDE (DULAGLUTIDE 0.75MG/0.5ML INJ, SOLN, PEN)",DULAGLUTIDE,1,,,,,Y,D,,,,,,,,2021,Q3,Cough,,2021,Q3,1,I,20210603.0,,20210929,20210929,DIR,,,FDA-CTU,,61.0,YR,,M,N,80.0,KG,20210818.0,N,HP,US,US,2021,Q3,Adult
198956001,19895600,1,PS,"DULAGLUTIDE (DULAGLUTIDE 0.75MG/0.5ML INJ, SOLN, PEN)",DULAGLUTIDE,1,,,,,Y,D,,,,,,,,2021,Q3,Dyspnoea,,2021,Q3,1,I,20210603.0,,20210929,20210929,DIR,,,FDA-CTU,,61.0,YR,,M,N,80.0,KG,20210818.0,N,HP,US,US,2021,Q3,Adult
198956001,19895600,1,PS,"DULAGLUTIDE (DULAGLUTIDE 0.75MG/0.5ML INJ, SOLN, PEN)",DULAGLUTIDE,1,,,,,Y,D,,,,,,,,2021,Q3,Pain,,2021,Q3,1,I,20210603.0,,20210929,20210929,DIR,,,FDA-CTU,,61.0,YR,,M,N,80.0,KG,20210818.0,N,HP,US,US,2021,Q3,Adult
198956001,19895600,1,PS,"DULAGLUTIDE (DULAGLUTIDE 0.75MG/0.5ML INJ, SOLN, PEN)",DULAGLUTIDE,1,,,,,Y,D,,,,,,,,2021,Q3,Pancreatitis acute,,2021,Q3,1,I,20210603.0,,20210929,20210929,DIR,,,FDA-CTU,,61.0,YR,,M,N,80.0,KG,20210818.0,N,HP,US,US,2021,Q3,Adult
199019571,19901957,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,0.75,MG,INJECTION,/wk,2021,Q3,Acute kidney injury,,2021,Q3,1,I,,20210920.0,20210929,20210929,EXP,,US-BAXTER-2021BAX030357,BAXTER,"LEE J, UMANA I, NGUYEN J. EXACERBATION OF ATRIAL FIBRILLATION RELATED TO DULAGLUTIDE USE. CLINICAL CASE REPORTS. 2021?9(5):1?5.",75.0,YR,,F,Y,,,20210929.0,,HP,US,US,2021,Q3,Elderly
199019571,19901957,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,0.75,MG,INJECTION,/wk,2021,Q3,Bradycardia,Bradycardia,2021,Q3,1,I,,20210920.0,20210929,20210929,EXP,,US-BAXTER-2021BAX030357,BAXTER,"LEE J, UMANA I, NGUYEN J. EXACERBATION OF ATRIAL FIBRILLATION RELATED TO DULAGLUTIDE USE. CLINICAL CASE REPORTS. 2021?9(5):1?5.",75.0,YR,,F,Y,,,20210929.0,,HP,US,US,2021,Q3,Elderly
199019571,19901957,8,C,DULAGLUTIDE.,DULAGLUTIDE,1,Unknown,,,,,,,,,0.75,MG,INJECTION,/wk,2021,Q3,Fatigue,Fatigue,2021,Q3,1,I,,20210920.0,20210929,20210929,EXP,,US-BAXTER-2021BAX030357,BAXTER,"LEE J, UMANA I, NGUYEN J. EXACERBATION OF ATRIAL FIBRILLATION RELATED TO DULAGLUTIDE USE. CLINICAL CASE REPORTS. 2021?9(5):1?5.",75.0,YR,,F,Y,,,20210929.0,,HP,US,US,2021,Q3,Elderly
199019571,19901957,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,SINGLE DOSE,,,,,,,,0.75,MG,,,2021,Q3,Acute kidney injury,,2021,Q3,1,I,,20210920.0,20210929,20210929,EXP,,US-BAXTER-2021BAX030357,BAXTER,"LEE J, UMANA I, NGUYEN J. EXACERBATION OF ATRIAL FIBRILLATION RELATED TO DULAGLUTIDE USE. CLINICAL CASE REPORTS. 2021?9(5):1?5.",75.0,YR,,F,Y,,,20210929.0,,HP,US,US,2021,Q3,Elderly
199019571,19901957,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,SINGLE DOSE,,,,,,,,0.75,MG,,,2021,Q3,Bradycardia,Bradycardia,2021,Q3,1,I,,20210920.0,20210929,20210929,EXP,,US-BAXTER-2021BAX030357,BAXTER,"LEE J, UMANA I, NGUYEN J. EXACERBATION OF ATRIAL FIBRILLATION RELATED TO DULAGLUTIDE USE. CLINICAL CASE REPORTS. 2021?9(5):1?5.",75.0,YR,,F,Y,,,20210929.0,,HP,US,US,2021,Q3,Elderly
199019571,19901957,9,C,DULAGLUTIDE.,DULAGLUTIDE,1,Subcutaneous,SINGLE DOSE,,,,,,,,0.75,MG,,,2021,Q3,Fatigue,Fatigue,2021,Q3,1,I,,20210920.0,20210929,20210929,EXP,,US-BAXTER-2021BAX030357,BAXTER,"LEE J, UMANA I, NGUYEN J. EXACERBATION OF ATRIAL FIBRILLATION RELATED TO DULAGLUTIDE USE. CLINICAL CASE REPORTS. 2021?9(5):1?5.",75.0,YR,,F,Y,,,20210929.0,,HP,US,US,2021,Q3,Elderly
167286417,16728641,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 milligram, Every Week",,,U,,,,,7.5,MG,,/WK,2021,Q4,Colitis ulcerative,,2021,Q4,7,F,,20211216.0,20190822,20211228,EXP,,CA-AUROBINDO-AUR-APL-2019-054419,AUROBINDO,,73.0,YR,,F,Y,,,20211228.0,,HP,CA,CA,2021,Q4,Elderly
167286417,16728641,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 milligram, Every Week",,,U,,,,,7.5,MG,,/WK,2021,Q4,Decreased activity,,2021,Q4,7,F,,20211216.0,20190822,20211228,EXP,,CA-AUROBINDO-AUR-APL-2019-054419,AUROBINDO,,73.0,YR,,F,Y,,,20211228.0,,HP,CA,CA,2021,Q4,Elderly
167286417,16728641,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 milligram, Every Week",,,U,,,,,7.5,MG,,/WK,2021,Q4,Frequent bowel movements,,2021,Q4,7,F,,20211216.0,20190822,20211228,EXP,,CA-AUROBINDO-AUR-APL-2019-054419,AUROBINDO,,73.0,YR,,F,Y,,,20211228.0,,HP,CA,CA,2021,Q4,Elderly
167286417,16728641,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 milligram, Every Week",,,U,,,,,7.5,MG,,/WK,2021,Q4,Colitis,,2021,Q4,7,F,,20211216.0,20190822,20211228,EXP,,CA-AUROBINDO-AUR-APL-2019-054419,AUROBINDO,,73.0,YR,,F,Y,,,20211228.0,,HP,CA,CA,2021,Q4,Elderly
167286417,16728641,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 milligram, Every Week",,,U,,,,,7.5,MG,,/WK,2021,Q4,Rectal haemorrhage,,2021,Q4,7,F,,20211216.0,20190822,20211228,EXP,,CA-AUROBINDO-AUR-APL-2019-054419,AUROBINDO,,73.0,YR,,F,Y,,,20211228.0,,HP,CA,CA,2021,Q4,Elderly
168377542,16837754,37,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2021,Q4,Decreased activity,,2021,Q4,2,F,,20211125.0,20190923,20211205,EXP,,CA-TEVA-2019-CA-1112284,TEVA,,73.0,YR,E,F,Y,,,20211205.0,,CN,CA,CA,2021,Q4,Elderly
168377542,16837754,37,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2021,Q4,Colitis,,2021,Q4,2,F,,20211125.0,20190923,20211205,EXP,,CA-TEVA-2019-CA-1112284,TEVA,,73.0,YR,E,F,Y,,,20211205.0,,CN,CA,CA,2021,Q4,Elderly
168377542,16837754,37,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2021,Q4,Frequent bowel movements,,2021,Q4,2,F,,20211125.0,20190923,20211205,EXP,,CA-TEVA-2019-CA-1112284,TEVA,,73.0,YR,E,F,Y,,,20211205.0,,CN,CA,CA,2021,Q4,Elderly
168377542,16837754,37,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2021,Q4,Rectal haemorrhage,,2021,Q4,2,F,,20211125.0,20190923,20211205,EXP,,CA-TEVA-2019-CA-1112284,TEVA,,73.0,YR,E,F,Y,,,20211205.0,,CN,CA,CA,2021,Q4,Elderly
168377542,16837754,37,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2021,Q4,Colitis ulcerative,,2021,Q4,2,F,,20211125.0,20190923,20211205,EXP,,CA-TEVA-2019-CA-1112284,TEVA,,73.0,YR,E,F,Y,,,20211205.0,,CN,CA,CA,2021,Q4,Elderly
168377542,16837754,38,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/WK,2021,Q4,Decreased activity,,2021,Q4,2,F,,20211125.0,20190923,20211205,EXP,,CA-TEVA-2019-CA-1112284,TEVA,,73.0,YR,E,F,Y,,,20211205.0,,CN,CA,CA,2021,Q4,Elderly
168377542,16837754,38,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/WK,2021,Q4,Colitis,,2021,Q4,2,F,,20211125.0,20190923,20211205,EXP,,CA-TEVA-2019-CA-1112284,TEVA,,73.0,YR,E,F,Y,,,20211205.0,,CN,CA,CA,2021,Q4,Elderly
168377542,16837754,38,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/WK,2021,Q4,Frequent bowel movements,,2021,Q4,2,F,,20211125.0,20190923,20211205,EXP,,CA-TEVA-2019-CA-1112284,TEVA,,73.0,YR,E,F,Y,,,20211205.0,,CN,CA,CA,2021,Q4,Elderly
168377542,16837754,38,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/WK,2021,Q4,Rectal haemorrhage,,2021,Q4,2,F,,20211125.0,20190923,20211205,EXP,,CA-TEVA-2019-CA-1112284,TEVA,,73.0,YR,E,F,Y,,,20211205.0,,CN,CA,CA,2021,Q4,Elderly
168377542,16837754,38,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/WK,2021,Q4,Colitis ulcerative,,2021,Q4,2,F,,20211125.0,20190923,20211205,EXP,,CA-TEVA-2019-CA-1112284,TEVA,,73.0,YR,E,F,Y,,,20211205.0,,CN,CA,CA,2021,Q4,Elderly
185612615,18561261,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q4,Gastrointestinal haemorrhage,,2021,Q4,5,F,20200510.0,20211105.0,20201130,20211116,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20211116.0,,CN,DE,DE,2021,Q4,Elderly
185612615,18561261,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q4,Eye haemorrhage,,2021,Q4,5,F,20200510.0,20211105.0,20201130,20211116,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20211116.0,,CN,DE,DE,2021,Q4,Elderly
185612615,18561261,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q4,Haemoglobin decreased,,2021,Q4,5,F,20200510.0,20211105.0,20201130,20211116,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20211116.0,,CN,DE,DE,2021,Q4,Elderly
185612615,18561261,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q4,Lacrimation increased,,2021,Q4,5,F,20200510.0,20211105.0,20201130,20211116,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20211116.0,,CN,DE,DE,2021,Q4,Elderly
185612615,18561261,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q4,Melaena,,2021,Q4,5,F,20200510.0,20211105.0,20201130,20211116,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20211116.0,,CN,DE,DE,2021,Q4,Elderly
185612615,18561261,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q4,Atrial fibrillation,,2021,Q4,5,F,20200510.0,20211105.0,20201130,20211116,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20211116.0,,CN,DE,DE,2021,Q4,Elderly
185612615,18561261,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q4,Coronary artery disease,,2021,Q4,5,F,20200510.0,20211105.0,20201130,20211116,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20211116.0,,CN,DE,DE,2021,Q4,Elderly
185612615,18561261,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q4,General physical health deterioration,,2021,Q4,5,F,20200510.0,20211105.0,20201130,20211116,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20211116.0,,CN,DE,DE,2021,Q4,Elderly
185612615,18561261,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2021,Q4,Ocular hyperaemia,,2021,Q4,5,F,20200510.0,20211105.0,20201130,20211116,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20211116.0,,CN,DE,DE,2021,Q4,Elderly
188172302,18817230,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, prn",,,,,,,,1.5,MG,,,2021,Q4,Nausea,,2021,Q4,2,F,20201209.0,20211029.0,20210201,20211108,EXP,,US-KARYOPHARM-2020KPT001550,KARYOPHARM THERAPEUTICS,,65.0,YR,,F,Y,,,20211108.0,,MD,US,US,2021,Q4,Elderly
190813922,19081392,14,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Colitis ulcerative,,2021,Q4,2,F,,20211227.0,20210401,20211230,EXP,,CA-BAUSCH-BL-2021-010407,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20211230.0,,CN,CA,CA,2021,Q4,Elderly
190813922,19081392,14,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Frequent bowel movements,,2021,Q4,2,F,,20211227.0,20210401,20211230,EXP,,CA-BAUSCH-BL-2021-010407,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20211230.0,,CN,CA,CA,2021,Q4,Elderly
190813922,19081392,14,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Rectal haemorrhage,,2021,Q4,2,F,,20211227.0,20210401,20211230,EXP,,CA-BAUSCH-BL-2021-010407,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20211230.0,,CN,CA,CA,2021,Q4,Elderly
190813922,19081392,14,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Decreased activity,,2021,Q4,2,F,,20211227.0,20210401,20211230,EXP,,CA-BAUSCH-BL-2021-010407,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20211230.0,,CN,CA,CA,2021,Q4,Elderly
190813922,19081392,14,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Colitis,,2021,Q4,2,F,,20211227.0,20210401,20211230,EXP,,CA-BAUSCH-BL-2021-010407,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20211230.0,,CN,CA,CA,2021,Q4,Elderly
191158393,19115839,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,.1071 Milligram Daily; 0.75mg weekly once,,,Y,,,,,0.75,MG,,/WK,2021,Q4,Vomiting,,2021,Q4,3,F,,20210927.0,20210409,20211008,EXP,,US-TEVA-2021-US-1898202,TEVA,"Lee J, Nguyen J, Umana I. Exacerbation of atrial fibrillation related to dulaglutide use: A case report. J-Am-Coll-Clin-Pharm 2019;2:No. 5.",75.0,YR,E,F,Y,,,20211008.0,,HP,US,US,2021,Q4,Elderly
191158393,19115839,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,.1071 Milligram Daily; 0.75mg weekly once,,,Y,,,,,0.75,MG,,/WK,2021,Q4,Atrial fibrillation,,2021,Q4,3,F,,20210927.0,20210409,20211008,EXP,,US-TEVA-2021-US-1898202,TEVA,"Lee J, Nguyen J, Umana I. Exacerbation of atrial fibrillation related to dulaglutide use: A case report. J-Am-Coll-Clin-Pharm 2019;2:No. 5.",75.0,YR,E,F,Y,,,20211008.0,,HP,US,US,2021,Q4,Elderly
191158393,19115839,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,.1071 Milligram Daily; 0.75mg weekly once,,,Y,,,,,0.75,MG,,/WK,2021,Q4,Bradycardia,Bradycardia,2021,Q4,3,F,,20210927.0,20210409,20211008,EXP,,US-TEVA-2021-US-1898202,TEVA,"Lee J, Nguyen J, Umana I. Exacerbation of atrial fibrillation related to dulaglutide use: A case report. J-Am-Coll-Clin-Pharm 2019;2:No. 5.",75.0,YR,E,F,Y,,,20211008.0,,HP,US,US,2021,Q4,Elderly
191158393,19115839,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,.1071 Milligram Daily; 0.75mg weekly once,,,Y,,,,,0.75,MG,,/WK,2021,Q4,Nausea,,2021,Q4,3,F,,20210927.0,20210409,20211008,EXP,,US-TEVA-2021-US-1898202,TEVA,"Lee J, Nguyen J, Umana I. Exacerbation of atrial fibrillation related to dulaglutide use: A case report. J-Am-Coll-Clin-Pharm 2019;2:No. 5.",75.0,YR,E,F,Y,,,20211008.0,,HP,US,US,2021,Q4,Elderly
191158393,19115839,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,.1071 Milligram Daily; 0.75mg weekly once,,,Y,,,,,0.75,MG,,/WK,2021,Q4,Decreased appetite,,2021,Q4,3,F,,20210927.0,20210409,20211008,EXP,,US-TEVA-2021-US-1898202,TEVA,"Lee J, Nguyen J, Umana I. Exacerbation of atrial fibrillation related to dulaglutide use: A case report. J-Am-Coll-Clin-Pharm 2019;2:No. 5.",75.0,YR,E,F,Y,,,20211008.0,,HP,US,US,2021,Q4,Elderly
191158393,19115839,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,.1071 Milligram Daily; 0.75mg weekly once,,,Y,,,,,0.75,MG,,/WK,2021,Q4,Increased appetite,,2021,Q4,3,F,,20210927.0,20210409,20211008,EXP,,US-TEVA-2021-US-1898202,TEVA,"Lee J, Nguyen J, Umana I. Exacerbation of atrial fibrillation related to dulaglutide use: A case report. J-Am-Coll-Clin-Pharm 2019;2:No. 5.",75.0,YR,E,F,Y,,,20211008.0,,HP,US,US,2021,Q4,Elderly
191158393,19115839,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,.1071 Milligram Daily; 0.75mg weekly once,,,Y,,,,,0.75,MG,,/WK,2021,Q4,Weight increased,,2021,Q4,3,F,,20210927.0,20210409,20211008,EXP,,US-TEVA-2021-US-1898202,TEVA,"Lee J, Nguyen J, Umana I. Exacerbation of atrial fibrillation related to dulaglutide use: A case report. J-Am-Coll-Clin-Pharm 2019;2:No. 5.",75.0,YR,E,F,Y,,,20211008.0,,HP,US,US,2021,Q4,Elderly
191158393,19115839,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,.1071 Milligram Daily; 0.75mg weekly once,,,Y,,,,,0.75,MG,,/WK,2021,Q4,Hypoglycaemia,,2021,Q4,3,F,,20210927.0,20210409,20211008,EXP,,US-TEVA-2021-US-1898202,TEVA,"Lee J, Nguyen J, Umana I. Exacerbation of atrial fibrillation related to dulaglutide use: A case report. J-Am-Coll-Clin-Pharm 2019;2:No. 5.",75.0,YR,E,F,Y,,,20211008.0,,HP,US,US,2021,Q4,Elderly
191158393,19115839,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,.1071 Milligram Daily; 0.75mg weekly once,,,Y,,,,,0.75,MG,,/WK,2021,Q4,Acute kidney injury,,2021,Q4,3,F,,20210927.0,20210409,20211008,EXP,,US-TEVA-2021-US-1898202,TEVA,"Lee J, Nguyen J, Umana I. Exacerbation of atrial fibrillation related to dulaglutide use: A case report. J-Am-Coll-Clin-Pharm 2019;2:No. 5.",75.0,YR,E,F,Y,,,20211008.0,,HP,US,US,2021,Q4,Elderly
191158393,19115839,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,.1071 Milligram Daily; 0.75mg weekly once,,,Y,,,,,0.75,MG,,/WK,2021,Q4,Asthenia,,2021,Q4,3,F,,20210927.0,20210409,20211008,EXP,,US-TEVA-2021-US-1898202,TEVA,"Lee J, Nguyen J, Umana I. Exacerbation of atrial fibrillation related to dulaglutide use: A case report. J-Am-Coll-Clin-Pharm 2019;2:No. 5.",75.0,YR,E,F,Y,,,20211008.0,,HP,US,US,2021,Q4,Elderly
193996742,19399674,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,Unknown,,,,,,,2021,Q4,Injury,,2021,Q4,2,F,,20211022.0,20210610,20211026,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-107471",BOEHRINGER INGELHEIM,,71.0,YR,E,F,Y,,,20211027.0,,MD,CA,CA,2021,Q4,Elderly
193996742,19399674,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,Unknown,,,,,,,2021,Q4,Road traffic accident,,2021,Q4,2,F,,20211022.0,20210610,20211026,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-107471",BOEHRINGER INGELHEIM,,71.0,YR,E,F,Y,,,20211027.0,,MD,CA,CA,2021,Q4,Elderly
193996742,19399674,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,Unknown,,,,,,,2021,Q4,Diabetic ketoacidosis,,2021,Q4,2,F,,20211022.0,20210610,20211026,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-107471",BOEHRINGER INGELHEIM,,71.0,YR,E,F,Y,,,20211027.0,,MD,CA,CA,2021,Q4,Elderly
197273263,19727326,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, Z(QW)",,,,,,,,1.5,MG,,,2021,Q4,Back pain,,2021,Q4,3,F,20210728.0,20211008.0,20210820,20211014,EXP,,ES-GLAXOSMITHKLINE-ES2021GSK171840,GLAXOSMITHKLINE,,67.0,YR,,F,Y,88.0,KG,20211014.0,,MD,ES,ES,2021,Q4,Elderly
197273263,19727326,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, Z(QW)",,,,,,,,1.5,MG,,,2021,Q4,Back pain,,2021,Q4,3,F,20210728.0,20211008.0,20210820,20211014,EXP,,ES-GLAXOSMITHKLINE-ES2021GSK171840,GLAXOSMITHKLINE,,67.0,YR,,F,Y,88.0,KG,20211014.0,,MD,ES,ES,2021,Q4,Elderly
197318473,19731847,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 milligram, 1/week",,,,,,,,7.5,MG,,/WK,2021,Q4,Colitis,,2021,Q4,3,F,,20211123.0,20210820,20211130,EXP,,CA-TAKEDA-2021TUS051938,TAKEDA,,73.0,YR,,F,Y,,,20211130.0,,HP,CA,CA,2021,Q4,Elderly
197318473,19731847,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 milligram, 1/week",,,,,,,,7.5,MG,,/WK,2021,Q4,Rectal haemorrhage,,2021,Q4,3,F,,20211123.0,20210820,20211130,EXP,,CA-TAKEDA-2021TUS051938,TAKEDA,,73.0,YR,,F,Y,,,20211130.0,,HP,CA,CA,2021,Q4,Elderly
197318473,19731847,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 milligram, 1/week",,,,,,,,7.5,MG,,/WK,2021,Q4,Frequent bowel movements,,2021,Q4,3,F,,20211123.0,20210820,20211130,EXP,,CA-TAKEDA-2021TUS051938,TAKEDA,,73.0,YR,,F,Y,,,20211130.0,,HP,CA,CA,2021,Q4,Elderly
197318473,19731847,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 milligram, 1/week",,,,,,,,7.5,MG,,/WK,2021,Q4,Colitis ulcerative,,2021,Q4,3,F,,20211123.0,20210820,20211130,EXP,,CA-TAKEDA-2021TUS051938,TAKEDA,,73.0,YR,,F,Y,,,20211130.0,,HP,CA,CA,2021,Q4,Elderly
197318473,19731847,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 milligram, 1/week",,,,,,,,7.5,MG,,/WK,2021,Q4,Decreased activity,,2021,Q4,3,F,,20211123.0,20210820,20211130,EXP,,CA-TAKEDA-2021TUS051938,TAKEDA,,73.0,YR,,F,Y,,,20211130.0,,HP,CA,CA,2021,Q4,Elderly
198174053,19817405,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Anaphylactic reaction,,2021,Q4,3,F,20210602.0,20211116.0,20210910,20211122,EXP,,US-GILEAD-2021-0534340,GILEAD,,68.0,YR,E,M,Y,,,20211122.0,,HP,US,US,2021,Q4,Elderly
198174053,19817405,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Acute respiratory failure,,2021,Q4,3,F,20210602.0,20211116.0,20210910,20211122,EXP,,US-GILEAD-2021-0534340,GILEAD,,68.0,YR,E,M,Y,,,20211122.0,,HP,US,US,2021,Q4,Elderly
198174053,19817405,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Pneumonia serratia,,2021,Q4,3,F,20210602.0,20211116.0,20210910,20211122,EXP,,US-GILEAD-2021-0534340,GILEAD,,68.0,YR,E,M,Y,,,20211122.0,,HP,US,US,2021,Q4,Elderly
198174053,19817405,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Acute kidney injury,,2021,Q4,3,F,20210602.0,20211116.0,20210910,20211122,EXP,,US-GILEAD-2021-0534340,GILEAD,,68.0,YR,E,M,Y,,,20211122.0,,HP,US,US,2021,Q4,Elderly
198174053,19817405,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Hypoxia,,2021,Q4,3,F,20210602.0,20211116.0,20210910,20211122,EXP,,US-GILEAD-2021-0534340,GILEAD,,68.0,YR,E,M,Y,,,20211122.0,,HP,US,US,2021,Q4,Elderly
198740415,19874041,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Haemorrhage intracranial,,2021,Q4,5,F,20210915.0,20211220.0,20210922,20211222,EXP,,US-GILEAD-2021-0549473,GILEAD,,49.0,YR,A,F,Y,107.94,KG,20211222.0,,MD,US,US,2021,Q4,Adult
198740415,19874041,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Respiratory acidosis,,2021,Q4,5,F,20210915.0,20211220.0,20210922,20211222,EXP,,US-GILEAD-2021-0549473,GILEAD,,49.0,YR,A,F,Y,107.94,KG,20211222.0,,MD,US,US,2021,Q4,Adult
198740415,19874041,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Cardiac arrest,,2021,Q4,5,F,20210915.0,20211220.0,20210922,20211222,EXP,,US-GILEAD-2021-0549473,GILEAD,,49.0,YR,A,F,Y,107.94,KG,20211222.0,,MD,US,US,2021,Q4,Adult
198740415,19874041,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,COVID-19,,2021,Q4,5,F,20210915.0,20211220.0,20210922,20211222,EXP,,US-GILEAD-2021-0549473,GILEAD,,49.0,YR,A,F,Y,107.94,KG,20211222.0,,MD,US,US,2021,Q4,Adult
198740415,19874041,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Acute respiratory distress syndrome,,2021,Q4,5,F,20210915.0,20211220.0,20210922,20211222,EXP,,US-GILEAD-2021-0549473,GILEAD,,49.0,YR,A,F,Y,107.94,KG,20211222.0,,MD,US,US,2021,Q4,Adult
198740415,19874041,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Acute kidney injury,,2021,Q4,5,F,20210915.0,20211220.0,20210922,20211222,EXP,,US-GILEAD-2021-0549473,GILEAD,,49.0,YR,A,F,Y,107.94,KG,20211222.0,,MD,US,US,2021,Q4,Adult
198740415,19874041,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,COVID-19 pneumonia,,2021,Q4,5,F,20210915.0,20211220.0,20210922,20211222,EXP,,US-GILEAD-2021-0549473,GILEAD,,49.0,YR,A,F,Y,107.94,KG,20211222.0,,MD,US,US,2021,Q4,Adult
199029481,19902948,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, once weekly",,,U,,,,,,,,,2021,Q4,Hypophosphataemia,,2021,Q4,1,I,,20210920.0,20211001,20211001,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-312447,RANBAXY,"Yoshida T, Takemoto M. Impaired cardiac and neurological function with mild hypophosphatemia during insulin therapy for diabetic ketoacidosis and marked improvement with phosphate supplementation: A case report. J Diabetes Investig. 2021;12(3):454-458",52.0,YR,,M,Y,71.4,KG,20211001.0,,HP,JP,JP,2021,Q4,Adult
199068231,19906823,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Dyspnoea,,2021,Q4,1,I,20210926.0,,20211001,20211001,DIR,584595,,FDA-CTU,,46.0,YR,,F,N,92.25,KG,20211001.0,Y,,US,US,2021,Q4,Adult
199068231,19906823,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Pleural effusion,,2021,Q4,1,I,20210926.0,,20211001,20211001,DIR,584595,,FDA-CTU,,46.0,YR,,F,N,92.25,KG,20211001.0,Y,,US,US,2021,Q4,Adult
199068231,19906823,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,COVID-19 pneumonia,,2021,Q4,1,I,20210926.0,,20211001,20211001,DIR,584595,,FDA-CTU,,46.0,YR,,F,N,92.25,KG,20211001.0,Y,,US,US,2021,Q4,Adult
199088311,19908831,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK every week,,,,,,,,,,,,2021,Q4,Cardiac failure congestive,,2021,Q4,1,I,,20210920.0,20211002,20211002,EXP,,JP-LUPIN PHARMACEUTICALS INC.-2021-18631,LUPIN,"Yoshida T, Takemoto M. Impaired cardiac and neurological function with mild hypophosphatemia during insulin therapy for diabetic ketoacidosis and marked improvement with phosphate supplementation: A case report. Journal of Diabetes Investigation. 2021;12(3):454-458",52.0,YR,,M,Y,71.4,KG,20211002.0,,HP,JP,JP,2021,Q4,Adult
199088311,19908831,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK every week,,,,,,,,,,,,2021,Q4,Depressed level of consciousness,,2021,Q4,1,I,,20210920.0,20211002,20211002,EXP,,JP-LUPIN PHARMACEUTICALS INC.-2021-18631,LUPIN,"Yoshida T, Takemoto M. Impaired cardiac and neurological function with mild hypophosphatemia during insulin therapy for diabetic ketoacidosis and marked improvement with phosphate supplementation: A case report. Journal of Diabetes Investigation. 2021;12(3):454-458",52.0,YR,,M,Y,71.4,KG,20211002.0,,HP,JP,JP,2021,Q4,Adult
199088311,19908831,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK every week,,,,,,,,,,,,2021,Q4,Electrocardiogram ST segment elevation,,2021,Q4,1,I,,20210920.0,20211002,20211002,EXP,,JP-LUPIN PHARMACEUTICALS INC.-2021-18631,LUPIN,"Yoshida T, Takemoto M. Impaired cardiac and neurological function with mild hypophosphatemia during insulin therapy for diabetic ketoacidosis and marked improvement with phosphate supplementation: A case report. Journal of Diabetes Investigation. 2021;12(3):454-458",52.0,YR,,M,Y,71.4,KG,20211002.0,,HP,JP,JP,2021,Q4,Adult
199088311,19908831,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK every week,,,,,,,,,,,,2021,Q4,Hypophosphataemia,,2021,Q4,1,I,,20210920.0,20211002,20211002,EXP,,JP-LUPIN PHARMACEUTICALS INC.-2021-18631,LUPIN,"Yoshida T, Takemoto M. Impaired cardiac and neurological function with mild hypophosphatemia during insulin therapy for diabetic ketoacidosis and marked improvement with phosphate supplementation: A case report. Journal of Diabetes Investigation. 2021;12(3):454-458",52.0,YR,,M,Y,71.4,KG,20211002.0,,HP,JP,JP,2021,Q4,Adult
199088311,19908831,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK every week,,,,,,,,,,,,2021,Q4,Myocardial injury,,2021,Q4,1,I,,20210920.0,20211002,20211002,EXP,,JP-LUPIN PHARMACEUTICALS INC.-2021-18631,LUPIN,"Yoshida T, Takemoto M. Impaired cardiac and neurological function with mild hypophosphatemia during insulin therapy for diabetic ketoacidosis and marked improvement with phosphate supplementation: A case report. Journal of Diabetes Investigation. 2021;12(3):454-458",52.0,YR,,M,Y,71.4,KG,20211002.0,,HP,JP,JP,2021,Q4,Adult
199115641,19911564,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,0.75 milligram,,,,,,,,0.75,MG,Injection,,2021,Q4,Nausea,,2021,Q4,1,I,20180508.0,20210324.0,20211004,20211004,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-290033,RANBAXY,"Lee J, Umana IE, Nguyen J. Exacerbation of atrial fibrillation related to dulaglutide use. Clin Case Rep. 2021;9No. 5:e04223",75.0,YR,,F,Y,,,20211004.0,,HP,US,US,2021,Q4,Elderly
199115641,19911564,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,0.75 milligram,,,,,,,,0.75,MG,Injection,,2021,Q4,Bradycardia,,2021,Q4,1,I,20180508.0,20210324.0,20211004,20211004,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-290033,RANBAXY,"Lee J, Umana IE, Nguyen J. Exacerbation of atrial fibrillation related to dulaglutide use. Clin Case Rep. 2021;9No. 5:e04223",75.0,YR,,F,Y,,,20211004.0,,HP,US,US,2021,Q4,Elderly
199115641,19911564,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,0.75 milligram,,,,,,,,0.75,MG,Injection,,2021,Q4,Fatigue,,2021,Q4,1,I,20180508.0,20210324.0,20211004,20211004,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-290033,RANBAXY,"Lee J, Umana IE, Nguyen J. Exacerbation of atrial fibrillation related to dulaglutide use. Clin Case Rep. 2021;9No. 5:e04223",75.0,YR,,F,Y,,,20211004.0,,HP,US,US,2021,Q4,Elderly
199118411,19911841,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qd",,,Y,U,,,,0.75,MG,Injection,QD,2021,Q4,Weight increased,,2021,Q4,1,I,,20210324.0,20211004,20211004,EXP,,US-MYLANLABS-2021M1019221,MYLAN,"Lee J, Nguyen J, Umana I. Exacerbation of atrial fibrillation related to dulaglutide use: A case report. J-Am-Coll-Clin-Pharm 2019;2:No. 5.",75.0,YR,,F,Y,,,20211004.0,,HP,US,US,2021,Q4,Elderly
199118411,19911841,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qd",,,Y,U,,,,0.75,MG,Injection,QD,2021,Q4,Increased appetite,,2021,Q4,1,I,,20210324.0,20211004,20211004,EXP,,US-MYLANLABS-2021M1019221,MYLAN,"Lee J, Nguyen J, Umana I. Exacerbation of atrial fibrillation related to dulaglutide use: A case report. J-Am-Coll-Clin-Pharm 2019;2:No. 5.",75.0,YR,,F,Y,,,20211004.0,,HP,US,US,2021,Q4,Elderly
199118411,19911841,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qd",,,Y,U,,,,0.75,MG,Injection,QD,2021,Q4,Hypoglycaemia,,2021,Q4,1,I,,20210324.0,20211004,20211004,EXP,,US-MYLANLABS-2021M1019221,MYLAN,"Lee J, Nguyen J, Umana I. Exacerbation of atrial fibrillation related to dulaglutide use: A case report. J-Am-Coll-Clin-Pharm 2019;2:No. 5.",75.0,YR,,F,Y,,,20211004.0,,HP,US,US,2021,Q4,Elderly
199118411,19911841,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qd",,,Y,U,,,,0.75,MG,Injection,QD,2021,Q4,Bradycardia,,2021,Q4,1,I,,20210324.0,20211004,20211004,EXP,,US-MYLANLABS-2021M1019221,MYLAN,"Lee J, Nguyen J, Umana I. Exacerbation of atrial fibrillation related to dulaglutide use: A case report. J-Am-Coll-Clin-Pharm 2019;2:No. 5.",75.0,YR,,F,Y,,,20211004.0,,HP,US,US,2021,Q4,Elderly
199170482,19917048,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Septic shock,,2021,Q4,2,F,20210906.0,20211006.0,20211005,20211008,EXP,,IL-ABBVIE-21K-082-4106653-00,ABBVIE,,84.0,YR,,M,Y,72.0,KG,20211008.0,,MD,COUNTRY NOT SPECIFIED,IL,2021,Q4,Elderly
199170482,19917048,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Febrile neutropenia,,2021,Q4,2,F,20210906.0,20211006.0,20211005,20211008,EXP,,IL-ABBVIE-21K-082-4106653-00,ABBVIE,,84.0,YR,,M,Y,72.0,KG,20211008.0,,MD,COUNTRY NOT SPECIFIED,IL,2021,Q4,Elderly
199236571,19923657,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,0.75 milligram once weekly,,,,,,,,0.75,MG,,,2021,Q4,Nausea,,2021,Q4,1,I,,20210921.0,20211006,20211006,PER,,US-HORMOSAN PHARMA GMBH-2021-18667,LUPIN,"Lee J, Umana IE, Nguyen J. Exacerbation of atrial fibrillation related to dulaglutide use. Clincal case reports. 2021;9:e04223:1-5",75.0,YR,,F,Y,,,20211006.0,,HP,US,US,2021,Q4,Elderly
199252291,19925229,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,,,,,,,,2021,Q4,Frequent bowel movements,,2021,Q4,1,I,,20210928.0,20211006,20211006,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-23280,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20211006.0,,CN,CA,CA,2021,Q4,Elderly
199252291,19925229,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,,,,,,,,2021,Q4,Decreased activity,,2021,Q4,1,I,,20210928.0,20211006,20211006,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-23280,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20211006.0,,CN,CA,CA,2021,Q4,Elderly
199252291,19925229,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,,,,,,,,2021,Q4,Colitis,,2021,Q4,1,I,,20210928.0,20211006,20211006,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-23280,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20211006.0,,CN,CA,CA,2021,Q4,Elderly
199252291,19925229,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,,,,,,,,2021,Q4,Rectal haemorrhage,,2021,Q4,1,I,,20210928.0,20211006,20211006,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-23280,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20211006.0,,CN,CA,CA,2021,Q4,Elderly
199252291,19925229,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,,,,,,,,2021,Q4,Colitis ulcerative,,2021,Q4,1,I,,20210928.0,20211006,20211006,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-23280,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20211006.0,,CN,CA,CA,2021,Q4,Elderly
199277951,19927795,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Urticaria,,2021,Q4,1,I,20210922.0,,20211006,20211006,DIR,585403,,FDA-CTU,,50.0,YR,,M,N,73.7,KG,20211006.0,N,PH,US,US,2021,Q4,Adult
199277951,19927795,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Infusion related reaction,,2021,Q4,1,I,20210922.0,,20211006,20211006,DIR,585403,,FDA-CTU,,50.0,YR,,M,N,73.7,KG,20211006.0,N,PH,US,US,2021,Q4,Adult
199277951,19927795,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Pruritus,,2021,Q4,1,I,20210922.0,,20211006,20211006,DIR,585403,,FDA-CTU,,50.0,YR,,M,N,73.7,KG,20211006.0,N,PH,US,US,2021,Q4,Adult
199347941,19934794,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,20210819.0,20211007.0,20211008,20211008,EXP,GB-MHRA-EYC 00262739,"GB-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-131530",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,94.8,KG,20211008.0,,MD,GB,GB,2021,Q4,Elderly
199457021,19945702,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK (Injection solution/Infusion solution),,,,,,,,,,,,2021,Q4,Pain,,2021,Q4,1,I,,20211006.0,20211012,20211012,EXP,,DE-MYLANLABS-2021M1070292,MYLAN,,82.0,YR,,F,Y,,,20211012.0,,PH,DE,DE,2021,Q4,Elderly
199457021,19945702,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK (Injection solution/Infusion solution),,,,,,,,,,,,2021,Q4,Fall,,2021,Q4,1,I,,20211006.0,20211012,20211012,EXP,,DE-MYLANLABS-2021M1070292,MYLAN,,82.0,YR,,F,Y,,,20211012.0,,PH,DE,DE,2021,Q4,Elderly
199463471,19946347,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Intramuscular,"1 time per week, injection/infusion solution",,,,,,,,,,Injection,,2021,Q4,Syncope,,2021,Q4,1,I,,20211006.0,20211012,20211012,EXP,,DE-MYLANLABS-2021M1070454,MYLAN,,80.0,YR,,F,Y,,,20211012.0,,MD,DE,DE,2021,Q4,Elderly
199463471,19946347,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Intramuscular,"1 time per week, injection/infusion solution",,,,,,,,,,Injection,,2021,Q4,Nausea,,2021,Q4,1,I,,20211006.0,20211012,20211012,EXP,,DE-MYLANLABS-2021M1070454,MYLAN,,80.0,YR,,F,Y,,,20211012.0,,MD,DE,DE,2021,Q4,Elderly
199521411,19952141,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram,  nach Schema, Fertigspritzen",,,,,,,,1.5,MG,,,2021,Q4,Night sweats,,2021,Q4,1,I,,20211008.0,20211013,20211013,EXP,,DE-MYLANLABS-2021M1071412,MYLAN,,79.0,YR,,F,Y,,,20211013.0,,PH,DE,DE,2021,Q4,Elderly
199521411,19952141,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram,  nach Schema, Fertigspritzen",,,,,,,,1.5,MG,,,2021,Q4,Pain,,2021,Q4,1,I,,20211008.0,20211013,20211013,EXP,,DE-MYLANLABS-2021M1071412,MYLAN,,79.0,YR,,F,Y,,,20211013.0,,PH,DE,DE,2021,Q4,Elderly
199521411,19952141,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram,  nach Schema, Fertigspritzen",,,,,,,,1.5,MG,,,2021,Q4,Weight decreased,,2021,Q4,1,I,,20211008.0,20211013,20211013,EXP,,DE-MYLANLABS-2021M1071412,MYLAN,,79.0,YR,,F,Y,,,20211013.0,,PH,DE,DE,2021,Q4,Elderly
199521411,19952141,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram,  nach Schema, Fertigspritzen",,,,,,,,1.5,MG,,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211008.0,20211013,20211013,EXP,,DE-MYLANLABS-2021M1071412,MYLAN,,79.0,YR,,F,Y,,,20211013.0,,PH,DE,DE,2021,Q4,Elderly
199521411,19952141,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram,  nach Schema, Fertigspritzen",,,,,,,,1.5,MG,,,2021,Q4,Headache,,2021,Q4,1,I,,20211008.0,20211013,20211013,EXP,,DE-MYLANLABS-2021M1071412,MYLAN,,79.0,YR,,F,Y,,,20211013.0,,PH,DE,DE,2021,Q4,Elderly
199521411,19952141,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram,  nach Schema, Fertigspritzen",,,,,,,,1.5,MG,,,2021,Q4,Haematochezia,,2021,Q4,1,I,,20211008.0,20211013,20211013,EXP,,DE-MYLANLABS-2021M1071412,MYLAN,,79.0,YR,,F,Y,,,20211013.0,,PH,DE,DE,2021,Q4,Elderly
199521411,19952141,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram,  nach Schema, Fertigspritzen",,,,,,,,1.5,MG,,,2021,Q4,Dizziness,,2021,Q4,1,I,,20211008.0,20211013,20211013,EXP,,DE-MYLANLABS-2021M1071412,MYLAN,,79.0,YR,,F,Y,,,20211013.0,,PH,DE,DE,2021,Q4,Elderly
199521411,19952141,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram,  nach Schema, Fertigspritzen",,,,,,,,1.5,MG,,,2021,Q4,Anaemia,,2021,Q4,1,I,,20211008.0,20211013,20211013,EXP,,DE-MYLANLABS-2021M1071412,MYLAN,,79.0,YR,,F,Y,,,20211013.0,,PH,DE,DE,2021,Q4,Elderly
199530561,19953056,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,1.5 mg,,,U,,,,,1.5,MG,,,2021,Q4,Surgery,Surgery,2021,Q4,1,I,,20211004.0,20211014,20211014,EXP,,US-ALS-000419,ALIGNSCIENCE PHARMA,"Butler J., Bjurstrom M., Marceau A. Possible dulaglutide-associated cholecystitis with safe continuation post cholecystectomy. Am J Health Syst Pharm. 2021;78(8):684-88. DOI: 10.1093/ajhp/zxab045",72.0,YR,E,M,Y,111.3,KG,20211014.0,,HP,US,US,2021,Q4,Elderly
199530561,19953056,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,1.5 mg,,,U,,,,,1.5,MG,,,2021,Q4,Cholecystectomy,Cholecystectomy,2021,Q4,1,I,,20211004.0,20211014,20211014,EXP,,US-ALS-000419,ALIGNSCIENCE PHARMA,"Butler J., Bjurstrom M., Marceau A. Possible dulaglutide-associated cholecystitis with safe continuation post cholecystectomy. Am J Health Syst Pharm. 2021;78(8):684-88. DOI: 10.1093/ajhp/zxab045",72.0,YR,E,M,Y,111.3,KG,20211014.0,,HP,US,US,2021,Q4,Elderly
199530561,19953056,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,1.5 mg,,,U,,,,,1.5,MG,,,2021,Q4,Cholecystitis infective,Cholecystitis infective,2021,Q4,1,I,,20211004.0,20211014,20211014,EXP,,US-ALS-000419,ALIGNSCIENCE PHARMA,"Butler J., Bjurstrom M., Marceau A. Possible dulaglutide-associated cholecystitis with safe continuation post cholecystectomy. Am J Health Syst Pharm. 2021;78(8):684-88. DOI: 10.1093/ajhp/zxab045",72.0,YR,E,M,Y,111.3,KG,20211014.0,,HP,US,US,2021,Q4,Elderly
199538161,19953816,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,Y,,D310381,,,1.5,MG,,/WK,2021,Q4,Palpitations,,2021,Q4,1,I,20210928.0,20211001.0,20211013,20211013,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202110001089,ELI LILLY AND CO,,58.0,YR,,F,Y,82.0,KG,20211013.0,,CN,CN,CN,2021,Q4,Adult
199538161,19953816,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,Y,,D310381,,,1.5,MG,,/WK,2021,Q4,Chest discomfort,,2021,Q4,1,I,20210928.0,20211001.0,20211013,20211013,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202110001089,ELI LILLY AND CO,,58.0,YR,,F,Y,82.0,KG,20211013.0,,CN,CN,CN,2021,Q4,Adult
199538161,19953816,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,Y,,D310381,,,1.5,MG,,/WK,2021,Q4,Tremor,,2021,Q4,1,I,20210928.0,20211001.0,20211013,20211013,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202110001089,ELI LILLY AND CO,,58.0,YR,,F,Y,82.0,KG,20211013.0,,CN,CN,CN,2021,Q4,Adult
199538161,19953816,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,Y,,D310381,,,1.5,MG,,/WK,2021,Q4,Discomfort,,2021,Q4,1,I,20210928.0,20211001.0,20211013,20211013,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202110001089,ELI LILLY AND CO,,58.0,YR,,F,Y,82.0,KG,20211013.0,,CN,CN,CN,2021,Q4,Adult
199538161,19953816,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,Y,,D310381,,,1.5,MG,,/WK,2021,Q4,Blood pressure increased,,2021,Q4,1,I,20210928.0,20211001.0,20211013,20211013,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202110001089,ELI LILLY AND CO,,58.0,YR,,F,Y,82.0,KG,20211013.0,,CN,CN,CN,2021,Q4,Adult
199538161,19953816,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,Y,,D310381,,,1.5,MG,,/WK,2021,Q4,Hyperhidrosis,,2021,Q4,1,I,20210928.0,20211001.0,20211013,20211013,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202110001089,ELI LILLY AND CO,,58.0,YR,,F,Y,82.0,KG,20211013.0,,CN,CN,CN,2021,Q4,Adult
199539301,19953930,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Hypotension,,2021,Q4,1,I,20211005.0,,20211014,20211014,DIR,586494,,FDA-CTU,,66.0,YR,,M,N,33.89,KG,20211014.0,N,,US,US,2021,Q4,Elderly
199539301,19953930,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Somnolence,,2021,Q4,1,I,20211005.0,,20211014,20211014,DIR,586494,,FDA-CTU,,66.0,YR,,M,N,33.89,KG,20211014.0,N,,US,US,2021,Q4,Elderly
199539301,19953930,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Blood creatinine increased,,2021,Q4,1,I,20211005.0,,20211014,20211014,DIR,586494,,FDA-CTU,,66.0,YR,,M,N,33.89,KG,20211014.0,N,,US,US,2021,Q4,Elderly
199539301,19953930,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Blood sodium decreased,,2021,Q4,1,I,20211005.0,,20211014,20211014,DIR,586494,,FDA-CTU,,66.0,YR,,M,N,33.89,KG,20211014.0,N,,US,US,2021,Q4,Elderly
199553673,19955367,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,1.5 milligram,,,U,,,,,1.5,MG,,,2021,Q4,Ileus,,2021,Q4,3,F,20211001.0,20211104.0,20211014,20211109,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-104214,BRISTOL MYERS SQUIBB,,66.0,YR,,F,Y,58.0,KG,20211109.0,,HP,US,US,2021,Q4,Elderly
199569771,19956977,12,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK (1.5 mg, by regimen, pre-filled syringes)",,,U,,,,,,,,,2021,Q4,Cellulitis,,2021,Q4,1,I,,20211008.0,20211014,20211014,EXP,,DE-MYLANLABS-2021M1071409,MYLAN,,70.0,YR,,M,Y,89.0,KG,20211014.0,,PH,DE,DE,2021,Q4,Elderly
199569771,19956977,12,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK (1.5 mg, by regimen, pre-filled syringes)",,,U,,,,,,,,,2021,Q4,Skin ulcer,,2021,Q4,1,I,,20211008.0,20211014,20211014,EXP,,DE-MYLANLABS-2021M1071409,MYLAN,,70.0,YR,,M,Y,89.0,KG,20211014.0,,PH,DE,DE,2021,Q4,Elderly
199726691,19972669,5,C,Dulaglutide 1.5 mg Weekly,,2,,,,,,,,,,,,,,2021,Q4,Urticaria,,2021,Q4,1,I,20211017.0,,20211019,20211019,DIR,587237,,FDA-CTU,,76.0,YR,,M,N,,,20211019.0,N,PH,US,US,2021,Q4,Elderly
199726691,19972669,5,C,Dulaglutide 1.5 mg Weekly,,2,,,,,,,,,,,,,,2021,Q4,Hypotension,,2021,Q4,1,I,20211017.0,,20211019,20211019,DIR,587237,,FDA-CTU,,76.0,YR,,M,N,,,20211019.0,N,PH,US,US,2021,Q4,Elderly
199726691,19972669,5,C,Dulaglutide 1.5 mg Weekly,,2,,,,,,,,,,,,,,2021,Q4,Anaphylactic reaction,,2021,Q4,1,I,20211017.0,,20211019,20211019,DIR,587237,,FDA-CTU,,76.0,YR,,M,N,,,20211019.0,N,PH,US,US,2021,Q4,Elderly
199737851,19973785,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Sepsis,,2021,Q4,1,I,,,20211020,20211020,DIR,587326,,FDA-CTU,,41.0,YR,,F,N,130.6,KG,20211020.0,N,PH,US,US,2021,Q4,Adult
199737851,19973785,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Headache,,2021,Q4,1,I,,,20211020,20211020,DIR,587326,,FDA-CTU,,41.0,YR,,F,N,130.6,KG,20211020.0,N,PH,US,US,2021,Q4,Adult
199737851,19973785,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Vomiting,,2021,Q4,1,I,,,20211020,20211020,DIR,587326,,FDA-CTU,,41.0,YR,,F,N,130.6,KG,20211020.0,N,PH,US,US,2021,Q4,Adult
199737851,19973785,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Cough,,2021,Q4,1,I,,,20211020,20211020,DIR,587326,,FDA-CTU,,41.0,YR,,F,N,130.6,KG,20211020.0,N,PH,US,US,2021,Q4,Adult
199737851,19973785,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Abdominal pain,,2021,Q4,1,I,,,20211020,20211020,DIR,587326,,FDA-CTU,,41.0,YR,,F,N,130.6,KG,20211020.0,N,PH,US,US,2021,Q4,Adult
199778521,19977852,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,?          OTHER FREQUENCY:Every 7 days;,,,Y,D,,,,1.5,UG,,,2021,Q4,Impaired gastric emptying,,2021,Q4,1,I,20210710.0,,20211020,20211020,DIR,587404,,FDA-CTU,,42.0,YR,,F,N,118.3,KG,20211020.0,N,PH,US,US,2021,Q4,Adult
199843941,19984394,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Angioedema,,2021,Q4,1,I,20211003.0,,20211022,20211022,DIR,587641,,FDA-CTU,,58.0,YR,,F,N,137.7,KG,20211022.0,N,PH,US,US,2021,Q4,Adult
199912371,19991237,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, QW (every week)",,,,,,,,0.75,MG,,/WK,2021,Q4,Drug interaction,,2021,Q4,1,I,,20211012.0,20211025,20211025,EXP,,US-GLENMARK PHARMACEUTICALS-2021GMK068570,GLENMARK,"Mcgrane IR, Lindbloom TJ, Munjal RC. Possible inhibitory effects of terbinafine on aripiprazole metabolism: Two case reports.. Ment Health Clin [Internet]. 2021;11 (5):297-300",43.0,YR,,F,Y,111.7,KG,20211025.0,,PH,US,US,2021,Q4,Adult
199912371,19991237,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, QW (every week)",,,,,,,,0.75,MG,,/WK,2021,Q4,Condition aggravated,,2021,Q4,1,I,,20211012.0,20211025,20211025,EXP,,US-GLENMARK PHARMACEUTICALS-2021GMK068570,GLENMARK,"Mcgrane IR, Lindbloom TJ, Munjal RC. Possible inhibitory effects of terbinafine on aripiprazole metabolism: Two case reports.. Ment Health Clin [Internet]. 2021;11 (5):297-300",43.0,YR,,F,Y,111.7,KG,20211025.0,,PH,US,US,2021,Q4,Adult
199912371,19991237,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, QW (every week)",,,,,,,,0.75,MG,,/WK,2021,Q4,Depression,,2021,Q4,1,I,,20211012.0,20211025,20211025,EXP,,US-GLENMARK PHARMACEUTICALS-2021GMK068570,GLENMARK,"Mcgrane IR, Lindbloom TJ, Munjal RC. Possible inhibitory effects of terbinafine on aripiprazole metabolism: Two case reports.. Ment Health Clin [Internet]. 2021;11 (5):297-300",43.0,YR,,F,Y,111.7,KG,20211025.0,,PH,US,US,2021,Q4,Adult
199912371,19991237,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, QW (every week)",,,,,,,,0.75,MG,,/WK,2021,Q4,Anxiety,,2021,Q4,1,I,,20211012.0,20211025,20211025,EXP,,US-GLENMARK PHARMACEUTICALS-2021GMK068570,GLENMARK,"Mcgrane IR, Lindbloom TJ, Munjal RC. Possible inhibitory effects of terbinafine on aripiprazole metabolism: Two case reports.. Ment Health Clin [Internet]. 2021;11 (5):297-300",43.0,YR,,F,Y,111.7,KG,20211025.0,,PH,US,US,2021,Q4,Adult
199912371,19991237,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, QW (every week)",,,,,,,,0.75,MG,,/WK,2021,Q4,Irritability,,2021,Q4,1,I,,20211012.0,20211025,20211025,EXP,,US-GLENMARK PHARMACEUTICALS-2021GMK068570,GLENMARK,"Mcgrane IR, Lindbloom TJ, Munjal RC. Possible inhibitory effects of terbinafine on aripiprazole metabolism: Two case reports.. Ment Health Clin [Internet]. 2021;11 (5):297-300",43.0,YR,,F,Y,111.7,KG,20211025.0,,PH,US,US,2021,Q4,Adult
199912371,19991237,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, QW (every week)",,,,,,,,0.75,MG,,/WK,2021,Q4,Insomnia,,2021,Q4,1,I,,20211012.0,20211025,20211025,EXP,,US-GLENMARK PHARMACEUTICALS-2021GMK068570,GLENMARK,"Mcgrane IR, Lindbloom TJ, Munjal RC. Possible inhibitory effects of terbinafine on aripiprazole metabolism: Two case reports.. Ment Health Clin [Internet]. 2021;11 (5):297-300",43.0,YR,,F,Y,111.7,KG,20211025.0,,PH,US,US,2021,Q4,Adult
199912371,19991237,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, QW (every week)",,,,,,,,0.75,MG,,/WK,2021,Q4,Drug level increased,,2021,Q4,1,I,,20211012.0,20211025,20211025,EXP,,US-GLENMARK PHARMACEUTICALS-2021GMK068570,GLENMARK,"Mcgrane IR, Lindbloom TJ, Munjal RC. Possible inhibitory effects of terbinafine on aripiprazole metabolism: Two case reports.. Ment Health Clin [Internet]. 2021;11 (5):297-300",43.0,YR,,F,Y,111.7,KG,20211025.0,,PH,US,US,2021,Q4,Adult
199955301,19995530,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, Every Week",,,Y,,,,,0.75,MG,,/WK,2021,Q4,Increased appetite,,2021,Q4,1,I,,20210927.0,20211026,20211026,EXP,,US-AUROBINDO-AUR-APL-2021-041312,AUROBINDO,"Lee J, Umana IE, Nguyen J. Exacerbation of atrial fibrillation related to dulaglutide use. Clinical Case Reports. 2021;9:1-5",75.0,YR,,F,Y,,,20211026.0,,PH,US,US,2021,Q4,Elderly
199955301,19995530,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, Every Week",,,Y,,,,,0.75,MG,,/WK,2021,Q4,Hypoglycaemia,,2021,Q4,1,I,,20210927.0,20211026,20211026,EXP,,US-AUROBINDO-AUR-APL-2021-041312,AUROBINDO,"Lee J, Umana IE, Nguyen J. Exacerbation of atrial fibrillation related to dulaglutide use. Clinical Case Reports. 2021;9:1-5",75.0,YR,,F,Y,,,20211026.0,,PH,US,US,2021,Q4,Elderly
199955301,19995530,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"30 milligram, Daily",,,Y,,,,,30.0,MG,,,2021,Q4,Increased appetite,,2021,Q4,1,I,,20210927.0,20211026,20211026,EXP,,US-AUROBINDO-AUR-APL-2021-041312,AUROBINDO,"Lee J, Umana IE, Nguyen J. Exacerbation of atrial fibrillation related to dulaglutide use. Clinical Case Reports. 2021;9:1-5",75.0,YR,,F,Y,,,20211026.0,,PH,US,US,2021,Q4,Elderly
199955301,19995530,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"30 milligram, Daily",,,Y,,,,,30.0,MG,,,2021,Q4,Hypoglycaemia,,2021,Q4,1,I,,20210927.0,20211026,20211026,EXP,,US-AUROBINDO-AUR-APL-2021-041312,AUROBINDO,"Lee J, Umana IE, Nguyen J. Exacerbation of atrial fibrillation related to dulaglutide use. Clinical Case Reports. 2021;9:1-5",75.0,YR,,F,Y,,,20211026.0,,PH,US,US,2021,Q4,Elderly
199976481,19997648,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Gait disturbance,,2021,Q4,1,I,20210427.0,20211020.0,20211026,20211026,EXP,FR-AFSSAPS-ST20213746,FR-ROCHE-2941135,ROCHE,,60.0,YR,,M,Y,118.0,KG,20211026.0,,HP,FR,FR,2021,Q4,Adult
199976481,19997648,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Balance disorder,,2021,Q4,1,I,20210427.0,20211020.0,20211026,20211026,EXP,FR-AFSSAPS-ST20213746,FR-ROCHE-2941135,ROCHE,,60.0,YR,,M,Y,118.0,KG,20211026.0,,HP,FR,FR,2021,Q4,Adult
199976481,19997648,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Tremor,,2021,Q4,1,I,20210427.0,20211020.0,20211026,20211026,EXP,FR-AFSSAPS-ST20213746,FR-ROCHE-2941135,ROCHE,,60.0,YR,,M,Y,118.0,KG,20211026.0,,HP,FR,FR,2021,Q4,Adult
199976481,19997648,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Vertigo,,2021,Q4,1,I,20210427.0,20211020.0,20211026,20211026,EXP,FR-AFSSAPS-ST20213746,FR-ROCHE-2941135,ROCHE,,60.0,YR,,M,Y,118.0,KG,20211026.0,,HP,FR,FR,2021,Q4,Adult
199976481,19997648,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Altered state of consciousness,,2021,Q4,1,I,20210427.0,20211020.0,20211026,20211026,EXP,FR-AFSSAPS-ST20213746,FR-ROCHE-2941135,ROCHE,,60.0,YR,,M,Y,118.0,KG,20211026.0,,HP,FR,FR,2021,Q4,Adult
199976481,19997648,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Antipsychotic drug level increased,,2021,Q4,1,I,20210427.0,20211020.0,20211026,20211026,EXP,FR-AFSSAPS-ST20213746,FR-ROCHE-2941135,ROCHE,,60.0,YR,,M,Y,118.0,KG,20211026.0,,HP,FR,FR,2021,Q4,Adult
199999061,19999906,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.75 mg every week,,,,,,,,0.75,MG,,,2021,Q4,Irritability,,2021,Q4,1,I,,20211014.0,20211027,20211027,EXP,,US-ACCORD-243692,ACCORD,"McGrane IR, Lindbloom TJ, Munjal RC. Possible inhibitory effects of terbinafine on aripiprazole metabolism: Two case reports. Ment Health Clin Internet. 2021;11(5):297-300.",43.0,YR,,F,Y,111.7,KG,20211027.0,,PH,US,GB,2021,Q4,Adult
199999061,19999906,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.75 mg every week,,,,,,,,0.75,MG,,,2021,Q4,Suicidal ideation,,2021,Q4,1,I,,20211014.0,20211027,20211027,EXP,,US-ACCORD-243692,ACCORD,"McGrane IR, Lindbloom TJ, Munjal RC. Possible inhibitory effects of terbinafine on aripiprazole metabolism: Two case reports. Ment Health Clin Internet. 2021;11(5):297-300.",43.0,YR,,F,Y,111.7,KG,20211027.0,,PH,US,GB,2021,Q4,Adult
199999061,19999906,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.75 mg every week,,,,,,,,0.75,MG,,,2021,Q4,Intentional self-injury,,2021,Q4,1,I,,20211014.0,20211027,20211027,EXP,,US-ACCORD-243692,ACCORD,"McGrane IR, Lindbloom TJ, Munjal RC. Possible inhibitory effects of terbinafine on aripiprazole metabolism: Two case reports. Ment Health Clin Internet. 2021;11(5):297-300.",43.0,YR,,F,Y,111.7,KG,20211027.0,,PH,US,GB,2021,Q4,Adult
199999061,19999906,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.75 mg every week,,,,,,,,0.75,MG,,,2021,Q4,Depression,,2021,Q4,1,I,,20211014.0,20211027,20211027,EXP,,US-ACCORD-243692,ACCORD,"McGrane IR, Lindbloom TJ, Munjal RC. Possible inhibitory effects of terbinafine on aripiprazole metabolism: Two case reports. Ment Health Clin Internet. 2021;11(5):297-300.",43.0,YR,,F,Y,111.7,KG,20211027.0,,PH,US,GB,2021,Q4,Adult
199999061,19999906,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.75 mg every week,,,,,,,,0.75,MG,,,2021,Q4,Drug level increased,,2021,Q4,1,I,,20211014.0,20211027,20211027,EXP,,US-ACCORD-243692,ACCORD,"McGrane IR, Lindbloom TJ, Munjal RC. Possible inhibitory effects of terbinafine on aripiprazole metabolism: Two case reports. Ment Health Clin Internet. 2021;11(5):297-300.",43.0,YR,,F,Y,111.7,KG,20211027.0,,PH,US,GB,2021,Q4,Adult
199999061,19999906,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.75 mg every week,,,,,,,,0.75,MG,,,2021,Q4,Drug interaction,,2021,Q4,1,I,,20211014.0,20211027,20211027,EXP,,US-ACCORD-243692,ACCORD,"McGrane IR, Lindbloom TJ, Munjal RC. Possible inhibitory effects of terbinafine on aripiprazole metabolism: Two case reports. Ment Health Clin Internet. 2021;11(5):297-300.",43.0,YR,,F,Y,111.7,KG,20211027.0,,PH,US,GB,2021,Q4,Adult
199999061,19999906,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.75 mg every week,,,,,,,,0.75,MG,,,2021,Q4,Insomnia,,2021,Q4,1,I,,20211014.0,20211027,20211027,EXP,,US-ACCORD-243692,ACCORD,"McGrane IR, Lindbloom TJ, Munjal RC. Possible inhibitory effects of terbinafine on aripiprazole metabolism: Two case reports. Ment Health Clin Internet. 2021;11(5):297-300.",43.0,YR,,F,Y,111.7,KG,20211027.0,,PH,US,GB,2021,Q4,Adult
199999061,19999906,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.75 mg every week,,,,,,,,0.75,MG,,,2021,Q4,Anxiety,,2021,Q4,1,I,,20211014.0,20211027,20211027,EXP,,US-ACCORD-243692,ACCORD,"McGrane IR, Lindbloom TJ, Munjal RC. Possible inhibitory effects of terbinafine on aripiprazole metabolism: Two case reports. Ment Health Clin Internet. 2021;11(5):297-300.",43.0,YR,,F,Y,111.7,KG,20211027.0,,PH,US,GB,2021,Q4,Adult
200109841,20010984,8,C,dulaglutide (Trulicty) 0.75mg/0.5mL pen: Inject 0.75 mg subQ q7days,,2,,,,,,,,,,,,,,2021,Q4,Appetite disorder,,2021,Q4,1,I,20211020.0,,20211029,20211029,DIR,588706,,FDA-CTU,,58.0,YR,,M,N,143.8,KG,20211029.0,N,PH,US,US,2021,Q4,Adult
200109841,20010984,8,C,dulaglutide (Trulicty) 0.75mg/0.5mL pen: Inject 0.75 mg subQ q7days,,2,,,,,,,,,,,,,,2021,Q4,Fournier's gangrene,,2021,Q4,1,I,20211020.0,,20211029,20211029,DIR,588706,,FDA-CTU,,58.0,YR,,M,N,143.8,KG,20211029.0,N,PH,US,US,2021,Q4,Adult
200109841,20010984,8,C,dulaglutide (Trulicty) 0.75mg/0.5mL pen: Inject 0.75 mg subQ q7days,,2,,,,,,,,,,,,,,2021,Q4,Asthenia,,2021,Q4,1,I,20211020.0,,20211029,20211029,DIR,588706,,FDA-CTU,,58.0,YR,,M,N,143.8,KG,20211029.0,N,PH,US,US,2021,Q4,Adult
200109841,20010984,8,C,dulaglutide (Trulicty) 0.75mg/0.5mL pen: Inject 0.75 mg subQ q7days,,2,,,,,,,,,,,,,,2021,Q4,Discomfort,,2021,Q4,1,I,20211020.0,,20211029,20211029,DIR,588706,,FDA-CTU,,58.0,YR,,M,N,143.8,KG,20211029.0,N,PH,US,US,2021,Q4,Adult
200174301,20017430,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,N,,,,,,,,,2021,Q4,Balance disorder,,2021,Q4,1,I,20210427.0,20211021.0,20211030,20211030,EXP,FR-AFSSAPS-ST20213746,FR-TEVA-2021-FR-1970537,TEVA,,60.0,YR,A,M,Y,118.0,KG,20211030.0,,HP,FR,FR,2021,Q4,Adult
200174301,20017430,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,N,,,,,,,,,2021,Q4,Altered state of consciousness,,2021,Q4,1,I,20210427.0,20211021.0,20211030,20211030,EXP,FR-AFSSAPS-ST20213746,FR-TEVA-2021-FR-1970537,TEVA,,60.0,YR,A,M,Y,118.0,KG,20211030.0,,HP,FR,FR,2021,Q4,Adult
200174301,20017430,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,N,,,,,,,,,2021,Q4,Vertigo,,2021,Q4,1,I,20210427.0,20211021.0,20211030,20211030,EXP,FR-AFSSAPS-ST20213746,FR-TEVA-2021-FR-1970537,TEVA,,60.0,YR,A,M,Y,118.0,KG,20211030.0,,HP,FR,FR,2021,Q4,Adult
200174301,20017430,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,N,,,,,,,,,2021,Q4,Tremor,,2021,Q4,1,I,20210427.0,20211021.0,20211030,20211030,EXP,FR-AFSSAPS-ST20213746,FR-TEVA-2021-FR-1970537,TEVA,,60.0,YR,A,M,Y,118.0,KG,20211030.0,,HP,FR,FR,2021,Q4,Adult
200174301,20017430,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,N,,,,,,,,,2021,Q4,Antipsychotic drug level increased,,2021,Q4,1,I,20210427.0,20211021.0,20211030,20211030,EXP,FR-AFSSAPS-ST20213746,FR-TEVA-2021-FR-1970537,TEVA,,60.0,YR,A,M,Y,118.0,KG,20211030.0,,HP,FR,FR,2021,Q4,Adult
200174301,20017430,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,N,,,,,,,,,2021,Q4,Gait disturbance,,2021,Q4,1,I,20210427.0,20211021.0,20211030,20211030,EXP,FR-AFSSAPS-ST20213746,FR-TEVA-2021-FR-1970537,TEVA,,60.0,YR,A,M,Y,118.0,KG,20211030.0,,HP,FR,FR,2021,Q4,Adult
200284782,20028478,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1.5 mg, nach Schema, Fertigpen",,,U,U,,,,1.5,MG,Injection,,2021,Q4,Abdominal pain lower,,2021,Q4,2,F,,20211029.0,20211103,20211108,EXP,,DE-MYLANLABS-2021M1079662,MYLAN,,67.0,YR,,F,Y,,,20211108.0,,PH,DE,DE,2021,Q4,Elderly
200284782,20028478,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1.5 mg, nach Schema, Fertigpen",,,U,U,,,,1.5,MG,Injection,,2021,Q4,Dysuria,,2021,Q4,2,F,,20211029.0,20211103,20211108,EXP,,DE-MYLANLABS-2021M1079662,MYLAN,,67.0,YR,,F,Y,,,20211108.0,,PH,DE,DE,2021,Q4,Elderly
200284782,20028478,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1.5 mg, nach Schema, Fertigpen",,,U,U,,,,1.5,MG,Injection,,2021,Q4,Pyrexia,,2021,Q4,2,F,,20211029.0,20211103,20211108,EXP,,DE-MYLANLABS-2021M1079662,MYLAN,,67.0,YR,,F,Y,,,20211108.0,,PH,DE,DE,2021,Q4,Elderly
200284782,20028478,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1.5 mg, nach Schema, Fertigpen",,,U,U,,,,1.5,MG,Injection,,2021,Q4,Blood creatinine increased,,2021,Q4,2,F,,20211029.0,20211103,20211108,EXP,,DE-MYLANLABS-2021M1079662,MYLAN,,67.0,YR,,F,Y,,,20211108.0,,PH,DE,DE,2021,Q4,Elderly
200284782,20028478,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1.5 mg, nach Schema, Fertigpen",,,U,U,,,,1.5,MG,Injection,,2021,Q4,Infection,,2021,Q4,2,F,,20211029.0,20211103,20211108,EXP,,DE-MYLANLABS-2021M1079662,MYLAN,,67.0,YR,,F,Y,,,20211108.0,,PH,DE,DE,2021,Q4,Elderly
200284782,20028478,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, 1.5 mg, nach Schema, Fertigpen",,,U,U,,,,1.5,MG,Injection,,2021,Q4,Chills,,2021,Q4,2,F,,20211029.0,20211103,20211108,EXP,,DE-MYLANLABS-2021M1079662,MYLAN,,67.0,YR,,F,Y,,,20211108.0,,PH,DE,DE,2021,Q4,Elderly
200294131,20029413,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.75mg/0.5milliter,,,,,,,,,,,,2021,Q4,Illness,,2021,Q4,1,I,20200101.0,20211021.0,20211103,20211103,PER,,US-PFIZER INC-202101420285,PFIZER,,46.0,YR,,F,Y,75.3,KG,20211103.0,,CN,US,US,2021,Q4,Adult
200294131,20029413,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.75mg/0.5milliter,,,,,,,,,,,,2021,Q4,Recalled product administered,,2021,Q4,1,I,20200101.0,20211021.0,20211103,20211103,PER,,US-PFIZER INC-202101420285,PFIZER,,46.0,YR,,F,Y,75.3,KG,20211103.0,,CN,US,US,2021,Q4,Adult
200294131,20029413,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.75mg/0.5milliter,,,,,,,,,,,,2021,Q4,Myocardial infarction,,2021,Q4,1,I,20200101.0,20211021.0,20211103,20211103,PER,,US-PFIZER INC-202101420285,PFIZER,,46.0,YR,,F,Y,75.3,KG,20211103.0,,CN,US,US,2021,Q4,Adult
200351162,20035116,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Acute myocardial infarction,,2021,Q4,2,F,20210830.0,20211111.0,20211104,20211115,EXP,,NVSC2021CH249185,NOVARTIS,,47.0,YR,,M,Y,98.0,KG,20211116.0,,HP,CH,CH,2021,Q4,Adult
200351162,20035116,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Vomiting,,2021,Q4,2,F,20210830.0,20211111.0,20211104,20211115,EXP,,NVSC2021CH249185,NOVARTIS,,47.0,YR,,M,Y,98.0,KG,20211116.0,,HP,CH,CH,2021,Q4,Adult
200351162,20035116,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Chest discomfort,,2021,Q4,2,F,20210830.0,20211111.0,20211104,20211115,EXP,,NVSC2021CH249185,NOVARTIS,,47.0,YR,,M,Y,98.0,KG,20211116.0,,HP,CH,CH,2021,Q4,Adult
200351162,20035116,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Chest pain,,2021,Q4,2,F,20210830.0,20211111.0,20211104,20211115,EXP,,NVSC2021CH249185,NOVARTIS,,47.0,YR,,M,Y,98.0,KG,20211116.0,,HP,CH,CH,2021,Q4,Adult
200351162,20035116,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Nausea,,2021,Q4,2,F,20210830.0,20211111.0,20211104,20211115,EXP,,NVSC2021CH249185,NOVARTIS,,47.0,YR,,M,Y,98.0,KG,20211116.0,,HP,CH,CH,2021,Q4,Adult
200402521,20040252,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Colitis ulcerative,,2021,Q4,1,I,,20211027.0,20211106,20211106,EXP,,CA-TEVA-2021-CA-1972902,TEVA,,73.0,YR,E,F,Y,,,20211106.0,,CN,CA,CA,2021,Q4,Elderly
200402521,20040252,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Frequent bowel movements,,2021,Q4,1,I,,20211027.0,20211106,20211106,EXP,,CA-TEVA-2021-CA-1972902,TEVA,,73.0,YR,E,F,Y,,,20211106.0,,CN,CA,CA,2021,Q4,Elderly
200402521,20040252,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Colitis,,2021,Q4,1,I,,20211027.0,20211106,20211106,EXP,,CA-TEVA-2021-CA-1972902,TEVA,,73.0,YR,E,F,Y,,,20211106.0,,CN,CA,CA,2021,Q4,Elderly
200402521,20040252,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Rectal haemorrhage,,2021,Q4,1,I,,20211027.0,20211106,20211106,EXP,,CA-TEVA-2021-CA-1972902,TEVA,,73.0,YR,E,F,Y,,,20211106.0,,CN,CA,CA,2021,Q4,Elderly
200402521,20040252,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Decreased activity,,2021,Q4,1,I,,20211027.0,20211106,20211106,EXP,,CA-TEVA-2021-CA-1972902,TEVA,,73.0,YR,E,F,Y,,,20211106.0,,CN,CA,CA,2021,Q4,Elderly
200701131,20070113,2,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,20211101.0,20211115.0,20211115,20211115,EXP,NL-LRB-00710274,"NL-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-138243",BOEHRINGER INGELHEIM,,51.0,YR,A,F,Y,82.0,KG,20211115.0,,MD,NL,NL,2021,Q4,Adult
200706921,20070692,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Infusion related reaction,,2021,Q4,1,I,20211112.0,,20211115,20211115,DIR,590896,,FDA-CTU,,63.0,YR,,M,N,119.3,KG,20211115.0,N,PH,US,,2021,Q4,Adult
200706921,20070692,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Nausea,,2021,Q4,1,I,20211112.0,,20211115,20211115,DIR,590896,,FDA-CTU,,63.0,YR,,M,N,119.3,KG,20211115.0,N,PH,US,,2021,Q4,Adult
200706921,20070692,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Feeling hot,,2021,Q4,1,I,20211112.0,,20211115,20211115,DIR,590896,,FDA-CTU,,63.0,YR,,M,N,119.3,KG,20211115.0,N,PH,US,,2021,Q4,Adult
200706921,20070692,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Electrocardiogram abnormal,,2021,Q4,1,I,20211112.0,,20211115,20211115,DIR,590896,,FDA-CTU,,63.0,YR,,M,N,119.3,KG,20211115.0,N,PH,US,,2021,Q4,Adult
200706921,20070692,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Bundle branch block left,,2021,Q4,1,I,20211112.0,,20211115,20211115,DIR,590896,,FDA-CTU,,63.0,YR,,M,N,119.3,KG,20211115.0,N,PH,US,,2021,Q4,Adult
200706921,20070692,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Dyspnoea,,2021,Q4,1,I,20211112.0,,20211115,20211115,DIR,590896,,FDA-CTU,,63.0,YR,,M,N,119.3,KG,20211115.0,N,PH,US,,2021,Q4,Adult
200706921,20070692,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Head discomfort,,2021,Q4,1,I,20211112.0,,20211115,20211115,DIR,590896,,FDA-CTU,,63.0,YR,,M,N,119.3,KG,20211115.0,N,PH,US,,2021,Q4,Adult
200706921,20070692,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Chest pain,,2021,Q4,1,I,20211112.0,,20211115,20211115,DIR,590896,,FDA-CTU,,63.0,YR,,M,N,119.3,KG,20211115.0,N,PH,US,,2021,Q4,Adult
200706921,20070692,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Vomiting,,2021,Q4,1,I,20211112.0,,20211115,20211115,DIR,590896,,FDA-CTU,,63.0,YR,,M,N,119.3,KG,20211115.0,N,PH,US,,2021,Q4,Adult
200706921,20070692,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Respiratory rate increased,,2021,Q4,1,I,20211112.0,,20211115,20211115,DIR,590896,,FDA-CTU,,63.0,YR,,M,N,119.3,KG,20211115.0,N,PH,US,,2021,Q4,Adult
200706921,20070692,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Dizziness,,2021,Q4,1,I,20211112.0,,20211115,20211115,DIR,590896,,FDA-CTU,,63.0,YR,,M,N,119.3,KG,20211115.0,N,PH,US,,2021,Q4,Adult
200706921,20070692,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Pain in jaw,,2021,Q4,1,I,20211112.0,,20211115,20211115,DIR,590896,,FDA-CTU,,63.0,YR,,M,N,119.3,KG,20211115.0,N,PH,US,,2021,Q4,Adult
200754411,20075441,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,OTHER FREQUENCY : Weekly;?,,,Y,D,,,,,,,999,2021,Q4,Nausea,,2021,Q4,1,I,,,20211116,20211116,DIR,591049,,FDA-CTU,,63.0,YR,,M,N,,,20211116.0,N,,US,,2021,Q4,Adult
200754411,20075441,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,OTHER FREQUENCY : Weekly;?,,,Y,D,,,,,,,999,2021,Q4,Acute kidney injury,,2021,Q4,1,I,,,20211116,20211116,DIR,591049,,FDA-CTU,,63.0,YR,,M,N,,,20211116.0,N,,US,,2021,Q4,Adult
200754411,20075441,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,OTHER FREQUENCY : Weekly;?,,,Y,D,,,,,,,999,2021,Q4,Diarrhoea,,2021,Q4,1,I,,,20211116,20211116,DIR,591049,,FDA-CTU,,63.0,YR,,M,N,,,20211116.0,N,,US,,2021,Q4,Adult
200754411,20075441,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,OTHER FREQUENCY : Weekly;?,,,Y,D,,,,,,,999,2021,Q4,Vomiting,,2021,Q4,1,I,,,20211116,20211116,DIR,591049,,FDA-CTU,,63.0,YR,,M,N,,,20211116.0,N,,US,,2021,Q4,Adult
200757881,20075788,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2021,Q4,Syncope,,2021,Q4,1,I,20180418.0,20210726.0,20211116,20211116,PER,,US-NOVOPROD-837152,NOVO NORDISK,,62.0,YR,,M,Y,84.821,KG,20211116.0,,CN,US,US,2021,Q4,Adult
200757881,20075788,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,Unknown,,,,,,,2021,Q4,Drug ineffective,,2021,Q4,1,I,20180418.0,20210726.0,20211116,20211116,PER,,US-NOVOPROD-837152,NOVO NORDISK,,62.0,YR,,M,Y,84.821,KG,20211116.0,,CN,US,US,2021,Q4,Adult
200806321,20080632,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Drug-induced liver injury,,2021,Q4,1,I,,20211110.0,20211117,20211117,EXP,,US-MYLANLABS-2021M1084758,MYLAN,"Raza HMA, Wall BM. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis. J-Am-Soc-Nephrol 2021;32:381 (plus poster) abstr. PO1164.",43.0,YR,,M,Y,,,20211117.0,,HP,US,US,2021,Q4,Adult
200806321,20080632,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q4,Lactic acidosis,,2021,Q4,1,I,,20211110.0,20211117,20211117,EXP,,US-MYLANLABS-2021M1084758,MYLAN,"Raza HMA, Wall BM. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis. J-Am-Soc-Nephrol 2021;32:381 (plus poster) abstr. PO1164.",43.0,YR,,M,Y,,,20211117.0,,HP,US,US,2021,Q4,Adult
200825812,20082581,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram (1.5 mg, by regimen, solution for injection/infusion)",,,,,,,,1.5,MG,Injection,,2021,Q4,Diarrhoea,,2021,Q4,2,F,,20211111.0,20211117,20211123,EXP,,DE-MYLANLABS-2021M1083632,MYLAN,,78.0,YR,,M,Y,80.0,KG,20211123.0,,PH,DE,DE,2021,Q4,Elderly
200825812,20082581,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram (1.5 mg, by regimen, solution for injection/infusion)",,,,,,,,1.5,MG,Injection,,2021,Q4,Duodenal ulcer haemorrhage,,2021,Q4,2,F,,20211111.0,20211117,20211123,EXP,,DE-MYLANLABS-2021M1083632,MYLAN,,78.0,YR,,M,Y,80.0,KG,20211123.0,,PH,DE,DE,2021,Q4,Elderly
200825812,20082581,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram (1.5 mg, by regimen, solution for injection/infusion)",,,,,,,,1.5,MG,Injection,,2021,Q4,Haematochezia,,2021,Q4,2,F,,20211111.0,20211117,20211123,EXP,,DE-MYLANLABS-2021M1083632,MYLAN,,78.0,YR,,M,Y,80.0,KG,20211123.0,,PH,DE,DE,2021,Q4,Elderly
200825812,20082581,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram (1.5 mg, by regimen, solution for injection/infusion)",,,,,,,,1.5,MG,Injection,,2021,Q4,Acute kidney injury,,2021,Q4,2,F,,20211111.0,20211117,20211123,EXP,,DE-MYLANLABS-2021M1083632,MYLAN,,78.0,YR,,M,Y,80.0,KG,20211123.0,,PH,DE,DE,2021,Q4,Elderly
200825812,20082581,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram (1.5 mg, by regimen, solution for injection/infusion)",,,,,,,,1.5,MG,Injection,,2021,Q4,Dyspnoea,,2021,Q4,2,F,,20211111.0,20211117,20211123,EXP,,DE-MYLANLABS-2021M1083632,MYLAN,,78.0,YR,,M,Y,80.0,KG,20211123.0,,PH,DE,DE,2021,Q4,Elderly
200825812,20082581,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram (1.5 mg, by regimen, solution for injection/infusion)",,,,,,,,1.5,MG,Injection,,2021,Q4,Oedema peripheral,,2021,Q4,2,F,,20211111.0,20211117,20211123,EXP,,DE-MYLANLABS-2021M1083632,MYLAN,,78.0,YR,,M,Y,80.0,KG,20211123.0,,PH,DE,DE,2021,Q4,Elderly
200846491,20084649,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,D,,,,,,,,,2021,Q4,Drug level increased,,2021,Q4,1,I,,20211110.0,20211118,20211118,EXP,,US-APOTEX-2021AP045415,APOTEX,"Raza HMA, Wall BM.. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis. Journal of the American Society of Nephrology. 2021;32:381",43.0,YR,,M,Y,,,20211118.0,,HP,US,US,2021,Q4,Adult
200846491,20084649,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,D,,,,,,,,,2021,Q4,Drug-induced liver injury,,2021,Q4,1,I,,20211110.0,20211118,20211118,EXP,,US-APOTEX-2021AP045415,APOTEX,"Raza HMA, Wall BM.. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis. Journal of the American Society of Nephrology. 2021;32:381",43.0,YR,,M,Y,,,20211118.0,,HP,US,US,2021,Q4,Adult
200865481,20086548,2,C,dulaglutide 3 mg per week,,2,,,,,,,,,,,,,,2021,Q4,Diarrhoea,,2021,Q4,1,I,20211117.0,,20211118,20211118,DIR,591372,,FDA-CTU,,58.0,YR,,M,N,91.6,KG,20211118.0,N,HP,US,,2021,Q4,Adult
200865481,20086548,2,C,dulaglutide 3 mg per week,,2,,,,,,,,,,,,,,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,20211117.0,,20211118,20211118,DIR,591372,,FDA-CTU,,58.0,YR,,M,N,91.6,KG,20211118.0,N,HP,US,,2021,Q4,Adult
200911511,20091151,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,0.75 mg once per week,,,,,,,,,,,,2021,Q4,Weight increased,,2021,Q4,1,I,20160301.0,20211111.0,20211119,20211119,EXP,,DE-AstraZeneca-2021A805942,ASTRAZENECA,,52.0,YR,,F,Y,124.0,KG,20211119.0,,MD,DE,,2021,Q4,Adult
200911511,20091151,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,0.75 mg once per week,,,,,,,,,,,,2021,Q4,Weight decreased,,2021,Q4,1,I,20160301.0,20211111.0,20211119,20211119,EXP,,DE-AstraZeneca-2021A805942,ASTRAZENECA,,52.0,YR,,F,Y,124.0,KG,20211119.0,,MD,DE,,2021,Q4,Adult
200911511,20091151,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,0.75 mg once per week,,,,,,,,,,,,2021,Q4,Insulin resistance,,2021,Q4,1,I,20160301.0,20211111.0,20211119,20211119,EXP,,DE-AstraZeneca-2021A805942,ASTRAZENECA,,52.0,YR,,F,Y,124.0,KG,20211119.0,,MD,DE,,2021,Q4,Adult
200925701,20092570,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q4,Metabolic acidosis,,2021,Q4,1,I,,20211110.0,20211119,20211119,EXP,,US-BAXTER-2021BAX035917,BAXTER,"RAZA H, WALL B. EFFECTS OF PSEUDOHYPONATREMIA ON THE DIAGNOSIS OF SEVERE METABOLIC ACIDOSIS. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2021;32:.",43.0,YR,,M,Y,,,20211119.0,,HP,US,US,2021,Q4,Adult
200925701,20092570,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q4,Lactic acidosis,,2021,Q4,1,I,,20211110.0,20211119,20211119,EXP,,US-BAXTER-2021BAX035917,BAXTER,"RAZA H, WALL B. EFFECTS OF PSEUDOHYPONATREMIA ON THE DIAGNOSIS OF SEVERE METABOLIC ACIDOSIS. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2021;32:.",43.0,YR,,M,Y,,,20211119.0,,HP,US,US,2021,Q4,Adult
200925701,20092570,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q4,Drug-induced liver injury,,2021,Q4,1,I,,20211110.0,20211119,20211119,EXP,,US-BAXTER-2021BAX035917,BAXTER,"RAZA H, WALL B. EFFECTS OF PSEUDOHYPONATREMIA ON THE DIAGNOSIS OF SEVERE METABOLIC ACIDOSIS. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2021;32:.",43.0,YR,,M,Y,,,20211119.0,,HP,US,US,2021,Q4,Adult
200925701,20092570,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2021,Q4,Drug level increased,,2021,Q4,1,I,,20211110.0,20211119,20211119,EXP,,US-BAXTER-2021BAX035917,BAXTER,"RAZA H, WALL B. EFFECTS OF PSEUDOHYPONATREMIA ON THE DIAGNOSIS OF SEVERE METABOLIC ACIDOSIS. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY. 2021;32:.",43.0,YR,,M,Y,,,20211119.0,,HP,US,US,2021,Q4,Adult
200927513,20092751,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Lactic acidosis,,2021,Q4,3,F,,20211126.0,20211120,20211207,EXP,,US-AUROBINDO-AUR-APL-2021-047104,AUROBINDO,"Raza HMA, Wall BM.. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis.. Journal of the American Society of Nephrology. 2021;32:381",43.0,YR,,M,Y,,,20211207.0,,HP,US,US,2021,Q4,Adult
200927513,20092751,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Drug level increased,,2021,Q4,3,F,,20211126.0,20211120,20211207,EXP,,US-AUROBINDO-AUR-APL-2021-047104,AUROBINDO,"Raza HMA, Wall BM.. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis.. Journal of the American Society of Nephrology. 2021;32:381",43.0,YR,,M,Y,,,20211207.0,,HP,US,US,2021,Q4,Adult
200927513,20092751,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Drug-induced liver injury,,2021,Q4,3,F,,20211126.0,20211120,20211207,EXP,,US-AUROBINDO-AUR-APL-2021-047104,AUROBINDO,"Raza HMA, Wall BM.. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis.. Journal of the American Society of Nephrology. 2021;32:381",43.0,YR,,M,Y,,,20211207.0,,HP,US,US,2021,Q4,Adult
200927513,20092751,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Metabolic acidosis,,2021,Q4,3,F,,20211126.0,20211120,20211207,EXP,,US-AUROBINDO-AUR-APL-2021-047104,AUROBINDO,"Raza HMA, Wall BM.. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis.. Journal of the American Society of Nephrology. 2021;32:381",43.0,YR,,M,Y,,,20211207.0,,HP,US,US,2021,Q4,Adult
200928871,20092887,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2021,Q4,Drug-induced liver injury,,2021,Q4,1,I,,20211109.0,20211120,20211120,EXP,,US-JNJFOC-20211130526,JOHNSON AND JOHNSON,,43.0,YR,A,M,Y,,,20211120.0,,HP,US,US,2021,Q4,Adult
200928871,20092887,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2021,Q4,Analgesic drug level increased,,2021,Q4,1,I,,20211109.0,20211120,20211120,EXP,,US-JNJFOC-20211130526,JOHNSON AND JOHNSON,,43.0,YR,A,M,Y,,,20211120.0,,HP,US,US,2021,Q4,Adult
200928871,20092887,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2021,Q4,Lactic acidosis,,2021,Q4,1,I,,20211109.0,20211120,20211120,EXP,,US-JNJFOC-20211130526,JOHNSON AND JOHNSON,,43.0,YR,A,M,Y,,,20211120.0,,HP,US,US,2021,Q4,Adult
200928871,20092887,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2021,Q4,Metabolic acidosis,,2021,Q4,1,I,,20211109.0,20211120,20211120,EXP,,US-JNJFOC-20211130526,JOHNSON AND JOHNSON,,43.0,YR,A,M,Y,,,20211120.0,,HP,US,US,2021,Q4,Adult
200975721,20097572,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,U,,,,,,,,,2021,Q4,Metabolic acidosis,,2021,Q4,1,I,,20211110.0,20211122,20211122,EXP,,US-PERRIGO-21US031133,PERRIGO,"Raza HMA, Wall BM. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis. Journal of the American Society of Nephrology. 2021;32:381.",43.0,YR,,M,Y,,,20211122.0,,HP,US,US,2021,Q4,Adult
200975721,20097572,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,U,,,,,,,,,2021,Q4,Lactic acidosis,,2021,Q4,1,I,,20211110.0,20211122,20211122,EXP,,US-PERRIGO-21US031133,PERRIGO,"Raza HMA, Wall BM. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis. Journal of the American Society of Nephrology. 2021;32:381.",43.0,YR,,M,Y,,,20211122.0,,HP,US,US,2021,Q4,Adult
200975721,20097572,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,U,,,,,,,,,2021,Q4,Drug level increased,,2021,Q4,1,I,,20211110.0,20211122,20211122,EXP,,US-PERRIGO-21US031133,PERRIGO,"Raza HMA, Wall BM. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis. Journal of the American Society of Nephrology. 2021;32:381.",43.0,YR,,M,Y,,,20211122.0,,HP,US,US,2021,Q4,Adult
200975721,20097572,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,U,,,,,,,,,2021,Q4,Drug-induced liver injury,,2021,Q4,1,I,,20211110.0,20211122,20211122,EXP,,US-PERRIGO-21US031133,PERRIGO,"Raza HMA, Wall BM. Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis. Journal of the American Society of Nephrology. 2021;32:381.",43.0,YR,,M,Y,,,20211122.0,,HP,US,US,2021,Q4,Adult
201048891,20104889,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Metabolic acidosis,,2021,Q4,1,I,,20211110.0,20211124,20211124,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-318547,RANBAXY,"Raza HMA, Wall BM.. Effects of Pseudohyponatremia on the Diagnosis of Severe Metabolic Acidosis. J Am Soc Nephrol. 2021;32381",43.0,YR,,M,Y,,,20211124.0,,HP,US,US,2021,Q4,Adult
201048891,20104889,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Hepatotoxicity,,2021,Q4,1,I,,20211110.0,20211124,20211124,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-318547,RANBAXY,"Raza HMA, Wall BM.. Effects of Pseudohyponatremia on the Diagnosis of Severe Metabolic Acidosis. J Am Soc Nephrol. 2021;32381",43.0,YR,,M,Y,,,20211124.0,,HP,US,US,2021,Q4,Adult
201048891,20104889,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Euglycaemic diabetic ketoacidosis,,2021,Q4,1,I,,20211110.0,20211124,20211124,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2021R1-318547,RANBAXY,"Raza HMA, Wall BM.. Effects of Pseudohyponatremia on the Diagnosis of Severe Metabolic Acidosis. J Am Soc Nephrol. 2021;32381",43.0,YR,,M,Y,,,20211124.0,,HP,US,US,2021,Q4,Adult
201054171,20105417,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,U,,,,0.75,MG,,/WK,2021,Q4,Swelling face,,2021,Q4,1,I,,20211119.0,20211124,20211124,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20211124.0,,CN,CA,CA,2021,Q4,Adult
201054171,20105417,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,U,,,,0.75,MG,,/WK,2021,Q4,Constipation,,2021,Q4,1,I,,20211119.0,20211124,20211124,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20211124.0,,CN,CA,CA,2021,Q4,Adult
201054171,20105417,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,U,,,,0.75,MG,,/WK,2021,Q4,Thirst decreased,,2021,Q4,1,I,,20211119.0,20211124,20211124,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20211124.0,,CN,CA,CA,2021,Q4,Adult
201054171,20105417,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,U,,,,0.75,MG,,/WK,2021,Q4,Weight increased,,2021,Q4,1,I,,20211119.0,20211124,20211124,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20211124.0,,CN,CA,CA,2021,Q4,Adult
201054171,20105417,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,U,,,,0.75,MG,,/WK,2021,Q4,Swelling,,2021,Q4,1,I,,20211119.0,20211124,20211124,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20211124.0,,CN,CA,CA,2021,Q4,Adult
201054171,20105417,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,U,,,,0.75,MG,,/WK,2021,Q4,Night sweats,,2021,Q4,1,I,,20211119.0,20211124,20211124,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20211124.0,,CN,CA,CA,2021,Q4,Adult
201054171,20105417,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,U,,,,0.75,MG,,/WK,2021,Q4,Blood glucose fluctuation,,2021,Q4,1,I,,20211119.0,20211124,20211124,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20211124.0,,CN,CA,CA,2021,Q4,Adult
201054171,20105417,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,U,,,,0.75,MG,,/WK,2021,Q4,Cardiac disorder,,2021,Q4,1,I,,20211119.0,20211124,20211124,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20211124.0,,CN,CA,CA,2021,Q4,Adult
201054171,20105417,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,U,,,,0.75,MG,,/WK,2021,Q4,Hypoaesthesia,,2021,Q4,1,I,,20211119.0,20211124,20211124,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20211124.0,,CN,CA,CA,2021,Q4,Adult
201054171,20105417,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,U,,,,0.75,MG,,/WK,2021,Q4,Abscess,,2021,Q4,1,I,,20211119.0,20211124,20211124,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20211124.0,,CN,CA,CA,2021,Q4,Adult
201054171,20105417,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,U,,,,0.75,MG,,/WK,2021,Q4,Headache,,2021,Q4,1,I,,20211119.0,20211124,20211124,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20211124.0,,CN,CA,CA,2021,Q4,Adult
201054171,20105417,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,U,,,,0.75,MG,,/WK,2021,Q4,Taste disorder,,2021,Q4,1,I,,20211119.0,20211124,20211124,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,,F,Y,75.0,KG,20211124.0,,CN,CA,CA,2021,Q4,Adult
201119231,20111923,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Death,,2021,Q4,1,I,20210812.0,20211119.0,20211125,20211125,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-124974,BRISTOL MYERS SQUIBB,,74.0,YR,,F,Y,,,20211125.0,,MD,US,US,2021,Q4,Elderly
201384251,20138425,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,Unknown,,,,,UNK,,2021,Q4,Drug-induced liver injury,,2021,Q4,1,I,,20211124.0,20211202,20211202,EXP,,US-GRANULES-US-2021GRALIT00552,GRANULES INDIA,Hafiz Muhammad Ali Raza.Effects of pseudohyponatremia on the diagnosis of severe metabolic acidosis.Journal of the American Society of Nephrology.2021;32:381,43.0,YR,A,M,Y,,,20211202.0,,HP,US,US,2021,Q4,Adult
201403771,20140377,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2021,Q4,Headache,,2021,Q4,1,I,,20211119.0,20211202,20211202,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20211202.0,,CN,CA,CA,2021,Q4,Adult
201403771,20140377,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2021,Q4,Weight increased,,2021,Q4,1,I,,20211119.0,20211202,20211202,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20211202.0,,CN,CA,CA,2021,Q4,Adult
201403771,20140377,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2021,Q4,Swelling face,,2021,Q4,1,I,,20211119.0,20211202,20211202,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20211202.0,,CN,CA,CA,2021,Q4,Adult
201403771,20140377,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2021,Q4,Blood glucose fluctuation,,2021,Q4,1,I,,20211119.0,20211202,20211202,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20211202.0,,CN,CA,CA,2021,Q4,Adult
201403771,20140377,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2021,Q4,Thirst decreased,,2021,Q4,1,I,,20211119.0,20211202,20211202,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20211202.0,,CN,CA,CA,2021,Q4,Adult
201403771,20140377,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2021,Q4,Hypoaesthesia,,2021,Q4,1,I,,20211119.0,20211202,20211202,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20211202.0,,CN,CA,CA,2021,Q4,Adult
201403771,20140377,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2021,Q4,Constipation,,2021,Q4,1,I,,20211119.0,20211202,20211202,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20211202.0,,CN,CA,CA,2021,Q4,Adult
201403771,20140377,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2021,Q4,Abscess,,2021,Q4,1,I,,20211119.0,20211202,20211202,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20211202.0,,CN,CA,CA,2021,Q4,Adult
201403771,20140377,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2021,Q4,Cardiac disorder,,2021,Q4,1,I,,20211119.0,20211202,20211202,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20211202.0,,CN,CA,CA,2021,Q4,Adult
201403771,20140377,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2021,Q4,Swelling,,2021,Q4,1,I,,20211119.0,20211202,20211202,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20211202.0,,CN,CA,CA,2021,Q4,Adult
201403771,20140377,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2021,Q4,Night sweats,,2021,Q4,1,I,,20211119.0,20211202,20211202,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20211202.0,,CN,CA,CA,2021,Q4,Adult
201403771,20140377,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2021,Q4,Taste disorder,,2021,Q4,1,I,,20211119.0,20211202,20211202,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20211202.0,,CN,CA,CA,2021,Q4,Adult
201449741,20144974,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1x a week,,,,,,,,,,,,2021,Q4,Cardiac failure,,2021,Q4,1,I,20210501.0,20211129.0,20211203,20211203,EXP,,DE-AstraZeneca-2021A849079,ASTRAZENECA,,72.0,YR,,M,Y,,,20211203.0,,MD,DE,,2021,Q4,Elderly
201449741,20144974,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1x a week,,,,,,,,,,,,2021,Q4,Oedema,,2021,Q4,1,I,20210501.0,20211129.0,20211203,20211203,EXP,,DE-AstraZeneca-2021A849079,ASTRAZENECA,,72.0,YR,,M,Y,,,20211203.0,,MD,DE,,2021,Q4,Elderly
201449741,20144974,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1x a week,,,,,,,,,,,,2021,Q4,Dyspnoea,,2021,Q4,1,I,20210501.0,20211129.0,20211203,20211203,EXP,,DE-AstraZeneca-2021A849079,ASTRAZENECA,,72.0,YR,,M,Y,,,20211203.0,,MD,DE,,2021,Q4,Elderly
201449741,20144974,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,10 mg 1x,,,,,,,,,,,,2021,Q4,Cardiac failure,,2021,Q4,1,I,20210501.0,20211129.0,20211203,20211203,EXP,,DE-AstraZeneca-2021A849079,ASTRAZENECA,,72.0,YR,,M,Y,,,20211203.0,,MD,DE,,2021,Q4,Elderly
201449741,20144974,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,10 mg 1x,,,,,,,,,,,,2021,Q4,Oedema,,2021,Q4,1,I,20210501.0,20211129.0,20211203,20211203,EXP,,DE-AstraZeneca-2021A849079,ASTRAZENECA,,72.0,YR,,M,Y,,,20211203.0,,MD,DE,,2021,Q4,Elderly
201449741,20144974,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,10 mg 1x,,,,,,,,,,,,2021,Q4,Dyspnoea,,2021,Q4,1,I,20210501.0,20211129.0,20211203,20211203,EXP,,DE-AstraZeneca-2021A849079,ASTRAZENECA,,72.0,YR,,M,Y,,,20211203.0,,MD,DE,,2021,Q4,Elderly
201507921,20150792,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 milligram, once in a week",,,,,,,,7.5,MG,,,2021,Q4,Treatment failure,,2021,Q4,1,I,,20211122.0,20211206,20211206,PER,,DE-LUPIN PHARMACEUTICALS INC.-2021-23882,LUPIN,"Van den Boom L, Stuecher T, Mader JK. Safe use of a once-a-week glucagon-like peptide-1 receptor agonist in a 16-year-old girl with type 2 diabetes when approved therapy options fail. Clinical case reports. 2021;9:e04811:1-5",16.0,YR,,F,Y,78.0,KG,20211206.0,,HP,DE,DE,2021,Q4,Youth
201546251,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2021,Q4,Swelling,,2021,Q4,1,I,,20211129.0,20211207,20211207,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20211207.0,,HP,CA,CA,2021,Q4,Adult
201546251,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2021,Q4,Taste disorder,,2021,Q4,1,I,,20211129.0,20211207,20211207,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20211207.0,,HP,CA,CA,2021,Q4,Adult
201546251,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2021,Q4,Hypoaesthesia,,2021,Q4,1,I,,20211129.0,20211207,20211207,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20211207.0,,HP,CA,CA,2021,Q4,Adult
201546251,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2021,Q4,Weight increased,,2021,Q4,1,I,,20211129.0,20211207,20211207,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20211207.0,,HP,CA,CA,2021,Q4,Adult
201546251,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2021,Q4,Constipation,,2021,Q4,1,I,,20211129.0,20211207,20211207,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20211207.0,,HP,CA,CA,2021,Q4,Adult
201546251,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2021,Q4,Abscess,,2021,Q4,1,I,,20211129.0,20211207,20211207,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20211207.0,,HP,CA,CA,2021,Q4,Adult
201546251,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2021,Q4,Headache,,2021,Q4,1,I,,20211129.0,20211207,20211207,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20211207.0,,HP,CA,CA,2021,Q4,Adult
201546251,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2021,Q4,Swelling face,,2021,Q4,1,I,,20211129.0,20211207,20211207,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20211207.0,,HP,CA,CA,2021,Q4,Adult
201546251,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2021,Q4,Blood glucose fluctuation,,2021,Q4,1,I,,20211129.0,20211207,20211207,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20211207.0,,HP,CA,CA,2021,Q4,Adult
201546251,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2021,Q4,Night sweats,,2021,Q4,1,I,,20211129.0,20211207,20211207,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20211207.0,,HP,CA,CA,2021,Q4,Adult
201546251,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2021,Q4,Thirst decreased,,2021,Q4,1,I,,20211129.0,20211207,20211207,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20211207.0,,HP,CA,CA,2021,Q4,Adult
201546251,20154625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2021,Q4,Cardiac disorder,,2021,Q4,1,I,,20211129.0,20211207,20211207,EXP,,CA-APOTEX-2020AP011665,APOTEX,,50.0,YR,,F,Y,75.0,KG,20211207.0,,HP,CA,CA,2021,Q4,Adult
201557781,20155778,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Injection,,2021,Q4,Diabetic ketoacidosis,,2021,Q4,1,I,,20211123.0,20211207,20211207,EXP,,CN-AstraZeneca-2021A837900,ASTRAZENECA,"Sun Jingbo, Xue Wenxin, et al.. A case of diabetic ketoacidosis caused by dapagliflozin. Chinese Journal of Drug Application and Monitoring 2021;18(5):345 to 348.",54.0,YR,,M,Y,,,20211207.0,,HP,CN,,2021,Q4,Adult
201601181,20160118,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,1.5 mg,,,Y,,,,,,,Solution for injection in pre-filled syringe,,2021,Q4,Vomiting,,2021,Q4,1,I,20210615.0,20211127.0,20211208,20211208,EXP,FR-AFSSAPS-AM20212847,FR-Accord-246754,ACCORD,,58.0,YR,A,F,Y,131.4,KG,20211208.0,,MD,FR,FR,2021,Q4,Adult
201601181,20160118,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,1.5 mg,,,Y,,,,,,,Solution for injection in pre-filled syringe,,2021,Q4,Acute kidney injury,,2021,Q4,1,I,20210615.0,20211127.0,20211208,20211208,EXP,FR-AFSSAPS-AM20212847,FR-Accord-246754,ACCORD,,58.0,YR,A,F,Y,131.4,KG,20211208.0,,MD,FR,FR,2021,Q4,Adult
201601181,20160118,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,1.5 mg,,,Y,,,,,,,Solution for injection in pre-filled syringe,,2021,Q4,Diabetic metabolic decompensation,,2021,Q4,1,I,20210615.0,20211127.0,20211208,20211208,EXP,FR-AFSSAPS-AM20212847,FR-Accord-246754,ACCORD,,58.0,YR,A,F,Y,131.4,KG,20211208.0,,MD,FR,FR,2021,Q4,Adult
201647861,20164786,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, weekly (1/W)",,,Y,U,,,125469.0,0.75,MG,,/WK,2021,Q4,Drug-induced liver injury,,2021,Q4,1,I,,20211128.0,20211209,20211209,EXP,,US-ELI_LILLY_AND_COMPANY-US202111012332,ELI LILLY AND CO,,53.0,YR,,F,Y,,,20211209.0,,MD,US,US,2021,Q4,Adult
201647861,20164786,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, weekly (1/W)",,,Y,U,,,125469.0,0.75,MG,,/WK,2021,Q4,Autoimmune hepatitis,,2021,Q4,1,I,,20211128.0,20211209,20211209,EXP,,US-ELI_LILLY_AND_COMPANY-US202111012332,ELI LILLY AND CO,,53.0,YR,,F,Y,,,20211209.0,,MD,US,US,2021,Q4,Adult
201651121,20165112,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,N,D,,,,,,,,2021,Q4,Neuroendocrine tumour,,2021,Q4,1,I,20200527.0,,20211208,20211208,DIR,FDA-CDER-CTU-2021-92353,,FDA-CTU,,70.0,YR,,M,N,113.0,KG,20210315.0,N,PH,US,,2021,Q4,Elderly
201749191,20174919,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Pruritus,,2021,Q4,1,I,20211127.0,,20211209,20211209,DIR,594373,,FDA-CTU,,66.0,YR,,F,N,62.55,KG,20211209.0,N,,US,,2021,Q4,Elderly
201749191,20174919,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Thermal burn,,2021,Q4,1,I,20211127.0,,20211209,20211209,DIR,594373,,FDA-CTU,,66.0,YR,,F,N,62.55,KG,20211209.0,N,,US,,2021,Q4,Elderly
201749191,20174919,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Rash,,2021,Q4,1,I,20211127.0,,20211209,20211209,DIR,594373,,FDA-CTU,,66.0,YR,,F,N,62.55,KG,20211209.0,N,,US,,2021,Q4,Elderly
201749191,20174919,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Rash,,2021,Q4,1,I,20211127.0,,20211209,20211209,DIR,594373,,FDA-CTU,,66.0,YR,,F,N,62.55,KG,20211209.0,N,,US,,2021,Q4,Elderly
201797301,20179730,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK (1x a week),,,U,,,,,,,,,2021,Q4,Cardiac failure,,2021,Q4,1,I,20210501.0,20211206.0,20211214,20211214,EXP,,NVSC2021DE280135,NOVARTIS,,72.0,YR,,M,Y,,,20211214.0,,MD,DE,DE,2021,Q4,Elderly
201797301,20179730,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK (1x a week),,,U,,,,,,,,,2021,Q4,Dyspnoea,,2021,Q4,1,I,20210501.0,20211206.0,20211214,20211214,EXP,,NVSC2021DE280135,NOVARTIS,,72.0,YR,,M,Y,,,20211214.0,,MD,DE,DE,2021,Q4,Elderly
201797301,20179730,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK (1x a week),,,U,,,,,,,,,2021,Q4,Oedema,,2021,Q4,1,I,20210501.0,20211206.0,20211214,20211214,EXP,,NVSC2021DE280135,NOVARTIS,,72.0,YR,,M,Y,,,20211214.0,,MD,DE,DE,2021,Q4,Elderly
201797301,20179730,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK (10 mg 1x),,,U,,,,,,,,,2021,Q4,Cardiac failure,,2021,Q4,1,I,20210501.0,20211206.0,20211214,20211214,EXP,,NVSC2021DE280135,NOVARTIS,,72.0,YR,,M,Y,,,20211214.0,,MD,DE,DE,2021,Q4,Elderly
201797301,20179730,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK (10 mg 1x),,,U,,,,,,,,,2021,Q4,Dyspnoea,,2021,Q4,1,I,20210501.0,20211206.0,20211214,20211214,EXP,,NVSC2021DE280135,NOVARTIS,,72.0,YR,,M,Y,,,20211214.0,,MD,DE,DE,2021,Q4,Elderly
201797301,20179730,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK (10 mg 1x),,,U,,,,,,,,,2021,Q4,Oedema,,2021,Q4,1,I,20210501.0,20211206.0,20211214,20211214,EXP,,NVSC2021DE280135,NOVARTIS,,72.0,YR,,M,Y,,,20211214.0,,MD,DE,DE,2021,Q4,Elderly
201915541,20191554,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Urethral stenosis,,2021,Q4,1,I,20210602.0,20211213.0,20211216,20211216,EXP,,GB-ABBVIE-21K-167-4198419-00,ABBVIE,,59.0,YR,,M,Y,104.0,KG,20211216.0,,HP,COUNTRY NOT SPECIFIED,GB,2021,Q4,Adult
201915541,20191554,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Dysuria,,2021,Q4,1,I,20210602.0,20211213.0,20211216,20211216,EXP,,GB-ABBVIE-21K-167-4198419-00,ABBVIE,,59.0,YR,,M,Y,104.0,KG,20211216.0,,HP,COUNTRY NOT SPECIFIED,GB,2021,Q4,Adult
201915541,20191554,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Urine flow decreased,,2021,Q4,1,I,20210602.0,20211213.0,20211216,20211216,EXP,,GB-ABBVIE-21K-167-4198419-00,ABBVIE,,59.0,YR,,M,Y,104.0,KG,20211216.0,,HP,COUNTRY NOT SPECIFIED,GB,2021,Q4,Adult
201915541,20191554,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Penile pain,,2021,Q4,1,I,20210602.0,20211213.0,20211216,20211216,EXP,,GB-ABBVIE-21K-167-4198419-00,ABBVIE,,59.0,YR,,M,Y,104.0,KG,20211216.0,,HP,COUNTRY NOT SPECIFIED,GB,2021,Q4,Adult
201915541,20191554,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Gait disturbance,,2021,Q4,1,I,20210602.0,20211213.0,20211216,20211216,EXP,,GB-ABBVIE-21K-167-4198419-00,ABBVIE,,59.0,YR,,M,Y,104.0,KG,20211216.0,,HP,COUNTRY NOT SPECIFIED,GB,2021,Q4,Adult
201915541,20191554,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Intestinal obstruction,,2021,Q4,1,I,20210602.0,20211213.0,20211216,20211216,EXP,,GB-ABBVIE-21K-167-4198419-00,ABBVIE,,59.0,YR,,M,Y,104.0,KG,20211216.0,,HP,COUNTRY NOT SPECIFIED,GB,2021,Q4,Adult
201923451,20192345,9,C,DULAGLUTIDEV,,2,,,,,,,,,,,,,,2021,Q4,Aortic valve incompetence,,2021,Q4,1,I,20210609.0,20211213.0,20211216,20211216,EXP,,GB-ABBVIE-21K-167-4198687-00,ABBVIE,,58.0,YR,,M,Y,104.0,KG,20211216.0,,HP,COUNTRY NOT SPECIFIED,GB,2021,Q4,Adult
201923451,20192345,9,C,DULAGLUTIDEV,,2,,,,,,,,,,,,,,2021,Q4,Agitation,,2021,Q4,1,I,20210609.0,20211213.0,20211216,20211216,EXP,,GB-ABBVIE-21K-167-4198687-00,ABBVIE,,58.0,YR,,M,Y,104.0,KG,20211216.0,,HP,COUNTRY NOT SPECIFIED,GB,2021,Q4,Adult
201923451,20192345,9,C,DULAGLUTIDEV,,2,,,,,,,,,,,,,,2021,Q4,Malaise,,2021,Q4,1,I,20210609.0,20211213.0,20211216,20211216,EXP,,GB-ABBVIE-21K-167-4198687-00,ABBVIE,,58.0,YR,,M,Y,104.0,KG,20211216.0,,HP,COUNTRY NOT SPECIFIED,GB,2021,Q4,Adult
201923451,20192345,9,C,DULAGLUTIDEV,,2,,,,,,,,,,,,,,2021,Q4,Loss of consciousness,,2021,Q4,1,I,20210609.0,20211213.0,20211216,20211216,EXP,,GB-ABBVIE-21K-167-4198687-00,ABBVIE,,58.0,YR,,M,Y,104.0,KG,20211216.0,,HP,COUNTRY NOT SPECIFIED,GB,2021,Q4,Adult
201923451,20192345,9,C,DULAGLUTIDEV,,2,,,,,,,,,,,,,,2021,Q4,Fall,,2021,Q4,1,I,20210609.0,20211213.0,20211216,20211216,EXP,,GB-ABBVIE-21K-167-4198687-00,ABBVIE,,58.0,YR,,M,Y,104.0,KG,20211216.0,,HP,COUNTRY NOT SPECIFIED,GB,2021,Q4,Adult
201923451,20192345,9,C,DULAGLUTIDEV,,2,,,,,,,,,,,,,,2021,Q4,Demyelination,,2021,Q4,1,I,20210609.0,20211213.0,20211216,20211216,EXP,,GB-ABBVIE-21K-167-4198687-00,ABBVIE,,58.0,YR,,M,Y,104.0,KG,20211216.0,,HP,COUNTRY NOT SPECIFIED,GB,2021,Q4,Adult
201923451,20192345,9,C,DULAGLUTIDEV,,2,,,,,,,,,,,,,,2021,Q4,Supraventricular tachycardia,,2021,Q4,1,I,20210609.0,20211213.0,20211216,20211216,EXP,,GB-ABBVIE-21K-167-4198687-00,ABBVIE,,58.0,YR,,M,Y,104.0,KG,20211216.0,,HP,COUNTRY NOT SPECIFIED,GB,2021,Q4,Adult
201923451,20192345,9,C,DULAGLUTIDEV,,2,,,,,,,,,,,,,,2021,Q4,Anxiety,,2021,Q4,1,I,20210609.0,20211213.0,20211216,20211216,EXP,,GB-ABBVIE-21K-167-4198687-00,ABBVIE,,58.0,YR,,M,Y,104.0,KG,20211216.0,,HP,COUNTRY NOT SPECIFIED,GB,2021,Q4,Adult
201923451,20192345,9,C,DULAGLUTIDEV,,2,,,,,,,,,,,,,,2021,Q4,Atrial fibrillation,,2021,Q4,1,I,20210609.0,20211213.0,20211216,20211216,EXP,,GB-ABBVIE-21K-167-4198687-00,ABBVIE,,58.0,YR,,M,Y,104.0,KG,20211216.0,,HP,COUNTRY NOT SPECIFIED,GB,2021,Q4,Adult
201923451,20192345,9,C,DULAGLUTIDEV,,2,,,,,,,,,,,,,,2021,Q4,Confusional state,,2021,Q4,1,I,20210609.0,20211213.0,20211216,20211216,EXP,,GB-ABBVIE-21K-167-4198687-00,ABBVIE,,58.0,YR,,M,Y,104.0,KG,20211216.0,,HP,COUNTRY NOT SPECIFIED,GB,2021,Q4,Adult
201972041,20197204,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2021,Q4,Hypoglycaemic encephalopathy,,2021,Q4,1,I,,20211207.0,20211217,20211217,EXP,,JP-NOVOPROD-870766,NOVO NORDISK,Genshou Maehara. A case of severe hypoglycaemic encephalopathy which was thought to have been caused by massive dose of long-acting insulin. Program and abstracts of The 23rd Annual Meeting of Japanese Society of Hospital. 2021;0-149,68.0,YR,,M,Y,,,20211217.0,,MD,JP,JP,2021,Q4,Elderly
201972041,20197204,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2021,Q4,Overdose,,2021,Q4,1,I,,20211207.0,20211217,20211217,EXP,,JP-NOVOPROD-870766,NOVO NORDISK,Genshou Maehara. A case of severe hypoglycaemic encephalopathy which was thought to have been caused by massive dose of long-acting insulin. Program and abstracts of The 23rd Annual Meeting of Japanese Society of Hospital. 2021;0-149,68.0,YR,,M,Y,,,20211217.0,,MD,JP,JP,2021,Q4,Elderly
202097631,20209763,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 milligram,,,U,,,,,0.75,MG,,,2021,Q4,Fall,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-135635,BRISTOL MYERS SQUIBB,,85.0,YR,,F,Y,60.0,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202097631,20209763,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 milligram,,,U,,,,,0.75,MG,,,2021,Q4,COVID-19,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-135635,BRISTOL MYERS SQUIBB,,85.0,YR,,F,Y,60.0,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202097631,20209763,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 milligram,,,U,,,,,0.75,MG,,,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-135635,BRISTOL MYERS SQUIBB,,85.0,YR,,F,Y,60.0,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202097631,20209763,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 milligram,,,U,,,,,0.75,MG,,,2021,Q4,Pyrexia,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-135635,BRISTOL MYERS SQUIBB,,85.0,YR,,F,Y,60.0,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202097631,20209763,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 milligram,,,U,,,,,0.75,MG,,,2021,Q4,Renal impairment,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-135635,BRISTOL MYERS SQUIBB,,85.0,YR,,F,Y,60.0,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202097631,20209763,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 milligram,,,U,,,,,0.75,MG,,,2021,Q4,Systemic infection,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-135635,BRISTOL MYERS SQUIBB,,85.0,YR,,F,Y,60.0,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202097631,20209763,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 milligram,,,U,,,,,0.75,MG,,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-135635,BRISTOL MYERS SQUIBB,,85.0,YR,,F,Y,60.0,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202098711,20209871,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 milligram,,,U,,,,,0.75,MG,,,2021,Q4,Death,,2021,Q4,1,I,20201115.0,20211213.0,20211221,20211221,EXP,,DE-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-138901,BRISTOL MYERS SQUIBB,,85.0,YR,,F,Y,60.0,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202108041,20210804,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 mg (schema),,,U,,,,,0.75,MG,,,2021,Q4,Fall,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,NVSC2021DE286561,NOVARTIS,,85.0,YR,,F,Y,60.0,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202108041,20210804,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 mg (schema),,,U,,,,,0.75,MG,,,2021,Q4,Pyrexia,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,NVSC2021DE286561,NOVARTIS,,85.0,YR,,F,Y,60.0,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202108041,20210804,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 mg (schema),,,U,,,,,0.75,MG,,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,NVSC2021DE286561,NOVARTIS,,85.0,YR,,F,Y,60.0,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202108041,20210804,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 mg (schema),,,U,,,,,0.75,MG,,,2021,Q4,Coronavirus test positive,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,NVSC2021DE286561,NOVARTIS,,85.0,YR,,F,Y,60.0,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202108041,20210804,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 mg (schema),,,U,,,,,0.75,MG,,,2021,Q4,Renal impairment,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,NVSC2021DE286561,NOVARTIS,,85.0,YR,,F,Y,60.0,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202108041,20210804,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 mg (schema),,,U,,,,,0.75,MG,,,2021,Q4,Systemic infection,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,NVSC2021DE286561,NOVARTIS,,85.0,YR,,F,Y,60.0,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202108041,20210804,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 mg (schema),,,U,,,,,0.75,MG,,,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211213.0,20211221,20211221,EXP,,NVSC2021DE286561,NOVARTIS,,85.0,YR,,F,Y,60.0,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202114231,20211423,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNKNOWN,,,0.75,MG,,QD,2021,Q4,Nausea,,2021,Q4,1,I,,20211215.0,20211221,20211221,EXP,,DE-drreddys-SPO/GER/21/0144890,DR REDDYS,,84.0,YR,E,F,Y,80.0,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202114231,20211423,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNKNOWN,,,0.75,MG,,QD,2021,Q4,Flank pain,,2021,Q4,1,I,,20211215.0,20211221,20211221,EXP,,DE-drreddys-SPO/GER/21/0144890,DR REDDYS,,84.0,YR,E,F,Y,80.0,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202114231,20211423,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNKNOWN,,,0.75,MG,,QD,2021,Q4,Systemic infection,,2021,Q4,1,I,,20211215.0,20211221,20211221,EXP,,DE-drreddys-SPO/GER/21/0144890,DR REDDYS,,84.0,YR,E,F,Y,80.0,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202114231,20211423,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNKNOWN,,,0.75,MG,,QD,2021,Q4,Renal impairment,,2021,Q4,1,I,,20211215.0,20211221,20211221,EXP,,DE-drreddys-SPO/GER/21/0144890,DR REDDYS,,84.0,YR,E,F,Y,80.0,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202114231,20211423,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNKNOWN,,,0.75,MG,,QD,2021,Q4,Pain,,2021,Q4,1,I,,20211215.0,20211221,20211221,EXP,,DE-drreddys-SPO/GER/21/0144890,DR REDDYS,,84.0,YR,E,F,Y,80.0,KG,20211221.0,,PH,DE,DE,2021,Q4,Elderly
202153871,20215387,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, Scheme",,,U,,,,,0.75,MG,,,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211213.0,20211222,20211222,EXP,,DE-AUROBINDO-AUR-APL-2021-052323,AUROBINDO,,85.0,YR,,F,Y,60.0,KG,20211222.0,,PH,DE,DE,2021,Q4,Elderly
202153871,20215387,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, Scheme",,,U,,,,,0.75,MG,,,2021,Q4,Fall,,2021,Q4,1,I,,20211213.0,20211222,20211222,EXP,,DE-AUROBINDO-AUR-APL-2021-052323,AUROBINDO,,85.0,YR,,F,Y,60.0,KG,20211222.0,,PH,DE,DE,2021,Q4,Elderly
202153871,20215387,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, Scheme",,,U,,,,,0.75,MG,,,2021,Q4,Renal impairment,,2021,Q4,1,I,,20211213.0,20211222,20211222,EXP,,DE-AUROBINDO-AUR-APL-2021-052323,AUROBINDO,,85.0,YR,,F,Y,60.0,KG,20211222.0,,PH,DE,DE,2021,Q4,Elderly
202153871,20215387,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, Scheme",,,U,,,,,0.75,MG,,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211213.0,20211222,20211222,EXP,,DE-AUROBINDO-AUR-APL-2021-052323,AUROBINDO,,85.0,YR,,F,Y,60.0,KG,20211222.0,,PH,DE,DE,2021,Q4,Elderly
202153871,20215387,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, Scheme",,,U,,,,,0.75,MG,,,2021,Q4,Systemic infection,,2021,Q4,1,I,,20211213.0,20211222,20211222,EXP,,DE-AUROBINDO-AUR-APL-2021-052323,AUROBINDO,,85.0,YR,,F,Y,60.0,KG,20211222.0,,PH,DE,DE,2021,Q4,Elderly
202153871,20215387,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, Scheme",,,U,,,,,0.75,MG,,,2021,Q4,Pyrexia,,2021,Q4,1,I,,20211213.0,20211222,20211222,EXP,,DE-AUROBINDO-AUR-APL-2021-052323,AUROBINDO,,85.0,YR,,F,Y,60.0,KG,20211222.0,,PH,DE,DE,2021,Q4,Elderly
202153871,20215387,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, Scheme",,,U,,,,,0.75,MG,,,2021,Q4,Coronavirus test positive,,2021,Q4,1,I,,20211213.0,20211222,20211222,EXP,,DE-AUROBINDO-AUR-APL-2021-052323,AUROBINDO,,85.0,YR,,F,Y,60.0,KG,20211222.0,,PH,DE,DE,2021,Q4,Elderly
202225681,20222568,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNKNOWN,,,0.75,MG,,,2021,Q4,Coronavirus test positive,,2021,Q4,1,I,,20211215.0,20211223,20211223,EXP,,DE-drreddys-SPO/GER/21/0145005,DR REDDYS,,85.0,YR,E,F,Y,60.0,KG,20211223.0,,PH,DE,DE,2021,Q4,Elderly
202225681,20222568,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNKNOWN,,,0.75,MG,,,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211215.0,20211223,20211223,EXP,,DE-drreddys-SPO/GER/21/0145005,DR REDDYS,,85.0,YR,E,F,Y,60.0,KG,20211223.0,,PH,DE,DE,2021,Q4,Elderly
202225681,20222568,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNKNOWN,,,0.75,MG,,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211215.0,20211223,20211223,EXP,,DE-drreddys-SPO/GER/21/0145005,DR REDDYS,,85.0,YR,E,F,Y,60.0,KG,20211223.0,,PH,DE,DE,2021,Q4,Elderly
202225681,20222568,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNKNOWN,,,0.75,MG,,,2021,Q4,Fall,,2021,Q4,1,I,,20211215.0,20211223,20211223,EXP,,DE-drreddys-SPO/GER/21/0145005,DR REDDYS,,85.0,YR,E,F,Y,60.0,KG,20211223.0,,PH,DE,DE,2021,Q4,Elderly
202225681,20222568,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNKNOWN,,,0.75,MG,,,2021,Q4,Pyrexia,,2021,Q4,1,I,,20211215.0,20211223,20211223,EXP,,DE-drreddys-SPO/GER/21/0145005,DR REDDYS,,85.0,YR,E,F,Y,60.0,KG,20211223.0,,PH,DE,DE,2021,Q4,Elderly
202225681,20222568,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNKNOWN,,,0.75,MG,,,2021,Q4,Renal impairment,,2021,Q4,1,I,,20211215.0,20211223,20211223,EXP,,DE-drreddys-SPO/GER/21/0145005,DR REDDYS,,85.0,YR,E,F,Y,60.0,KG,20211223.0,,PH,DE,DE,2021,Q4,Elderly
202225681,20222568,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNKNOWN,,,0.75,MG,,,2021,Q4,Systemic infection,,2021,Q4,1,I,,20211215.0,20211223,20211223,EXP,,DE-drreddys-SPO/GER/21/0145005,DR REDDYS,,85.0,YR,E,F,Y,60.0,KG,20211223.0,,PH,DE,DE,2021,Q4,Elderly
202237961,20223796,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 milligram,,,,,,,,0.75,MG,,,2021,Q4,Death,,2021,Q4,1,I,20201115.0,20211213.0,20211223,20211223,EXP,,DE-PFIZER INC-202101831397,PFIZER,,85.0,YR,,F,Y,60.0,KG,20211223.0,,PH,DE,DE,2021,Q4,Elderly
202264673,20226467,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 milligram,,,,,,,,0.75,MG,,,2021,Q4,Death,,2021,Q4,3,F,,20211228.0,20211224,20211229,EXP,,DE-PFIZER INC-202101795215,PFIZER,,85.0,YR,,F,Y,60.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202264673,20226467,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 milligram,,,,,,,,0.75,MG,,,2021,Q4,Systemic infection,,2021,Q4,3,F,,20211228.0,20211224,20211229,EXP,,DE-PFIZER INC-202101795215,PFIZER,,85.0,YR,,F,Y,60.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202264673,20226467,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 milligram,,,,,,,,0.75,MG,,,2021,Q4,Hyperglycaemia,,2021,Q4,3,F,,20211228.0,20211224,20211229,EXP,,DE-PFIZER INC-202101795215,PFIZER,,85.0,YR,,F,Y,60.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202264673,20226467,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 milligram,,,,,,,,0.75,MG,,,2021,Q4,COVID-19,,2021,Q4,3,F,,20211228.0,20211224,20211229,EXP,,DE-PFIZER INC-202101795215,PFIZER,,85.0,YR,,F,Y,60.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202264673,20226467,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 milligram,,,,,,,,0.75,MG,,,2021,Q4,Fall,,2021,Q4,3,F,,20211228.0,20211224,20211229,EXP,,DE-PFIZER INC-202101795215,PFIZER,,85.0,YR,,F,Y,60.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202264673,20226467,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 milligram,,,,,,,,0.75,MG,,,2021,Q4,Pyrexia,,2021,Q4,3,F,,20211228.0,20211224,20211229,EXP,,DE-PFIZER INC-202101795215,PFIZER,,85.0,YR,,F,Y,60.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202264673,20226467,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 milligram,,,,,,,,0.75,MG,,,2021,Q4,Renal impairment,,2021,Q4,3,F,,20211228.0,20211224,20211229,EXP,,DE-PFIZER INC-202101795215,PFIZER,,85.0,YR,,F,Y,60.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202264673,20226467,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 milligram,,,,,,,,0.75,MG,,,2021,Q4,Dyspnoea,,2021,Q4,3,F,,20211228.0,20211224,20211229,EXP,,DE-PFIZER INC-202101795215,PFIZER,,85.0,YR,,F,Y,60.0,KG,20211229.0,,PH,DE,DE,2021,Q4,Elderly
202275731,20227573,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, Schema",,,U,,,,,1.5,MG,Solution for injection,,2021,Q4,Urogenital haemorrhage,,2021,Q4,1,I,,20211213.0,20211224,20211224,EXP,,NVSC2021DE285831,NOVARTIS,,69.0,YR,,M,Y,110.0,KG,20211224.0,,PH,DE,DE,2021,Q4,Elderly
202275731,20227573,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, Schema",,,U,,,,,1.5,MG,Solution for injection,,2021,Q4,Condition aggravated,,2021,Q4,1,I,,20211213.0,20211224,20211224,EXP,,NVSC2021DE285831,NOVARTIS,,69.0,YR,,M,Y,110.0,KG,20211224.0,,PH,DE,DE,2021,Q4,Elderly
202275731,20227573,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, Schema",,,U,,,,,1.5,MG,Solution for injection,,2021,Q4,Weight increased,,2021,Q4,1,I,,20211213.0,20211224,20211224,EXP,,NVSC2021DE285831,NOVARTIS,,69.0,YR,,M,Y,110.0,KG,20211224.0,,PH,DE,DE,2021,Q4,Elderly
202276401,20227640,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"-1 UNK, weekly (1/W)",,,,,,,,,,,/WK,2021,Q4,Diarrhoea,,2021,Q4,1,I,20211127.0,20211213.0,20211224,20211224,EXP,,IT-ELI_LILLY_AND_COMPANY-IT202112004381,ELI LILLY AND CO,,78.0,YR,,M,Y,73.0,KG,20211224.0,,CN,DE,IT,2021,Q4,Elderly
202276401,20227640,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"-1 UNK, weekly (1/W)",,,,,,,,,,,/WK,2021,Q4,Acute kidney injury,,2021,Q4,1,I,20211127.0,20211213.0,20211224,20211224,EXP,,IT-ELI_LILLY_AND_COMPANY-IT202112004381,ELI LILLY AND CO,,78.0,YR,,M,Y,73.0,KG,20211224.0,,CN,DE,IT,2021,Q4,Elderly
202276401,20227640,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"-1 UNK, weekly (1/W)",,,,,,,,,,,/WK,2021,Q4,Hypotension,,2021,Q4,1,I,20211127.0,20211213.0,20211224,20211224,EXP,,IT-ELI_LILLY_AND_COMPANY-IT202112004381,ELI LILLY AND CO,,78.0,YR,,M,Y,73.0,KG,20211224.0,,CN,DE,IT,2021,Q4,Elderly
202276401,20227640,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"-1 UNK, weekly (1/W)",,,,,,,,,,,/WK,2021,Q4,Diabetic ketoacidosis,,2021,Q4,1,I,20211127.0,20211213.0,20211224,20211224,EXP,,IT-ELI_LILLY_AND_COMPANY-IT202112004381,ELI LILLY AND CO,,78.0,YR,,M,Y,73.0,KG,20211224.0,,CN,DE,IT,2021,Q4,Elderly
202281251,20228125,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, qd",,,,,,,,0.75,MG,,QD,2021,Q4,Nausea,,2021,Q4,1,I,,20211214.0,20211224,20211224,EXP,,DE-TAKEDA-2021TUS081888,TAKEDA,,84.0,YR,,F,Y,80.0,KG,20211224.0,,HP,DE,DE,2021,Q4,Elderly
202281251,20228125,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, qd",,,,,,,,0.75,MG,,QD,2021,Q4,Renal impairment,,2021,Q4,1,I,,20211214.0,20211224,20211224,EXP,,DE-TAKEDA-2021TUS081888,TAKEDA,,84.0,YR,,F,Y,80.0,KG,20211224.0,,HP,DE,DE,2021,Q4,Elderly
202281251,20228125,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, qd",,,,,,,,0.75,MG,,QD,2021,Q4,Flank pain,,2021,Q4,1,I,,20211214.0,20211224,20211224,EXP,,DE-TAKEDA-2021TUS081888,TAKEDA,,84.0,YR,,F,Y,80.0,KG,20211224.0,,HP,DE,DE,2021,Q4,Elderly
202281251,20228125,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, qd",,,,,,,,0.75,MG,,QD,2021,Q4,Pain,,2021,Q4,1,I,,20211214.0,20211224,20211224,EXP,,DE-TAKEDA-2021TUS081888,TAKEDA,,84.0,YR,,F,Y,80.0,KG,20211224.0,,HP,DE,DE,2021,Q4,Elderly
202281251,20228125,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, qd",,,,,,,,0.75,MG,,QD,2021,Q4,Systemic infection,,2021,Q4,1,I,,20211214.0,20211224,20211224,EXP,,DE-TAKEDA-2021TUS081888,TAKEDA,,84.0,YR,,F,Y,80.0,KG,20211224.0,,HP,DE,DE,2021,Q4,Elderly
202355921,20235592,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,Unknown,,,,,,,2021,Q4,Fall,,2021,Q4,1,I,,20211213.0,20211228,20211228,EXP,DE-ADRED-05289-03,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-08026,ALKEM,,85.0,YR,,F,Y,60.0,KG,20211228.0,,PH,DE,DE,2021,Q4,Elderly
202355921,20235592,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,Unknown,,,,,,,2021,Q4,Pyrexia,,2021,Q4,1,I,,20211213.0,20211228,20211228,EXP,DE-ADRED-05289-03,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-08026,ALKEM,,85.0,YR,,F,Y,60.0,KG,20211228.0,,PH,DE,DE,2021,Q4,Elderly
202355921,20235592,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,Unknown,,,,,,,2021,Q4,Systemic infection,,2021,Q4,1,I,,20211213.0,20211228,20211228,EXP,DE-ADRED-05289-03,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-08026,ALKEM,,85.0,YR,,F,Y,60.0,KG,20211228.0,,PH,DE,DE,2021,Q4,Elderly
202355921,20235592,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,Unknown,,,,,,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211213.0,20211228,20211228,EXP,DE-ADRED-05289-03,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-08026,ALKEM,,85.0,YR,,F,Y,60.0,KG,20211228.0,,PH,DE,DE,2021,Q4,Elderly
202355921,20235592,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,Unknown,,,,,,,2021,Q4,Coronavirus test positive,,2021,Q4,1,I,,20211213.0,20211228,20211228,EXP,DE-ADRED-05289-03,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-08026,ALKEM,,85.0,YR,,F,Y,60.0,KG,20211228.0,,PH,DE,DE,2021,Q4,Elderly
202355921,20235592,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,Unknown,,,,,,,2021,Q4,Renal impairment,,2021,Q4,1,I,,20211213.0,20211228,20211228,EXP,DE-ADRED-05289-03,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-08026,ALKEM,,85.0,YR,,F,Y,60.0,KG,20211228.0,,PH,DE,DE,2021,Q4,Elderly
202355921,20235592,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,Unknown,,,,,,,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211213.0,20211228,20211228,EXP,DE-ADRED-05289-03,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2021-08026,ALKEM,,85.0,YR,,F,Y,60.0,KG,20211228.0,,PH,DE,DE,2021,Q4,Elderly
202541331,20254133,14,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Decreased activity,,2021,Q4,1,I,,20211227.0,20211230,20211230,EXP,,CA-BAUSCH-BL-2021-042672,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20211230.0,,HP,CA,CA,2021,Q4,Elderly
202541331,20254133,14,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Colitis,,2021,Q4,1,I,,20211227.0,20211230,20211230,EXP,,CA-BAUSCH-BL-2021-042672,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20211230.0,,HP,CA,CA,2021,Q4,Elderly
202541331,20254133,14,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Frequent bowel movements,,2021,Q4,1,I,,20211227.0,20211230,20211230,EXP,,CA-BAUSCH-BL-2021-042672,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20211230.0,,HP,CA,CA,2021,Q4,Elderly
202541331,20254133,14,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Colitis ulcerative,,2021,Q4,1,I,,20211227.0,20211230,20211230,EXP,,CA-BAUSCH-BL-2021-042672,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20211230.0,,HP,CA,CA,2021,Q4,Elderly
202541331,20254133,14,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2021,Q4,Rectal haemorrhage,,2021,Q4,1,I,,20211227.0,20211230,20211230,EXP,,CA-BAUSCH-BL-2021-042672,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20211230.0,,HP,CA,CA,2021,Q4,Elderly
202551721,20255172,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, scheme",,,,,,,,,,,,2021,Q4,Fall,,2021,Q4,1,I,,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992743,TEVA,,85.0,YR,E,F,Y,60.0,KG,20211230.0,,PH,DE,DE,2021,Q4,Elderly
202551721,20255172,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, scheme",,,,,,,,,,,,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992743,TEVA,,85.0,YR,E,F,Y,60.0,KG,20211230.0,,PH,DE,DE,2021,Q4,Elderly
202551721,20255172,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, scheme",,,,,,,,,,,,2021,Q4,Renal impairment,,2021,Q4,1,I,,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992743,TEVA,,85.0,YR,E,F,Y,60.0,KG,20211230.0,,PH,DE,DE,2021,Q4,Elderly
202551721,20255172,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, scheme",,,,,,,,,,,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992743,TEVA,,85.0,YR,E,F,Y,60.0,KG,20211230.0,,PH,DE,DE,2021,Q4,Elderly
202551721,20255172,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, scheme",,,,,,,,,,,,2021,Q4,Coronavirus test positive,,2021,Q4,1,I,,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992743,TEVA,,85.0,YR,E,F,Y,60.0,KG,20211230.0,,PH,DE,DE,2021,Q4,Elderly
202551721,20255172,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, scheme",,,,,,,,,,,,2021,Q4,Pyrexia,,2021,Q4,1,I,,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992743,TEVA,,85.0,YR,E,F,Y,60.0,KG,20211230.0,,PH,DE,DE,2021,Q4,Elderly
202551721,20255172,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, scheme",,,,,,,,,,,,2021,Q4,Systemic infection,,2021,Q4,1,I,,20211220.0,20211230,20211230,EXP,,DE-TEVA-2021-DE-1992743,TEVA,,85.0,YR,E,F,Y,60.0,KG,20211230.0,,PH,DE,DE,2021,Q4,Elderly
